Chelation-Assisted C–H Activation by Ruthenium and Osmium Catalysts and Recyclable Hybrid Catalysts by Choi, Isaac
 
 
Chelation-Assisted C–H Activation by Ruthenium and 




for the award of the degree 
“Doctor rerum naturalium” 
of the Georg-August-Universität Göttingen 
 
 
within the doctoral program of chemistry 















Prof. Dr. Lutz Ackermann, Institute of Organic and Biomolecular Chemistry 
Prof. Dr. Shoubhik Das, Department of Chemistry, University of Antwerp 
 
 
Members of the Examination Board 
 
Reviewer: Prof. Dr. Lutz Ackermann, Institute of Organic and Biomolecular 
Chemistry 




Further members of the Examination Board 
 
Prof. Dr. Manuel Alcarazo, Institute of Organic and Biomolecular Chemistry 
Jun.-Prof. Dr. Johannes C. L. Walker, Institute of Organic and Biomolecular 
Chemistry 
Dr. Michael John, Institute of Organic and Biomolecular Chemistry 












1. Introduction ...................................................................................................................................... 1 
1.1 Homogeneous Metal-Catalyzed C–H Functionalization .............................................................. 2 
1.2 Ruthenium-Catalyzed C–H Activation ........................................................................................ 5 
1.2.1 Ruthenium-Catalyzed C–N Formation .................................................................................. 7 
1.2.2 Ruthenium-Catalyzed Distal C–H Functionalization .......................................................... 23 
1.3 Osmium-Catalyzed C–H Activation .......................................................................................... 34 
1.3.1 Osmium-Mediated C–H Functionalizations ........................................................................ 36 
1.3.2 Osmium-Catalyzed C–H Functionalizations ....................................................................... 37 
1.4 Manganese-Catalyzed C–H Activation ...................................................................................... 40 
1.4.1 Manganese-Catalyzed C–H Arylations ............................................................................... 50 
1.5 Copper-Catalyzed C–H Activation ............................................................................................ 52 
1.5.1 Copper-Catalyzed C–H Arylations ...................................................................................... 53 
1.6 Hybrid-Metal-Catalyzed C–H Activation .................................................................................. 65 
2. Objectives........................................................................................................................................ 70 
3. Results and Discussion ................................................................................................................... 74 
3.1 Ruthenium(II)-Catalyzed C7–H Amidations and Alkenylations of Indoles .............................. 74 
3.1.1 Optimization Studies ........................................................................................................... 75 
3.1.2 Substrate Scope.................................................................................................................... 78 
3.1.3 Investigations of Practical Utility ........................................................................................ 80 
3.1.4 Mechanistic Studies ............................................................................................................. 82 




3.2 Ruthenium(II)-Catalyzed C4/C6–H Dual Alkylations of Indoles.............................................. 87 
3.2.1 Optimization Studies ........................................................................................................... 88 
3.2.2 Substrate Scope.................................................................................................................... 91 
3.2.3 Mechanistic Studies ............................................................................................................. 93 
3.3 Osmium-Catalyzed Electrooxidative C–H Annulations ............................................................ 94 
3.3.1 Optimization Studies ........................................................................................................... 95 
3.3.2 Substrate Scope.................................................................................................................... 98 
3.1.3 Site-Selectivity Studies ...................................................................................................... 100 
3.3.4 Mechanistic Studies ........................................................................................................... 102 
3.4 Photo-Induced C–H Arylation by Reusable Heterogeneous Copper Catalyst ......................... 111 
3.4.1 Preparation of Hybrid Copper Catalyst ............................................................................. 112 
3.4.2 Optimization Studies ......................................................................................................... 113 
3.4.3 Substrate Scope.................................................................................................................. 116 
3.4.4 Mechanistic Studies ........................................................................................................... 119 
3.4.5 Heterogeneity Studies ........................................................................................................ 121 
3.4.6 Characterization of Hybrid Copper Catalyst ..................................................................... 123 
3.4.7 Proposed Mechanism ......................................................................................................... 125 
3.5 Distal C–H Activation by Reusable Heterogeneous Ruthenium Catalyst ............................... 126 
3.5.1 Optimization Studies ......................................................................................................... 127 
3.5.2 Substrate Scope.................................................................................................................. 129 
3.5.3 Mechanistic Studies ........................................................................................................... 130 
3.5.4 Heterogeneity Studies ........................................................................................................ 132 
3.5.5 Characterizations of Hybrid Ruthenium Catalyst .............................................................. 134 




3.6 C–H Arylations and Alkylations by Reusable Heterogeneous Manganese Catalyst ............... 138 
3.6.1 Preparation of Hybrid Manganese Catalyst ....................................................................... 139 
3.6.2 Optimization Studies ......................................................................................................... 140 
3.6.3 Substrate Scope.................................................................................................................. 142 
3.6.4 Heterogeneity Studies ........................................................................................................ 144 
3.6.5 Characterizations of Heterogeneous Catalyst .................................................................... 146 
4. Summary and Outlook ................................................................................................................ 147 
5. Experimental Data ....................................................................................................................... 151 
5.1 General Remarks ...................................................................................................................... 151 
5.2 General Procedures .................................................................................................................. 155 
5.2.1 General Procedure A: Ruthenium-Catalyzed C7–H Indole Amidations ........................... 155 
5.2.2 General Procedure B: Ruthenium-Catalyzed C7–H Indole Alkenylations ....................... 155 
5.2.3 General Procedure C: Ruthenium-Catalyzed C4–H/C6–H Indole Dual Alkylations........ 155 
5.2.4 General Procedure D: Osmium-Catalyzed Electrooxidative [4+1] C–H annulations ....... 155 
5.2.5 General Procedure E: Osmium-Catalyzed Electrooxidative [4+2] C–H annulations ....... 156 
5.2.6 General Procedure F: Photo-Induced Hybrid Copper-Catalyzed C–H Arylations (1) ...... 156 
5.2.7 General Procedure G: Photo-Induced Hybrid Copper-Catalyzed C–H Arylations (2) ..... 156 
5.2.8 General Procedure H: Photo-Induced Hybrid Copper-Catalyzed C–H Arylations (3) ..... 157 
5.2.9 General Procedure I: Hybrid Ruthenium-Catalyzed meta-C–H Alkylation ...................... 157 
5.2.10 General Procedure J: Hybrid Manganese-Catalyzed C–H Arylations ............................ 157 
5.2.11 General Procedure K: Hybrid Manganese-Catalyzed C–H Alkylations ......................... 157 
5.3 Ruthenium(II)-Catalyzed C7–H Amidations and Alkenylations of Indoles ............................ 159 
5.3.1 Characterization Data ........................................................................................................ 159 




5.3.3 Flow Reaction Setup .......................................................................................................... 182 
5.3.4 Competition Experiment.................................................................................................... 182 
5.3.5 Removal of Pivaloyl Directing Group ............................................................................... 183 
5.3.6 Hammett Correlation ......................................................................................................... 186 
5.3.7 H/D Exchange Study ......................................................................................................... 187 
5.3.8 KIE Study .......................................................................................................................... 190 
5.3.9 Kinetic Analysis ................................................................................................................ 191 
5.4 Ruthenium(II)-Catalyzed C4/C6–H Dual Alkylations of Indoles............................................ 194 
5.4.1 Characterization Data ........................................................................................................ 194 
5.4.2 Mechanistic Investigation .................................................................................................. 207 
5.5 Osmium-Catalyzed Electrooxidative C–H Annulations .......................................................... 209 
5.5.1 Characterization Data ........................................................................................................ 209 
5.5.2 Reaction Comparison with External Oxidant .................................................................... 229 
5.5.3 Selectivity Comparison with Different Catalysis (1) ........................................................ 230 
5.5.4 Selectivity Comparison with Different Catalysis (2) ........................................................ 232 
5.5.5 Synthesis of Osmium Complex ......................................................................................... 236 
5.5.6 Reactions with Osmium Complex ..................................................................................... 240 
5.5.7 In-Operando NMR and HR-ESI-MS Studies .................................................................... 243 
5.5.8 Competition Experiment.................................................................................................... 245 
5.5.9 Hammett Correlation ......................................................................................................... 247 
5.5.10 KIE Study ........................................................................................................................ 248 
5.5.11 Crystallographic Information .......................................................................................... 251 
5.6 Photo-Induced C–H Arylation by Reusable Heterogeneous Copper Catalyst ......................... 256 




5.6.2 Synthesis of Hybrid Copper Catalyst ................................................................................ 289 
5.6.3 Determination of Catalyst Loading ................................................................................... 291 
5.6.4 Competition Experiment.................................................................................................... 292 
5.6.5 Radical Experiment ........................................................................................................... 292 
5.6.7 On-Off Light Test .............................................................................................................. 293 
5.6.8 Heterogeneity Test ............................................................................................................. 294 
5.7 Distal C–H Activation by Reusable Heterogeneous Ruthenium Catalysis .............................. 296 
5.7.1 Characterization Data ........................................................................................................ 296 
5.7.2 Preparation of Hybrid Ruthenium Catalyst ....................................................................... 310 
5.7.3 Determination of Catalyst Loading ................................................................................... 310 
5.7.4 Competition Experiment.................................................................................................... 311 
5.7.5 H/D Exchange Study ......................................................................................................... 312 
5.7.6 KIE Study .......................................................................................................................... 314 
5.7.7 Heterogeneity test .............................................................................................................. 316 
5.8 C–H Arylations and Alkylations by Reusable Heterogeneous Manganese Catalyst ............... 320 
5.8.1 Characterization Data ........................................................................................................ 320 
5.8.2 Synthesis of Hybrid Manganese Catalyst .......................................................................... 343 
5.8.3 Determination of Catalyst Loading ................................................................................... 345 
5.8.4 Heterogeneity Test ............................................................................................................. 346 
6. References ..................................................................................................................................... 349 
7. Appendix: NMR Spectra ............................................................................................................. 377 
 




List of Abbreviateions 
 
Ac  acetyl  
acac  acetyl acetonate  
Alk  alkyl  
AMLA  ambiphilic metal-ligand activation  
aq.  aqueous  
Ar  aryl  
atm  atmospheric pressure  
BHT  2,6-di-tert-butyl-4-methylphenol  
BIES  base-assisted internal electrophilic substitution  
Bn  benzyl  
Boc  tert-butyloxycarbonyl  
Bu  butyl  
Bz  benzoyl  
calc.  calculated  
cat.  catalytic  
CMD  concerted metalation deprotonation  
conv.  conversion  
Cp*  cyclopentadienyl  
Cy  cyclohexyl  
δ  chemical shift  
d  doublet  
DCB dichlorobutane 
DCE  1,2-dichloroethane  
DCM dichloromethane 
List of Abbreviations 
VII 
 
dd  doublet of doublet  
DFT  density functional theory  
DG  directing group  
DME  dimethoxyethane  
DMF  N,N-dimethylformamide  
DMSO  dimethyl sulfoxide  
DMPU  1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone  
dt  doublet of triplet  
EI  electron ionization  
equiv  equivalent  
ES electrophilic substitution 
ESI  electronspray ionization  
Et  ethyl  
FG  functional group  
g  gram  
GC  gas chromatography  
h  hour  
Hal  halogen  
Het  hetero atom  
Hept  heptyl  
Hex  hexyl  
HPLC  high performance liquid chromatography  
HR-MS  high resolution mass spectrometry  
Hz  Hertz  
i  iso  
IR  infrared spectroscopy  
IES internal electrophilic substitution 
J  coupling constant  
List of Abbreviations 
VIII 
 
KIE  kinetic isotope effect  
L  ligand  
m  meta  
m  multiplet  
M  molar  
[M]+  molecular ion peak  
Me  methyl  
Mes  mesityl  
mg  milligram  
MHz  megahertz  
min  minute  
mL  milliliter  
mmol  millimol  
M. p.  melting point  
MS  mass spectrometry  
m/z  mass-to-charge ratio  
NCTS  N-cyano-4-methyl-N-phenyl benzenesulfonamide  
NMTS N-cyano-N-(4-methoxy)phenyl-p-toluenesulfonamide 
NMP  N-methylpyrrolidinone  
NMR  nuclear magnetic resonance  
o  ortho  
OA oxidative addition 
OPV  oil pump vacuum  
p  para  
Ph  phenyl  
PMP  para-methoxyphenyl  
Piv  pivaloyl  
ppm  parts per million  
List of Abbreviations 
IX 
 
Pr  propyl  
PTSA p-Toluenesulfonic acid 
py pyridyl  
pym pyrimidine 
pyr pyrazol 
q  quartet  
RT  room temperature  
s  singlet  
sat.  saturated  
SPS  solvent purification system  
t  tert  
t  triplet  
T  temperature  
THF  tetrahydrofuran  
TLC  thin layer chromatography  
TM  transition metal  
TMEDA tetramethylethylenediamine 
TMP  2,2,6,6-tetramethylpiperidine  
TMS  trimethylsilyl  
Ts  para-toluenesulfonyl  
TS  transition state  







During the last century, tremendous advances in organic synthesis have been accomplished, allowing 
our life to be fertile, convenient, and efficient. For instance, crop protection products enable an 
unprecedented increase in the agricultural production output, while the development of 
pharmaceuticals saves many people’s lives. In addition, petroleum becomes an inevitable part of our 
daily life, while materials are found everywhere around us. These enormous progress in organic 
chemistry, however, have brought about a series of problems related to environmental pollution and 
resource depletion by generating toxic materials and consuming a huge amount of energy.  
In order to alleviate the dark side of the chemical reactions, a new approach toward resource-,[1] step- 
and atom-economical[2] synthetic methodologies are in high demand. In 1998, Anastas and Warner 
proposed the “12 Principles of Green Chemistry”,[3] which provides chemists with a general guideline 
for sustainable chemistry, which advises synthetic chemists to pursue environmentally benign 
chemical processes (Scheme 1.1.1). In this regard, catalysis helps to operate the chemical reactions 
with a reduced amount of chemicals in lieu of its excess uses, thus setting the stage for resource 
economical synthesis. Furthermore, direct utilization of easily accessible chemicals without pre-
functionalization assists to achieve step- and atom-efficiency in the chemistry process. Additionally, 
mild reaction conditions and less toxic chemicals are expected to provide safer chemical processes.[4] 
 
 




1.1 Homogeneous Metal-Catalyzed C–H Functionalization 
Since hydrocarbons are omnipresent structural units in organic compounds, the utilization of C–H 
bonds of hydrocarbons has great potential. Thereby, organic chemists have had utmost interests in the 
transformation of hydrocarbons to useful and high-valued compounds by straightforward and 
sustainable methods. Previously, a significant achievement of catalysis for C–C bond and C–Het bond 
formations has been made by transition metals (Scheme 1.1.2a),[5] leading to the development of 
numerous name reactions, such as the Suzuki–Miyaura,[6] Negishi,[7] Mizoroki–Heck,[8] Kumada–
Corriu,[9] Hiyama,[10] Stille,[11] and Sonogashira–Hagihara[12] cross-couplings as well as the Tsuji–
Trost reaction,[13] the Goldberg-Ullmann amination,[14] and the related Buchwald–Hartwig reaction.[15] 
The importance of the palladium-catalyzed chemical transformations was recognized by the Nobel 
Prize in Chemistry awarded collectively to Heck, Negishi, and Suzuki in 2010.[16]  
 
 
Scheme 1.1.2 Metal-catalyzed cross-coupling versus C–H functionalization. 
 
Although these palladium catalyses enabled to change paradigm of C–C bond formation reactions 
(Scheme 1.1.2a), there still existed a drawback where pre-functionalization should be involved, which 
impedes fulfilling atom- and step-economy as well as user-friendly access. For instance, 
organostannane reagents used in the Stille coupling are highly toxic, while organomagnesium reagents 
in the Kumada-Corriu cross-coupling or organozinc reagents in the Negishi cross-coupling are air- and 




stoichiometric byproducts. In order to obviate such disadvantages of classical cross-coupling reactions, 
a new approach, namely C–H functionalization, was introduced to the synthetic community.[17] With 
this strategy, the organometallic nucleophile is directly replaced by an inert C–H bond, thereby forming 
a new C–C bond (Scheme 1.1.2b).[18] Additionally, oxidative C–H/C–H functionalization allowed for 
another scenario for C–C bond formation in the presence of a stoichiometric oxidant (Scheme 
1.1.2c).[19] 
Since C–H functionalization methods provide a sustainable approach for chemical transformation, 
synthetic chemists became interested in its detailed mechanistic understandings. Except metalloradical 
or metal carbene/nitrene outer-sphere mechanisms, the organometallic C–H cleavage is proposed to 
proceed via five different possible pathways: (i) oxidative addition; (ii) σ-bond metathesis; (iii) 
electrophilic substitution; (iv) concerted metalation deprotonation (CMD); (v) base-assisted internal 
electrophilic substitution (BIES) (Scheme 1.1.3).[20] 
 
 
Scheme 1.1.3 Five different modes of C–H bond cleavage process. 
 
Among these plausible C–H scission pathways, base-assisted metallation models have been most 
generally accepted for transition metal-catalyzed C–H activation reactions. In this regard, transition 
state structure and partial charge accumulation are key criteria to subcategorize the base-assisted 




pathway, in which the formation of a deprotonative transition state is suggested in the case where C–
H bond cleavage step is proposed to be a rate-demermining step.[21] In a similar way, Macgregor and 
Davies proposed ambiphilic metal ligand activation (AMLA) pathway where agostic interaction occurs 
between the metal center and the C–H bond.[22] In sharp contrast, Ackermann proposed base-assisted 
internal electrophilic substitution (BIES), featuring that competition experiments between 
electronically differentiated substrates show the preferred functionalization of the more electron-rich 
substrate.[23] Notably, this finding cannot be explained by the deprotonative pathway through kinetic 
C–H acidity.[24] 
Based on these proposals, general catalytic cycles for the transition metal-catalyzed C–H 
functionalization can be envisaged, while the mechanistic details can vary reactions (Scheme 1.1.4).  
 
 
Scheme 1.1.4 General catalytic pathways for transition metal-catalyzed C–H activation reactions. 
 
In the following chapters, C–H activation reactions using representative metals, including ruthenium, 
osmium, manganese, and copper are described. Beyond homogeneous realm, recyclable hybrid metal-




1.2 Ruthenium-Catalyzed C–H Activation 
Transition metal-catalyzed C–H functionalization has gained enormous attention with precious 4d and 
5d metal catalysis, such as rhodium,[25] palladium,[26] and iridium,[27] providing the direct 
transformation from omnipresent C–H bonds to new C–C or C–Het bonds. In sharp contrast, ruthenium 
has recently come into the spotlight due to its cost-effectiveness and unique selectivities and 
reactivities.[28] The first example of the stoichiometric C–H activation with ruthenium complex was 
reported by Chatt and Davidson, with sodium naphthalene salts by in-situ generated ruthenium(0) 
complex, which was in equilibrium between 3 and 4 (Scheme 1.2.1).[29] 
 
 
Scheme 1.2.1 Ruthenium-mediated C–H functionalization. 
 
The first ruthenium-catalyzed C–H activation was arguably reported by Lewis and Smith in 1986 
(Scheme 1.2.2).[30] In this study, the ortho-position of phenol 5 was functionalized with ethylene gas 
6, affording mono-alkylated 8 and di-alkylated phenol 9 with the aid of phosphites as transient 
directing group.  
 
 
Scheme 1.2.2 The first catalytic C–H activation with the ruthenium complex. 
 
In 1993, Kakiuchi and Murai showed ruthenium-catalyzed C–H hydroarylations with aromatic ketones 




occurred via a five-membered ruthenacycle formation, which was later rationalized by DFT studies 
from the Morokuma group.[32] This achievement was key to enable other researchers to develop related 
ruthenium-catalyzed C–H activations. 
 
 
Scheme 1.2.3 Ruthenium-catalyzed direct C–H hydroarylation. 
 
Inspired by base-assisted metalation manifold by Shaw[33] and Davies,[34] Ackermann[23, 20a] 
demonstrated a significant advance in ruthenium catalysis, in which carboxylate assistance played the 
key role in the C–H activation process (Scheme 1.2.4).[35] Importantly, the mechanistic rationale of the 
carboxylate-assisted ruthenium-catalyzed C–H activation was suggested to proceed via a six-
membered transition state.[36a, 21b, 36b] 
 
 
Scheme 1.2.4 Base-assisted ruthenium-catalyzed C–H activation. 
 
While the thus established ruthenium(II)-catalysis has enabled various types of C–H activation 





1.2.1 Ruthenium-Catalyzed C–N Formation 
Carbon–nitrogen bonds are prevalent in a plethora of pharmaceuticals, natural products, and 
biologically active compounds.[37] For this reason, there is a strong demand to achieve sustainable and 
selective C–N bond formation reactions. Among the conventional approaches toward C–N bond 
formations, copper-catalyzed Goldberg–Ullmann amination reactions[14a, 38a, 14b, 38b] and palladium-
catalyzed Buchwald−Hartwig amination reactions[39] have been utilized, giving synthetic chemists a 
facile method for a broad range of aryl amines (Scheme 1.2.5). 
 
 
Scheme 1.2.5 Copper and palladium-catalyzed aminations. 
 
Although these aminations provided easy access to C–N bond formations, such approaches have highly 
relied on the pre-functionaliztion of substrates, producing inherently stoichiometric amounts of 
byproducts. In stark contrast, the transition metal-catalyzed C–H activation approach was able to 
overcome the limitation, thereby offering synthetic and economic efficiency. The initial contributions 
for C–H aminations had mainly been achieved by precious metals, such as rhodium,[40] palladium,[41] 
and iridium.[42] Thereby, the motivation of the search for inexpensive, but active metal catalysts to 
utilizing ruthenium complexes for C–N bond formations.  
Ruthenium-catalyzed C−H amination reactions can be categorized by three realms (Scheme 1.2.6). 




including Metal–C bond and thus generated ruthenacycle complexes is subsequently engaged in C–N 
bond forming process. The outer-sphere mechanism[43] commonly represents C–H insertion catalysis, 
in which ruthenium−nitrenoid species react with a coupling partner, resulting in C−H aminations. The 
third approach is to utilize ruthenium-based photoredox catalysis via a single electron transfer process, 
in which the organoradical species indirectly generated upon irradiation interacts with a substrate, thus 
giving amidated products.   
 
Scheme 1.2.6 Different modes of C–N formations. 
 
Notably, in a general scenario of amination reactions, C(sp2)–H (∼113 kcal/mol) and N–H (∼108 
kcal/mol) bonds are transformed to new C–N (∼103 kcal/mol) and H–H (∼104 kcal/mol) bonds, 
which is thermodynamically uphill process.[44] Therefore, a selection of reaction components is the 
key to success for the amination reactions.  
In 2013, Ackermann and co-workers successfully showed C–H amidations of arenes with tosyl azide 
26 as an amidating reagent (Scheme 1.2.7).[45] With the aid of pyrazole directing groups, ortho C–H 
bonds of arenes 25 could be selectively functionalized. Detailed mechanistic studies revealed that 
electrophilic-type ruthenation was likely operative and the C–H scission process was reversible. Based 
on their mechanistic studies, the catalytic cycle was proposed. Thus, ruthenium cation species 30 is in-




coordinated to the ruthenium center. Insertion followed by protodemetallation affords the amidated 
product 27 and regenerates the active catalyst 30. 
 




Using a strong directing group strategy, Ding[46] and Chen[47] independently reported C–H amidation, 
in which benzothiazoles and triazole directing groups were employed although one ortho- or meta-
position was required to be sterically blocked to inhibit difunctionalizations of the arenes 34 or 36 
(Scheme 1.2.8).   
 
 
Scheme 1.2.8 C–N bond formation using strong N-directing groups. 
 
Instead of strongly coordinating directing groups, weak coordination also allowed for efficient C–H 
amination reactions. In 2013, Chang and co-workers showed that amide or ketone based substrates 
were effective for the C(sp2)–H amidations (Scheme 1.2.9).[48]  
 
 




Similar to the approach presented by Chang, Jiao also reported C–H amidations of the aromatic ketone 
40, in which a catalytic amount of copper acetate was used as addition to in-situ form a ruthenium(II)-
carboxylate complex (Scheme 1.2.10).[49]  
 
 
Scheme 1.2.10 Ketones as a directing group for ruthenium-catalyzed C–N bond formation. 
 
In 2014, Kim disclosed ruthenium-catalyzed C–H amidations of xanthones 42, which enabled to access 
mono-amidated xanthones 43 as a sole product (Scheme 1.2.11).[50] Notably, the thus synthesized 
nitrogenated products were screened for growth inhibition activity against human breast cancer MCF-
7 cells.  
 
 
Scheme 1.2.11 Ruthenium-catalyzed C–H amidation of xanthones 42. 
 
At the same time, Zhu reported ruthenium-catalyzed C7–H amidation of indolines 44 through the 
installation of a ketone directing group (Scheme 1.2.12).[51] Here, six-membered metallacycles were 
presumably formed, enabling direct access toward C7 indoline functionalizations.  
 
 




Interestingly, Sahoo used sufoximine directing group strategy which had been commonly used for 
rhodium catalysis (Scheme 1.2.13).[52] Particularly, the reported method was used for the synthesis of 
a potent medication, namely Ataciguat, which had been studied for calcific aortic valve stenosis.[53]  
 
 
Scheme 1.2.13 Sulfoximine directing group approach for C–H amidation and its use for natural 
product synthesis. 
 
Other organic azides and hydroxylamines were also viable for ruthenium-catalyzed amidations. Chang 
thus showed the use of acyl azides 53 as an aminating reagent for ruthenium-catalyzed amidation 
reactions (Scheme 1.2.14).[54] Although benzoyl azides 53 are prone to undergo Curtius rearrangement, 






Scheme 1.2.14 C–H amidations with acyl azides 53.  
 
Additionally, the Yu group used O-benzoylhydroxylamines 56 as an amine source, providing ortho-
C–H aminations of benzamides 55 under mild conditions at room temperature (Scheme 1.2.15).[55]  
 
 
Scheme 1.2.15 C–H amidations through N–O bond cleavage.  
 
Ackermann showed ruthenium(II)carboxylate-catalyzed C–H imidations with (N-OTs)phthalimide 58 
as the amination source (Scheme 1.2.16).[56] Notable, a wide range of substrates was presented. A 
simple additional step allowed for easy access to aminophenones 60. The catalytic cycle has been also 
proposed, in which an in-situ generated the cationic ruthenium(II)carboxylate catalyst 61 forms 
cyclometalated intermediate 62. The subsequent imidating reagent coordinates followed by the N−O 
cleavage to deliver the cationic complex 64. Lastly, the active ruthenium catalyst 61 is regenerated 












As the second manifold of C–H amination, various ruthenium-nitrenoid formation strategies were 
employed. In 1997, Che[57] and co-workers showed that stoichiometric use of 
bis(tosyl)imidoruthenium(VI) porphyrin complex 62 enabled amino group transfer, which was later 
highlighted by detailed mechanistic studies as well as by the scope of aziridinations and C–H 
amidations (Scheme 1.2.17).[58]  
 
 
Scheme 1.2.17 Stoichiometric C–N bond formation with ruthenium-porphyrin complex 62. 
 
Two years later, Che reported the ruthenium(II) porphyrin-catalyzed C–H amidations with 
exceptionally high turnovers (Scheme 1.2.18).[59] The combination of PIDA and tosylamide 67 or the 
direct use of N-tosyliminobenzyliodinane 68 enabled a broad range of C–H bond formations.  
 
 
Scheme 1.2.18 Ruthenium-catalyzed C–N bond formation. 
 
Around the same time, the same research group disclosed asymmetric C–N bond formations catalyzed 
by chiral ruthenium complex 69 (Scheme 1.2.19).[60] While the dimethanoanthracene-based porphyrin 
macrocycle induced relatively low enantioselectivity (6% ee to 48 % ee), the stoichiometric use of 





Scheme 1.2.19 Enantioselective ruthenium-catalyzed C–H amidation. 
 
In 2008, Group of Blakey reported enantioselective ruthenium-catalyzed C–H amidations, in which 
the chiral pybox ligand was employed to construct cyclosulfamates under mild conditions (Scheme 
1.2.20).[61] In the presence of hypervalent iodine oxidant, the benzylic C–H bond was selectively 
transformed to a new C–N bond, while a five-membered sulfamate was not observed. 
 
 




The next year, Gallo and co-workers revealed C(sp3)–H amidations at the vinyl position with aryl 
azides 75 (Scheme 1.2.21).[62] Notably, the isolated stable ruthenium(IV) intermediate 78 allowed for 
detailed mechanistic investigation by means of spectrometric analyses. Later, independent DFT studies 
showed two possible mechanisms, in which a pathway through monoimido Ru(IV) species formation 
cannot be ruled out.[63]  
 
 
Scheme 1.2.21 Ruthenium-catalyzed C(sp3)–H amination. 
 
In 2011, Du Bois disclosed diruthenium(II/III)-catalyzed ring-closing allylic C−H aminations (Scheme 
1.2.22).[64] Taking advantage of the mixed valent ruthenium complex 80, a one-electron oxidation 
could be achieved by catalytic atom-transfer process. Additionally, the selectivity toward C–H 
insertion process over aziridination was analyzed by computational studies.  
 
 




In 2013, Katsuki reported enantioselective intermolecular benzylic amidation using the salen-based 
chiral ruthenium(II) complex 84 (Scheme 1.2.23).[65] Interestingly, an analogous iridium catalyst fell 
short in delivering the desired product. 
 
 
Scheme 1.2.23 Enantioselective C–H amidation with salen complexes 84 and 86. 
 
Recently, Meggers showed asymmetric intramolecular C–H amination by a chiral-at-metal ruthenium 
complex, affording five-membered heterocycles with high enantioselectivity (Scheme 1.2.24).[66] 
Notably, high catalytic efficiency (TON = 740) was also accomplished. Detailed mechanistic studies 






Scheme 1.2.24 Enantioselective intramolecular C–N bond formation. 
 
Very recently, Yu and co-workers reported ruthenium-catalyzed enantioselective γ‑lactam formation 
via intramolecular C–N bond formation (Scheme 1.2.25).[67] The nitrene C–H insertion process was 
enabled by a chiral diphenylethylene diamine-based ligands, which bear an electron-withdrawing 
arylsulfonyl substituent. Similar to Chang’s report,[54] the competing Curtius-type rearrangement was 
not observed.  
 
 




As the last approach toward C–N bond formation, single electron transfer manifold through 
photoredox catalysis has recently gained major attention due to its sustainability, even though it has 
been scarcely reported for amidation reactions.  
In 2015, Studer showed visible-light-induced C–H amidation and imidation by using ruthenium-based 
photocatalyst 95 (Scheme 1.2.26).[68] N-aminopyridinium salts were employed as an amidyl radical 
source 101 through a deaminative process, allowing divergent C–N bond formations.  
 
 
Scheme 1.2.26 Visible-light-induced deaminative C–H amidation. 
 
In 2017, Itami and Murakami reported photoredox ruthenium-catalyzed C–H/N–H coupling by blue-
light irradiation (Scheme 1.2.27).[69] Thus, a wide range of polycyclic aromatic hydrocarbons was 
transformed to aryl amines through the oxidation of sulfonimides by the photoredox catalyst 95. 
Additionally, catalytic cycle was proposed based on the detailed mechanistic studies by means of 






Scheme 1.2.27 Photo-induced C–H/N–H coupling by ruthenium-based photocatalyst 95. 
 
Inspired by cation pool methods of Yoshida,[70] Morofuki and Kano very recently disclosed 
photocatalytic C−H aminations of aromatic compounds 106 (Scheme 1.2.28).[71] Taking advantage of 
substrates with higher oxidation potentials than the reduction potential of the oxidation state of the 
ruthenium-based photocatalyst 108 among other photocatalysts, 109 and 110, a variety of functional 














1.2.2 Ruthenium-Catalyzed Distal C–H Functionalization 
Ruthenium-catalyzed C–H activation has generally provided robust methods for ortho-selective C–H 
functionalization for new C–C bond or C–Het bond formations via a proximity-induced approach. In 
sharp contrast, C–H functionalizations at distal positions of arenes have been considerably less 
investigated (Scheme 1.2.29).[72a-e, 26e, 72f] In most methods, either the intrinsic electronic properties of 
substrates[73] or less atom-economical templates[74] and ligands[75, 26f] have been utilized to guide 
selectivity. Also, such reactions required cost-intensive metals, such as iridium and palladium catalysts. 
In stark contrast, ruthenium complexes have recently gained major attention for distal C–H 
functionalizations, in which C–H ruthenation results in remote meta-functionalizations.[76, 72d]  
 
 
Scheme 1.2.29 Strategies for distal C–H functionalizations. 
 
Early examples of distal functionalization were reported by Roper and Wright in a stoichiometric 
manner (Scheme 1.2.30a).[77] Thereafter, van Koten employed a similar stoichiometric approach for 






Scheme 1.2.30 Stoichiometric distal C–H functionalization of ruthenium complexes. 
 
Thereafter, the groups of Coudret,[79] Roper/Wright,[80] and van Koten[78] extended this method towards 
oxidative transformations of cyclometalated ruthenium complexes.  
In 2011, Ackermann observed the first catalytic meta-C–H functionalization by C–H ruthenation 
(Scheme 1.2.31).[35e] Albeit in low yield, the result became a milestone for the further developments 
of ruthenium-catalyzed distal functionalizations.  
 
 
Scheme 1.2.31 The first observation of ruthenium-catalyzed meta-C–H alkylation. 
 
At the same time, Li showed the para-selective, oxidative C–H/C–H alkylation of arenes 28, albeit 
with limited selectivity.[81] In contrast, Ackermann disclosed a general strategy for meta-C–H 
alkylations via carboxylate-assisted ortho-ruthenation, featuring excellent levels of unusual meta-




transformation occurred via reversible C–H ruthenation, while the use of typical radical scavenger 
TEMPO inhibited the meta-C–H alkylation. Notably, direct meta-alkylation with enantiomerically 




Scheme 1.2.32 Ruthenium-catalyzed meta-C–H alkylations with secondary alkyl bromide 121a. 
 
Distal C–C bond formation was not limited to secondary alkylation, but tertiary alkyl halides also were 
viable reaction partners. In 2015, Ackermann[83] and then Frost[84] independently showed the 








Scheme 1.2.33 Ruthenium-catalyzed meta-C–H alkylations with tertiary bromides 124. 
 
Two years later, Ackermann and co-workers reported meta-C–H functionalizations of ketimines 128 
(Scheme 1.2.34).[85] It was not until then that the majority of the ruthenium-catalyzed meta-C–C bond 
formation reaction had highly relied on N-containing strong directing groups, which were not readily 
modified under mild conditions. However, this reaction allowed for the access to meta-functionalizaed 
aryl ketones 130 from imines through acidic work-up. Moreover, various alkyl halides including 






Scheme 1.2.34 Ruthenium-catalyzed distal C–H functionalization with the aid of a removable 
directing group. 
 
Additionally, azobenzenes 131[86] and pyridylphenol 134[87] were introduced for ruthenium-catalyzed 
remote C–H alkylations, in which the directing groups were transformed to other interesting functional 
groups, such as anilines and phenols, respectively (Scheme 1.2.35).  
 
 




In 2017, the group of Ackermann accomplished the first remote C–H mono- and difluoromethylation 
through the combination of ruthenium(II) carboxylate and a phosphine ligand (Scheme 1.2.36).[88] 
Various directing groups, such as pyridines, pyrimidines, pyrazoles, and purine, efficiently afforded 
meta-decorated fluoromethylated products. It is noteworthy that the difluoromethylations did not occur 
at the kinetically more acidic C8–H positions of the purine motif. Around the same time, Wang group 
showed a similar approach for ruthenium-catalyzed remote mono- and difluoromethylations, utilizing 
a ruthenium and palladium bimetallic catalysis.[89] 
 
 
Scheme 1.2.36 Ruthenium-catalyzed meta-C–H difluoroalkylations. 
 
Ackermann and co-workers disclosed sequential meta-/ortho-C–H difunctionalizations in 2018 
(Scheme 1.2.37).[90] Thus, the double C−H activation proved viable in a one-pot fashion, providing 
operationally simple twofold C−H functionalizations. In addition, detailed mechanistic studies 
provided strong support for homolytic C−X bond cleavage and facile C−H ruthenation, while a radical 







Scheme 1.2.37 Distal C–H alkylation via ruthenium (II/III) catalysis and sequential strategy for dual 
functionalizations 
 
The established cooperative use of phosphine and carboxylate ligands in ruthenium catalysis was 





Scheme 1.2.38 Three-component ruthenium-catalyzed meta-C–H alkylation. 
 
It is noteworthy that since the arene-ligand-free phosphine-coordinated ruthenium complexes are 
catalytically competent species, the complex can be directly employed for the synergistic 
ruthenium(II)-catalyzed remote C–H functionalizations. Thus, Ackermann and co-workers reported 
that well-defined arene-ligand-free ruthenium complex Ru(OAc)2(PPh3)2 was used for meta-C–H 
alkylations (Scheme 1.2.39).[92] 
 
 
Scheme 1.2.39 Arene-ligand-free ruthenium(II/III) manifold for meta-C–H alkylation. 
 
Among distal C–C bond formation in ruthenium catalysis, meta-C–H acylation was disclosed by Wang 
using α-oxocarboxylic acid 156 (Scheme 1.2.40)[93] In the presence of silver salt and persulfates, 
oxidative decarboxylation of the activated ketoacids 156 generated an acyl radical, leading to the 
ruthenium-catalyzed remote functionalizations. 
 
 




Very recently, the group of Ackermann reported on visible-light-induced ruthenium-catalyzed meta-
C–H alkylation at ambient temperature (Scheme 1.2.41).[94] Notably, the photocatalytic reactions were 
performed under exceedingly mild reaction conditions at ambient temperature and without any 
additional exogeneous photocatalysts. Around the same time, Greaney also reported similar remote C–
H alkylations with alkyl iodide under visible-light induced conditions.[95]   
 
 
Scheme 1.2.41 Visible-light-induced ruthenium-catalyzed meta-C–H alkylation. 
 
In addition to the aforementioned site-selective distal C–C bond formation, ruthenium catalysis 









In contrast to the indisputable progress in meta-selective C–H functionalizations, general procedures 
for ruthenium-catalyzed para-C–H functionalization are under developed. Frost[99] and Ackermann[90] 
independently reported on ruthenium-catalyzed para-C–H alkylations of pyrimidylanilines 167 with 
α-halo carbonyl compound 168 (Scheme 1.2.43). Notably, Frost suggested that the formation of four-
membered ruthenacycle 170 is the key intermediate. 
 
 
Scheme 1.2.43 Ruthenium-catalyzed para-C–H alkylations. 
 
Later, Zhao/Lan and Liang utilized a similar ruthenium-catalyzed para-C–H functionalization method 
to achieve mono- and difluoroalkylations (Scheme 1.2.44).[100] Unlike the mechanistic hypothesis 
offered by Frost, Zhao/Lan proposed that ortho-C–H ruthenation enabled the para-selectivity, although 










1.3 Osmium-Catalyzed C–H Activation 
Osmium is the heaviest and rarest element in the earth’s crust, with a concentration of approximately 
0.05 parts per billion.[101] Osmium complexes – for instance, osmium tetroxide – are often considered 
toxic. In addition, osmium forms relatively strong Os–C bonds due to the stability in its higher 
oxidation state. For these reasons, osmium is a less attractive metal for catalysis compared to other 
group 8 metals[102] 
Interestingly, osmium complexes have been introduced for useful chemical transformations.[103] As 
major example, inspired by the pioneering work by Criegee,[104] Sharpless significantly expanded this 
realm to osmium-catalyzed enantioselective dihydroxylations (Scheme 1.3.1).[105]  
 
 
Scheme 1.3.1 Representative examples of chemical transformation with osmium tetroxide. 
 
C−H functionalizations by osmium complexes have also emerged as a powerful toolbox for chemical 
transformations. In 1973, Bruce disclosed the formation of osmacycle complex through C–H bond 






Scheme 1.3.2 Synthesis of osmacycle complex 184. 
 
On the basis of this work, well-defined osmacycles were successfully isolated in a stoichiometric 
fashion (Scheme 1.3.3).[107] Thus, N-, P- and O-directing groups are coordinated to the osmium center, 
leading to C–H cleavage, resulting in the formation of osmacycle 185–190. 
 
 





1.3.1 Osmium-Mediated C–H Functionalizations 
With this progress in the stoichiometric formation of osmacycles, such complexes were subjected to 
subsequent C–H functionalizations. In 1999, Roper and Wright disclosed an electrophilic substitution-
type C–H bromination and nitration of 2-(2’-pyridyl)phenyl osmium complex 191 (Scheme 1.3.4).[80a] 
The C–H functionalizations of osmium complex 191 selectively occurred at the position para-to-the-
osmium center. Interestingly, while the excess use of bromination source provided a ligand exchange 
from phosphine to pyridine, the prolonged reaction time in the nitration afforded dual C–H 
functionalized product 193. With brominated osmium complex 194, further diversifications were also 
presented, thus generating carboxylated 196 or stannylated osmium complex 197.  
 
 




1.3.2 Osmium-Catalyzed C–H Functionalizations 
Despite the aforementioned advances in stoichiometric osmacycle synthesis and its reactions, osmium 
complexes have rarely been used for catalytic C–H functionalization. In 2007, Iida disclosed 
osmium(II) porphyrin complex-catalyzed oxidative C–H oxygenation of steroid 198 (Scheme 
1.3.5).[108] In this study, the least hindered tertiary C–H bond was selectively transformed, albeit with 
low efficiency. Additional reports also showed that pentacyclic triterpenoids 201 were converted to 




Scheme 1.3.5 Osmium porphyrin-catalyzed C–H oxygenations. 
 
In 2020, Meggers and co-workers disclosed osmium-catalyzed enantioselective C–H amidation 
(Scheme 1.3.6).[110] As an extension of their previous studies, newly synthesized non-C2-symmetric 





Scheme 1.3.6 Enantioselective C–H amidations with chiral-at-osmium catalyst 204. 
 
In 2020, the Rovis group showcased near-infrared-induced photocatalysis regime utilizing an osmium-
based photocatalyst 210 (Scheme 1.3.7).[111] Unlike ruthenium-based polypyridyl photocatalysts, 
osmium analogous featured a spin-forbidden S0 →T1 excitation in the near-infrared region, thereby 
increasing light penetration into the reaction medium. 
 
 
Scheme 1.3.7 Near-infrared photo-catalyzed C–H arylations with osmium-based photocatalyst 210. 
 
Recently, Yi and co-workers reported on unprecedented osmium(II)-catalyzed C–H activation 
(Scheme 1.3.8).[112] While transition metal-catalyzed C–H annulation has been well established,[113] 
the osmium complex was firstly employed in this study. Notably, the use of internal oxidant brought 
about less atom efficiency in this reaction, while a wide range of substrates was amenable. Additionally, 
experimental mechanistic studies revealed that the C–H bond scission process is irreversible, while 










1.4 Manganese-Catalyzed C–H Activation 
As the twelfth most abundant element in the earth’s crust, manganese has a huge potential for 
sustainable, low toxic and cost-effective C−H activation.[114] In addition, a wide range of oxidation 
states of manganese from –3 to +7 enables various coordination geometries.[115] Notably, manganese 
complexes have been widely used in epoxidation reactions[116] and radical-type C–H 
functionalizations,[117] but limitedly employed in cross-coupling,[118] Together with these indisputable 
advances, organometallic C−H functionalizations have recently emerged as a powerful toolbox for 
chemical transformations.  
In 1970, Stone and Bruce reported the stoichiometric manganese-mediated C–H activation of 




Scheme 1.4.1 Stoichiometric C–H activation with manganese. 
 
On the basis of this work, a plethora of well-defined manganacycles was successfully prepared in a 
stoichiometric fashion (Scheme 1.4.2).[120] Thus, the directing groups are coordinated to the manganese 
center, leading to C–H cleavage followed by manganacycle formations. 
 
 




Despite the indisputable progress, manganese-catalyzed C–H activation had been put in the shade 
before Kuninobu and Takai disclosed a seminal study in 2007.[121] Thereby, a manganese(I) complex 
catalytically enabled C–H activation of arenes 226 with aldehydes 227 and Et3SiH, affording silylated 
alcohols 228. Additionally, the catalytic cycle was proposed, in which Mn–C bond was suggested as a 
manganese(III)-hydride species 229 is formed via an oxidative addition. The exact structure of the 
active catalyst has thus far remained elusive, while recent manganese-catalyzed hydroarylation 
reactions are generally proposed to undergo redox-neutral isohypsic pathway. Thereafter, a migratory 
insertion followed by reductive eliminations afforded the desired product 228. 
 
 





In 2013, Wang showcased manganese-catalyzed C–H alkenylation of arenes 229 with terminal alkynes 
230 (Scheme 1.4.4).[122] The hydroarylation manifold was functional group tolerate. Detailed 
experimental mechanistic studies along with computational DFT studies suggested that the reaction 
proceeds through the formation of five-membered manganacycle 232 followed by seven-membered 
intermediate 233 construction.[123] 
  
 





Then, researchers utilized different combinations of arenes and alkynes, providing synthetically useful 
products. For instance, while manganese-catalyzed annulation reactions with various types of alkynes 
were reported by Ackermann,[124] Wang[125] among others,[126] Glorius showed the manganese-
catalyzed C–H allenylation of indoles by using propargylic carbonate.[127] Recently, Ackermann and 
coworkers employed bromo alkynes 238, for the first time, delivering alkynylated heteroarenes 239 
by manganese catalysis (Scheme 1.4.5).[128] Notably, this reaction manifold was extended to feature 
peptide modification, thus providing acyclic and cyclic alkynylated peptides under epimerization-free 
reaction conditions. Based on detailed mechanistic studies, they proposed a plausible catalytic cycle, 
in which the substrate 237 undergoes facile and reversible C–H manganesation, followed by alkyne 
migratory insertion and β-Br-elimination. 
 
 





The manganese(I) catalysis was not limited to reactions with alkynes. Indeed, the manganese-catalyzed 
hydroarylation process was also applied to feature alkenes as coupling partners. In 2014, Wang and 
co-workers developed the manganese-catalyzed direct aromatic C–H conjugate addition to α,β-
unsaturated carbonyls (Scheme 1.4.6).[129]  
 
 
Scheme 1.4.6 Manganese-catalyzed C–H alkylation with acrylates 240. 
 
As an extension of this approach, in 2017, Song reported manganese-catalyzed hydroarylations of 
indoles 242 with maleimides 243 (Scheme 1.4.7a).[130] Later, Glorius employed in-situ generated α,β-
unsaturated carbonyls from α-diazoketones 245 with the aid of silver additives (Scheme 1.4.7b).[131]  
 
 
Scheme 1.4.7 C–H alkylations or arenes 242 via manganese-catalyzed hydroarylation manifold. 
 
In 2016, Ackermann and co-workers disclosed manganese-catalyzed C–H allylations of arenes 247 
with allyl carbonates 248 (Scheme 1.4.8).[132] While valuable functional groups, including halides, 




synthesis of 1,2,3-substituted arene 249c. While mechanistic investigation showed that C–H the 
manganesation process is not involved in the rate-determining step, a base-assisted intramolecular 
electrophilic-type substitution (BIES) regime for manganese-catalyzed C–H allylation was proposed 
by among other competition experiments. 
 
 
Scheme 1.4.8 Manganese-catalyzed C–H allylations. 
 
In 2017, the same group reported manganese-catalyzed decarboxylative C–H allylations of 
heteroarenes 242 and arenes 247d with dioxolanones 250 (Scheme 1.4.9).[133] Thus, C–H/C–O bond 
cleavages with concomitant formation of CO2 delivered the desired allyl alcohols 251 or 252 with high 
levels of the site- and chemo-selectivity. Later, this manganese catalysis manifold was further extended 






Scheme 1.4.9 Manganese-catalyzed C–H allylation via C–H/C–O or C–H/C–C cleavage. 
 
Thereafter, Glorius reported a similar manganese-catalyzed C–H allylation.[135] Along the same lines, 
Wang[136] and Zhang[137] independently reported manganese-catalyzed C–H allylation reactions with 
allenes and perfluoroallyl bromides as coupling partners respectively.  
Manganese-catalyzed C–H functionalizations with substrates including C–C double bonds are not 
limited to allylations. Indeed, Ackermann and coworkers developed manganese-catalyzed C–H 
annulation[138] of arenes 247 with acrylates 255, affording cis-β-amino acid esters 256 (Scheme 
1.4.10).[139] This interesting transformation involved the formation of a nucleophilic manganese 
intermediate, followed by intramolecular nucleophilic addition to the iminyl carbon. The operationally 
simple transformation featured high catalytic efficacy, good functional group tolerance, and an 





Scheme 1.4.10 Manganese-catalyzed alkene annulations. 
 
Allenes are a class of unique compounds with two π-orbitals perpendicular to each other at the centered 
carbon. These unique features of allenes have been also introduced into manganese-catalyzed C–H 
activation reactions, thereby producing interesting and useful chemical transformations. While Glorius 
reported manganese-catalyzed C–H propagylation with bromoallenes with the aid of a borane-based 
Lewis acid,[140] Wang[141] and Rueping,[142] among others,[143] showcased C–H annulations of 
heteroarenes with allene moieties via Smiles rearrangement.  
Apart from C–C multiple bonds, electrophilic C–Het multiple bonds were also found to be viable 
reaction partners.[144] Thus, aldehydes, imines, or nitrile-containing substrates were introduced to the 
manganese-catalyzed hydroarylation reactions. In 2015, Ackermann and coworkers reported 
manganese-catalyzed C–H aminocarbonylation of heteroarenes 242 with isocyanates 259, featuring a 
broad range of functional groups (Scheme 1.4.11).[145] In addition, traceless removal of the pyridiyl 






Scheme 1.4.11 Manganese-catalyzed C–H aminocarbonylations. 
 
Around the same time, the Wang group showed the manganese-catalyzed Grignard-type nucleophilic 
addition to aldehydes 261 or nitriles 263, providing benzylic alcohols 262 or ketones 264, respectively 
(Scheme 1.4.12).[146]  
 
 





Ackermann[147] and others[148] additionally reported manganese-catalyzed hydroarylations with 
substrates having electrophilic C–Het multiple bonds (Scheme 1.4.13).   
 
 







1.4.1 Manganese-Catalyzed C–H Arylations 
Manganese(I)-catalyzed C–H activation of arenes has been generally governed by isohypsic 
mechanisms, which often impedes redox active catalysis. For this reason, manganese-catalyzed C–H 
arylation reaction requires a different approach.  
Ackermann and coworkers disclosed a manganese-catalyzed C−H arylation by using a user-friendly 
and scalable flow technique (Scheme 1.4.14).[149] The combination of the manganese salts MnCl2 and 
neocuproine allowed for expedient C–H arylations of azines 273 with a broad substrate scope. On the 
basis of detailed experimental and computational studies, a Mn(II/III/I) manifold was proposed to be 
operative. Interestingly, the same group, later, reported electrochemical manganese-catalyzed C–H 
arylations, in which electricity could replace the external oxidant DCIB.[150]  
 
Scheme 1.4.14 Manganese-catalyzed C–H arylations using flow technique. 
 
More recently, Ackermann developed photo-induced manganese-catalyzed C−H arylations by flow-
chemistry (Scheme 1.4.15).[151] Thus, a plethora of aryldiazonium salts 276 was transformed to biaryls 
278 under the optimized conditions. The robustness of the manganese-catalyzed C−H arylation in 
continuous photoflow was extended to feature heteroarenes (278e–278h) with high functional group 
tolerance. Interestingly, an intermolecular kinetic isotope effect was not observed, indicating a non-












1.5 Copper-Catalyzed C–H Activation 
Similar to manganese, copper is an inexpensive and environmentally benign element. In addition, its 
readily accessible oxidation states from 0 to +3 provide new bond formation processes through radical 
or one- and two-electron transfer processes.[152] With these inherent benefits, copper catalysis has 
emerged as an important tool for organic reactions with a long history. Starting from the Glaser 
coupling,[153] copper-mediated reaction enabled a plethora of chemical transformations. Hence, copper 
has played a significant role in catalysis. Inspired by the pioneering work of Ullmann and Goldberg 









1.5.1 Copper-Catalyzed C–H Arylations 
In 1901, Ullmann disclosed the first arylation using a stoichiometric amount of copper via reductive 
coupling.[38b] Thereafter, Ullmann reported copper-catalyzed N–H arylations of anilines as well as O–
H arylations of phenol.[38a, 14b] In 1906, Goldberg additionally revealed copper-catalyzed aminations 
with anilines or amides.[14a] With these pioneering reports, copper enabled C–C, C–N, and C–O bond 
formations, which became a milestone for the development of copper-catalyzed C–H arylations.  
Copper-catalyzed C–H arylation can be categorized by four different approaches, including (i) the use 
of electrophilic reagents, (ii) the use of nucleophilic reagents, (iii) the use of carboxylic acids for 
decarboxylations, and (iv) cross-dehydrogenative couplings.  
 
 
Scheme 1.5.2 Strategies for copper-catalyzed C–H arylations. 
 
Nilsson[156] and Wahen[157] reported an early C–H arylation with copper complexes in 1968 and in 
1973 respectively. Although the stoichiometric use of copper complex was required in presence of the 




H arylations (Scheme 1.5.3).[158] Notably, since C5–H arylation of N-methylimidazole 284 occurs via 
an electrophilic palladation, the copper complex plays a significant role in the C2–H arylations.[159] 
Interestingly, N-methylbenzimidazole only showed C2–H arylation with stoichiometric use of copper 
iodide in absence of the palladium(II) catalyst.  
 
 
Scheme 1.5.3 The effect of copper additives in palladium-catalyzed C–H arylation. 
 
These findings allowed researchers to envisage the involvement of catalytic organocopper 
intermediates in the C–H arylation reactions. Inspired by these studies, Daugulis disclosed copper-
catalyzed C–H arylation of electron-rich heterocycles, including oxazoles, benzoxazoles, thiazoles, 
and benzothiazoles (Scheme 1.5.4).[160] The combination of lithium alkoxide bases and aryl iodides 
enabled sustainable C–H arylations, while other aryl halides or tosylates fell short in delivering the 
desired arylated product. In their mechanistic proposal, deprotonation followed by lithium-copper 
transmetallation affords organocopper species, while the involvement of arynes intermediates could 






Scheme 1.5.4 Copper-catalyzed C–H arylations. 
 
Then, the same group reported copper-catalyzed C–H arylations of electron-deficient as well as 
polyfluorinated arenes,[161] which was further extended to the new methods where both electron-rich 
and electron-poor heterocycles could be employed as viable substrates (Scheme 1.5.5).[162] 
Pentafluorophenyl copper intermediate 297 was separately prepared with the aid of phenanthroline 
ligand. The copper complex 297 was transformed to the biaryl product in a stoichiometric fashion, 
which showed to conclude that C–H cuperation is the key to the success of the copper-catalyzed C–H 
arylations. Notably, while the early example of copper-catalyzed C–H activation was proposed to 






Scheme 1.5.5 Copper-catalyzed C–H arylations of perfluoroarene 294. 
 
Concurrently, Ackermann disclosed the copper-catalyzed C–H arylation of triazoles 298 (Scheme 
1.5.6).[163] The 1,2,3-triazoles 298 were readily obtained by copper-catalyzed click reaction followed 








Inspired by these studies by Daugulis, Miura, and Ackermann, a plethora of C–H arylation studies was 
reported with various heterocycles, including azoles,[164] benzotriazepines,[165] caffeine,[166] uracil,[167] 
among others.[168] 
In 2016, Ackermann and coworkers reported unprecedented photo-induced copper-catalyzed C–H 
arylation under exceedingly mild conditions at room temperature (Scheme 1.5.7).[169] Additionally, 




Scheme 1.5.7 Photo-induced copper-catalyzed C–H arylations. 
 
With these aforementioned established studies, intramolecular approaches of copper-catalyzed C–H 
arylations were also developed. Namely, Ackermann showed the intramolecular C−H/C−X activation, 
in which the construction of fully substituted cyclic 1,2,3-triazoles 311 was successfully achieved 
through [3+2] azide−alkyne cycloadditions followed by C−H activation (Scheme 1.5.8).[170] 
 
 






The use of electrophilic reagents was not limited to aryl halides, but was extended to include 
diaryliodonium salts. In 2008, Gaunt disclosed a copper-catalyzed divergent C−H arylation of indoles 
312 with diphenyliodonium salt 313(Scheme 1.5.9).[171] Thus, C2–H and C3–H of indoles could be 
independently functionalized under slightly different conditions. They also proposed possible reaction 
mechanisms for each functionalization, starting from the key aryl−copper(III) intermediate. Notably, 
the established method was further applied to the synthesis of alkaloid dictyodendrin B.[172]  
 
 
Scheme 1.5.9 Divergent copper-catalyzed C–H arylations of indole 312 with diaryliodonium salt 313. 
 
Gaunt also expanded the copper catalysis using diaryliodonium salts to C−H arylation, particularly 
providing meta-C–H functionalizations of arenes (Scheme 1.5.10).[173, 73c] The catalytic cycle was 




Scheme 1.5.10 Copper-catalyzed C–H arylations with diphenyliodonium salt 313. 
 
Later, Gaunt reported para-C–H arylations of anisole and anilines using copper catalysis with 




As the use of nucleophile organometallic reagents, in 2008, Itami showed the copper-mediated C–H 
arylation of arenes 321 and heteroarenes 312 with aryl boronic acids 322 (Scheme 1.5.11).[176] 
Afterwards, this reaction manifold was extended for the arylation of various heteroarene with aryl 
boronic esters as well as aryl Grignard reagents.[177] 
 
 
Scheme 1.5.11 Copper-mediated C–H arylations with aryl boronic acid 322. 
 
In 2014, Dai and Yu group disclosed oxidative C–H arylations with organoboron reagents with the aid 
of a bidentate directing group (Scheme 1.5.12a).[178] Thereafter, Wang reported the copper-catalyzed 
C−H arylation of azacalix[1]arene[3]-pyridines 332 with aryl boronic acids 322 (Scheme 1.5.12b).[179] 
Interestingly, these two studies proposed slightly different catalytic mechanisms. In Yu’s study, the 
reaction was proposed to proceed through aryl copper(III) intermediates followed by reductive 
elimination and oxidation, regenerating the active copper(II) species. However, Wang performed 
stoichiometric reactions with independently prepared well-defined copper(II) and copper(III) 
intermediates, but interestingly, only the reaction with the copper(II) compound 334 afforded the 











For the third type of copper-catalyzed C–H arylations, decarboxylation of aryl carboxylic acid has also 
emerged as a viable arylating method.[180] Hoover and coworkers reported decarboxylative arylations 
by copper catalysis in 2015 (Scheme 1.5.13a).[181] In the next year, Maiti reported a similar copper-
catalyzed C–H arylation via decarboxylation (Scheme 1.5.13b).[182]  
 
 
Scheme 1.5.13 Decarboxylative copper-catalyzed C–H arylations. 
 
This arylation could be extended to arenes with bidentate directing group. Shi reported decarboxylative 
copper-catalyzed C–H arylation enabled by the (pyridin-2-yl)isopropyl amine (PIP-amine) directing 
group (Scheme 1.5.14a).[183] Hirano and Miura also reported a similar reactivity with the 8-
aminoquinoline-based bidentate auxiliary (Scheme 1.5.14b).[184]  
  
 




The fourth method for copper-catalyzed C–H arylations are dehydrogenative C−H/C−H arylation. 
Although this approach does not require prefunctionalization of substrates, the achievement of 
selectivity control is the key challenging issue.[185] In this regard, while copper-catalyzed oxidative C–
H/C–H arylations for homo-couplings could be readily achieved,[186] unsymmetric biaryl formation 

















Furthermore, the bidentate directing group enabled various C–H/C–H cleavage (Scheme 1.5.17).[190] 
 
 





1.6 Hybrid-Metal-Catalyzed C–H Activation 
While there are indisputable and considerable advances in homogeneous metal-catalyzed C–H 
functionalization, the homogeneous catalytic process possessed inherent disadvantages of difficult 
catalyst reusability, which can be directly connected to environmental issues as well as economical 
concerns in the industries.[191] In sharp contrast, the advent of heterogeneous catalysts enabled a shift 
of paradigm. The heterogeneous catalyst basically consisted of different phases[192] which are exposed 
to the reacting chemicals, allowing the recovery of the catalyst.[193] Thereby, heterogeneous catalysis 
often provides sustainable pathways toward molecular syntheses.[194]  
In 1817, the first heterogeneous catalysis was discovered by the Cornish chemist Humphry Davy who 
identified that gas burning could occur without a flame in presence of platinum wire in his research on 
miner’s safety lamps.[195] A few years later, Döbereiner discovered the reaction of hydrogen gas with 
a platinum sponge could produce a flame at room temperature.[196] At the end of the 1990s, the Deacon 
process was developed, which generated chlorine from hydrochloric acid with the copper salt CuCl2 
as a catalyst.[197] This discovery provided a catalytic approach as well as a sustainable replacement of 
the previous process using stoichiometric MnO2. At the beginning of the twentieth century, the Haber-
Bosch process was developed, in which iron oxide carriers accompanied with promoters could catalyze 
the ammonia production.[198]  
Thereafter, a number of recyclable and reusable heterogeneous catalysts have been developed, which 
could also recently be used for C–H activation chemistry.[199]  
The first example of heterogeneous metal-catalyzed C–H activation was disclosed by Nakamura in 
1982 (Scheme 1.6.1).[200] In this report, palladium on charcoal catalyzed C–H arylations of 








In 2005, Fagnou extended heterogeneous palladium catalysis to intra- and intermolecular C–H 
arylations (Scheme 1.6.2).[201] Here, a wide range of substrate scopes was presented with Pearlman’s 
catalyst, while a three-phase test revealed that a homogeneous process is likely operative. 
 
 
Scheme 1.6.2 The seminal example of recyclable heterogeneous palladium-catalyzed C–H arylation. 
 
In 2017, Ackermann and Vaccaro reported heterogeneous palladium-catalyzed Fujiwara-Moritani 
reaction in continuous flow (Scheme 1.6.3). Thus, a tailor-made flow reactor set the stage to not only 
reuse the catalyst but also scale the reaction, while detailed ICP-OES analysis of the reaction medium 
only showed less than 5 ppm of palladium leaching. In addition, various heterogeneity tests, such as 




Scheme 1.6.3 Heterogeneous palladium-catalyzed Fujiwara-Moritani reaction in flow. 
 
Inspired by these early examples, the heterogeneous catalysis realm in C–H activation was expanded 
to feature not only palladium catalysis but also other transition metal catalysis. In 2010, Wada and 




oxide support to immobilize the ruthenium catalyst (Scheme 1.6.4).[202] Although the developed 
heterogeneous ruthenium catalyst was required to perform reactivation for the reuse, later, this reaction 
manifold could be efficiently introduced to C–H hydroarylation reactions.[203]  
 
 
Scheme 1.6.4 Heterogeneous ruthenium-catalyzed C–H activations. 
 
In 2017, Ackermann developed heterogeneous ruthenium-catalyzed meta-C–H bromination of purines 
154 (Scheme 1.6.5).[98c] In this study, the silica-based heterogeneous ruthenium catalyst was highly 
recyclable without a significant loss of reactivity and selectivity, while a broad range of functional 
groups was tolerated, which set the stage of direct fluorescent labeling of purines. 
 
 




Despite indisputable advances in heterogeneous catalysis for C–H activation, it remains a critical 
concern that such catalysis is restricted by the surface area of the supported catalyst due to the physical 
limitation of active site. To overcome this disadvantage, researchers devised a new concept – hybrid 
catalysts cooperating inorganic materials and homogeneous catalysts – expecting to have a designable 
and tailorable heterogeneous catalyst while being recyclable and reusable.[204] 
In 2005, Davies reported a strategy for the immobilization of chiral dirhodium(II) catalysts (Scheme 
1.6.6).[205] In this study, various dirhodium catalysts were anchored to pyridine-containing resin by a 
simple preparation, which was directly employed for C–H arylation reactions in a reusable manner. 
 
 
Scheme 1.6.6 Hybrid rhodium catalyst for enantioselective C–H arylation. 
 
Thereafter, Jones and Davies developed silica-based hybrid dirhodium(II) catalyst for C(sp3)–H 
functionalizations.[206] In contrast to the previous report,[207] this study described covalent anchoring 
approach, enabling to have a more stable hybrid rhodium catalyst. Later, this reaction manifold was 
further extended to introduce a continuous flow technique, in which the dirhodium complexes were 
immobilized inside of a hollow fiber flow reactor, thus providing potential scalability and 
sustainability.[208]  
In 2016, Jones and Yu reported polymer-supported hybrid palladium catalyst for C(sp3)–H arylations 
(Scheme 1.6.7).[209] While ample substrates scope with a wide range of functional group tolerance was 












Transition metal-catalyzed C−H activations have emerged as a robust toolbox for synthetic 
chemistry.[18b, 18i, 18j] The development of new synthetic pathways and approaches is in high demand. 
In this regard, Ackermann and coworkers have presented remarkable achievements during the last two 
decades,[210a, 72d, 113c, 20a, 210b, 210c] which have focused on the development of new and sustainable 
catalysis in a wide range of metals. Thus, the objective of this thesis was to aim at the development of 
cost-effective and environmentally-sound homogeneous and recyclable hybrid metal-catalyzed C−H 
activations, along with mechanistic understandings and characterizations. 
Indole benzenoid functionalizations have recently gained major attention from organic chemists, since 
such methods enable access biologically active molecules. For this reason, we became interested in 
exploring ruthenium-catalyzed C7–H indole amidations and alkenylations with the aid of a removable 
directing group under mild reaction conditions (Scheme 2.1.1).[211]  
 
 
Scheme 2.1.1 Ruthenium-catalyzed C7–H indole amidation and alkenylation. 
 
Beyond thus developed C7–H indole activations, we also sought for a general synthetic pathway to 
functionalize other bonds of the indole motif. Thus, inspired by great progress in ruthenium-catalyzed 
distal C–H functionalization by Ackermann and coworkers, we developed site-selective dual C4–






Scheme 2.1.2 Ruthenium-catalyzed C4–H/C6–H dual alkylations. 
 
While ruthenium and iron among group 8 metals have been extensively studied for C–H activation, 
osmium-catalyzed C–H activation is under developed. Motivated by the recent trend of 
electrochemical methods for C–H activation, which has been mainly developed by Ackermann and 
coworkers, we became interested in electrochemical osmium-catalyzed C–H activation (Scheme 2.1.3). 
Thereby, osmium catalyst enabled [4+1] and [4+2] annulations under electrooxidative conditions.  
 
 
Scheme 2.1.3 Osmium-catalyzed electrooxidative C–H activation. 
 
Despite enormous advances in homogeneous catalysis for C–H activation, recyclable heterogeneous 
catalysis has emerged as a powerful tool to improve sustainability. Particularly, the combination of 
organic ligands immobilized onto inorganic support, namely hybrid catalyst, enabled to tune the 
heterogeneous catalyst and simultaneously provide recyclability. In this regard, we became intrigued 




On the basis of Ackermann’s report in 2016,[169] we developed recyclable hybrid copper catalyst for 
photo-induced C–H arylation (Scheme 2.1.4).[213] The SBA-15 silica-based hybrid copper catalyst 
enabled a wide range of arylations of heterocycles under exceedingly mild conditions at room 
temperature and was reusable at least up to five times.  
 
 
Scheme 2.1.4 Recyclable hybrid copper-catalyzed C–H arylation. 
 
Based on the concept of hybrid catalysis, we envisaged site-selective C–H activation with hybrid metal 
catalysts. Especially, Ackermann and coworkers have recently presented numerous studies about 
ruthenium-catalyzed meta-C–H functionalization with the aid of phosphine ligand as a key component 
for the reaction. Thus, we introduced phosphine-based polymers to immobilize ruthenium(II) catalyst, 
enabling distal C–H functionalizations (Scheme 2.1.5).[214]   
 
 
Scheme 2.1.5 Recyclable ruthenium-catalyzed meta-C–H alkylation. 
 
During the past decades, the activation of inert C–H bonds has been predominantly made with the aid 
of noble 4d and 5d transition metals.[215a-c, 210b, 215d] In sharp contrast, the introduction of Earth-abundant 




activations.[216] Here, we envisioned adding the value of heterogeneity to manganese catalysis. Thus, 
we developed a hybrid manganese catalyst, providing C–H arylation and C–H alkylation in a reusable 
manner (Scheme 2.1.6).  
 
 
Scheme 2.1.6 Hybrid manganese-catalyzed C–H arylation and alkylation. 
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3. Results and Discussion 
3.1 Ruthenium(II)-Catalyzed C7–H Amidations and Alkenylations of Indoles 
Substituted indoles[217] are a key structural motif in a plethora of important bio-relevant compounds, 
drugs, and pharmaceuticals (Scheme 3.1.1).[218] Since the precise synthesis of structural complex 
indoles having substituent groups in a specific position is often challenging, various researches have 
tested site-selective indole functionalizations. While C2- or C3-selective functionalizations have been 




Scheme 3.1.1 Bioactive C7-functionalized indoles. 
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3.1.1 Optimization Studies  
The C7–H functionalization of indole 392 was envisaged with the aid of pivaloyl directing group 
(Table 3.1.1). In this context, organic azide 391 was used as the amidating reagent for ruthenium(II) 
catalysis. Particularly, the use of a ruthenium catalyst together with metal acetate and silver salts was 
expected to in-situ generate a cationic ruthenium(II)-carboxylate. Also, N-pivaloyl orienting group was 
expected to enable the formation of a six-membered ruthenacycle. The optimization studies were 
commenced by testing solvents. While various reaction mediums, including ethereal (entries 1–2) and 
alcoholic solvents (entries 3–4) as well as other solvents (entries 5–12) were attempted. Unfortunately, 
the desired product was not detected. Only when DCE, DCM, or TFE were used as the solvent, the 
C7–H amidated product 392 was formed (entries 13–15). It is noteworthy that the nitrogenated product 
was selectively formed at the C7–H position as the sole product, while the C2–H bond remained 
unmodified. Next, the effect of the reaction temperature was explored. Interestingly, while the decrease 
in the temperature to 40 ºC provided an increase in the yield, temperature lower than 40 ºC were not 
beneficial (entries 16–19). Bases fell short in providing the desired product in a high yield (entries 20–
22). Although the use of AgNTf2 showed comparable results (entry 23), AgSbF6 was chosen for the 
issue of cost. The employment of Ru(OAc)2(p-cymene)2 allowed to avoid additional acetate sources 
(entry 24), not only highlighting the importance of the ruthenium(II)biscarboxylate catalysis regime. 
While prolonged reaction time provided increased C7–H amidated indole production (entry 25), 
elevated temperature gave unsatisfactory results (entry 26).  
 
  
Results and Discussion 
76 
 














1 [RuCl2(p-cymene)]2 AgSbF6 AgOAc 1,4-dioxane 60 16 NR 
2 [RuCl2(p-cymene)]2 AgSbF6 AgOAc DME 60 16 NR 
3 [RuCl2(p-cymene)]2 AgSbF6 AgOAc MeOH 60 16 NR 
4 [RuCl2(p-cymene)]2 AgSbF6 AgOAc tAmOH 60 16 NR 
5 [RuCl2(p-cymene)]2 AgSbF6 AgOAc o-xylene 60 16 NR 
6 [RuCl2(p-cymene)]2 AgSbF6 AgOAc NMP 60 16 NR 
7 [RuCl2(p-cymene)]2 AgSbF6 AgOAc DMA 60 16 NR 
8 [RuCl2(p-cymene)]2 AgSbF6 AgOAc DMF 60 16 NR 
9 [RuCl2(p-cymene)]2 AgSbF6 AgOAc DMSO 60 16 NR 
10 [RuCl2(p-cymene)]2 AgSbF6 AgOAc MeCN 60 16 NR 
11 [RuCl2(p-cymene)]2 AgSbF6 AgOAc CHCl3 60 16 NR 
12 [RuCl2(p-cymene)]2 AgSbF6 AgOAc CCl4 60 16 NR 
13 [RuCl2(p-cymene)]2 AgSbF6 AgOAc DCE 60 16 25 
14 [RuCl2(p-cymene)]2 AgSbF6 AgOAc DCM 60 16 42 
15 [RuCl2(p-cymene)]2 AgSbF6 AgOAc TFE 60 16 41 
16 [RuCl2(p-cymene)]2 AgSbF6 AgOAc TFE 50 16 52 
17 [RuCl2(p-cymene)]2 AgSbF6 AgOAc TFE 40 16 60 
18 [RuCl2(p-cymene)]2 AgSbF6 AgOAc TFE 30 16 54 
19 [RuCl2(p-cymene)]2 AgSbF6 AgOAc TFE 25 16 32 
20 [RuCl2(p-cymene)]2 AgSbF6 CsOAc TFE 40 16 trace 
21 [RuCl2(p-cymene)]2 AgSbF6 LiOAc TFE 40 16 32 




Thereafter, the indole N-substituent pattern was examined, and a variety of ketones, amide, ester, 
phosphine oxide, sulfone, and pyridine were explored (Scheme 3.1.2). Interestingly, only the N-
pivaloyl indole 390 provided the C7−H amidation product, illustrating the importance of steric and 




Scheme 3.1.2 Examination of N-substitution pattern. 
 
  
22 [RuCl2(p-cymene)]2 AgSbF6 AgOTFA TFE 40 16 NR 
23 [RuCl2(p-cymene)]2 AgNTf2
[c] AgOAc TFE 40 16 63 
24[b] Ru(OAc)2(p-cymene) AgSbF6 -- TFE 40 16 64 
25[b] Ru(OAc)2(p-cymene) AgSbF6 -- TFE 40 24 78 
26[b] Ru(OAc)2(p-cymene) AgSbF6 -- TFE 60 24 48 
[a] Reaction condition: 390 (0.25 mmol), 391 (0.75 mmol), [Ru] (5.0 mol %), additive 1 (20 mol %), 
additive 2 (50 mol %), solvent (1.0 mL), isolated yield. [b] [Ru] (10 mol %). [c] Price comparison (in 
Sigma-Aldrich): AgSbF6: $60.10/5g, AgNTF2: $476.00/5g. 
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3.1.2 Substrate Scope 
With the optimized reaction conditions in hand, the scope of the C7–H functionalization was explored 
with various indoles 390 and organic azides 391 (Scheme 3.1.3). Differently substituted indoles 390 
bearing alkyl and alkoxy groups at the C3-, C4-, C5-, and C6-position were site-selectively 
transformed into the desired C7–H nitrogenated products. It is noteworthy that indole 390e having 
labile aldehyde group was efficiently transformed to the desired product 392e and synthetically 
valuable halogen functional groups were tolerated under the optimized reaction conditions (392d, 
392g–392k). The ruthenium(II)biscarboxylate-catalyzed C7–H activation also tolerated various azides 
bearing arenesulfonyl (392l–392m) and alkanesulfonyl groups (392n–392o).  
 
 
Scheme 3.1.3 Scope of ruthenium-catalyzed C7–N formation of indoles 390. 
 
  
Results and Discussion 
79 
 
The robustness of the ruthenium(II)-catalyzed C7–H activation was further reflected by the C7–H 
alkenylation of N-pivaloyl indoles 390 with acrylates 393 through a redox process (Scheme 3.1.4). 
Thus, the site-selective alkenylated products 394 were efficiently obtained under slightly modified 
reaction conditions using copper(II) acetate as the oxidant. A variety of substituted indoles 390 bearing 
alkyl or halogen groups and different acrylates 393 were fully tolerated, thus efficiently giving into the 
desired indole-7-alkenyl derivatives 394 with excellent site-selectivity. 
 
 
Scheme 3.1.4 Scope of ruthenium-catalyzed C7–C bond formation of indoles 390. 
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3.1.3 Investigations of Practical Utility 
The traceless removal of the N-pivaloyl motif was performed to showcase the practical utility into the 
established carboxylate-assisted ruthenium(II)-catalyzed C7–H activation (Scheme 3.1.5). Thus, the 
pivaloyl orienting group was readily removed at room temperature. It is noteworthy that the traceless 
removal of N-pivaloyl directing group could also sequentially be carried out in a one-pot strategy. 
 
 
Scheme 3.1.5 The traceless removal of N-pivaloyl orienting group and a one-pot process. 
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Additionally, the ruthenium(II)-catalyzed C7–H amidation and alkenylation could be easily conducted 
on a gram scale without significant loss of catalytic efficacy, thereby highlighting the robustness of the 
ruthenium(II)biscarboxylate catalysis (Scheme 3.1.6). 
 
 
Scheme 3.1.6 Gram-scale C7–H indole activations. 
 
Flow technology provides organic chemists with tremendous benefits, including an improved heat and 
mass transfer, reaction safeness, and scalability.[221] The C7–H activation of indoles was indeed 
demonstrated in a flow set-up, giving the desired amidated product 392 without loss of efficiency and 
selectivity at shortened reaction time (Scheme 3.1.7). 
 
 
Scheme 3.1.7 Scalable flow reaction for C7–H amidation of indole. 
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3.1.4 Mechanistic Studies 
Given the unique robustness, broad applicability, and synthetic utility of the unprecedented 
carboxylate-assisted ruthenium(II)-catalyzed C7–H activation, we became interested in delineating its 
mode of action. To this end, intermolecular competition experiments with differently substituted N-
pivaloyl indoles 390 were conducted (Scheme 3.1.8). Thus, electron-rich substrate possessed an 
inherent higher reactivity, proposing that a concerted metalation deprotonation (CMD) less likely, 
while providing support for a base-assisted internal electrophile-type substitution (BIES) manifold.[23] 
 
 
Scheme 3.1.8 Competition experiment. 
 
The Hammett equation exhibits a linear free-energy relationship between two reactions that only differ 
in the substituents. Thus, a substituent constant and the reaction constant become the parameter of the 
x and the y axis, respectively, which enables to derive the ρ value. Here, a Hammett correlation was 
found in electronically different substrates which have a substituent in meta-position to the reaction 
center where C–H bond cleavage occurs, showing that electrophilic mechanism might occur in the C–
H scission step (Scheme 3.1.9). 
 
  
























Scheme 3.1.9 Independent reactions for Hammett plot analysis. 
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Furthermore, we performed the C7–H activation in the presence of isotopically labeled TFE (Scheme 
3.1.10). H/D-scrambling in the C7- and C2-position was observed in the absence of substrate 391a, 
indicating the reversible nature of the C–H bond cleavage event. Also, a H/D exchange experiment in 
the presence of 391a provided evidence for a facile C–H cleavage.  
 
 
Scheme 3.1.10 H/D exchange studies. 
 
Subsequently, independent reactions performed with substrate 390a and isotopically labeled 
compound [D]4-390a showed a primary kinetic isotope effect (KIE) of kH/kD ≈ 1.1, giving a support 
for a fast C7–H scission (Scheme 3.1.11). 
 
 
Scheme 3.1.11 KIE study. 
 
In good agreement with this finding, detailed kinetic experiments unraveled a zero-order dependence 
of the reaction rate on the N-pivaloyl indole 390a, while a first-order dependence was observed for the 
concentration of the tosyl azide 391a as well as the catalyst Ru(OAc)2(p-cymene) (Scheme 3.1.12).  







Scheme 3.1.12 Detailed kinetic experiments. 
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3.1.5 Proposed Catalytic Cycle 
On the basis of our detailed experimental mechanistic studies, a plausible catalytic cycle for the 
carboxylate-assisted ruthenium(II)-catalyzed C7–H indole activation is proposed in Scheme 3.1.13. 
The mechanism rationale commences with the coordination of substrate 391a to the active ruthenium 
catalyst 419 to form ruthenium amide intermediate 420, which previously has been often described as 
the latter step after C–H activation. C–H activation occurs through a BIES mechanism, preferentially 
leading to ruthenium(II) species 423 rather than 422. The intermediate 423 is transformed to 
ruthenium(II) amido intermediate 424 via amido insertion. Finally, a proto-demetalation affords 
product 392 and regenerates the active catalyst 419. 
 
 
Scheme 3.1.13 Proposed catalytic cycle. 
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3.2 Ruthenium(II)-Catalyzed C4/C6–H Dual Alkylations of Indoles 
The C2–H and C3–H bonds of indoles has been widely modified by both direct and directed C−H 
functionalization methods.[222, 219] In sharp contrast, site-selective C−H functionalization on the 
benzenoid ring has remained challenging. Particularly, C4–H or C6–H functionalized indole scaffolds 
exhibit noteworthy medical or agrochemical properties (Scheme 3.2.1).[223] As a consequence, there is 
a continued interest for general strategies providing easy access to C4/C6-substituted indoles in a 
sustainable fashion.  
 
 
Scheme 3.2.1 Bioactive compounds with C4/C6 functionalized indoles. 
 
While different methods have provided access to C4 and C6-functionalized indoles by Prabhu,[224] 
Shi,[225] Yu,[226] and Baran[227] among others,[228] challenging dual functionalizations of C4– and C6–H 
bonds of indoles have thus far remained elusive. 
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3.2.1 Optimization Studies  
At the outset, various reaction conditions were probed for the envisioned ruthenium(II)-catalyzed 
C4/C6–H alkylations of indole 395 with ethyl 2-bromoisobutyrate (396) (Table 3.2.1). In the initial 
studies with RuCl2(PPh3)(p-cymene) as the catalyst, the C3-alkylated product 425 was formed as a by-
product, likely obtained via electrophilic substitution (entry 1). While KOAc as the base was crucial 
to obtain a good conversion in the absence of acetic acid (entries 2–3), C3-alkylated product 425 was 
still observed. Thus, we focused our optimization towards reducing the formation of the C3-
functionalized product 425, while increasing the desired C4/C6–H alkylated product 397. Although 
arene-liand-free ruthenium complex RuCl2(PPh3)3 with different bases showed a poor reactivity 
(entries 4–6), Ru(OAc)2(PPh3)2 demonstrated effective conversion to the desired product 397 (entry 
7). Among various bases, such as acetates (entries 7–10), carbonate (entry 11), and phosphate (entry 
12), NaOAc gave the most effective reactivity while reducing the formation of by-product 425 (entry 
8). Furthermore, among a variety of solvents, DCE proved to be the most efficient for C4/C6–H 
alkylation (entries 13–16). Interestingly, as the reaction temperature was decreased, both the reactivity 
and the selectivity were significantly improved (entries 16–20). Although the arene-containing 
ruthenium catalyst was again probed under the optimized conditions, it afforded a less satisfactory 
result, highlighting the unique feature of arene-ligand-free ruthenium catalysis (entry 21). 
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Table 3.2.1 Optimization of the ruthenium(II)-catalyzed dual alkylation[a] 
 
 




395 425 397 
1 RuCl2PPh3(p-cymene) HOAc KOAc THF 120 trace 19 58 
2 RuCl2PPh3(p-cymene) -- KOAc THF 120 4 23 58 
3 RuCl2PPh3(p-cymene) HOAc -- THF 120 94 0 0 
4 RuCl2(PPh3)3 -- KOAc THF 120 82 trace 5 
5 RuCl2(PPh3)3 -- K2CO3 THF 120 76 2 14 
6 RuCl2(PPh3)3 -- K3PO4 THF 120 70 3 15 
7 Ru(OAc)2(PPh3)2 -- KOAc THF 120 26 13 43 
8 Ru(OAc)2(PPh3)2 -- NaOAc THF 120 32 4 46 
9 Ru(OAc)2(PPh3)2 -- LiOAc THF 120 80 trace 16 
10 Ru(OAc)2(PPh3)2 -- CsOAc THF 120 84 4 10 
11 Ru(OAc)2(PPh3)2  K2CO3 THF 120 85 3 trace 
12 Ru(OAc)2(PPh3)2  K3PO4 THF 120 86 trace trace 
13 Ru(OAc)2(PPh3)2 -- NaOAc 1,4-dioxane 120 8 33 53 
14 Ru(OAc)2(PPh3)2 -- NaOAc PhMe 120 0 23 50 
15 Ru(OAc)2(PPh3)2 -- NaOAc PhCF3 120 0 21 59 
16 Ru(OAc)2(PPh3)2 -- NaOAc DCE 120 0 8 63 
17 Ru(OAc)2(PPh3)2 -- NaOAc DCE 100 0 12 65 
18 Ru(OAc)2(PPh3)2 -- NaOAc DCE 80 0 11 72 
19 Ru(OAc)2(PPh3)2 -- NaOAc DCE 70 0 4 80 (77) 
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20 Ru(OAc)2(PPh3)2 -- NaOAc DCE 60 58 10 24 
21 RuCl2PPh3(p-cymene) -- NaOAc DCE 70 64 5 4 
[a] Reaction condition: 395 (0.25 mmol), 396 (1.25 mmol), [Ru] (10 mol %). Yields were determined 
by 1H NMR with CH2Br2 as an internal standard. Isolated yield in the parenthesis. 
 
Thereafter, we examined the effect of the N-substituent pattern in indoles 395 on the outcome of the 
reaction (Scheme 3.2.2). Hence, indoles 395 with a variety of orienting groups, such as pyridine (395a) 
amides (395b) and (395c), phosphine oxide (395d), and phosphine (395e), as well as free-indole (395f) 
were subjected to the established reaction conditions for the C4/C6−H distal functionalizations of the 
heterocycle. Interestingly, only the pyridine group afforded the desired C4/C6–H alkylation product 
397, clearly demonstrating the unique ability of the pyridine directing group in this transformation. 
These results illustrated the importance of the five-membered ruthenacycles formation by the N(sp2)-
group for allowing for C4/C6–H double functionalizations. 
 
 
Scheme 3.2.2 Examination of N-substitution pattern. 
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3.2.2 Substrate Scope 
With the optimal reaction conditions in hand, we next explored the versatility of the C4/C6–H 
functionalization with a set of representative indoles 395 and alkyl bromides 396 (Scheme 3.2.3). 
Indeed, alkyl bromides 396 having different types of alkyl groups were selectively transformed into 
the desired C4/C6–H double alkylated products 397. Notably, a synthetically valuable aryl iodide was 
fully tolerated under the reaction conditions. It is noteworthy that the reaction could be easily 
conducted on a gram scale without significant loss of catalytic efficacy.  
 
Scheme 3.2.3 C4–H/C6–H alkylations with differently substituted alkyl bromides 396. 
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This reaction manifold was further extended to exploit natural product-derived alkyl bromides, 
including menthol 396k, rose oil 396l, estrone 396m, and galactopyranose 396n, providing selectively 
C4–H and C6–H dual functionalized indoles 397k–397n without racemization (Scheme 3.2.4).  
 
 
Scheme 3.2.4 Dual C–H alkylations of indoles 395 with natural product motifs. 
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3.2.3 Mechanistic Studies  
Given the unique features of the unprecedented arene-ligand-free ruthenium-catalyzed dual C4/C6–H 
alkylations, we became interested in deciphering its mode of action (Scheme 3.2.4). To this end, we 
performed the C4/C6–H alkylation in the presence of isotopically labeled D2O under the optimized 
reaction conditions (Scheme 3.2.5a). Hence, H/D-scrambling was only observed in the C2– and C3–
H positions, while the C7–H position was not deuterated. This finding clearly proved that C2–H bond 
scission occurs in a reversible fashion and indicates that C4/C6–H double alkylations were presumably 
governed by the C2-ruthenation event. Further experiments showed that the C7–H blocked substrate 
395b efficiently underwent the C4/C6–H alkylation process, showing a C7-metallation-initiated distal-
functionalization unlikely to be operative (Scheme 3.2.5b). 
 
 
Scheme 3.2.5 Mechanistic investigations for C4/C6–H functionalizations. 
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3.3 Osmium-Catalyzed Electrooxidative C–H Annulations 
Carboxylate-assisted[20a] oxidative C–H annulations by weak O-coordination have been realized by 
consecutive C–H and O–H bond scission of aromatic carboxylic acids. With pioneering contributions 
in rhodium, ruthenium, and iridium catalysis by Miura/Satoh,[229] Ackermann,[230] and Ison[231] among 
others,[232] the modular assembly of five- or six-membered heterocycles has been established.[233, 215d]  
However, these reactions require the additional use of stoichiometric chemical oxidants, such as 
copper(II) or silver(I) salts, to facilitate the redox processes. To overcome this disadvantage, 
metallaelectrocatalysis has recently emerged as a sustainable platform.[234a-d, 1a, 234e-n] Specifically, C–
H activations enabled by electricity, facilitating the crucial catalysts reoxidation by an anodic event, 
allowed for a variety of oxidative chemical transformations, thus avoiding cost-intensive or toxic 
chemical oxidants.[235] Recently, Ackermann[236] and others[237] have developed electrooxidative C–H 
annulations by ruthenium, rhodium, and iridium catalysts (Scheme 3.3.1). 
 
 
Scheme 3.3.1 Timeline of C–H annulations by rhodium(III), ruthenium(II), and iridium(III) catalysis: 
chemical oxidants versus electrocatalysis. 
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3.3.1 Optimization Studies  
Reaction conditions for osmium(II)-catalyzed oxidative C–H activations were tested with o-toluic acid 
(398) and n-butyl acrylate (399) in an undivided cell setup with a graphite felt (GF) anode and a 
platinum plate cathode (Table 3.3.1). We were delighted to observe that the desired annulated product 
400 was obtained in 75 % yield in HFIP and H2O as the solvent mixture along with the use of KI as 
an additive (entry 1). A variety of additives, such as representative redox mediators (entries 2–4), alkali 
metal-based salts (entries 5–8), organic salts (entry 9), and iodine (entry 10), were subjected to the 
osmaelectro-catalyzed C–H annulation. Here, non-toxic and inexpensive KI provided optimal 
efficiency, while the increased amount of KI did not result in the increase of the yield. Other bases, 
such as NaOAc or NaOPiv, gave lower reactivity (entries 12–13). Interestingly, while the rhodium and 
the iridium catalyst which were used for analogous reactions did not provide satisfactory results, the 
use of the ruthenium catalyst afforded a higher yield than the osmium catalyst (entries 17–19). Control 
experiments highlighted the importance of the catalyst, electricity, and the additive for electrooxidative 
C–H annulation reaction (entries 20–22). 
 
Table 3.3.1 Optimization of the osmium(II)-catalyzed electrooxidative C–H activation[a] 
 
 
Entry Base Additive Solvent (ratio) Temp (°C) Yield (%) 
1 KOAc KI HFIP/H2O (1/1) 100 77 (75) 
2 KOAc BQ HFIP/H2O (1/1) 100 0 
3 KOAc Fc HFIP/H2O (1/1) 100 0 
4 KOAc HOBt HFIP/H2O (1/1) 100 0 
5 KOAc NaI HFIP/H2O (1/1) 100 29 
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6 KOAc KPF6 HFIP/H2O (1/1) 100 38 
7 KOAc KSbF6 HFIP/H2O (1/1) 100 54 
8 KOAc NaSbF6 HFIP/H2O (1/1) 100 60 
9 KOAc nBuN4I HFIP/H2O (1/1) 100 20 
10 KOAc I2 HFIP/H2O (1/1) 100 23 
11 KOAc KI HFIP/H2O (1/1) 100 76
[b] 
12 NOAc KI HFIP/H2O (1/1) 100 36 
13 NOPiv KI HFIP/H2O (1/1) 100 38 
14 KOAc KI HFIP/H2O (1/1) 60 35 
15 KOAc KI HFIP/H2O (1/1) 25 0 
16 KOAc KI HFIP/H2O (3/1) 100 76 
17 KOAc KI HFIP/H2O (1/1) 100 7
[c] 
18 KOAc KI HFIP/H2O (1/1) 100 16
[d] 
19 KOAc KI HFIP/H2O (1/1) 100 90
[e] 
20 KOAc KI HFIP/H2O (1/1) 100 0
[f] 
21 KOAc KI HFIP/H2O (1/1) 100 6
[g] 
22 KOAc -- HFIP/H2O (1/1) 100 11 
[a] Reaction conditions: 398 (0.20 mmol), 399 (0.60 mmol), [OsCl2(p-cymene)]2 (5.0 mol %), base 
(2.0 equiv), additive (2.0 equiv), solvent mixture (4.0 mL), 100 °C, 16 h. Yield was determined by 
1H NMR with CH2Br2 as the internal standard. Yield in the parenthesis is isolated yield. [b] KI (4.0 
equiv) was used. [c] [Cp*RhCl2]2 (2.5 mol %) was used. [d] [Cp*IrCl2]2 (2.5 mol %) was used. [e] 
[RuCl2(p-cymene)]2 (5.0 mol %) was used. [f] Without catalyst. [g] Without electricity. The reaction 
was equipped with electrodes, but no electricity. GF = Graphite Felt. HFIP = Hexafluoroisopropyl 
alcohol. BQ = Benzoquinone. Fc = Ferrocene. HOBt = Hydroxybenzotriazole. 
 
To highlight the advantages of the electrochemical approach, a set of experiments were carried out 
under air or with commonly employed chemical oxidants, such as AgOAc, Cu(OAc)2, Mn(OAc)3, 
PhI(OAc)2, or K2S2O8 (Scheme 3.3.2). All of the attempts met with unsatisfactory results, showing 
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that electricity not only played a crucial role in sustainable oxidation, but also gave optimal and unique 
















Scheme 3.3.2 Comparison between electricity and representative chemical oxidants. 
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3.3.2 Substrate Scope 
Next, we explored the viable substrate scope of the electrochemical osmium-catalyzed [4+1] and [4+2] 
C–H/O–H annulations of benzoic acids 398 with alkenes 399 and alkynes 400 (Scheme 3.3.3). A wide 
range of benzoic acids gave the desired heterocycles, fully tolerating valuable functional groups, such 
as halides (400d, 400f, 400g, 400m, 400n, 400o, and 400p) or basic amines (400i and 400q). Notably, 
the C–H activation with the substrate having two competing olefins selectively afforded a single 
annulated product 400x.  
 
 
Scheme 3.3.3 Substrate scope for electrooxidative osmium-catalyzed [4+1] annulations. 
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The annulation manifold was not limited to the assembly of five-membered rings, but six-membered 
heterocycle assembly with differently-substituted alkynes 401 was also found to be viable, thus 
providing the extension of conjugated π-system. Thereby, differently substituted alkynes 401 having 
alkyl (402a), methoxy (402c) or halides (402d) groups were fully acceptable by the optimized osmium 
catalysis (Scheme 3.3.4).  
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3.1.3 Site-Selectivity Studies 
Inspired by the unprecedented reactivity, we were interested to interrogate the selectivity feature 
(Figure 3.3.5). To this end, we performed a series of metallaelectro-catalyzed reactions with benzoic 
acid 398b possessing two accessible ortho-C–H bonds. First, we assessed the catalysts that were 
already used for the electrooxidative C–H annulation reactions. Thus, the rhodium, iridium, and 
ruthenium catalysts were examined, giving 68%/13% (5.2:1), 74%/10% (7.4:1), and 59%/9% (6.3:1) 
of mono- and difunctionalized product 400b and 426, respectively. In sharp contrast, the use of the 
osmium electrocatalysis showed a significantly improved mono-selectivity. 
 
 
Scheme 3.3.5 Selectivity comparisons by different catalysis. 
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The excellent chemo-selectivity was also observed in the H/D scrambling experiments in the presence 
of an isotopically labelled solvent (Scheme 3.3.6). Ruthenium dimer [RuCl2(p-cymene)]2 showed 
comparable deuterations on C2–H and C6–H of 3-trifluoromethyl benzoic acid (398h) with and 
without n-butyl acrylate (399a). However, the osmium-electrocatalysis provided significantly 
increased deuteration at the C6–H position as compared to sterically hindered C2–H position.  
 
 
Scheme 3.3.6 Reaction comparisons for H/D exchange experiments. 
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3.3.4 Mechanistic Studies 
Subsequently, we set out to study the working mode of the electrooxidative osmium-catalyzed C–H 
activation. To this end, novel key intermediates, 430 and 431, were independently prepared (Scheme 
3.3.7). It is noteworthy that these osmium complexes have not been obtained earlier and the structures 
were characterized by X-ray crystallographic analyses.  
 
 
Scheme 3.3.7 Synthesis of osmacomplexes and their X-ray structures. 
 
The thus synthesized osmium complexes were found to be competent to afford the desired products 
400s and 402a in both stoichiometric and catalytic reactions (Scheme 3.3.8). The five-membered 
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osmium complex 430 was transformed to the desired product under the optimized conditions, while 
osmium(0) sandwich complex was converted to the annulated product in the presence of KI or NaSbF6. 
The synthesized osmium complex 430 was also used as a catalyst, providing the [4+1] or [4+2] 
cycloadditions product under the optimized conditions. 
 
 
Scheme 3.3.8 Stoichiometric and catalytic reactions with the synthesized osmacomplexes 430–431. 
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Furthermore, with the assistance of Dr. Antonis M. Messinis of the Ackermann group, high resolution-
electrospray ionization-mass spectrometric (HR-ESI-MS) analysis was performed, demonstrating the 











Scheme 3.3.9 HR-ESI-MS study of electrooxidative osmium-catalyzed C–H annulation. 
 
By detailed investigation of the isotopic patterns, we could analyze each component, in which red, 
blue, green, and purple bars correspond to the annulation product 402a, the cyclometalated osmium 
intermediate 432, the sandwich osmium(0) intermediate 431 with its possible isomers, and alkyne-
coordinated osmium intermediate 433, respectively (Scheme 3.3.10).  




Scheme 3.3.10 Investigation of the isotopic patterns from HR-ESI-MS study. 
 
Additionally, Dr. Antonis M. Messinis of the Ackermann group performed in-operando NMR studies 
with the isolated osmium complex 430 and alkyne 401a, which highlighted the formation of the 
osmium(0) sandwich complex, along with the consumption of complex 430 and alkyne 401a (Scheme 
3.3.11). Here, we were not able to observe an induction period and the seven-membered intermediate 
formed by the migratory insertion of alkyne 401a was hardly observed. These results presumably 
suggest the facile formation of the osmium(0) complex 431 after the insertion step.  
 
 
Scheme 3.3.11 In-operando NMR study with osmacomplex 430 and alkyne 401a. 
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Thereafter, Xiaoyan Hou of the Ackermann group performed cyclic voltammetric analysis for the 
oxidation potential of the osmium(0) sandwich complex 431, showing that the oxidation event 
occurred at E = 0.58 V vs. Fc/Fc+ (Scheme 3.3.12). This oxidation potential is slightly lower than the 




Scheme 3.3.12 Cyclic voltammetry measurement. 
 
Next, an intermolecular competition experiment with differently substituted benzoic acids (398e and 
398h) was carried out (Scheme 3.3.13a). The competition experiment showed that electron-donating 
groups on the benzoic acid 398e resulted in a higher reactivity, suggesting a BIES mechanism.[238a, 238b, 
24a, 238c] Additionally, an intermolecular competition experiment with differently substituted alkynes 
401a and 401d was also performed (Scheme 3.3.13b), in which an alkyne 401a having electron-
donating groups afforded less product.   
431 
KI 
KI + 431 




Scheme 3.3.13 Competition experiments. 
 
A series of reactions with differently decorated benzoic acids in the meta-position to the C–H bond to 
be cleaved provided a linear Hammett correlation with a negative ρ value (Scheme 3.3.14). This result 
indicates that an electrophilic mechanism is likely operative in the C–H cleavage.  
























Scheme 3.3.14 Hammett correlation. 
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Subsequently, an intermolecular competition experiment and a pair of parallel reactions were 
performed with o-toluic acid 398a and the isotopically labelled compound [D]7-398a to determine the 
kinetic isotope effect (Scheme 3.3.15). In both cases, a negligible KIE of kH/kD ≈ 1.1 and 1.2 were 
observed, respectively, suggesting a facile C–H scission. 
 
 
Scheme 3.3.15 Experiments for kinetic isotope effect. 
 
On the basis of our mechanistic findings, a plausible catalytic cycle for the osmaelectro-catalyzed C–
H activation is depicted in Scheme 3.3.16. The mechanistic rationale commences with a facile C−H 
bond cleavage, which gives osmacycle 434. Thereafter, migratory insertion of alkenes 399 or alkynes 
401 occurs, which enables the formation of intermediate 435 or 437, respectively. Next, reductive 
elimination delivers osmium(0) sandwich complex 436 or 438. Finally, the key anodic oxidation 
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3.4 Photo-Induced C–H Arylation by Reusable Heterogeneous Copper Catalyst 
Recently, significant progress was realized in C–H activation chemistry with the aid of Earth-abundant, 
cost-effective 3d metal catalysts.[216] Among the 3d metals, copper has emerged as a viable metal for 
C–H activation.[152b, 155c, 189g, 239] Particularly, copper-catalyzed C–H arylations have been extensively 
investigated with notable contributions by Daugulis,[160, 161, 162] Miura[240] and Ackermann,[163] among 
others. Despite these major advances, copper-catalyzed C–H activation with aryl halides has been 
severely restricted by their harsh reaction conditions with reaction temperatures commonly ranging 
from 120 to 160 °C. 
In recent years, photocatalysis[241] has been identified as an increasingly powerful approach towards 
various sustainable organic syntheses,[242] such as C–N bond formations, immensely elaborated by 
Fu,[243] MacMillan,[244] and Kobayashi.[245] Thus, Photoredox-catalyzed C–H functionalizations proved 
viable, albeit predominantly relying on precious transition metals, such as rhodium, palladium, and 
ruthenium complexes.[94, 246] In contrast, the Ackermann group has very recently devised photo-
induced C–H arylations and chalcogenations by less toxic base metal catalysts.[247, 169] In spite of 
notable progress, photo-induced organometallic C–H activations were thus far limited to homogeneous 
catalysis, often leading to undesired trace metal impurities in the target products, and, more importantly, 
inherently preventing the catalysts from their reuse. While selected silica-supported catalysts[204a, 248a-
c, 192h, 248d-f, 204b, 193b, 193m, 248g, 248h] were developed by Jones/Davies[208, 249, 206] and Sawamura[250] with 
non-excited-state reactivity, heterogeneous catalysis for photo-induced C–H activation has thus far 
unfortunately proven elusive.  
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3.4.1 Preparation of Hybrid Copper Catalyst  
The hybrid copper catalyst 406 was synthesized by a modified procedure from Christopher’s study 
(Scheme 3.4.1).[249a] To construct a linker, LDA deprotonated a C–H bond of a methyl group of 4,4’-
dimethyl-2,2’-dipyridyl (439), which underwent a substitution reaction with (3-chloropropyl)trime-
thoxysilane (440). The thus synthesized linker 441 was grafted on SBA-15 in toluene by heating, 
giving the tethered linker 442. Since the covalently anchored linker 442 contains hydroxyl groups on 
the surface, the end-capping procedure was subsequently carried out with hexamethyldisilazane, 
providing the globally protected hydroxyl groups. Lastly, CuI was used as a catalyst precursor for the 
metallation step, thus generating hybrid copper catalyst 406. 
 
 
Scheme 3.4.1 Preparation of hybrid copper catalyst. 
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3.4.2 Optimization Studies  
Next, we probed representative reaction conditions for the envisioned C–H arylation of heteroarenes 
using the hybrid copper catalyst 406 (Table 3.4.1). Thereby, the desired C–H arylated product 405 was 
obtained under mild photo-induced conditions (entry 1). The re-isolated hybrid copper catalyst 406 
was used for the next run to test the reusability and provided a comparable result to the initial run 
(entry 2). While the sole use of copper iodide fell short in efficiently delivering the desired product 
(entry 3), the mixture of copper iodide and the bipyridine ligand 439 or the tethered linker 443 provided 
a lower reactivity (entries 4–5). The thus optimized hybrid catalyst was efficiently employed in the 
reaction with benzoxazoles 444, showing the robustness of photo-induced hybrid copper-catalyzed C–
H arylations (entry 6). Control experiments, excluding key reaction components, highlighted the 
essential role of the hybrid copper catalyst 406 as well as of the light source for C–H the arylation 
(entries 7–9).  
 
Table 3.4.1 Optimization of photo-induced C–H arylation by reusable heterogeneous copper catalyst[a] 
 
Entry Deviation from the standard reaction conditions Yield (%) 
1 None 93[b] 
2 reused catalyst of entry 1 406 85[b] 
3 CuI instead of 406 58 
4 CuI + 4,4’-dimethyl-2,2’-dipyridyl instead 439 of 406 50 
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5 CuI + 443 instead of 406 36[c] 
6 Benzoxazole 444 instead of 403 79 
7 Only 443 instead of 406 Trace 
8 Without hybrid copper catalyst 406 Trace 
9 Without light Trace 
[a] Reaction conditions: 403 (0.25 mmol), 404 (1.25 mmol), 405 (11 mol %), LiOtBu (0.75 mmol), 
Et2O (0.5 mL), 254 nm, RT, 24 h, isolated yield. 
[b] Average yield over two runs. [c] 25 mg of 443 
was used. 
 
Interestingly, the versatile photo-induced hybrid copper-catalyzed C–H arylation was not limited to 
the azole-based heterocycles 403 and 444, having a relatively acidic C2–H bond, but N-methyl 
benzimidazole 445 was also found to be a viable substrate under slightly changed reaction conditions, 
where K3PO4 and THF were used as a base and solvent, respectively (Table 3.4.2).  
 
Table 3.4.2 Optimization of photo-induced C–H arylation of N-methyl benzimidazole 445[a] 
 
 
Entry Base Solvent Yield (%) 
1 LiOtBu DMF 0 
2 K3PO4 DMF 12 
3 K3PO4 1,4-dioxane trace 
4 K3PO4 THF 70
[b] 
5 K3PO4 THF 61
[c] 
[a] Reaction conditions: 445 (0.25 mmol), 404b (1.25 mmol), 406 (11 mol %), base (0.75 mmol), 
solvent (1.0 mL), 254 nm, RT, 24 h, isolated yield. [b] Average yield over two runs. [c] With the 
reused 406. 
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Additionally, the photo-induced heterogeneous C–H arylation manifold could be extended to the use 
of more cost-effective aryl bromides 447 (Table 3.4.3). Among various attempts employing different 
bases, Cs2CO3 proved most efficient, affording 59% of C–H arylated product 446 under photo-induced 
conditions, and a subsequent reaction with the re-isolated hybrid copper catalyst 406 provided only a 
slightly lower yield. The use of relatively weak carbonate bases should prove instrumental for 
applications to substrates with sensitive functional groups.  
 
Table 3.4.3 Optimization of photo-induced C–H arylation with aryl bromide 447[a] 
 
Entry Base Solvent Yield (%) 
1 LiOtBu Et2O 0 
2 KOtBu Et2O 0 
3 Li2CO3 Et2O trace 
4 Na2CO3 Et2O trace 
5 K2CO3 Et2O 21 
6 Cs2CO3 Et2O 59
[b] 
7 Cs2CO3 Et2O 47
[c] 
[a] Reaction conditions: 445 (0.25 mmol), 447 (1.25 mmol), 406 (11 mol %), base (0.75 mmol), 
solvent (1.0 mL), 254 nm, RT, 24 h, isolated yield. [b] Average yield over two runs. [c] With the 
reused 406. 
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3.4.3 Substrate Scope 
We explored the versatility of the hybrid copper catalysis for the photo-induced C–H arylation of 
thiazoles 403 with diversely substituted aryl iodides 404 (Scheme 3.4.2). Thus, we gladly observed 
high functional group tolerance, including both electron-rich and electron-deficient aryl halides. 
Particularly, valuable halide functional groups, such as bromo or chloro arenes, remained unreacted, 
thereby providing high chemoselectivity for C–H arylations.  
 
 
Scheme 3.4.2 Scope of hybrid copper-catalyzed C–H arylation of (benzo)thiazoles 403 with aryl 
iodide 404. 
 
The hybrid copper catalysis manifold was also demonstrated with (benz)oxazoles 444 under photo-
induced conditions (Scheme 3.4.3). Likewise, a wide range of functional groups tolerance was depicted 
with a set of diversely decorated aryl iodides 404. Notably, with this approach, facile and sustainable 
access to the alkaloid natural product texamine 447m was realized.   
 




Scheme 3.4.3 Substrate scope for heterogeneous photo-induced C–H arylation of (benz)oxazole 444. 
 
The heterogeneous photocatalysis for C–H arylation of N-methyl benzimidazoles 445 efficiently 
provided the C2–H arylated products 446 with a variety of aryl iodides 404 (Scheme 3.4.4). Besides 
valuable halides groups, this catalytic system tolerated sensitive functional groups, such as ketones 
446e and ester 446f, by the use of the weak base K3PO4 instead of LiOtBu. Additionally, a steroid 
derivative was converted to the arylated product 446j by the photo-induced hybrid copper catalysis. 
 
 
Scheme 3.4.4 Hybrid copper-catalyzed C–H arylations of N-methyl benzimidazole 445. 
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Under the slightly modified condition, aryl bromides 447 were fully acceptable for the direct arylation 
by the heterogeneous photocatalysis (Scheme 3.4.5). Interestingly, benzothiazole 403 and N-methyl 
benzimidazoles 445 were transformed to the arylated products 405 and 446, respectively. Consequently, 
the robustness of the photo-induced C–H arylation by hybrid-copper catalyst was shown by mild and 
sustainable catalysis along with ample substrate scope. 
 
 
Scheme 3.4.5 Photo-induced hybrid copper-catalyzed C–H arylations with aryl bromides 447. 
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3.4.4 Mechanistic Studies 
To gain mechanistic insights, an intermolecular competition experiment was performed with 
differently substituted aryl iodides 404c and 404e (Scheme 3.4.6) Here, it was found that the electron-
deficient aryl iodide 404 underwent faster direct arylation. This result suggests the oxidative addition 
of the aryl halide onto the copper(I) intermediate to be rate-determining.  
 
 
Scheme 3.4.6 Intermolecular competition experiment. 
 
Furthermore, the reaction in the presence of representative radical scavenger TEMPO probed a SET-
type regime by resulting in significant inhibition of the photo-induced hybrid-copper catalysis for C–
H arylation (Scheme 3.4.7). 
 
 
Scheme 3.4.7 Radical experiment. 
 
Finally, we probed the photo-induced C–H arylation by an on-off experiment, in which the light source 
was turned off every two hours. This study highlighted that the hybrid-copper-catalyzed C–H arylation 
was fully suppressed in the absence of light, and simultaneously showed that constant irradiation is 
required for effective product formation (Scheme 3.4.8). 
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3.4.5 Heterogeneity Studies 
Next, we became intrigued to probing potential reusable nature. We were delighted to observe that the 
hybrid copper catalyst 406 could be recycled without a significant loss of catalytic efficacy over the 
five runs of the reaction (Scheme 3.4.9). Especially, this approach enabled us to construct the natural 
product 447m in a sustainable fashion. Within a collaboration with Dr. Volker Karius, a ICP-OES 
analysis of the reaction mixture was performed, thus revealing that less than 4 ppm of copper was 
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Scheme 3.4.9 Reuse test for the hybrid-copper catalyzed photo-induced C–H arylation. 
 
Additionally, the reusability was also demonstrated in a gram-scale reaction (Scheme 3.4.10a). The 
classical heterogeneity experiment, a filtration test (Scheme 3.4.10b), was performed, reflecting 
homogeneous catalysis not to be operative. 




Scheme 3.4.10 Reuse test and filtration test. 
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3.4.6 Characterization of Hybrid Copper Catalyst 
In a collaboration with Prof. Dr. Wolfgang Viöl and Dr. Robert Köhler, X-ray photoelectron 
spectroscopic analysis was performed (Scheme 3.4.11). In this study, the Cu 2p3/2 peak was 
investigated for the determination of the oxidation state of copper. The peaks of the hybrid copper 
catalyst 406 and the reused hybrid copper catalyst were located at 932.6 eV, indicating the presence of 
either Cu(0) or Cu(I). For the differentiation of Cu(0) and Cu(I), the Cu LMM-Auger peak was 
additionally analyzed. The measured Cu LMM peaks were compared with the reported results, which 
clearly revealed Cu(I) of the oxidation state of hybrid copper catalyst 406 as well as the reused hybrid 
copper catalyst. These results showed that the oxidation state of the hybrid catalyst was not changed 
after the photo-induced C–H arylation reaction. 
 
 
Scheme 3.4.11 X-ray photoelectron spectroscopic (XPS) analysis of 406 and reused 406. 
 
In a collaboration with Prof. Dr. Christian Jooss and Gaurav Lole, detailed transmission electron 
microscopic studies were performed (Scheme 3.4.12). Thereby, SBA-15, 443, the hybrid copper 
catalyst 406, and the reused hybrid copper catalyst were subjected to the microscopic analyses. TEM 
images of the SBA-15 and 406 showed homogenously ordered one-dimensional mesoporous channels 
with homogeneous morphology, which was observed by the striped contrast with the average distance 
of 10.2 nm between the centers of the one-dimensional mesoporous channel and its adjacent channel 
(Scheme 3.4.12I–VI). TEM images of the hybrid copper catalyst 406 revealed that the highly ordered 
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structure of SBA-15 was preserved and a tendency of aggregation was not observed (Scheme 
3.4.12VII–XII). TEM analysis of the reused hybrid copper catalyst also showed that there were no 
copper nanoparticles formed by agglomeration while ordered striped contrast remained unchanged in 
the one-dimensional mesoporous channels (Figure 3.4.12). These results highlighted the outstanding 
reusability and stability during the preparation of the hybrid copper catalyst 406 as well as the course 
of the photo-induced C–H arylations.  
 
 
Scheme 3.4.12 Transmission electron microscopic (TEM) studies of hybrid copper catalysts 406. 
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3.4.7 Proposed Mechanism 
On the basis of our detailed mechanistic studies and the characterization of the hybrid copper catalyst, 
a plausible catalytic cycle for the photo-induced heterogeneous C–H arylation is proposed in Scheme 
3.4.13. The mechanistic rationale commences with hybrid copper(I) catalyst 406 and N-Methyl 
benzimidazole 445, forming copper complex 447 with the aid of a base. Irradiation of the copper 
complex 447 leads to a photo-excited state 448, followed by a SET process involving aryl iodides 404 
generating intermediate 449. Finally, subsequent reductive elimination affords arylated product 446, 
while simultaneously regenerating the hybrid copper(I) catalyst. 
 
 
Scheme 3.4.13 Proposed catalytic cycle of photo-induced hybrid copper-catalyzed C–H arylation. 
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3.5 Distal C–H Activation by Reusable Heterogeneous Ruthenium Catalyst 
A plethora of ortho-selective aromatic C–H functionalizations has been accomplished by proximity-
induced C–H activation through chelation assistance.[20a] In sharp contrast, distal C–H 
functionalizations continue to be challenging with considerable momentum gained by steric control, 
template assistance, weak hydrogen bonding, or transient mediator as described in the Chapter 1.2.2. 
Recently, Ackermann,[82, 83, 85, 88, 90, 92, 251] Greaney,[252] and Frost[72f, 96d] among others[253] developed 
site-selective C–H functionalization via ruthenium-catalyzed σ-activation, allowing meta- and para-
functionalization of arenes.[72c, 72d] In spite of recent notable progress, the realm of C–H 
functionalizations was thus far considerably limited to homogeneous catalysis. Taking advantage of 
the use of phosphine ligands in the ruthenium-catalyzed distal functionalizations,[88, 251] we envisaged 
using phosphine-based polymer support to immobilize the ruthenium catalyst (Scheme 3.5.1). 
 
 
Scheme 3.5.1 Preparation of the hybrid ruthenium catalyst. 
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3.5.1 Optimization Studies 
We initiated our studies by probing various reaction conditions with the thus synthesized polymer-
based hybrid ruthenium catalyst for the meta-C–H alkylation of arene 407 (Table 3.5.1). First, we 
explored different types of bases in 1,4-dioxane as the solvent at 100 °C (entries 1–5). However, it was 
found that the addition of acid was not necessary for the ruthenium-catalyzed meta-C–H alkylation, 
while KOAc provided better conversion among various bases (entries 6–10). After a considerable 
testing of solvents and reaction temperatures, we were delighted to obtain the optimized conditions 
where the use of 2-MeTHF as the solvent and 60 °C of reaction temperature could provide 70% of 
isolated yield (entries 11–15). Notably, biomass-derived 2-MeTHF is considered as a green alternative 
to THF, and can be produced from renewable resources.[254] A control experiment confirmed the 
essential role of the recyclable hybrid-ruthenium catalyst (entry 16), while the recyclability of the 
hybrid ruthenium catalyst 410 was proved (entry 17).   
 
Table 3.5.1 Optimization studies for hybrid-ruthenium-catalyzed meta-C–H alkylation.[a] 
 
 
Entry Acid Base (X equiv) Solvent Temp (°C) Yield (%)a 
1 MesCO2H Na2CO3 (1.0) 1,4-Dioxane 100 31 
2 MesCO2H K2CO3 (1.0) 1,4-Dioxane 100 32 
3 MesCO2H K3PO4 (1.0) 1,4-Dioxane 100 40 
4 MesCO2H NaOAc (1.0) 1,4-Dioxane 100 25 
5 MesCO2H KOAc (1.0) 1,4-Dioxane 100 11 
6 -- K2CO3 (1.0) 1,4-Dioxane 100 trace 
7 -- Na2CO3 (1.0) 1,4-Dioxane 100 21 
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8 -- K3PO4 (1.0) 1,4-Dioxane 100 31 
9 -- KOAc (1.0) 1,4-Dioxane 100 33 
10 -- KOAc (1.0) 1,4-Dioxane 80 40 
11 -- KOAc (1.0) PhCMe3 80 25 
12 -- KOAc (1.0) 2-MeTHF 80 44 
13 -- KOAc (2.0) 2-MeTHF 80 61 
14 -- KOAc (2.0) 2-MeTHF 60 70 
15 -- KOAc (2.0) 2-MeTHF 40 53 
16 -- KOAc (2.0) 2-MeTHF 60 0[b] 
17 -- KOAc (2.0) 2-MeTHF 60 69[c] 
[a] Reaction conditions: 407 (0.25 mmol), 408 (0.75 mmol), 410 (10 mol %), solvent (1.0 mL), 24 h, 
isolated yield. [b] Without 410. [c] With the reused 410. 
 
The optimized heterogeneous catalyst was not limited to substrates bearing the pyridine directing 
group. Indeed, other directing groups, such as pyrimidines, oxazolines, pyrazoles, and purines were 
acceptable for the hybrid ruthenium-catalyzed meta-C–H alkylation (Scheme 3.5.2).  
 
 
Scheme 3.5.2 Different directing groups for hybrid ruthenium-catalyzed meta-C–H alkylation. 
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3.5.2 Substrate Scope  
We commenced exploring the versatility of the hybrid-ruthenium-catalyzed meta-C–H 
functionalization with a set of representative arenes 407 (Scheme 3.5.3). Differently substituted arenes 
407 bearing electron-deficient and electron-rich functional groups were position-selectively 
transformed to the desired meta-functionalized products 408. Distal meta-C–H alkylation by the hybrid 
ruthenium catalyst 410 tolerated various alkyl bromides 408, including valuable functional groups, 
featuring halides, ethers, esters, and amides, while natural product derivatives 409p and 409q were 
selectively converted.   
 
 
Scheme 3.5.3 Substrate scope for hybrid ruthenium-catalyzed meta-C–H alkylations. 
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3.5.3 Mechanistic Studies 
Furthermore, we performed detailed mechanistic studies to elucidate the hybrid ruthenium catalyst’s 
mode of action. To this end, an intermolecular competition experiment was carried out, revealing that 
the electron-rich arene 407k was preferentially reacted (Scheme 3.5.4). This result suggests that a 




Scheme 3.5.4 Competition experiment between arenes 407k and 407l. 
 
Additionally, the reaction in the presence of isotopically labelled CD3OD afforded 69% of deuteration 
in the reisolated substrate [D]n-407k and 72% and 49% of deuteration in the ortho-positions of the 
desired product 409r (Scheme 3.5.5). These experimental results provided a strong support for a 
reversible C–H activation. 
 
 
Scheme 3.5.5 H/D exchange study. 
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In addition, the KIE was studied, indicating a primary isotope effect in both competition and 
independent experiments (Scheme 3.5.6). This study clearly revealed that C–H cleavages at the ortho 
and meta positions are not kinetically relevant. 
 
Scheme 3.5.6 Kinetic isotope effect studies.  
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3.5.4 Heterogeneity Studies 
To probe the heterogeneity of the hybrid-ruthenium-catalyst, a variety of experiments were conducted. 
We were hence delighted to observe that the hybrid-ruthenium featured an excellent reusability, 
enabling practical access to meta-C–H alkylated arenes (Scheme 3.5.7). Industries and pharma 
companies performing large-scale reactions or flow applications in homogeneous catalysis mainly are 
concerned with the removal of metal impurities, which are detrimental to synthetic and economic 
efficiency, while the well-designed heterogeneous catalysts could avoid the additional processes by a 
simple separation. Within a collaboration with Dr. Volker Karius, less than 8 ppm of ruthenium was 


















































Scheme 3.5.7 Reuse test for hybrid ruthenium-catalyzed meta-C–H alkylation and the determination 
of ruthenium leaching.  
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The sustainable feature of the hybrid-ruthenium catalysis was also mirrored by a gram-scale reaction, 
maintaining a high efficiency with position-selectivity and reusability of the hybrid-ruthenium catalyst 
(Scheme 3.5.8).  
 
 
Scheme 3.5.8 Scaled reuse test. 
 
Additionally, a hot-filtration test demonstrated that the physical removal of the hybrid-ruthenium 
catalyst completely inhibited the hybrid catalysis for meta-C–H alkylation (Scheme 3.5.9).    
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3.5.5 Characterizations of Hybrid Ruthenium Catalyst 
Given the unique features of recyclable and reusable hybrid ruthenium catalyst 410, we sought to 
determine its chemical and physical properties. Within a collaboration with the Loren group, we 
conducted detailed solid-state NMR spectroscopic studies of the 448, RuCl2PPh3(p-cymene), 410, and 
reused 410 (Scheme 3.5.10). Interestingly, 13C and 31P NMR spectra showed similar chemical shifts 
among RuCl2PPh3(p-cymene), 410, and the reused 410, providing a strong evidence that the 
coordination of ruthenium by phosphorus remained stable during the course of the hybrid-ruthenium 
catalysis.  
 
Scheme 3.5.10 Solid-state NMR analysis 
 
Furthermore, with the assistance of the Alauzun group, the powder X-ray diffraction (PXRD) patterns 
of the 410 identified two very wide peaks around 10° and 20° showing the amorphous support, whereas 
the formation of crystalline ruthenium compounds, for example, ruthenium oxide, was not detected 
(Scheme 3.5.11). The PXRD patterns from the reused 410 confirmed crystalline KBr (JCPDS 730381) 
as an insoluble byproduct in 2-MeTHF, while the residue was proven to be innocuous to the reusability 
of the hybrid-ruthenium catalyst. 
 




Scheme 3.5.11 Powder X-ray diffraction studies.  
 
Dr. Alauzun and Dr. Wang also performed X-ray photoelectron spectroscopy to determine the 
oxidation state of ruthenium from 410 and the reused 410 (Scheme 3.5.12). In this analysis, the peak 
of Ru 3d5/2 at 281.1 eV from the surface of both catalysts was observed, which corresponds to 



























Scheme 3.5.12 X-ray photoelectron spectroscopic analysis. 
 
Additionally, the Alauzun group performed detailed microscopic studies, including scanning electron 
microscopy (SEM), transmission electron microscopy (TEM), and transmission electron microscopy 
energy-dispersive X-ray spectroscopy (TEM-EDX) studies of the hybrid catalyst 410 and the reused 
catalyst 410 (Scheme 3.5.13). SEM analysis of the 410 revealed non-aggregated spheres up to 100 µm 
in diameter with a relatively smooth surface. The reused 410 in SEM studies showed innocent KBr on 
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the surface previously detected by PXRD. TEM analysis of the 410 and the reused 410 revealed that 
both hybrid catalysts have homogeneous non-porous amorphous morphology.  
 
 
Scheme 3.5.12 X-ray photoelectron spectroscopic analysis. 
 
  
Results and Discussion 
137 
 
3.5.6 Proposed Mechanism 
On the basis of our detailed experimental mechanistic studies along with the spectroscopic and 
microscopic characterization of the hybrid-ruthenium catalyst, a plausible catalytic cycle for the 
heterogeneous meta-C–H alkylation is proposed in Scheme 3.5.13. The mechanistic rationale 
commences by a carboxylate-assisted, BIES-C–H ruthenation. Subsequently, ruthenium(III) 
intermediate is generated via a single electron transfer from the ruthenium(II) complex 449 to the alkyl 
halide 408. The alkyl radical attacks the aromatic moiety at the para-position to ruthenium, giving 
intermediate 451. Thereafter, aromatization followed by protodemetallation delivers the desired meta-
alkylated product 409 and regenerates the catalytically active ruthenium hybrid catalyst 449.  
 
 
Scheme 3.5.13 Proposed mechanism of hybrid ruthenium-catalyzed meta-C–H alkylation. 
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3.6 C–H Arylations and Alkylations by Reusable Heterogeneous Manganese 
Catalyst 
Azines are key structural motifs in a plethora of bio-relevant, pharmaceuticals, and drugs.[217, 255] 
Particularly, C3–H functionalized pyridine scaffolds broadly exhibit numerous biological activities 
(Scheme 3.6.1).[256] Consequently, there is a continued strong demand for efficient C–H 
functionalizations of pyridines in a sustainable manner.[257] 
  
 
Scheme 3.6.1 Selected bio-active drugs containing C3–H functionalized pyridine motifs. 
 
Earth-abundant 3d metal catalysts provide prospect for less toxic metals in C–H activations[216] with 
notable advances in manganese-catalyzed C–H activation[258, 168c] by Kuninobu/Takai,[259] Wang,[260, 
122] and Ackermann,[261, 128, 132, 147b, 186b] among others.[140, 262, 127] Despite the indisputable progress, 
manganese-catalyzed-C–H functionalizations continue to be largely limited to homogeneous catalysis.  
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3.6.1 Preparation of Hybrid Manganese Catalyst  
The hybrid manganese catalyst 416 was synthesized under a modified protocol from Christopher 
(Scheme 3.6.2).[249a] To construct the linker, LDA deprotonated a C–H bond of a methyl group of 4,4’-
dimethyl-2,2’-dipyridyl (439), which underwent a substitution reaction with (3-chloropropyl)trime-
thoxysilane (440). The thus obtained linker 441 was grafted on SBA-15 in toluene under the reflux 
conditions, giving the tethered linker 442. Since the covalently anchored ligand 442 contains hydroxyl 
groups on the surface, the end-capping procedure was subsequently carried out with HMDS. Lastly, 




Scheme 3.6.2 Preparation of hybrid manganese catalyst. 
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3.6.2 Optimization Studies 
Next, we probed various reaction conditions for the envisioned C–H arylation of pyridines 411 with 
the synthesized hybrid-manganese catalyst 416 (Table 3.6.1). We were pleased to observe that the 
desired arylated product 413 was obtained (entry 1). It is noteworthy that the hybrid catalyst could be 
successfully recycled and reused (entry 2). In contrast, the use of simple MnCl2 provided unsatisfactory 
results (entry 3). Control experiments verified the essential role of the hybrid-manganese catalyst, the 
ligand, and the DCB oxidant for C–H arylations (entries 4–7).  
 




Entry Deviation from standard condition Yield (%) 
1 Standard conditions 80 
2 Second run with the reused 416 75 
3 MnCl2 as catalyst 17 
4 Immobilized ligand 443 instead of 416 NR 
5 Without 416 NR 
6 Without TMEDA 43 
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7 Without 2,3-DCB 5 
[a] Reaction conditions: 411 (0.25 mmol), 412 (1.00 mmol, 1.0 M in THF), 416 (9.0 mol %), 
TMEDA (0.50 mmol), 2,3-DCB (0.75 mmol), 70 °C, 16 h, under N2 atmosphere, isolated yields. 
TMEDA = Tetramethylethylenediamine. 2,3-DCB = 2,3-Dichlorobutane. NR = No Reaction. 
 
Thereafter, we probed the effect exerted by changing the substitution pattern on the azines 411 (Scheme 
3.6.3). Differently decorated heteroarenes, such as structural isomeric azines (411a, 411b, and 411c) 
or diazines (411d and 411e), were thus subjected to the optimized reaction conditions for the C–H 
arylation. While the picolinic amide 411a gave an effective transformation, other heteroarenes afforded 
lower conversion.  
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3.6.3 Substrate Scope 
With the optimized reaction conditions in hand, we set out to explore the catalytic performance in the 
C3–H arylations of azines 411 (Scheme 3.6.4). Various pyridines 411 were efficiently converted to the 
desired C3-arylated product 413 by weak amide-chelation assistance, while alkyl, benzyl, and aryl 
substituted amides were fully tolerated.  
 
 
Scheme 3.6.4 Substrate scope of hybrid manganese-catalyzed C–H arylation. 
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Additionally, the versatility of the hybrid-manganese catalysis was highlighted by C–H alkylations, 
providing a broadly applicable strategy (Scheme 3.6.5). Therefore, the robust hybrid-manganese-
catalyzed C–H functionalization enabled direct primary alkylations. It is noteworthy that the hybrid-
manganese catalysis also enabled the installation of the methyl group[263] onto azines 411. Furthermore, 
challenging secondary alkylations proved viable, including cyclopropylation 415g and cyclobutylation 
415h, while isomerizations were not observed. 
 
 
Scheme 3.6.5 Substrate scope of hybrid manganese-catalyzed C–H alkylation. 
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3.6.4 Heterogeneity Studies 
A reuse test for C–H arylation was performed and we observed that the hybrid-manganese catalyst was 
recyclable and could be reused up to at least three times (Scheme 3.6.6). Within a collaboration with 
Dr. Volker Karius, less than 1 ppm of manganese was detected by ICP-OES studies of the reaction 
mixture, reflecting negligible leaching of the transition metal during the course of catalysis.  
 
 
Scheme 3.6.6 Reuse test of hybrid manganese-catalyzed C–H arylation and the determination of 
manganese leaching. 
 
The reusable nature of the hybrid manganese catalyst 416 was not only found for the C–H arylation 
reactions. Indeed, the hybrid manganese catalyst 416 was recyclable in a C–H alkylation reaction at 
least up to three time, although a decrease in the yield was observed. 
  
 
Scheme 3.6.6 Reuse test of hybrid manganese-catalyzed C–H arylation and the determination of 
manganese leaching. 
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The addition of mercury and a hot-filtration test were subsequently probed, showing that the hybrid-
manganese-catalyzed C–H arylation was operating by heterogeneous catalysis (Scheme 3.6.7).  
 
 
Scheme 3.6.7 Various heterogeneity tests. 
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3.6.5 Characterizations of Heterogeneous Catalyst 
Thereafter, the pristine ligand-support 443, the hybrid-manganese catalyst 416, and reused 416 were 
characterized in detail by TEM techniques to determine the morphological properties (Scheme 3.6.8). 
Thereby, we observed highly ordered one-dimensional mesoporous channels without morphological 




Scheme 3.6.8 Microscopic analysis of hybrid manganese catalysts. 
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4. Summary and Outlook 
Classical C–C or C–Het bond formation reactions have been considered to be user-friendly methods, 
while pre-functionalizations are generally accompanied for desired reactivities and selectivities. In 
stark contrast, metal-catalyzed C–H activation enabled direct C–C or C–Het bond formation in an 
atom- and step-economical fashion. In addition to this emerging synthesis tool, photochemistry and 
electrochemistry have recently added a great value to the C–H activation manifold. Furthermore, 
hybrid catalysis allows for recyclability and reusability of the catalyst, resulting in the accomplishment 
of environmentally-sound syntheses.  
 
In the first project, ruthenium(II)carboxylate-catalyzed C7–H indole functionalization was achieved 
via challenging six-membered ruthenacycles (Scheme 4.1.1). Notable features of this development 
were a wide substrate scope, including C–C and C–N bond formation at C7 position of indoles with a 
tolerance of various functional groups under mild conditions. The detailed kinetic study by 
spectroscopic and spectrometric analyses highlighted the importance of ruthenium nitrenoid 
intermediate for the unique C7–H amidation. Additionally, the traceless removal of the pivaloyl group, 
utilization of flow technique, and gram-scale reaction clearly showed the robustness and versatility of 
the ruthenium-catalyzed C7–H activations.  
 
 
Scheme 4.1.1 Ruthenium(II)-catalyzed C7–H indole amidation and alkenylation. 
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In the second project, arene-ligand-free ruthenium(II)-catalyzed remote C4/C6–H functionalization of 
indoles benzenoid was developed (Scheme 4.1.2). The unique ruthenium catalysis enabled double C–
C bond formation with excellent levels of site-selectivity. The versatility and robustness of the 
ruthenium catalysis were demonstrated by ample substrate scope and a gram-scale reaction. 
Additionally, the mechanistic investigation highlighted the key importance of C2-ruthenation, 
affording unique C4/C6–H double indole alkylations.   
 
 
Scheme 4.1.2 Ruthenium(II)-catalyzed C4–H/C6–H dual indole alkylations.  
 
In the third project, electrochemical osmium(II)-catalyzed C–H annulations were accomplished 
(Scheme 4.1.3). Weak O-coordination enabled to provide ample substrate scope for [4+1] and [4+2] 
annulations under osmaelectrooxidative C–H activation. Notably, detailed reaction comparison with 
other transition metal catalytic systems highlighted advantageous characteristics of the osmium 




Scheme 4.1.3 Electrooxidative osmium-catalyzed C–H annulation. 
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In the fourth project, a photo-induced C−H arylation by hybrid copper catalysis was achieved under 
exceedingly mild reaction conditions at room temperature (Scheme 4.1.4). The hybrid copper catalyst 
enabled site-selective C−H arylations with ample scope, including a wide range of functional group 
tolerance. Also, the hybrid copper catalyst was reusable without significant loss of catalytic efficacy, 
the heterogeneity of which was experimentally proved. Detailed microscopic and spectroscopic 
analyses showed the physical and chemical stability of the hybrid copper catalyst for photoinduced 
C−H arylation.   
 
 
Scheme 4.1.4 Photo-induced copper-catalyzed heterogeneous C–H arylation. 
 
In the fifth project, a recyclable ruthenium hybrid catalyst was developed for remote C−H 
functionalizations (Scheme 4.1.5). The hybrid ruthenium catalyst featured remarkable robustness 
towards meta-C−H alkylations, while the catalyst was highly recyclable. Microscopic and 
spectroscopic analyses together with mechanistic studies delineated the excellent physical and 
chemical properties of the hybrid ruthenium catalyst for position-selective C−H functionalization.  
 
 
Scheme 4.1.5 Hybrid ruthenium(II)-catalyzed meta-C–H alkylation. 
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In the last project, a recyclable hybrid manganese catalyst was described for C–H arylation and 
alkylation of azines (Scheme 4.1.6). The hybrid manganese catalyst showed a remarkable catalytic 
performance towards site-selective C3–H arylations and C3–H alkylations of azines by weak amide-
chelation assistance in a reusable fashion. Detailed heterogeneity investigations and characterizations 
of the hybrid-manganese catalyst reflected its stability during the course of azine C–H activation.  
 
 





5. Experimental Data 
5.1 General Remarks  
Reactions involving air- or moisture-sensitive compounds were conducted under an atmosphere of 
nitrogen using pre-dried glassware and standard Schlenk or glovebox techniques. If not otherwise 
noted, yields refer to isolated compounds, estimated to be >95% pure by GC and NMR. 
 
Vacuum 
The following average pressure was measured on the used rotary vane pump RD4 from Vacuubrand®: 
0.8×10−1 mbar (uncorrected value). 
 
Melting points 
Melting points were measured on a Stuart® Melting Point Apparatus SMP3 from Barloworld Scientific. 
All values are uncorrected. 
 
Liquid Chromatography 
Analytical thin layer chromatography (TLC) was performed on TLC Silica gel 60 F254 from Merck 
with detection at 254 nm or 360 nm or developed by treatment with a KMnO4 solution followed by 
careful warming. Preparative chromatographic separations were carried out on Merck Geduran® SI 
60 (40–63 μm, 70–230 mesh ASTM) silica gel. 
 
Gas Chromatography 
Gas chromatographic analysis (GC) was performed on an Agilent 7890A or 7890B GC System 
equipped with an Agilent HP-5 column (30 m, 0.320 mm diameter, 0.25 μm film thickness) and a 
flame-ionization detector (FID) using hydrogen as the carrier gas. Gas chromatography coupled with 
mass spectrometry (GC-MS) was performed on the same instrument equipped with an Agilent 5875C 
Triple-Axis-Detector or an Agilent 5977B MSD. Mass spectra were obtained with electron-ionization 






Electron-ionization (EI) mass spectra were recorded on a time-of flight mass spectrometer AccuTOF™ 
from Jeol at 70 eV. Electrospray-ionization (ESI) mass spectra were recorded on a quadrupole time-
of-flight maXis or on a time-of-flight mass spectrometer microTOF, both from Bruker Daltonic. The 




Infrared (IR) spectra of were measured on a Bruker Alpha-P FT-IR spectrometer with a diamond ATR 
probe in the range of 4000–400 cm–1. In-situ IR measurements were performed with a Mettler-Toledo 
ReactIR 15 spectrometer equipped with a diamond ATR probe and an MCT detector. Spectra were 
acquired using Mettler-Toledo iC IR software version 7.0.297 in the range of 650–2200 cm–1 with a 4 
cm–1 resolution. A Pearson’s Correction was used as baseline correction in all measurements. 
 
Nuclear Magnetic Resonance Spectroscopy 
Nuclear magnetic resonance (NMR) spectra were recorded on Varian MercuryPlus™ 300, Bruker 
Avance™ III 300, Avance III HD 300, Avance III 400, Avance III HD 400, Avance Neo 400, Avance 
III HD 500 and Bruker Avance Neo 600 spectrometer. Unless stated otherwise, all measurements were 
performed at 298 K. Chemical shifts (δ) are reported relative to tetramethylsilane and are referenced 
using the residual proton or carbon solvent signal.[264] 
 
Table 5.1.1 Chemical shifts of common deuterated solvents. 
Solvent  1H NMR  13C NMR  
CDCl3  7.26 ppm  77.16 ppm  
DMSO-d6 2.50 ppm  39.52 ppm  
Acetone-d6 2.05 ppm  206.7, 29.92 ppm  
Methanol-d4 4.78, 3.31 ppm  49.15 ppm  




Data Analysis and Plots 
Data analysis and plotting were performed using Microsoft Excel 2016 software. 
 
Solvents 
All solvents used for work-up and purification were distilled prior to use. Solvents used in reactions 
involving air- or moisture-sensitive compounds were dried and stored under an inert atmosphere of 
nitrogen or argon according to the following standard procedures: Solvents purified by solvent 
purification system (SPS-800) from M. Braun: Toluene, tetrahydrofuran, diethylether, 
dichloromethane and N,N-dimethylformamide. Solvents dried and distilled over CaH2: 1,2-
dichloroethane, N,N-dimethylacetamide and N-methyl-2-pyrrolidone. Solvents dried over 4Å 
molecular sieves and degassed using multiple cycles of freeze-pump-thaw:  t-Amylalcohol, o-, m-, p-
xylene, 1,4-dioxane, 1,2-dimethoxyethane, n-butyl ether, methanol, trifluoroethanol, and 
hexafluoroisopropanol, 2-methyltetrahydrofuran, n-hexane, toluene-d8, and THF-d8. Water was 
degassed before its use applying repeated freeze-pump-thaw cycles. 
 
Electrochemistry 
Platinum electrodes (10 mm × 25 mm × 0.125 mm, 99.9%; obtained from ChemPur® Karlsruhe, 
Germany) and CF electrodes (10 mm × 25 mm × 6 mm, SIGRACELL®GFA 6 EA, obtained from 
SGL Carbon, Wiesbaden, Germany) were connected using stainless steel adapters. Electrolysis was 
conducted using an AXIOMET AX-3003P potentiostat in constant current mode, CV studies were 
performed using a Metrohm Autolab PGSTAT204 workstation and Nova 2.0 software.  
 
Reagents 
Reagents obtained from commercial sources with a purity >95% were used without further purification 
unless stated otherwise. The following compounds were synthesized according to previously reported 






The following compounds were kindly synthesized and/or provided by the persons listed below: 
Karsten Rauch: [RuCl2(p-cymene)]2 and [Ru(OAc)2p-cymene] 
Dr. Uttam Dhawa: 399 
Dr. Nikolaos Kaplaneris: 395, 396, 402, and 407 
Dr. Julian Koeller: 404 and 444 
Dr. Valentin Mueller: 407 






5.2 General Procedures 
5.2.1 General Procedure A: Ruthenium-Catalyzed C7–H Indole Amidations  
A suspension of N-pivaloyl indoles 390 (0.25 mmol, 1.0 equiv), organic azides 391 (0.75 mmol, 3.0 
equiv), Ru(OAc)2(p-cymene) (10 mol %), AgSbF6 (20 mol %), in TFE (1.0 mL) was stirred at 40 °C 
for 24 h under N2. After cooling to ambient temperature, the mixture was concentrated in vacuo. 
Purification by column chromatography on silica gel afforded the desired products 392.  
 
5.2.2 General Procedure B: Ruthenium-Catalyzed C7–H Indole Alkenylations 
A suspension of N-pivaloyl indoles 390 (0.25 mmol, 1.0 equiv), acrylates 393 (0.75 mmol, 3.0 equiv), 
Ru(OAc)2(p-cymene) (10 mol %), AgSbF6 (20 mol %), and Cu(OAc)2 (0.50 mmol, 2.0 equiv) in TFE 
(1.0 mL) was stirred at 40 °C for 24 h under N2. After cooling to ambient temperature, the mixture was 
concentrated in vacuo. Purification by column chromatography on silica gel afforded the desired 
products 394.  
 
5.2.3 General Procedure C: Ruthenium-Catalyzed C4–H/C6–H Indole Dual Alkylations 
A suspension of 1-(pyridin-2-yl)-1H-indoles (395) (0.25 mmol, 1.0 equiv), alkyl bromides 396 (1.25 
mmol, 5 equiv), Ru(OAc)2(PPh3)2 (10 mol %), and NaOAc (0.50 mmol, 2.0 equiv) in DCE (2.0 mL) 
was stirred at 70 °C for 16 h under N2. After cooling to room temperature, the mixture was concentrated 
in vacuo. Purification by column chromatography on silica gel afforded the desired products 397.  
 
5.2.4 General Procedure D: Osmium-Catalyzed Electrooxidative [4+1] C–H annulations 
A suspension of benzoic acids 398 (0.20 mmol), olefins 399 (3.0 equiv), [OsCl2(p-cymene)]2 (5.0 
mol %), KI (0.40 mmol, 2.0 equiv), and KOAc (0.40 mmol, 2.0 equiv) in HFIP (2.0 mL) and H2O (2.0 
mL) was stirred at 100 °C for 16 h at 4.0 mA of a constant current under N2. After cooling to ambient 
temperature, the electrodes were washed with ethyl acetate (3 × 10 mL). The reaction mixtures were 
extracted with brine (20 mL), dried over Na2SO4, and concentrated under reduced pressure. 




5.2.5 General Procedure E: Osmium-Catalyzed Electrooxidative [4+2] C–H annulations 
A suspension of benzoic acids 398 (0.20 mmol), alkynes 401 (3.0 equiv), [OsCl2(p-cymene)]2 (5.0 
mol %), KI (0.40 mmol, 2.0 equiv), and KOAc (0.40 mmol, 2.0 equiv) in HFIP (2.0 mL) and H2O (2.0 
mL) was stirred at 100 °C for 16 h at 4.0 mA of a constant current under N2. After cooling to ambient 
temperature, the electrodes were washed with ethyl acetate (3 × 10 mL). The reaction mixtures were 
extracted with brine (20 mL), dried over Na2SO4, and concentrated under reduced pressure. 
Purification by column chromatography on silica gel afforded the desired products 402. 
 
5.2.6 General Procedure F: Photo-Induced Hybrid Copper-Catalyzed C–H Arylations (1) 
To a pre-dried 10 mL quartz tube was added azoles 403 (0.25 mmol, 1.0 equiv), aryl iodide 404 (1.25 
mmol, 5.0 equiv), 406 (30 mg, 11 mol %), LiOtBu (0.75 mmol, 3.0 equiv), and Et2O (0.5 mL) under 
N2 atmosphere. The tube was sealed and stirred under 254 nm irradiation in a Luzchem LZC-ICH2 
photoreactor at ambient temperature for 24 h. The temperature was determined to be 30 °C in the 
reaction mixture. Afterwards, the solvent was removed under reduced pressure. Purification by column 
chromatography on silica gel afforded the desired products 405. 
 
5.2.7 General Procedure G: Photo-Induced Hybrid Copper-Catalyzed C–H Arylations (2) 
To a pre-dried 10 mL quartz tube was added N-methyl benzimidazole (445) (0.25 mmol), aryl iodide 
404 (1.25 mmol), 406 (30 mg, 11 mol %), K3PO4 (0.75 mmol, 3.0 equiv), and THF (0.5 mL) under N2 
atmosphere. The tube was sealed and stirred under 254 nm irradiation in a Luzchem LZC-ICH2 
photoreactor at ambient temperature for 24 h. The temperature was determined to be 30 °C in the 
reaction mixture. Afterwards, the solvent was removed under reduced pressure. Purification by column 






5.2.8 General Procedure H: Photo-Induced Hybrid Copper-Catalyzed C–H Arylations (3) 
To a pre-dried 10 mL quartz tube was added heterocycles 403 or 445 (0.25 mmol, 1.0 equiv), aryl 
bromide 447 (1.25 mmol, 5.0 equiv), 406 (30 mg, 11 mol %), Cs2CO3 (0.75 mmol, 3.0 equiv), and 
Et2O (0.5 mL) under N2 atmosphere. The tube was sealed and stirred under 254 nm irradiation in a 
Luzchem LZC-ICH2 photoreactor at ambient temperature for 24 h. The temperature was determined 
to be 30 °C in the reaction mixture. Afterwards, the solvent was removed under reduced pressure. 
Purification by column chromatography on silica gel afforded the desired products 405 or 446. 
 
5.2.9 General Procedure I: Hybrid Ruthenium-Catalyzed meta-C–H Alkylation 
A suspension of arenes 407 (0.25 mmol, 1.0 equiv), alkyl halides 408 (0.75 mmol, 3.0 equiv), 410 
(30.0 mg, 10 mol %) and KOAc (0.50 mmol, 2.0 equiv) in 2-MeTHF (2.0 mL) was stirred at 60 °C for 
24 h under N2. After cooling to ambient temperature, the mixture was concentrated in vacuo. 
Purification by column chromatography on silica gel afforded the desired products 409. 
 
5.2.10 General Procedure J: Hybrid Manganese-Catalyzed C–H Arylations 
A suspension of picolinamides 411 (0.25 mmol, 1.0 equiv), aryl Grignards 412 (4 equiv, 1.0 mL, 1.0 
M in THF) was added to a pre-dried Schlenk tube at room temperature under N2. After stirring for 10 
min, 416 (30 mg, 9.0 mol %), TMEDA (0.50 mmol, 2.0 equiv) and 2,3-DCB (0.75 mmol, 3.0 equiv) 
were added to the suspension under N2. The Schlenk tube was transferred to pre-heated oil bath (70 °C) 
and stirred for 16 h. After cooling to ambient temperature, saturated aqueous NH4Cl (15 mL) was 
added and the reaction mixture was extracted with EtOAc (3 × 15 mL). The combined organic layers 
were dried over Na2SO4, filtered, and concentrated in vacuo. Purification by column chromatography 
on silica gel afforded the desired products 415.  
 
5.2.11 General Procedure K: Hybrid Manganese-Catalyzed C–H Alkylations 
A suspension of picolinamides 411 (0.25 mmol, 1.0 equiv), alkly Grignards 414 (4 equiv, 1.0 mL, 1.0 
M in THF) was added to a pre-dried Schlenk tube at room temperature under N2. After stirring for 10 




were added to the suspension under N2. The Schlenk tube was transferred to pre-heated oil bath (70 °C) 
and stirred for 16 h. After cooling to ambient temperature, saturated aqueous NH4Cl (15 mL) was 
added and the reaction mixture was extracted with EtOAc (3 × 15 mL). The combined organic layers 
were dried over Na2SO4, filtered, and concentrated in vacuo. Purification by column chromatography 





5.3 Ruthenium(II)-Catalyzed C7–H Amidations and Alkenylations of Indoles 
5.3.1 Characterization Data 
4-Methyl-N-(1-pivaloyl-1H-indol-7-yl)benzenesulfonamide (392a) 
 
The General Procedure A was followed using N-pivaloyl indole 390a (50.3 mg, 0.25 mmol), tosyl 
azide 391a (148 mg, 0.75 mmol), Ru(OAc)2(p-cymene) (8.8 mg, 10 mol %) and AgSbF6 (17.2 mg, 20 
mol %) in TFE (1.0 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 4/1) 
yielded 392a (72.2 mg, 78%) as a light brown solid. 
M. p. 120 ºC. 
1H NMR (400 MHz, CDCl3) δ 9.21 (s, 1H), 7.51 (dd, J = 7.8, 1.2 Hz, 1H), 7.49 (d, J = 4.0 Hz, 1H), 
7.38 (ddd, J = 8.3, 4.0, 2.2 Hz, 2H), 7.35 (dd, J = 7.8, 1.2 Hz, 1H), 7.28 (t, J = 7.8 Hz, 1H), 7.08 – 7.03 
(m, 2H), 6.55 (d, J = 4.0 Hz, 1H), 2.27 (s, 3H), 1.35 (s, 9H). 
13C NMR (100 MHz, CDCl3) δ 179.2 (Cq), 143.1 (Cq), 137.4 (Cq), 132.2 (Cq), 129.3 (Cq), 129.3 (CH), 
126.7 (CH), 126.4 (CH), 125.1 (CH), 125.1 (Cq), 122.8 (CH), 118.7 (CH), 109.2 (CH), 41.6 (Cq), 28.9 
(CH3), 21.3 (CH3). 
IR (ATR): 3174, 2991, 1745, 1570, 1322, 1164, 1099, 901, 818, 712 cm-1. 
MS (ESI) m/z (relative intensity): 371 (34) [M+H]+, 393 (60) [M+Na]+. 
HR-MS (ESI) C20H23N2O3S [M+H]
+: 371.1427, found: 371.1424. 




The General Procedure A was followed using 2,2-dimethyl-1-(3-methyl-1H-indol-1-yl)propan-1-one 




mol %) and AgSbF6 (17.2 mg, 20 mol %) in TFE (1.0 mL). Purification by column chromatography 
on silica gel (n-hexane/EtOAc: 4/1) yielded 392b (40.4 mg, 42%) as a light yellow solid. 
M. p. 135 ºC. 
1H NMR (400 MHz, CDCl3) δ 9.43 (s, 1H), 7.52 (dd, J = 7.1, 1.9 Hz, 1H), 7.40 (ddd, J = 8.0, 1.9, 1.7 
Hz, 2H), 7.30 – 7.23 (m, 3H), 7.06 (dd, J = 8.0, 1.7 Hz, 2H), 2.28 (s, 3H), 2.19 (s, 3H), 1.34 (s, 9H). 
13C NMR (100 MHz, CDCl3) δ 178.8 (Cq), 143.0 (Cq), 137.5 (Cq), 133.2 (Cq), 129.6 (Cq), 129.3 (CH), 
126.8 (CH), 125.2 (Cq), 124.9 (CH), 123.3 (CH), 122.6 (CH), 118.1 (Cq), 116.4 (CH), 41.4 (Cq), 28.9 
(CH3), 21.4 (CH3), 9.7 (CH3). 
IR (ATR): 2975, 1665, 1440, 1342, 1162, 1091, 968, 909, 766, 554 cm-1. 
MS (ESI) m/z (relative intensity): 385 (34) [M+H]+, 407 (66) [M+Na]+. 
HR-MS (ESI) C21H25N2O3S [M+H]
+: 385.1582, found: 385.1580. 




The General Procedure A was followed using 2,2-dimethyl-1-(4-methyl-1H-indol-1-yl)propan-1-one 
390c (53.8 mg, 0.25 mmol), tosyl azide 391a (148 mg, 0.75 mmol), Ru(OAc)2(p-cymene) (8.8 mg, 10 
mol %) and AgSbF6 (17.2 mg, 20 mol %) in TFE (1.0 mL). Purification by column chromatography 
on silica gel (n-hexane/EtOAc: 4/1) yielded 392c (66.3 mg, 69%) as a light yellow solid. 
M. p. 165 ºC. 
1H NMR (400 MHz, CDCl3) δ 8.95 (s, 1H), 7.47 (d, J = 4.0 Hz, 1H), 7.39 (d, J = 8.2 Hz, 1H), 7.36 
(dd, J = 8.2, 1.8 Hz, 2H), 7.08 (d, J = 8.2 Hz, 1H), 7.07 – 7.03 (m, 2H), 6.58 (d, J = 4.0 Hz, 1H), 2.45 
(s, 3H), 2.28 (s, 3H), 1.33 (s, 9H). 
13C NMR (100 MHz, CDCl3) δ 179.20 (Cq), 142.95 (Cq), 137.57 (Cq), 131.37 (Cq), 129.37 (Cq), 129.24 




41.58 (Cq), 28.92 (CH3), 21.33 (CH3), 18.11 (CH3). 
IR (ATR): 3193, 2977, 1671, 1498, 1329, 1164, 1091, 899, 814, 721 cm-1. 
MS (ESI) m/z (relative intensity): 385 (66) [M+H]+, 407 (34) [M+Na]+. 
HR-MS (ESI) C21H25N2O3S [M+H]
+: 385.1585, found: 385.1583. 




The General Procedure A was followed using 1-(4-bromo-1H-indol-1-yl)-2,2-dimethylpropan-1-one 
390d (70.0 mg, 0.25 mmol), tosyl azide 391a (148 mg, 0.75 mmol), Ru(OAc)2(p-cymene) (8.8 mg, 10 
mol %) and AgSbF6 (17.2 mg, 20 mol %) in TFE (1.0 mL). Purification by column chromatography 
on silica gel (n-hexane/EtOAc: 4/1) yielded 392d (44.9 mg, 40%) as a light yellow solid. 
M. p. 143 ºC. 
1H NMR (400 MHz, CDCl3) δ 8.99 (s, 1H), 7.55 (d, J = 4.0 Hz, 1H), 7.44 – 7.40 (d, J = 8.6, 2H), 7.38 
(d, J = 8.6, 2H), 7.14 – 7.05 (m, 2H), 6.65 (d, J = 4.0 Hz, 1H), 2.29 (s, 3H), 1.35 (s, 9H). 
13C NMR (100 MHz, CDCl3) δ 179.5 (Cq), 143.4 (Cq), 137.2 (Cq), 132.3 (Cq), 129.7 (Cq), 129.4 (CH), 
127.9 (CH), 126.9 (CH), 126.7 (CH), 124.4 (Cq), 123.6 (CH), 112.2 (Cq), 109.1 (CH), 41.8 (Cq), 28.8 
(CH3), 21.3 (CH3). 
IR (ATR): 3190, 2976, 1679, 1478, 1328, 1164, 1090, 910, 867, 670 cm-1. 
MS (ESI) m/z (relative intensity): 449 (100) (79Br) [M+H]+, 451 (100) (81Br) [M+H]+. 
HR-MS (ESI) C20H22
79BrN2O3S [M+H]
+: 449.0534, found: 449.0529. 










The General Procedure A was followed using 1-pivaloyl-1H-indole-4-carbaldehyde 390e (57.3 mg, 
0.25 mmol), tosyl azide 391a (148 mg, 0.75 mmol), Ru(OAc)2(p-cymene) (8.8 mg, 10 mol %) and 
AgSbF6 (17.2 mg, 20 mol %) in TFE (1.0 mL). Purification by column chromatography on silica gel 
(n-hexane/EtOAc: 4/1) yielded 392e (80.7 mg, 81%) as a light yellow solid. 
M. p. 125 ºC. 
1H NMR (400 MHz, CDCl3) δ 10.28 (s, 1H), 9.78 (s, 1H), 8.81 (d, J = 8.2 Hz, 1H), 8.09 (m, 1H), 7.67 
(dd, J = 7.5, 1.1 Hz, 1H), 7.64 (d, J = 8.2, 2.0 Hz, 2H), 7.44 (dd, J = 8.2, 7.5 Hz, 1H), 7.12 – 7.09 (m, 
2H), 2.28 (s, 3H), 1.51 (s, 9H). 
13C NMR (100 MHz, CDCl3) δ 195.7 (CH), 177.2 (Cq), 143.6 (Cq), 136.3 (Cq), 136.0 (Cq), 134.0 (CH), 
129.4 (CH), 128.3 (Cq), 127.1 (CH), 125.1 (CH), 124.6 (CH), 121.8 (Cq), 120.1 (Cq), 117.4 (CH), 41.6 
(Cq), 28.5 (CH3), 21.4 (CH3). 
IR (ATR): 3180, 2742, 1670, 1303, 1264, 1164, 1091, 905, 732, 547 cm-1. 
MS (ESI) m/z (relative intensity): 399 (30) [M+H]+, 421 (70) [M+Na]+. 
HR-MS (ESI) C21H23N2O4S [M+H]
+: 399.1372, found: 399.1373. 




The General Procedure A was followed using 1-(5-methoxy-1H-indol-1-yl)-2,2-dimethylpropan-1-
one 390f (57.8 mg, 0.25 mmol), tosyl azide 391a (148 mg, 0.75 mmol), Ru(OAc)2(p-cymene) (8.8 mg, 
10 mol %) and AgSbF6 (17.2 mg, 20 mol %) in TFE (1.0 mL). Purification by column chromatography 




M. p. 128 ºC. 
1H NMR (400 MHz, CDCl3) δ 9.62 (s, 1H), 7.47 (d, J = 3.9 Hz, 1H), 7.45 (ddd, J = 8.2, 3.9, 1.9 Hz, 
2H), 7.14 (dd, J = 2.5, 0.5 Hz, 1H), 7.08 (dd, J = 8.2, 1.9 Hz, 2H), 6.79 (d, J = 2.5 Hz, 1H), 6.46 (d, J 
= 3.9 Hz, 1H), 3.82 (s, 3H), 2.28 (s, 3H), 1.35 (s, 9H). 
13C NMR (100 MHz, CDCl3) δ 178.8 (Cq), 157.4 (Cq), 143.1 (Cq), 137.4 (Cq), 133.0 (Cq), 129.3 (CH), 
127.2 (CH), 126.9 (CH), 126.1 (Cq), 123.6 (Cq), 109.4 (CH), 109.3 (CH), 101.8 (CH), 55.7 (CH3), 41.5 
(Cq), 29.0 (CH3), 21.4 (CH3). 
IR (ATR): 3182, 2976, 1663, 1614, 1287, 1160, 1090, 1041, 905, 739 cm-1. 
MS (ESI) m/z (relative intensity): 401 (66) [M+H]+, 423 (34) [M+Na]+. 
HR-MS (ESI) C21H25N2O4S [M+H]
+: 401.1528, found: 401.1530. 




The General Procedure A was followed using 1-(5-fluoro-1H-indol-1-yl)-2,2-dimethylpropan-1-one 
390g (54.8 mg, 0.25 mmol), tosyl azide 391a (148 mg, 0.75 mmol), Ru(OAc)2(p-cymene) (8.8 mg, 10 
mol %) and AgSbF6 (17.2 mg, 20 mol %) in TFE (1.0 mL). Purification by column chromatography 
on silica gel (n-hexane/EtOAc: 4/1) yielded 392g (47.6 mg, 49%) as a light yellow solid. 
M. p. 125 ºC. 
1H NMR (500 MHz, CDCl3) δ 9.55 (s, 1H), 7.56 (d, J = 3.9 Hz, 1H), 7.49 (ddd, J = 8.3, 3.9, 2.0 Hz, 
2H), 7.28 (ddd, J = 10.5, 2.6, 0.5 Hz, 1H), 7.15 – 7.09 (m, 2H), 6.98 (dd, J = 7.5, 2.6 Hz, 1H), 6.51 (d, 
J = 3.9 Hz, 1H), 2.30 (s, 3H), 1.38 (s, 9H). 
13C NMR (125 MHz, CDCl3) δ 179.2 (Cq), 160.0 (d, JC–F = 242.2 Hz, Cq), 143.4 (Cq), 137.1 (Cq), 
132.9 (d, JC–F = 11.1 Hz, Cq), 129.4 (CH), 128.0 (CH), 126.8 (CH), 126.5 (d, JC–F = 12.0 Hz, Cq), 125.2 
(d, JC–F = 2.0 Hz, Cq), 109.2 (d, JC–F = 4.1 Hz, CH), 109.1 (d, JC–F = 28.2 Hz, CH), 103.7 (d, JC–F = 
23.6 Hz, CH), 41.7 (Cq), 29.0 (CH3), 21.4 (CH3). 




IR (ATR): 3179, 2997, 1622, 1609, 1310, 1089, 1090, 1053, 899, 817, 739 cm-1. 
MS (ESI) m/z (relative intensity): 389 (33) [M+H]+, 411 (66) [M+Na]+. 
HR-MS (ESI) C21H25N2O4S [M+H]
+: 389.1329, found: 389.1330. 




The General Procedure A was followed using 1-(5-chloro-1H-indol-1-yl)-2,2-dimethylpropan-1-one 
390h (58.9 mg, 0.25 mmol), tosyl azide 391a (148 mg, 0.75 mmol), Ru(OAc)2(p-cymene) (8.8 mg, 10 
mol %) and AgSbF6 (17.2 mg, 20 mol %) in TFE (1.0 mL). Purification by column chromatography 
on silica gel (n-hexane/EtOAc: 4/1) yielded 392h (76.9 mg, 76%) as a light yellow solid. 
M. p. 150 ºC. 
1H NMR (400 MHz, CDCl3) δ 9.36 (s, 1H), 7.53 (dd, J = 3.9, 0.5 Hz, 1H), 7.50 (dd, J = 2.1, 0.5 Hz, 
1H), 7.45 (ddd, J = 8.2, 3.9, 2.1 Hz, 2H), 7.29 (d, J = 2.1 Hz, 1H), 7.13 – 7.06 (m, 2H), 6.49 (d, J = 
3.9 Hz, 1H), 2.29 (s, 3H), 1.35 (s, 9H). 
13C NMR (100 MHz, CDCl3) δ 179.3 (Cq), 143.5 (Cq), 137.1 (Cq), 133.1 (Cq), 130.5 (Cq), 129.4 (CH), 
127.7 (CH), 127.6 (Cq), 126.8 (CH), 126.1 (Cq), 121.7 (CH), 117.9 (CH), 108.7 (CH), 41.7 (Cq), 28.9 
(CH3), 21.4 (CH3). 
IR (ATR): 3210, 2980, 1674, 1581, 1404, 1332, 1163, 1091, 904, 792 cm-1. 
MS (ESI) m/z (relative intensity): 405 (80) [M+H]+, 809 (20) [2M+H]+. 
HR-MS (ESI) C20H22
35ClN2O3S [M+H]
+: 405.1034, found: 405.1034. 







The General Procedure A was followed using 1-(5-bromo-1H-indol-1-yl)-2,2-dimethylpropan-1-one 
390i (70.0 mg, 0.25 mmol), tosyl azide 391a (148 mg, 0.75 mmol), Ru(OAc)2(p-cymene) (8.8 mg, 10 
mol %) and AgSbF6 (17.2 mg, 20 mol %) in TFE (1.0 mL). Purification by column chromatography 
on silica gel (n-hexane/EtOAc: 4/1) yielded 392i (92.1 mg, 82%) as a light yellow solid. 
M. p. 160 ºC. 
1H NMR (400 MHz, CDCl3) δ 9.31 (s, 1H), 7.63 (d, J = 1.9 Hz, 1H), 7.51 (d, J = 3.9 Hz, 1H), 7.45 
(dd, J = 7.1, 1.9 Hz, 3H), 7.09 (d, J = 7.8 Hz, 2H), 6.49 (d, J = 3.9 Hz, 1H), 2.29 (s, 3H), 1.35 (s, 9H). 
13C NMR (100 MHz, CDCl3) δ 179.3 (Cq), 143.5 (Cq), 137.1 (Cq), 133.5 (Cq), 129.4 (CH), 128.0 (Cq), 
127.6 (CH), 126.8 (CH), 126.2 (Cq), 124.4 (CH), 121.0 (CH), 118.0 (Cq), 108.5 (CH), 41.7 (Cq), 28.8 
(CH3), 21.4 (CH3). 
IR (ATR): 3180, 2978, 1637, 1579, 1330, 1299, 1160, 1089, 903, 852 cm-1. 
MS (ESI) m/z (relative intensity): 449 (100) (79Br) [M+H]+, 451 (100) (81Br) [M+H]+. 
HR-MS (ESI) C20H22
79BrN2O3S [M+H]
+: 449.0531, found: 449.0529. 




The General Procedure A was followed using 1-(5-iodo-1H-indol-1-yl)-2,2-dimethylpropan-1-one 
390j (81.8 mg, 0.25 mmol), tosyl azide 391a (148 mg, 0.75 mmol), Ru(OAc)2(p-cymene) (8.8 mg, 10 
mol %) and AgSbF6 (17.2 mg, 20 mol %) in TFE (1.0 mL). Purification by column chromatography 
on silica gel (n-hexane/EtOAc: 4/1) yielded 392j (105.4 mg, 85%) as a light yellow solid. 
M. p. 160 ºC. 
1H NMR (400 MHz, CDCl3) δ 9.20 (s, 1H), 7.77 (dd, J = 1.6, 0.4 Hz, 1H), 7.67 (d, J = 1.6 Hz, 1H), 
7.48 (d, J = 3.9 Hz, 1H), 7.45 (ddd, J = 8.3, 3.9, 1.6 Hz, 2H), 7.13 – 7.08 (m, 2H), 6.48 (d, J = 3.9 Hz, 
1H), 2.30 (s, 3H), 1.36 (s, 9H). 
13C NMR (100 MHz, CDCl3) δ 179.3 (Cq), 143.4 (Cq), 137.2 (Cq), 133.9 (Cq), 130.2 (CH), 129.4 (CH), 




(CH3), 21.4 (CH3). 
IR (ATR): 3187, 2977, 1674, 1575, 1331, 1164, 1090, 905, 812, 716 cm-1. 
MS (ESI) m/z (relative intensity): 497 (70) [M+H]+, 519 (30) [M+Na]+. 
HR-MS (ESI)C20H22IN2O3S [M+H]




The general procedure was followed using 1-(6-fluoro-1H-indol-1-yl)-2,2-dimethylpropan-1-one 
390k (54.8 mg, 0.25 mmol), tosyl azide 391a (148 mg, 0.75 mmol), Ru(OAc)2(p-cymene) (8.8 mg, 10 
mol %) and AgSbF6 (17.2 mg, 20 mol %) in TFE (1.0 mL). Purification by column chromatography 
on silica gel (n-hexane/EtOAc: 4/1) yielded 392k (67.0 mg, 69%) as a light yellow solid. 
M. p. 125 ºC. 
1H NMR (400 MHz, CDCl3) δ 7.80 (s, 1H), 7.57 (ddd, J = 8.4, 3.8, 1.5 Hz, 2H), 7.54 (d, J = 3.8 Hz, 
1H), 7.40 (dd, J = 8.4, 4.9 Hz, 1H), 7.20 – 7.16 (m, 2H), 7.11 (dd, J = 10.0, 8.5 Hz, 1H), 6.56 (d, J = 
3.8 Hz, 1H), 2.36 (s, 3H), 1.41 (s, 9H). 
13C NMR (100 MHz, CDCl3) δ 179.5 (Cq), 157.7 (d, JC–F = 246.9 Hz, Cq), 143.6 (Cq), 137.7 (Cq), 
132.9 (d, JC–F = 3.7 Hz, Cq), 129.5 (CH), 128.1 (d, JC–F = 1.9 Hz, Cq), 127.4 (CH), 127.0 (d, JC–F = 3.8 
Hz, CH), 120.4 (d, JC–F = 9.8 Hz, CH), 113.6 (d, JC–F = 24.1 Hz, CH), 113.4 (d, JC–F = 17.5 Hz, Cq), 
108.4 (d, JC–F = 1.6 Hz, CH), 41.8 (Cq), 29.0 (CH3), 21.6 (CH3). 
19F NMR (282 MHz, CDCl3) δ -121.9 (dd, J = 10.1, 4.9 Hz). 
IR (ATR): 3181, 2978, 1675, 1406, 1305, 1164, 1091, 899, 813, 739 cm-1. 
MS (ESI) m/z (relative intensity): 389 (30) [M+H]+, 411 (70) [M+Na]+. 
HR-MS (ESI) C20H21FN2O3S [M+H]
+: 389.1330, found: 389.1330. 









The General Procedure A was followed using N-pivaloyl indole 390a (50.3 mg, 0.25 mmol), 3-
bromobenzenesulfonyl azide 391b (197 mg, 0.75 mmol), Ru(OAc)2(p-cymene) (8.8 mg, 10 mol %) 
and AgSbF6 (17.2 mg, 20 mol %) in TFE (1.0 mL). Purification by column chromatography on silica 
gel (n-hexane/EtOAc: 4/1) yielded 392l (87.1 mg, 80%) as a dark yellow solid. 
M. p. 105 ºC. 
1H NMR (400 MHz, CDCl3) δ 9.42 (s, 1H), 7.68 (ddd, J = 1.9, 1.7, 0.4 Hz, 1H), 7.52 (ddd, J = 3.9, 
1.9, 1.3 Hz, 3H), 7.40 (dd, J = 7.8, 1.3 Hz, 1H), 7.30 (t, J = 7.8 Hz, 1H), 7.28 (ddd, J = 7.8, 1.7, 1.0 
Hz, 1H), 7.10 (t, J = 7.8 Hz, 1H), 6.57 (d, J = 3.9 Hz, 1H), 1.37 (s, 9H). 
13C NMR (100 MHz, CDCl3) δ 179.3 (Cq), 142.0 (Cq), 135.4 (CH), 132.3 (Cq), 130.1 (CH), 129.6 
(CH), 129.4 (Cq), 126.6 (CH), 125.3 (CH), 125.2 (CH), 124.5 (Cq), 122.9 (CH), 122.7 (Cq), 119.2 (CH), 
109.4 (CH), 41.7 (Cq), 29.0 (CH3). 
IR (ATR): 3180, 2988, 1671, 1479, 1301, 1264, 1168, 1084, 731, 565 cm-1. 
MS (ESI) m/z (relative intensity): 435 (100) (79Br) [M+H]+, 437 (100) (81Br) [M+H]+.  
HR-MS (ESI) C19H20
79BrN2O3S [M+H]




The General Procedure A was followed using N-pivaloyl indole 390a (50.3 mg, 0.25 mmol), 
benzenesulfonyl azide 391c (137 mg, 0.75 mmol), Ru(OAc)2(p-cymene) (8.8 mg, 10 mol %) and 




(n-hexane/EtOAc: 4/1) yielded 392m (52.6 mg, 59%) as a light yellow solid. 
M. p. 134 ºC. 
1H NMR (400 MHz, CDCl3) δ 9.27 (s, 1H), 7.53 (dd, J = 7.7, 1.3 Hz, 1H), 7.51 – 7.49 (m, 2H), 7.48 
(d, J = 3.9 Hz, 1H), 7.39 (ddd, J = 7.7, 2.6, 1.3 Hz, 1H), 7.36 (dd, J = 7.7, 1.3 Hz, 1H), 7.28 (t, J = 7.7 
Hz, 1H) 7.29 – 7.23 (m, 2H), 6.54 (d, J = 3.9 Hz, 1H), 1.35 (s, 9H). 
13C NMR (100 MHz, CDCl3) δ 179.3 (Cq), 140.30 (Cq), 132.4 (CH), 132.2 (Cq), 129.4 (Cq), 128.7 
(CH), 126.7 (CH), 126.5 (CH), 125.2 (CH), 125.0 (Cq), 122.8 (CH), 118.9 (CH), 109.3 (CH), 41.6 (Cq), 
29.0 (CH3). 
IR (ATR): 3174, 2976, 1667, 1446, 1326, 1299, 1160, 1090, 904, 716 cm-1. 
MS (ESI) m/z (relative intensity): 357 (30) [M+H]+, 379 (70) [M+Na]+. 
HR-MS (ESI) C19H21N2O3S [M+H]
+: 357.1269, found: 357.1267. 




The General Procedure A was followed using N-pivaloyl indole 390a (50.3 mg, 0.25 mmol), 
methanesulfonyl azide 391d (90.8 mg, 0.75 mmol), Ru(OAc)2(p-cymene) (8.8 mg, 10 mol %) and 
AgSbF6 (17.2 mg, 20 mol %) in TFE (1.0 mL). Purification by column chromatography on silica gel 
(n-hexane/EtOAc: 4/1) yielded 392n (50.0 mg, 68%) as a light yellow liquid. 
1H NMR (400 MHz, CDCl3) δ 9.01 (s, 1H), 7.71 (d, J = 3.9 Hz, 1H), 7.49 (dd, J = 7.8, 1.3 Hz, 1H), 
7.40 (dd, J = 7.8, 1.3 Hz, 1H), 7.31 (t, J = 7.8 Hz, 1H), 6.67 (d, J = 3.9 Hz, 1H), 2.90 (s, 3H), 1.54 (s, 
9H). 
13C NMR (100 MHz, CDCl3) δ 179.9 (Cq), 132.7 (Cq), 128.9 (Cq), 126.8 (CH), 125.5 (Cq), 125.3 (CH), 
120.6 (CH), 118.6 (CH), 109.4 (CH), 42.0 (Cq), 39.8 (CH3), 29.2 (CH3). 
IR (ATR): 3196, 2976, 1670, 1590, 1359, 1317, 1153, 905, 755, 510 cm-1. 




HR-MS (ESI) C14H19N2O3S [M+H]
+: 295.1111, found: 295.1111. 




The General Procedure A was followed using N-pivaloyl indole 390a (50.3 mg, 0.25 mmol), 
cyclohexanesulfonyl azide 391e (142 mg, 0.75 mmol), Ru(OAc)2(p-cymene) (8.8 mg, 10 mol %) and 
AgSbF6 (17.2 mg, 20 mol %) in TFE (1.0 mL). Purification by column chromatography on silica gel 
(n-hexane/EtOAc: 4/1) yielded 392o (48.9 mg, 54%) as a light yellow solid. 
M. p. 113 ºC. 
1H NMR (400 MHz, CDCl3) δ 8.72 (s, 1H), 7.69 (d, J = 3.9 Hz, 1H), 7.53 (dd, J = 7.7, 1.3 Hz, 1H), 
7.35 (dd, J = 7.7, 1.3 Hz, 1H), 7.27 (t, J = 7.3 Hz, 1H), 6.65 (d, J = 3.9 Hz, 1H), 2.88 (tt, J = 12.1, 3.5 
Hz, 1H), 2.18 – 2.03 (m, 2H), 1.86 – 1.77 (m, 2H), 1.67 – 1.54 (m, 2H), 1.53 (s, 9H), 1.49 – 1.52 (m, 
2H), 1.19 – 1.10 (m, 2H). 
13C NMR (100 MHz, CDCl3) δ 180.0 (Cq), 132.5 (Cq), 128.5 (Cq), 126.6 (CH), 125.9 (Cq), 125.3 (CH), 
119.7 (CH), 117.9 (CH), 109.4 (CH), 60.7 (CH), 42.0 (Cq), 29.2 (CH3), 26.3 (CH2), 25.1 (CH2), 25.1 
(CH2). 
IR (ATR): 3188, 2945, 1552, 1413, 1391, 1135, 909, 723, 405 cm-1. 
MS (ESI) m/z (relative intensity): 363 (10) [M+H]+, 385 (90) [M+Na]+. 
HR-MS (ESI) C19H27N2O3S [M+H]







The General Procedure B was followed using N-pivaloyl indole 390a (50.3 mg, 0.25 mmol), methyl 
acrylate 393a (64.6 mg, 0.75 mmol), Ru(OAc)2(p-cymene) (8.8 mg, 10 mol %), AgSbF6 (17.2 mg, 20 
mol %) and Cu(OAc)2 (90.8 mg, 2 equiv) in TFE (1.0 mL). Purification by column chromatography 
on silica gel (n-hexane/EtOAc: 10/1) yielded 394a (53.5 mg, 75%) as a light yellow solid. 
M. p. 121 ºC. 
1H NMR (400 MHz, CDCl3) δ 7.81 (d, J = 15.7 Hz, 1H), 7.58 (d, J = 7.6 Hz, 1H), 7.57 (d, J = 3.8 Hz, 
1H), 7.44 (d, J = 7.6, 1H), 7.26 (t, J = 7.6 Hz, 1H), 6.62 (d, J = 3.8 Hz, 1H), 6.28 (d, J = 15.7 Hz, 1H), 
3.79 (s, 3H), 1.54 (s, 9H). 
13C NMR (100 MHz, CDCl3) δ 179.4 (Cq), 167.4 (Cq), 143.3 (CH), 134.8 (Cq), 131.2 (Cq), 126.5 (CH), 
124.0 (CH), 123.5 (CH), 123.2 (Cq), 122.4 (CH), 117.2 (CH), 107.5 (CH), 51.6 (CH3), 42.0 (Cq), 29.0 
(CH3). 
IR (ATR): 2958, 2156, 1704, 1636, 1312, 1309, 1167, 949, 753, 592 cm-1. 
MS (ESI) m/z (relative intensity): 286 (10) [M+H]+, 308 (90) [M+Na]+. 
HR-MS (ESI) C17H20NO3 [M+H]
+: 286.1437, found: 286.1438. 




The General Procedure B was followed using 2,2-dimethyl-1-(3-methyl-1H-indol-1-yl)propan-1-one 
390b (53.8 mg, 0.25 mmol), methyl acrylate 393a (64.6 mg, 0.75 mmol), Ru(OAc)2(p-cymene) (8.8 
mg, 10 mol %), AgSbF6 (17.2 mg, 20 mol %) and Cu(OAc)2 (90.8 mg, 2 equiv) in TFE (1.0 mL). 
Purification by column chromatography on silica gel (n-hexane/EtOAc: 10/1) yielded 394b (27.7 mg, 
37%) as a light yellow solid. 
M. p. 107 ºC. 




7.7 Hz, 1H), 7.35 (q, J = 1.2 Hz, 1H), 7.28 (t, J = 7.7 Hz, 1H), 6.26 (d, J = 15.8 Hz, 1H), 3.78 (s, 3H), 
2.27 (s, 3H), 1.52 (s, 9H). 
13C NMR (100 MHz, CDCl3) δ 179.0 (Cq), 167.5 (Cq), 143.6 (CH), 135.4 (Cq), 132.3 (Cq), 124.1 (CH), 
123.6 (CH), 123.4 (Cq), 123.3 (CH), 120.3 (CH), 116.9 (CH), 116.6 (Cq), 51.6 (CH3), 41.8 (Cq), 29.0 
(CH3), 9.7 (CH3). 
IR (ATR): 2970, 2169, 1711, 1434, 1371, 1265, 1170, 1038, 906, 731 cm-1. 
MS (ESI) m/z (relative intensity): 300 (10) [M+H]+, 322 (34) [M+Na]+. 
HR-MS (ESI) C18H22NO3 [M+H]




The General Procedure B was followed using 2,2-dimethyl-1-(4-methyl-1H-indol-1-yl)propan-1-one 
390c (53.8 mg, 0.25 mmol), methyl acrylate 393a (64.6 mg, 0.75 mmol), Ru(OAc)2(p-cymene) (8.8 
mg, 10 mol %), AgSbF6 (17.2 mg, 20 mol %) and Cu(OAc)2 (90.8 mg, 2 equiv) in TFE (1.0 mL). 
Purification by column chromatography on silica gel (n-hexane/EtOAc: 10/1) yielded 394c (41.9 mg, 
56%) as a light yellow solid. 
M. p. 113 ºC. 
1H NMR (400 MHz, CDCl3) δ 7.73 (d, J = 15.7 Hz, 1H), 7.51 (d, J = 3.8 Hz, 1H), 7.32 (d, J = 7.9 Hz, 
1H), 7.02 (ddd, J = 7.9, 1.4, 0.7 Hz, 1H), 6.59 (d, J = 3.8 Hz, 1H), 6.20 (d, J = 15.7 Hz, 1H), 3.73 (s, 
3H), 2.47 (s, 3H), 1.49 (s, 9H). 
13C NMR (100 MHz, CDCl3) δ 179.7 (Cq), 167.6 (Cq), 143.3 (CH), 134.6 (Cq), 132.5 (Cq), 130.8 (Cq), 
125.9 (CH), 124.1 (CH), 124.0 (CH), 120.8 (Cq), 116.3 (CH), 105.8 (CH), 51.5 (CH3), 42.1 (Cq), 29.0 
(CH3), 18.6 (CH3). 
IR (ATR): 2969, 1706, 1633, 1264, 1159, 1080, 900, 730, 616, 444 cm-1. 




HR-MS (ESI) C18H22NO3 [M+H]
+: 300.1598, found: 300.1596. 




The General Procedure B was followed using 1-(4-methoxy-1H-indol-1-yl)-2,2-dimethylpropan-1-
one 390d (57.8 mg, 0.25 mmol), methyl acrylate 393a (64.6 mg, 0.75 mmol), Ru(OAc)2(p-cymene) 
(8.8 mg, 10 mol %), AgSbF6 (17.2 mg, 20 mol %) and Cu(OAc)2 (90.8 mg, 2 equiv) in TFE (1.0 mL). 
Purification by column chromatography on silica gel (n-hexane/EtOAc: 10/1) yielded 394d (41.8 mg, 
53%) as a light yellow solid. 
M. p. 132 ºC. 
1H NMR (400 MHz, CDCl3) δ 7.75 (d, J = 15.7 Hz, 1H), 7.46 (d, J = 3.7 Hz, 1H), 7.43 (d, J = 8.3 Hz, 
1H), 6.73 (d, J = 3.7 Hz, 1H), 6.69 (d, J = 8.3 Hz, 1H), 6.18 (d, J = 15.7 Hz, 1H), 3.94 (s, 3H), 3.77 (s, 
3H), 1.53 (s, 9H). 
13C NMR (100 MHz, CDCl3) δ 179.8 (Cq), 167.7 (Cq), 154.6 (Cq), 142.9 (CH), 136.2 (Cq), 125.6 (CH), 
125.0 (CH), 121.3 (Cq), 116.4 (Cq), 115.1 (CH), 104.3 (CH), 103.8 (CH), 55.6 (CH3), 51.5 (CH3), 42.2 
(Cq), 28.9 (CH3). 
IR (ATR): 2967, 1706, 1601, 1498, 1262, 1156, 1065, 901, 731, 584 cm-1. 
MS (ESI) m/z (relative intensity): 316 (10) [M+H]+, 338 (34) [M+Na]+. 
HR-MS (ESI) C18H22NO4 [M+H]
+: 316.1539, found: 316.1540. 










The General Procedure B was followed using 1-(4-bromo-1H-indol-1-yl)-2,2-dimethylpropan-1-one 
390e (70.0 mg, 0.25 mmol), methyl acrylate 393a (64.6 mg, 0.75 mmol), Ru(OAc)2(p-cymene) (8.8 
mg, 10 mol %), AgSbF6 (17.2 mg, 20 mol %) and Cu(OAc)2 (90.8 mg, 2 equiv) in TFE (1.0 mL). 
Purification by column chromatography on silica gel (n-hexane/EtOAc: 10/1) yielded 394e (62.8 mg, 
69%) as a light yellow solid. 
M. p. 101 ºC. 
1H NMR (400 MHz, CDCl3) δ 7.70 (d, J = 15.7 Hz, 1H), 7.60 (dd, J = 3.7, 0.4 Hz, 1H), 7.42 (dd, J = 
8.1, 0.4 Hz, 1H), 7.28 (ddd, J = 8.1, 1.1, 0.4 Hz, 1H), 6.70 (d, J = 3.7 Hz, 1H), 6.26 (d, J = 15.7 Hz, 
1H), 3.78 (s, 3H), 1.50 (s, 9H). 
13C NMR (100 MHz, CDCl3) δ 179.5 (Cq), 167.2 (Cq), 142.2 (CH), 134.9 (Cq), 131.7 (Cq), 126.9 (CH), 
126.4 (CH), 124.7 (CH), 122.3 (Cq), 117.8 (CH), 116.5 (Cq), 107.4 (CH), 51.7 (CH3), 42.2 (Cq), 28.8 
(CH3). 
IR (ATR): 2968, 1041, 1714, 1475, 1263, 1170, 1009, 875, 703, 534 cm-1. 
MS (ESI) m/z (relative intensity): 364 (10) (79Br) [M+H]+, 366 (10) (81Br) [M+H]+, 386 (90) (79Br) 
[M+Na]+, 388 (90) (81Br) [M+Na]+. 
HR-MS (ESI) C17H19
79BrNO3 [M+H]
+: 364.0553, found: 364.0554. 







The General Procedure B was followed using 1-(5-methyl-1H-indol-1-yl)-2,2-dimethylpropan-1-one 
390f (53.8 mg, 0.25 mmol), methyl acrylate 393a (64.6 mg, 0.75 mmol), Ru(OAc)2(p-cymene) (8.8 
mg, 10 mol %), AgSbF6 (17.2 mg, 20 mol %) and Cu(OAc)2 (90.8 mg, 2 equiv) in TFE (1.0 mL). 
Purification by column chromatography on silica gel (n-hexane/EtOAc: 10/1) yielded 394f (49.4 mg, 
66%) as a light yellow solid. 
M. p. 121 ºC. 
1H NMR (400 MHz, CDCl3) δ 7.80 (d, J = 15.7 Hz, 1H), 7.54 (d, J = 3.7 Hz, 1H), 7.35 – 7.36 (m, 
1H), 7.27 – 7.26 (m, 1H), 6.53 (d, J = 3.7 Hz, 1H), 6.25 (d, J = 15.7 Hz, 1H), 3.78 (s, 3H), 2.42 (s, 
3H), 1.53 (s, 9H). 
13C NMR (100 MHz, CDCl3) δ 179.2 (Cq), 167.5 (Cq), 143.5 (CH), 133.2 (Cq), 133.1 (Cq), 131.6 (Cq), 
126.6 (CH), 125.6 (CH), 122.9 (Cq), 122.4 (CH), 117.0 (CH), 107.3 (CH), 51.6 (CH3), 41.9 (Cq), 29.0 
(CH3), 21.1 (CH3). 
IR (ATR): 2973, 1709, 1612, 1495, 1301, 1257, 1168, 902, 713, 622 cm-1. 
MS (ESI) m/z (relative intensity): 300 (10) [M+H]+, 322 (90) [M+Na]+. 
HR-MS (ESI) C18H22NO3 [M+H]




The General Procedure B was followed using 1-(5-methoxy-1H-indol-1-yl)-2,2-dimethylpropan-1-
one 390g (57.8 mg, 0.25 mmol), methyl acrylate 393a (64.6 mg, 0.75 mmol), Ru(OAc)2(p-cymene) 
(8.8 mg, 10 mol %), AgSbF6 (17.2 mg, 20 mol %) and Cu(OAc)2 (90.8 mg, 2 equiv) in TFE (1.0 mL). 
Purification by column chromatography on silica gel (n-hexane/EtOAc: 10/1) yielded 394g (49.7 mg, 
63%) as a light yellow solid. 
M. p. 102 ºC. 




(d, J = 3.7 Hz, 1H), 6.25 (d, J = 15.7 Hz, 1H), 3.84 (s, 3H), 3.78 (s, 3H), 1.52 (s, J = 4.5 Hz, 9H). 
13C NMR (100 MHz, CDCl3) δ 178.9 (Cq), 167.3 (Cq), 156.4 (Cq), 143.2 (CH), 132.4 (Cq), 129.8 (Cq), 
127.3 (CH), 124.1 (Cq), 117.5 (CH), 112.3 (CH), 107.5 (CH), 105.2 (CH), 55.8 (CH3), 51.6 (CH3), 
41.8 (Cq), 29.0 (CH3). 
IR (ATR): 2970, 1713, 1620, 1487, 1315, 1260, 1043, 902, 722, 691 cm-1. 
MS (ESI) m/z (relative intensity): 316 (20) [M+H]+, 338 (80) [M+Na]+. 
HR-MS (ESI) C18H22NO4 [M+H]
+: 316.1541, found: 316.1543. 




The General Procedure B was followed using 1-(5-chloro-1H-indol-1-yl)-2,2-dimethylpropan-1-one 
390h (58.9 mg, 0.25 mmol), methyl acrylate 393a (64.6 mg, 0.75 mmol), Ru(OAc)2(p-cymene) (8.8 
mg, 10 mol %), AgSbF6 (17.2 mg, 20 mol %) and Cu(OAc)2 (90.8 mg, 2 equiv) in TFE (1.0 mL). 
Purification by column chromatography on silica gel (n-hexane/EtOAc: 10/1) yielded 394h (55.2 mg, 
69%) as a light yellow solid. 
M. p. 105 ºC. 
1H NMR (400 MHz, CDCl3) δ 7.72 (d, J = 15.7 Hz, 1H), 7.59 (dd, J = 3.7, 0.5 Hz, 1H), 7.53 (d, J = 
2.0 Hz, 1H), 7.39 (dd, J = 2.0, 0.5 Hz, 1H), 6.55 (d, J = 3.7 Hz, 1H), 6.26 (d, J = 15.7 Hz, 1H), 3.79 
(s, 3H), 1.52 (s, 9H). 
13C NMR (100 MHz, CDCl3) δ 179.2 (Cq), 167.0 (Cq), 142.0 (CH), 133.2 (Cq), 132.4 (Cq), 129.1 (Cq), 
127.7 (CH), 124.4 (Cq), 123.8 (CH), 121.6 (CH), 118.4 (CH), 106.8 (CH), 51.7 (CH3), 42.1 (Cq), 28.9 
(CH3). 
IR (ATR): 2971, 1707, 1639, 1400, 1259, 1166, 1043, 905, 811, 714 cm-1. 






+: 320.1043, found: 320.1045. 




The General Procedure B was followed using 1-(5-bromo-1H-indol-1-yl)-2,2-dimethylpropan-1-one 
390i (70.0 mg, 0.25 mmol), methyl acrylate 393a (64.6 mg, 0.75 mmol), Ru(OAc)2(p-cymene) (8.8 
mg, 10 mol %), AgSbF6 (17.2 mg, 20 mol %) and Cu(OAc)2 (90.8 mg, 2 equiv) in TFE (1.0 mL). 
Purification by column chromatography on silica gel (n-hexane/EtOAc: 10/1) yielded 394i (65.6 mg, 
72%) as a light yellow solid. 
M. p. 97 ºC. 
1H NMR (400 MHz, CDCl3) δ 7.71 (d, J = 15.7 Hz, 1H), 7.69 (t, J = 1.9 Hz, 1H), 7.57 (d, J = 3.8 Hz, 
1H), 7.52 (ddd, J = 1.9, 1.1, 0.6 Hz, 1H), 6.56 (d, J = 3.8 Hz, 1H), 6.26 (d, J = 15.7 Hz, 1H), 3.79 (s, 
3H), 1.51 (s, 9H). 
13C NMR (100 MHz, CDCl3) δ 179.2 (Cq), 167.0 (Cq), 141.9 (CH), 133.6 (Cq), 132.8 (Cq), 127.6 (CH), 
126.4 (CH), 124.7 (Cq), 124.6 (CH), 118.5 (CH), 116.7 (Cq), 106.8 (CH), 51.7 (CH3), 42.1 (Cq), 28.9 
(CH3). 
IR (ATR): 2971, 1706, 1444, 1399, 1285, 1258, 1165, 1042, 904, 809 cm-1. 
MS (ESI) m/z (relative intensity): 364 (10) (79Br) [M+H]+, 366 (10) (81Br) [M+H]+, 386 (90) (79Br) 
[M+H]+, 388 (90) (81Br) [M+H]+ 
HR-MS (ESI) C17H19
79BrNO3 [M+H]
+: 364.0547, found: 364.0544. 









The General Procedure B was followed using N-pivaloyl indole 390j (50.3 mg, 0.25 mmol), ethyl 
acrylate 393b (75.1 mg, 0.75 mmol), Ru(OAc)2(p-cymene) (8.8 mg, 10 mol %), AgSbF6 (17.2 mg, 20 
mol %) and Cu(OAc)2 (90.8 mg, 2 equiv) in TFE (1.0 mL). Purification by column chromatography 
on silica gel (n-hexane/EtOAc: 10/1) yielded 394j (52.4 mg, 70%) as a light yellow solid. 
M. p. 76 ºC. 
1H NMR (400 MHz, CDCl3) δ 7.79 (d, J = 15.8 Hz, 1H), 7.57 (dd, J = 7.7, 0.6 Hz, 1H) 7.56 (d, J = 
3.8 Hz, 1H), 7.45 (ddd, J = 7.7, 1.4, 0.6 Hz, 1H), 7.25 (t, J = 7.7 Hz, 1H), 6.61 (d, J = 3.8 Hz, 1H), 
6.27 (d, J = 15.8 Hz, 1H), 4.24 (q, J = 7.1 Hz, 2H), 1.54 (s, 9H), 1.32 (t, J = 7.1 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 179.5 (Cq), 166.9 (Cq), 142.9 (CH), 134.8 (Cq), 131.2 (Cq), 126.5 (CH), 
123.9 (CH), 123.5 (CH), 123.3 (Cq), 122.3 (CH), 117.7 (CH), 107.4 (CH), 60.3 (CH2), 42.1 (Cq), 29.0 
(CH3), 14.3 (CH3). 
IR (ATR): 2975, 1703, 1635, 1477, 1413, 1286, 1268, 1164, 1038, 715 cm-1. 
MS (ESI) m/z (relative intensity): 300 (34) [M+H]+, 322 (66) [M+Na]+. 
HR-MS (ESI) C18H22NO3 [M+H]




The General Procedure B was followed using N-pivaloyl indole 390k (50.3 mg, 0.25 mmol), butyl 
acrylate 393c (96.1 mg, 0.75 mmol), Ru(OAc)2(p-cymene) (8.8 mg, 10 mol %), AgSbF6 (17.2 mg, 20 
mol %) and Cu(OAc)2 (90.8 mg, 2 equiv) in TFE (1.0 mL). Purification by column chromatography 
on silica gel (n-hexane/EtOAc: 10/1) yielded 394k (49.9 mg, 61%) as a light yellow liquid. 




1.1 Hz, 1H), 7.45 (ddd, J = 7.5, 1.1, 0.6 Hz, 1H), 7.25 (dd, J = 7.5, 0.6 Hz, 1H), 6.61 (d, J = 3.8 Hz, 
1H), 6.28 (d, J = 15.8 Hz, 1H), 4.19 (t, J = 6.6 Hz, 2H), 1.73 – 1.62 (m, 2H), 1.53 (s, 9H), 1.48 – 1.38 
(m, 2H), 0.95 (t, J = 7.4 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 179.3 (Cq), 167.0 (Cq), 142.9 (CH), 134.8 (Cq), 131.2 (Cq), 126.5 (CH), 
124.0 (CH), 123.5 (CH), 123.3 (Cq), 122.3 (CH), 117.7 (CH), 107.5 (CH), 64.3 (CH2), 42.0 (Cq), 30.8 
(CH2), 29.0 (CH3), 19.2 (CH2), 13.7 (CH3). 
IR (ATR): 2959, 1704, 1636, 1413, 1284, 1165, 1075, 906, 714, 583 cm-1. 
MS (ESI) m/z (relative intensity): 328 (45) [M+H]+, 350 (55) [M+Na]+. 
HR-MS (ESI) C20H26NO3 [M+H]
+: 328.1910, found: 328.1907. 




The General Procedure B was followed using N-pivaloyl indole 390l (50.3 mg, 0.25 mmol), benzyl 
acrylate 393d (121.6 mg, 0.75 mmol), Ru(OAc)2(p-cymene) (8.8 mg, 10 mol %), AgSbF6 (17.2 mg, 
20 mol %) and Cu(OAc)2 (90.8 mg, 2 equiv) in TFE (1.0 mL). Purification by column chromatography 
on silica gel (n-hexane/EtOAc: 10/1) yielded 394l (59.6 mg, 66%) as a light yellow liquid. 
1H NMR (400 MHz, CDCl3) δ 7.86 (d, J = 15.7 Hz, 1H), 7.58 (dd, J = 7.6, 1.1 Hz, 1H), 7.57 (d, J = 
3.6 Hz, 1H) 7.45 (ddd, J = 7.6, 1.1, 0.5 Hz, 1H), 7.43 – 7.39 (m, 2H), 7.38 – 7.33 (m, 3H), 7.26 (dd, J 
= 7.6, 0.5 Hz, 1H), 6.61 (d, J = 3.6 Hz, 1H), 6.34 (d, J = 15.7 Hz, 1H), 5.24 (s, 2H), 1.50 (s, 9H). 
13C NMR (100 MHz, CDCl3) δ 179.3 (Cq), 166.7 (Cq), 143.6 (CH), 136.1 (Cq), 134.8 (Cq), 131.2 (Cq), 
128.2 (CH), 128.2 (CH), 128.1 (CH), 126.5 (CH), 124.0 (CH), 123.5 (CH), 123.2 (Cq), 122.4 (CH), 
117.2 (CH), 107.5 (CH), 66.2 (CH2), 42.0 (Cq), 28.9 (CH3). 
IR (ATR): 2970, 1704, 1635, 1477, 1413, 1286, 1159, 1076, 980, 732 cm-1. 
MS (ESI) m/z (relative intensity): 362 (55) [M+H]+, 384 (45) [M+Na]+. 
HR-MS (ESI) C23H24NO3 [M+H]




5.3.2 Various Attempted C7–H Activations 
Not only were C7–H amidations and alkenylations tried, but also a variety of coupling partners was 
chosen to gain a wider perspective toward more broadly applicable ruthenium(II)-catalyzed C7–H 
activation. Although different types of reactions such as hydroarylations, phosphorylations, 
trifluoromethylations, arylations, and halogenations among others were additionally attmpted, 
respective desired products were hardly observed, in which a part of the optimization study was 































5.3.3 Flow Reaction Setup 
A Schleck tube was charged with a suspension of N-pivaloyl indole 390a (0.25 mmol, 1.0 equiv), tosyl 
azide 391a (0.75 mmol, 3.0 equiv), Ru(OAc)2(p-cymene) (10 mol %), AgSbF6 (20 mol %), and TFE 
(1.0 mL) under air (Scheme 5.3.6). Subsequently, the solution was connected to the inlet of the 10 mL 
standard pre-heated reactor by a syringe pump (Vapourtec V-3). The flow rate, back pressure, and 
temperature were set at 500 µL/min (20 min residence time), 4.0 bar, and 40 °C respectively. 
Afterwards, the reaction mixture was automatically collected and concentrated in vacuo. Purification 
by column chromatography on silica gel afforded the desired products 392a.  
 
 
Scheme 5.3.6 Scalable flow reaction for C7–H amidation of indole. 
 
5.3.4 Competition Experiment 
A suspension of 1-(5-methoxy-1H-indol-1-yl)-2,2-dimethylpropan-1-one 390f (0.25 mmol, 1.0 equiv) 
and 1-(5-fluoro-1H-indol-1-yl)-2,2-dimethylpropan-1-one 390k (0.25 mmol, 1.0 equiv), tosyl azide 
(391a) (0.75 mmol, 3.0 equiv), Ru(OAc)2(p-cymene) (10 mol %), AgSbF6 (20 mol %), in TFE (1.0 
mL) was stirred at 40 °C for 10 h under N2 (Scheme 5.3.7). After cooling to ambient temperature, the 
mixture was concentrated in vacuo. Purification by column chromatography on silica gel (n-
hexane/EtOAc: 20/1 → 10/1 → 4/1) afforded the desired products 392f and 392g, respectively.  
 
 




5.3.5 Removal of Pivaloyl Directing Group 
1) Procedure for the traceless removal of pivaloyl group 
A suspension of 4-methyl-N-(1-pivaloyl-1H-indol-7-yl)benzenesulfonamide 392a (0.25 mmol, 1.0 
equiv) or methyl-3-(1-pivaloyl-1H-indol-7-yl)acrylate 394a (0.25 mmol, 1.0 equiv) in NEt3 (0.5 mL) 
and MeOH (0.5 mL) was stirred at room temperature for 12 h (Scheme 5.3.8). The mixture was 
concentrated in vacuo. Purification by column chromatography on silica gel afforded the desired 
products 417 and 418, respectively.  
 
 
Scheme 5.3.8 Competition experiments. 
 
2) Procedure for one-pot strategy of removal of pivaloyl group 
Reactions were initially performed by using general procedure described in the general procedure. 
After cooling to ambient temperature, the solvent is removed by rotary evaporator. Triethylamine (0.5 
mL) and MeOH (0.5 mL) were added and stirred at room temperature for 12 h (Scheme 5.3.9). The 
mixture was concentrated in vacuo. Purification by column chromatography on silica gel afforded the 










A suspension of 4-Methyl-N-(1-pivaloyl-1H-indol-7-yl)benzenesulfonamide 390a (92.6 mg, 0.25 
mmol), triethylamine (0.5 mL) in MeOH (0.5 mL) was stirred at room temperature for 12 h. 
Purification by column chromatography on silica gel (n-hexane/EtOAc: 10/1) yielded 417 (68.0 mg, 
95%) as a light yellow solid. 
M. p. 152 ºC. 
1H NMR (400 MHz, CDCl3) δ 9.27 (s, 1H), 7.53 (ddd, J = 8.2, 3.5, 2.1 Hz, 2H), 7.46 (ddd, J = 8.2, 
2.1, 0.9 Hz, 1H), 7.24 (dd, J = 3.5, 2.1 Hz, 1H), 7.15 (ddd, J = 7.6, 2.1, 0.9 Hz, 2H), 6.83 (t, J = 7.6 
Hz, 1H), 6.79 (s, 1H), 6.52 (dd, J = 3.5, 2.1 Hz, 1H), 6.42 (d, J = 7.6 Hz, 1H), 2.34 (s, 3H). 
13C NMR (100 MHz, CDCl3) δ 144.04 (Cq), 134.77 (Cq), 131.8 (Cq), 130.06 (Cq), 129.55 (CH), 127.37 
(CH), 125.25 (CH), 119.92 (Cq), 119.78 (CH), 119.61 (CH), 117.87 (CH), 102.61 (CH), 21.53 (CH3). 
IR (ATR): 3413, 3251, 2922, 1583, 1334, 1156, 1090, 1038, 730, 551 cm-1. 
MS (ESI) m/z (relative intensity): 287 (10) [M+H]+, 309 (90) [M+Na]+. 
HR-MS (ESI) C15H15N2O2S [M+H]






A suspension of Methyl-3-(1-pivaloyl-1H-indol-7-yl)acrylate 394a (71.3 mg, 0.25 mmol), 
triethylamine (0.5 mL) in MeOH (0.5 mL) was stirred at room temperature for 12 h. Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 10/1) yielded 418 (48.3 mg, 96%) as a light 
yellow solid. 
M. p. 101 ºC. 
1H NMR (400 MHz, CDCl3) δ 9.06 (s, 1H), 8.13 (d, J = 16.0 Hz, 1H), 7.71 (d, J = 7.9 Hz, 1H), 7.43 
(d, J = 7.9 Hz, 1H), 7.22 (dd, J = 3.2, 1.9 Hz, 1H), 7.15 (t, J = 7.9 Hz, 1H), 6.61 (dd, J = 3.2, 1.9 Hz, 
1H), 6.57 (d, J = 16.0 Hz, 1H), 3.85 (s, 3H). 
13C NMR (100 MHz, CDCl3) δ 168.0 (Cq), 141.4 (CH), 134.3 (Cq), 128.9 (Cq), 124.9 (CH), 123.4 
(CH), 121.9 (CH), 120.0 (CH), 118.1 (Cq), 117.3 (CH), 103.1 (CH), 51.8 (CH3). 
IR (ATR): 3431, 3339, 2949, 1691, 1308, 1264, 975, 796, 716, 429 cm-1. 
MS (ESI) m/z (relative intensity): 202 (40) [M+H]+, 224 (60) [M+Na]+. 
HR-MS (ESI) C12H12NO2 [M+H]





5.3.6 Hammett Correlation 



























5.3.7 H/D Exchange Study 
1) Procedure for H/D exchange experiment 1 
A suspension of N-pivaloyl indole 390a (0.25 mmol, 1.0 equiv), Ru(OAc)2(p-cymene) (10 mol %), 
AgSbF6 (20 mol %), in [D]1-TFE (CF3CH2OD, 1.0 mL) was stirred at 40 °C for 16 h under N2 (Scheme 
5.3.11). After cooling to ambient temperature, the mixture was concentrated in vacuo. Purification by 










2) Procedure for H/D exchange experiment 2 
A suspension of N-pivaloyl indole 390a (0.25 mmol, 1.0 equiv), tosyl azide 391a (0.75 mmol, 3.0 
equiv), Ru(OAc)2(p-cymene) (10 mol %), AgSbF6 (20 mol %), in [D]1-TFE (CF3CH2OD, 1.0 mL) was 
stirred at 40 °C for 6 h under N2 (Scheme 5.3.12 and 5.3.13). After cooling to ambient temperature, the 
mixture is concentrated in vacuo. Purification by column chromatography on silica gel afforded the 
desired products [D]n-390a and [D]n-392a. 
 
 











5.3.8 KIE Study 
Two independent reactions using substrate 390a and [D]4-390a were performed to determine the KIE 
by comparison of the initial rates (Scheme 5.3.14). The conversion was determined by 1H NMR 
spectroscopy using 1,3,5-trimethoxybezene as the internal standard. Blue line is for 392a and red line 











5.3.9 Kinetic Analysis 
1) Reaction order with respect to 390a 
The reaction order with respect to 390a was examined using the initial rate method. A Schlenk-tube 
was charged with N-pivaloyl indole 390a (0.15, 0.20, 0.25, 0.30, 0.35 mmol), tosyl azide 391a (0.75 
mmol), Ru(OAc)2(p-cymene) (0.025 mmol) and 1,3,5-trimethoxybenzene (0.25 mmol) under N2 
condition (Table 5.3.1 and Scheme 5.3.15). TFE (2.0 mL) was added and the mixture was stirred at 
40 °C. Aliquots up to ca. 10% conversion (25μL; 30, 40, 50, 60, 70 min) were periodically removed 
by a syringe and directly analyzed by gas chromatography.   
 
Table 5.3.1 Kinetic analysis with respect to 390a. 
Entry k / mol L-1 s-1 10-6 log(k / mol L-1 s-1 10-6) c log(c) 
1 0.7118 -6.1476 0.075 -1.1249 
2 0.7421 -6.1295 0.1 -1.0000 
3 0.7659 -6.1158 0.125 -0.9031 
4 0.7973 -6.0984 0.15 -0.8239 
5 0.8226 -6.0848 0.175 -0.7570 
 
 





2) Reaction order with respect to 391a 
The reaction order with respect to 391a was examined using the initial rate method. A Schlenk-tube 
was charged with N-pivaloyl indole 390a (0.25 mmol), tosyl azide 391a (0.25, 0.375, 0.50, 0.625, 0.75 
mmol), Ru(OAc)2(p-cymene) (0.025 mmol) and 1,3,5-trimethoxybenzene (0.25 mmol) under N2 
condition (Table 5.3.2 and Scheme 5.3.16). TFE (2.0 mL) was added and the mixture was stirred at 
40 °C. Aliquots up to ca. 10% conversion (25μL; 30, 40, 50, 60, 70 min) were periodically removed 
by a syringe and directly analyzed by gas chromatography.   
 
Table 5.3.2 Kinetic analysis with respect to 391a. 
Entry k / mol L-1 s-1 10-6 log(k / mol L-1 s-1 10-6) c log(c) 
1 0.2584 -6.5877 0.125 -0.9031 
2 0.3831 -6.4167 0.1875 -0.7270 
3 0.5478 -6.2614 0.25 -0.6021 
4 0.7163 -6.1449 0.3125 -0.5051 
5 0.7621 -6.1180 0.375 -0.4260 
 
 





3) Reaction order with respect to Ru(OAc)2(p-cymene) 
The reaction order with respect to Ru(OAc)2(p-cymene) was examined using the initial rate method. 
A Schlenk-tube was charged with N-pivaloyl indole 390a (0.25 mmol), tosyl azide 391a (0.75 mmol), 
Ru(OAc)2(p-cymene) (0.01250, 0.01875, 0.02500, 0.03125, 0.03750 mmol) and 1,3,5-
trimethoxybenzene (0.25 mmol) under N2 condition (Table 5.3.3 and Scheme 5.3.17). TFE (2.0 mL) 
was added and the mixture was stirred at 40 °C. Aliquots up to ca. 10% conversion (25μL; 30, 40, 50, 
60, 70 min) were periodically removed by a syringe and directly analyzed by gas chromatography.  
  
Table 5.3.3 Kinetic analysis with respect to Ru(OAc)2(p-cymene). 
Entry k / mol L-1 s-1 10-6 log(k / mol L-1 s-1 10-6) c log(c) 
1 0.4556 -6.3414 5 -2.2041 
2 0.6298 -6.2008 7.5 -2.0280 
3 0.8541 -6.0685 10 -1.9031 
4 1.0745 -5.9688 12.5 -1.8062 
5 1.4067 -5.8518 15 -1.7270 
 
 





5.4 Ruthenium(II)-Catalyzed C4/C6–H Dual Alkylations of Indoles 
5.4.1 Characterization Data 
Diethyl 2,2'-[1-(pyridin-2-yl)-1H-indole-4,6-diyl]bis(2-methylpropanoate) (397a) 
 
The General Procedure C was followed using 1-(pyridin-2-yl)-1H-indole 395a (48.6 mg, 0.25 
mmol), ethyl 2-bromo-2-methylpropanoate 396a (243 mg, 1.25 mmol), Ru(OAc)2(PPh3)2 (18.6 mg, 10 
mol %), NaOAc (41.0 mg, 0.50 mmol) in DCE (2.0 mL). Purification by column chromatography on 
silica gel (n-hexane/EtOAc: 5/1) yielded 397a (81.3 mg, 77%) as colorless oil. 
1H NMR (400 MHz, CDCl3) δ 8.55 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 8.10 (dd, J = 1.6, 0.9 Hz, 1H), 
7.80 (ddd, J = 8.2, 7.4, 2.0 Hz, 1H), 7.60 (d, J = 3.6 Hz, 1H), 7.43 (dd, J = 8.2, 0.9 Hz, 1H), 7.16 (ddd, 
J = 7.4, 4.9, 0.9 Hz, 1H), 7.13 (d, J = 1.6 Hz, 1H), 6.64 (dd, J = 3.6, 0.9 Hz, 1H), 4.12 (q, J = 7.1 Hz, 
2H), 4.08 (q, J = 7.1 Hz, 2H), 1.65 (s, 6H), 1.64 (s, 6H), 1.16 (t, J = 7.1 Hz, 3H), 1.09 (t, J = 7.1 Hz, 
3H). 
13C NMR (100 MHz, CDCl3) δ 177.7 (Cq), 177.1 (Cq), 152.4 (Cq), 149.0 (CH), 139.7 (Cq), 138.4 (CH), 
136.9 (Cq), 135.4 (Cq), 126.7 (Cq), 125.8 (CH), 120.2 (CH), 115.7 (CH), 115.1 (CH), 108.4 (CH), 104.2 
(CH), 60.7 (CH2), 60.6 (CH2), 46.9 (Cq), 46.5 (Cq), 26.9 (CH3), 26.3 (CH3), 14.1 (CH3), 14.0 (CH3). 
IR (ATR): 2979, 1721, 1468, 1439, 1249, 1134, 1024, 912, 772, 717 cm-1. 
MS (ESI) m/z (relative intensity): 423 (70) [M+H]+, 440 (30) [M+NH4]
+. 
HR-MS (ESI) C25H31N2O4 [M+H]
+: 423.2278, found: 423.2282. 





Dimethyl 2,2'-[1-(pyridin-2-yl)-1H-indole-4,6-diyl]bis(2-methylpropanoate) (397b) 
 
The General Procedure C was followed using 1-(pyridin-2-yl)-1H-indole 395a (48.6 mg, 0.25 
mmol), methyl 2-bromo-2-methylpropanoate 396b (148 mg, 0.75 mmol), Ru(OAc)2(PPh3)2 (18.6 mg, 
10 mol %), NaOAc (41.0 mg, 0.50 mmol) in DCE (2.0 mL). Purification by column chromatography 
on silica gel (n-hexane/EtOAc: 5/1) yielded 397b (79.8 mg, 81%) as colorless oil. 
1H NMR (400 MHz, CDCl3) δ 8.55 (ddd, J = 4.9, 1.6, 0.9 Hz, 1H), 8.09 (dd, J = 1.6, 0.9 Hz, 1H), 
7.81 (ddd, J = 8.2, 7.4, 1.6 Hz, 1H), 7.61 (d, J = 3.6 Hz, 1H), 7.43 (dd, J = 8.2, 0.9 Hz, 1H), 7.16 (ddd, 
J = 7.4, 4.9, 0.9 Hz, 1H), 7.13 (d, J = 1.6 Hz, 1H), 6.60 (dd, J = 3.6, 0.9 Hz, 1H), 3.64 (s, 3H), 3.59 
(s, 3H), 1.67 (s, 6H), 1.65 (s, 6H). 
13C NMR (100 MHz, CDCl3) δ 178.3 (Cq), 177.6 (Cq), 152.3 (Cq), 149.0 (CH), 139.5 (Cq), 138.4 (CH), 
136.9 (Cq), 135.3 (Cq), 126.8 (Cq), 126.1 (CH), 120.3 (CH), 115.4 (CH), 115.1 (CH), 108.6 (CH), 103.8 
(CH), 52.2 (CH3), 52.1 (CH3), 46.9 (Cq), 46.5 (Cq), 26.9 (CH3), 26.3 (CH3). 
IR (ATR): 2976, 2949, 1729, 1721, 1469, 1436, 1250, 1130, 730, 719 cm-1. 
MS (ESI) m/z (relative intensity): 395 (80) [M+H]+, 412 (20) [M+NH4]
+. 
HR-MS (ESI) C23H27N2O4 [M+H]
+: 395.1965, found: 395.1967. 
 
Dipropyl 2,2'-[1-(pyridin-2-yl)-1H-indole-4,6-diyl]bis(2-methylpropanoate) (397c) 
 
The General Procedure C was followed using 1-(pyridin-2-yl)-1H-indole 395a (48.6 mg, 0.25 




10 mol %), NaOAc (41.0 mg, 0.50 mmol) in DCE (2.0 mL). Purification by column chromatography 
on silica gel (n-hexane/EtOAc: 5/1) yielded 397c (77.7 mg, 69%) as colorless oil. 
1H NMR (400 MHz, CDCl3) δ 8.55 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 8.10 (dd, J = 1.6, 0.9 Hz, 1H), 
7.80 (ddd, J = 8.2, 7.4, 2.0 Hz, 1H), 7.60 (d, J = 3.6 Hz, 1H), 7.43 (dd, J = 8.2, 0.9 Hz, 1H), 7.15 (ddd, 
J = 7.4, 4.9, 0.9 Hz, 1H), 7.14 (d, J = 1.6 Hz, 1H), 6.64 (dd, J = 3.6, 0.9 Hz, 1H), 4.01 (t, J = 6.6 Hz, 
2H), 3.97 (t, J = 6.6 Hz, 2H), 1.67 (s, 6H), 1.65 (s, 6H), 1.50 – 1.59 (m, 2H), 1.43 – 1.51 (m, 2H), 0.79 
(t, J = 7.4 Hz, 3H), 0.69 (t, J = 7.4 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 177.7 (Cq), 177.2 (Cq), 152.4 (Cq), 149.0 (CH), 139.7 (Cq), 138.3 (CH), 
137.0 (Cq), 135.4 (Cq), 126.7 (Cq), 125.8 (CH), 120.2 (CH), 115.7 (CH), 115.1 (CH), 108.5 (CH), 104.2 
(CH), 66.3 (CH2), 66.3 (CH2), 46.9 (Cq), 46.6 (Cq), 26.9 (CH3), 26.3 (CH3), 21.9 (CH2), 21.8 (CH2), 
10.4 (CH3), 10.1 (CH3). 
IR (ATR): 2971, 2933, 2880, 1722, 1467, 1439, 1247, 1131, 773, 727 cm-1. 
MS (ESI) m/z (relative intensity): 451 (66) [M+H]+, 473 (34) [M+Na]+. 
HR-MS (ESI) C27H35N2O4 [M+H]
+: 451.2595, found: 451.2591. 
 
Diisopropyl 2,2'-[1-(pyridin-2-yl)-1H-indole-4,6-diyl]bis(2-methylpropanoate) (397d) 
 
The General Procedure C was followed using 1-(pyridin-2-yl)-1H-indole 395a (48.6 mg, 0.25 
mmol), isopropyl 2-bromo-2-methylpropanoate 396d (261 mg, 1.25 mmol), Ru(OAc)2(PPh3)2 (18.6 
mg, 10 mol %), NaOAc (41.0 mg, 0.50 mmol) in DCE (2.0 mL). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 5/1) yielded 397d (81.1 mg, 72%) as colorless oil. 
1H NMR (400 MHz, CDCl3) δ 8.54 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 8.09 (dd, J = 1.6, 0.9 Hz, 1H), 
7.79 (ddd, J = 8.3, 7.4, 2.0 Hz, 1H), 7.59 (d, J = 3.6 Hz, 1H), 7.43 (dd, J = 8.3, 0.9 Hz, 1H), 7.14 (ddd, 
J = 7.4, 4.9, 0.9 Hz, 1H), 7.10 (d, J = 1.6 Hz, 1H), 6.65 (dd, J = 3.6, 0.9 Hz, 1H), 4.94 – 5.05 (m, 2H), 




13C NMR (100 MHz, CDCl3) δ 177.1 (Cq), 176.6 (Cq), 152.5 (Cq), 148.9 (CH), 139.9 (Cq), 138.3 (CH), 
137.0 (Cq), 135.4 (Cq), 126.6 (Cq), 125.5 (CH), 120.1 (CH), 115.9 (CH), 115.0 (CH), 108.2 (CH), 104.4 
(CH), 67.9 (CH), 67.7 (CH), 46.9 (Cq), 46.6 (Cq), 26.8 (CH3), 26.3 (CH3), 21.5 (CH3), 21.5 (CH3). 
IR (ATR): 2978, 2934, 1713, 1573, 1469, 1439, 1253, 1152, 1104, 906, 729, 718 cm-1. 
MS (ESI) m/z (relative intensity): 451 (60) [M+H]+, 473 (40) [M+Na]+. 
HR-MS (ESI) C27H35N2O4 [M+H]
+: 451.2592, found: 451.2591. 
 
Dibutyl 2,2'-[1-(pyridin-2-yl)-1H-indole-4,6-diyl]bis(2-methylpropanoate) (397e) 
 
The General Procedure C was followed using 1-(pyridin-2-yl)-1H-indole 395a (48.6 mg, 0.25 
mmol), butyl 2-bromo-2-methylpropanoate 396e (279 mg, 1.25 mmol), Ru(OAc)2(PPh3)2 (18.6 mg, 10 
mol %), NaOAc (41.0 mg, 0.50 mmol) in DCE (2.0 mL). Purification by column chromatography on 
silica gel (n-hexane/EtOAc: 5/1) yielded 397e (101.7 mg, 85%) as colorless oil. 
1H NMR (400 MHz, CDCl3) δ 8.55 (ddd, J = 4.8, 2.0, 0.9 Hz, 1H), 8.09 (dd, J = 1.6, 0.9 Hz, 1H), 
7.80 (ddd, J = 8.2, 7.3, 2.0 Hz, 1H), 7.60 (d, J = 3.6 Hz, 1H), 7.43 (dd, J = 8.2, 0.9 Hz, 1H), 7.15 (ddd, 
J = 7.3, 4.8, 0.9 Hz, 1H), 7.13 (d, J = 1.6 Hz, 1H), 6.64 (dd, J = 3.6, 0.9 Hz, 1H), 4.05 (d, J = 6.6 Hz, 
2H), 4.01 (d, J = 6.6 Hz, 2H), 1.67 (s, 6H), 1.64 (s, 6H), 1.51 (dt, J = 14.4, 6.6 Hz, 2H), 1.44 (dt, J = 
14.4, 6.6 Hz, 2H), 1.24 (dq, J = 14.4, 7.4 Hz, 2H), 1.12 (dq, J = 14.4, 7.4 Hz, 2H), 0.81 (t, J = 7.4 Hz, 
3H), 0.74 (t, J = 7.4 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 177.7 (Cq), 177.2 (Cq), 152.4 (Cq), 149.0 (CH), 139.7 (Cq), 138.3 (CH), 
136.9 (Cq), 135.4 (Cq), 126.7 (Cq), 125.8 (CH), 120.2 (CH), 115.7 (CH), 115.0 (CH), 108.5 (CH), 104.1 
(CH), 64.6 (CH2), 64.5 (CH2), 46.9 (Cq), 46.6 (Cq), 30.6 (CH2), 30.4 (CH2), 26.9 (CH3), 26.2 (CH3), 
19.0 (CH2), 18.9 (CH2), 13.6 (CH3), 13.5 (CH3). 
IR (ATR): 2959, 2932, 2876, 1720, 1469, 1437, 1247, 1133, 730, 717 cm-1. 




HR-MS (ESI) C29H39N2O4 [M+H]
+: 479.2907, found: 479.2904. 
 
Diisobutyl 2,2'-[1-(pyridin-2-yl)-1H-indole-4,6-diyl]bis(2-methylpropanoate) (397f) 
 
The General Procedure C was followed using 1-(pyridin-2-yl)-1H-indole 395a (48.6 mg, 0.25 
mmol), isobutyl 2-bromo-2-methylpropanoate 396f (243 mg, 1.25 mmol), Ru(OAc)2(PPh3)2 (18.6 mg, 
10 mol %), NaOAc (41.0 mg, 0.50 mmol) in DCE (2.0 mL). Purification by column chromatography 
on silica gel (n-hexane/EtOAc: 5/1) yielded 397f (90.9 mg, 76%) as colorless oil. 
1H NMR (400 MHz, CDCl3) δ 8.55 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 8.14 – 8.07 (m, 1H), 7.79 (ddd, J 
= 8.2, 7.3, 1.9 Hz, 1H), 7.59 (d, J = 3.5 Hz, 1H), 7.43 (dd, J = 8.2, 1.0 Hz, 1H), 7.15 (ddd, J = 7.4, 
4.9, 0.9 Hz, 1H), 7.11 (d, J = 1.6 Hz, 1H), 6.66 (dd, J = 3.6, 0.8 Hz, 1H), 4.75 – 4.87 (m, 2H), 1.66 (s, 
3H), 1.65 (s, 3H), 1.64 (s, 3H), 1.63 (s, 3H), 1.50 – 1.40 (m, 2H), 1.39 – 1.30 (m, 2H), 1.09 (dd, J = 
6.3, 1.0 Hz, 3H), 1.01 (dd, J = 6.3, 2.4 Hz, 3H), 0.74 (td, J = 7.4, 1.2 Hz, 3H), 0.61 (td, J = 7.4, 5.0 
Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 177.3 (Cq), 176.8 (Cq), 152.5 (Cq), 149.0 (CH), 139.9 (Cq), 138.3 (CH), 
137.0 (Cq), 135.4 (Cq), 126.6 (Cq), 125.5 (CH), 120.1 (CH), 115.9 (CH), 115.0 (CH), 108.2 (CH), 104.5 
(CH), 72.5 (CH), 72.3 (CH), 47.0 (Cq), 46.6 (Cq), 28.7 (CH2), 28.6 (CH2), 26.9 (CH3), 26.2 (CH3), 19.2 
(CH3), 19.1 (CH3), 9.72 (CH3), 9.42 (CH3). 
IR (ATR): 2973, 2935, 2878, 1715, 1470, 1437, 1250, 1150, 1110, 733 cm-1. 
MS (ESI) m/z (relative intensity): 479 (66) [M+H]+, 501 (34) [M+Na]+. 
HR-MS (ESI) C29H39N2O4 [M+H]





Bis(2-methoxyethyl) 2,2'-[1-(pyridin-2-yl)-1H-indole-4,6-diyl]bis(2-methylpropanoate) (397g) 
 
The General Procedure C was followed using 1-(pyridin-2-yl)-1H-indole 395a (48.6 mg, 0.25 
mmol), 2-methoxyethyl 2-bromo-2-methylpropanoate 396g (281 mg, 1.25 mmol), Ru(OAc)2(PPh3)2 
(18.6 mg, 10 mol %), NaOAc (41.0 mg, 0.50 mmol) in DCE (2.0 mL). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 5/1) yielded 397g (103 mg, 85%) as colorless oil. 
1H NMR (400 MHz, CDCl3) δ 8.55 (ddd, J = 4.8, 1.9, 0.8 Hz, 1H), 8.08 (dd, J = 1.6, 0.8 Hz, 1H), 
7.81 (ddd, J = 8.2, 7.4, 1.9 Hz, 1H), 7.61 (d, J = 3.5 Hz, 1H), 7.44 (dd, J = 8.2, 0.9 Hz, 1H), 7.22 – 
7.10 (m, 2H), 6.65 (dd, J = 3.5, 0.8 Hz, 1H), 4.28 – 4.06 (m, 4H), 3.55 – 3.47 (m, 2H), 3.47 – 3.37 (m, 
2H), 3.21 (s, 3H), 3.14 (s, 3H), 1.69 (s, 6H), 1.66 (s, 6H). 
13C NMR (100 MHz, CDCl3) δ δ 177.6 (Cq), 177.0 (Cq), 152.4 (Cq), 149.1 (CH), 139.5 (Cq), 138.4 
(CH), 136.8 (Cq), 135.4 (Cq), 126.8 (Cq), 126.0 (CH), 120.3 (CH), 115.7 (CH), 115.1 (CH), 108.7 (CH), 
104.1 (CH), 70.3 (CH2), 70.3 (CH2), 64.0 (CH2), 63.8 (CH2), 58.8 (CH3), 58.8 (CH3), 46.9 (Cq), 46.6 
(Cq), 26.9 (CH3), 26.2 (CH3). 
IR (ATR): 2981, 2928, 1727, 1584, 1470, 1441, 1250, 1194, 1153, 1125 cm-1. 
MS (ESI) m/z (relative intensity): 483 (70) [M+H]+, 500 (30) [M+NH4]
+. 
HR-MS (ESI) C27H35N2O6 [M+H]
+: 483.2491, found: 483.2490. 
 
Bis(2-ethylbutyl) 2,2'-[1-(pyridin-2-yl)-1H-indole-4,6-diyl]bis(2-methylpropanoate) (397h) 
 




mmol), 2-ethylbutyl 2-bromo-2-methylpropanoate 396h (314 mg, 1.25 mmol), Ru(OAc)2(PPh3)2 (18.6 
mg, 10 mol %), NaOAc (41.0 mg, 0.50 mmol) in DCE (2.0 mL). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 5/1) yielded 397h (119 mg, 89%) as colorless oil. 
1H NMR (400 MHz, CDCl3) δ 8.55 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 8.08 (dd, J = 1.6, 0.8 Hz, 1H), 
7.79 (ddd, J = 8.2, 7.4, 2.0 Hz, 1H), 7.60 (d, J = 3.6 Hz, 1H), 7.42 (dd, J = 8.2, 1.0 Hz, 1H), 7.17 – 
7.13 (ddd, J = 7.4, 4.9, 0.9 Hz, 1H),  7.16 (d, J = 1.6 Hz, 1H), 6.63 (dd, J = 3.6, 0.8 Hz, 1H), 3.96 (d, 
J = 5.7 Hz, 2H), 3.91 (d, J = 5.8 Hz, 2H), 1.67 (s, 6H), 1.64 (s, 6H), 1.45 – 1.39 (m, 1H), 1.35 – 1.29 
(m, 1H), 1.24 – 1.17 (m, 4H), 1.13 – 0.98 (m, 4H), 0.75 (t, J = 7.5 Hz, 6H), 0.65 (t, J = 7.5 Hz, 6H). 
13C NMR (100 MHz, CDCl3) δ 177.8 (Cq), 177.2 (Cq), 152.4 (Cq), 149.0 (CH), 139.7 (Cq), 138.3 (CH), 
136.9 (Cq), 135.4 (Cq), 126.8 (Cq), 125.8 (CH), 120.2 (CH), 115.6 (CH), 115.0 (CH), 108.5 (CH), 104.1 
(CH), 66.7 (CH2), 66.6 (CH2), 47.0 (Cq), 46.6 (Cq), 40.2 (CH), 40.0 (CH), 26.9 (CH3), 26.1 (CH3), 23.2 
(CH2), 23.1 (CH2), 10.9 (CH3), 10.8 (CH3). 
IR (ATR): 2964, 2930, 2870, 1724, 1466, 1438, 1249, 1130, 992, 774 cm-1. 
MS (ESI) m/z (relative intensity): 535 (70) [M+H]+, 557 (30) [M+Na]+. 
HR-MS (ESI) C33H47N2O4 [M+H]
+: 535.3533, found: 535.3530. 
 
Bis(4-phenylbutan-2-yl) 2,2'-[1-(pyridin-2-yl)-1H-indole-4,6-diyl]bis(2-methylpropanoate) (397i) 
 
The General Procedure C was followed using 1-(pyridin-2-yl)-1H-indole 395a (48.6 mg, 0.25 
mmol), 4-phenylbutan-2-yl 2-bromo-2-methylpropanoate 396i (374 mg, 1.25 mmol), 
Ru(OAc)2(PPh3)2 (18.6 mg, 10 mol %), NaOAc (41.0 mg, 0.50 mmol) in DCE (2.0 mL). Purification 
by column chromatography on silica gel (n-hexane/EtOAc: 5/1) yielded 397i (99.4 mg, 63%) as 
colorless oil. 
1H NMR (400 MHz, CDCl3) δ 8.54 (ddd, J = 4.9, 1.9, 0.7 Hz, 1H), 8.16 (d, J = 2.5 Hz, 1H), 7.80 – 




– 7.15 (m, 2H), 7.15 – 7.07 (m, 5H), 7.00 – 6.96 (m, 2H), 6.90 – 6.84 (m, 2H), 6.71 (d, J = 3.7 Hz, 
1H), 4.98 – 4.80 (m, 2H), 2.53 – 2.38 (m, 2H), 2.32 – 2.15 (m, 2H), 1.86 – 1.71 (m, 2H), 1.70 (s, 3H), 
1.69 (s, 3H), 1.68 (s, 3H), 1.67 (s, 3H), 1.65 – 1.53 (m, 2H), 1.13 (dd, J = 6.3, 1.8 Hz, 3H), 1.05 (dd, 
J = 12.4, 6.2 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 177.2 (Cq), 176.7 (Cq), 152.4 (Cq), 149.0 (CH), 141.6 (Cq), 141.5 (Cq), 
139.9 (Cq), 138.3 (CH), 137.0 (Cq), 135.5 (Cq), 128.3 (CH), 128.3 (CH), 128.2 (CH), 128.2 (CH), 
126.7 (Cq), 125.8 (CH), 125.7 (CH), 125.6 (CH), 120.2 (CH),115.8 (CH), 115.0 (CH), 108.6 (CH), 
104.5 (CH), 70.6 (CH), 70.5 (CH), 47.0 (Cq), 46.7 (Cq), 37.6 (CH2), 37.4 (CH2), 31.7 (CH2), 31.2 
(CH2), 26.9 (CH3), 26.2 (CH3), 19.8 (CH3), 19.7 (CH3). 
IR (ATR): 2976, 2935, 1719, 1466, 1442, 1250, 1155, 1127, 741, 726 cm-1. 
MS (ESI) m/z (relative intensity): 631 (66) [M+H]+, 653 (34) [M+Na]+. 
HR-MS (ESI) C41H47N2O4 [M+H]
+: 631.3530, found: 631.3530. 
 
Bis(4-iodobenzyl) 2,2'-[1-(pyridin-2-yl)-1H-indole-4,6-diyl]bis(2-methylpropanoate) (397j) 
 
The General Procedure C was followed using 1-(pyridin-2-yl)-1H-indole 395a (48.6 mg, 0.25 
mmol), 4-iodobenzyl 2-bromo-2-methylpropanoate 396j (479 mg, 1.25 mmol), Ru(OAc)2(PPh3)2 (18.6 
mg, 10 mol %), NaOAc (41.0 mg, 0.50 mmol) in DCE (2.0 mL). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 5/1) yielded 397j (184 mg, 92%) as colorless oil. 
1H NMR (400 MHz, CDCl3) δ 8.54 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 8.15 (dd, J = 1.4, 0.8 Hz, 1H), 
7.79 (ddd, J = 8.2, 7.4, 2.0 Hz, 1H), 7.50 (d, J = 3.6 Hz, 1H), 7.47 (d, J = 8.3 Hz, 2H), 7.46 (d, J = 
8.3 Hz, 2H), 7.36 (d, J = 8.2 Hz, 1H), 7.17 (ddd, J = 7.4, 4.9, 0.9 Hz, 1H), 7.08 (d, J = 1.6 Hz, 1H), 
6.87 (d, J = 8.3 Hz, 2H), 6.75 (d, J = 8.3 Hz, 2H), 6.48 (dd, J = 3.6, 0.8 Hz, 1H), 4.99 (s, 2H), 4.97 (s, 
2H), 1.68 (s, 6H), 1.63 (s, 6H). 




137.4 (CH), 137.2 (CH), 136.5 (Cq), 135.8 (Cq), 135.7 (Cq), 135.4 (Cq), 129.6 (CH), 129.5 (CH), 126.7 
(Cq), 125.9 (CH), 120.3 (CH), 115.5 (CH), 115.0 (CH), 109.0 (CH), 103.9 (CH), 93.5 (Cq), 93.4 (Cq), 
65.6 (CH2), 65.5 (CH2), 46.9 (Cq), 46.5 (Cq), 26.8 (CH3), 26.0 (CH3). 
IR (ATR): 2976, 1722, 1466, 1441, 1314, 1247, 1132, 742, 726, 696 cm-1. 
MS (ESI) m/z (relative intensity): 799 (66) [M+H]+, 821 (34) [M+Na]+. 
HR-MS (ESI) C35H33I2N2O4 [M+H]





The General Procedure C was followed using 1-(pyridin-2-yl)-1H-indole 395a (48.6 mg, 0.25 
mmol), (1R,2S,5R)-2-isopropyl-5-methylcyclohexyl 2-bromo-2-methylpropanoate 396k (382 mg, 
1.25 mmol), Ru(OAc)2(PPh3)2 (18.6 mg, 10 mol %), NaOAc (41.0 mg, 0.50 mmol) in DCE (2.0 mL). 
Purification by column chromatography on silica gel (n-hexane/EtOAc: 5/1) yielded 397k (137 mg, 
85%) as colorless oil. 
1H NMR (400 MHz, CDCl3) δ 8.55 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 8.06 (dd, J = 1.5, 0.8 Hz, 1H), 
7.79 (ddd, J = 8.2, 7.3, 1.9 Hz, 1H), 7.58 (d, J = 3.6 Hz, 1H), 7.42 (d, J = 8.2 Hz, 1H), 7.14 (ddd, J = 
7.4, 4.9, 0.9 Hz, 1H), 7.09 (d, J = 1.5 Hz, 1H), 6.68 (dd, J = 3.6, 0.8 Hz, 1H), 4.64 (td, J = 10.9, 4.3 
Hz, 1H), 4.53 (td, J = 10.9, 4.3 Hz, 1H), 2.09 – 1.86 (m, 2H), 1.67 (s, 3H), 1.65 (s, 3H), 1.64 (s, 3H), 
1.60 (s, 3H), 1.58 – 1.47 (m, 3H), 1.47 – 1.37 (m, 2H), 1.35 – 1.29 (m, 1H), 1.30 – 1.22 (m, 1H), 1.17 
– 1.10 (m, 1H), 1.03 – 0.86 (m, 2H), 0.83 (d, J = 2.6 Hz, 3H), 0.81 (d, J = 2.6 Hz, 3H), 0.80 – 0.73 
(m, 6H), 0.71 (d, J = 7.0 Hz, 3H), 0.61 (d, J = 7.0 Hz, 3H), 0.59 (d, J = 7.0 Hz, 3H), 0.46 (d, J = 7.0 
Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 177.0 (Cq), 176.8 (Cq), 152.5 (Cq), 149.0 (CH), 140.0 (Cq), 138.3 (CH), 




(CH), 74.6 (CH), 74.3 (CH), 47.1 (CH2), 47.1 (CH2), 46.8 (CH), 46.7 (CH), 40.5 (Cq), 40.3 (Cq), 34.2 
(CH2), 47.1 (CH2), 31.3 (CH), 31.3 (CH), 27.2 (CH3), 26.8 (CH3), 26.2 (CH), 26.0 (CH), 25.8 (CH3), 
23.1 (CH2), 23.1 (CH2), 22.0 (CH3), 20.7 (CH3), 15.9 (CH3). 
IR (ATR): 2975, 1724, 1474, 1465, 1439, 1245, 1127, 909, 772, 727 cm-1. 
MS (ESI) m/z (relative intensity): 643 (30) [M+H]+, 660 (70) [M+NH4]
+. 
HR-MS (ESI) C41H59N2O4 [M+H]
+: 643.4472, found: 643.4469. 
 
Diphenethyl 2,2'-[1-(pyridin-2-yl)-1H-indole-4,6-diyl]bis(2-methylpropanoate) (397l) 
 
The General Procedure C was followed using 1-(pyridin-2-yl)-1H-indole 395a (48.6 mg, 0.25 
mmol), phenethyl 2-bromo-2-methylpropanoate 396l (339 mg, 1.25 mmol), Ru(OAc)2(PPh3)2 (18.6 
mg, 10 mol%), NaOAc (41.0 mg, 0.50 mmol) in DCE (2.0 mL). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 5/1) yielded 397l (92.0 mg, 64%) as colorless oil. 
1H NMR (400 MHz, CDCl3) δ 8.56 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 8.12 (dd, J = 1.5, 0.8 Hz, 1H), 
7.80 (ddd, J = 8.3, 7.4, 2.0 Hz, 1H), 7.58 (d, J = 3.6 Hz, 1H), 7.39 (d, J = 8.3 Hz, 1H), 7.19 – 7.16 (m, 
2H), 7.13 – 7.08 (m, 6H), 7.02 – 6.98 (m, 2H), 6.94 – 6.87 (m, 2H), 6.58 (dd, J = 3.6, 0.9 Hz, 1H), 
4.25 (t, J = 7.0 Hz, 2H), 4.20 (t, J = 6.9 Hz, 2H), 2.81 (t, J = 7.0 Hz, 2H), 2.72 (t, J = 7.0 Hz, 2H), 
1.66 (s, 6H), 1.65 (s, 6H). 
13C NMR (100 MHz, CDCl3) δ 177.6 (Cq), 177.0 (Cq), 152.4 (Cq), 149.0 (CH), 139.5 (Cq), 138.3 (CH), 
137.8 (Cq), 137.8 (Cq), 136.8 (Cq), 135.5 (Cq), 128.9 (CH), 128.8 (CH), 128.2 (CH), 128.1 (CH), 126.8 
(Cq), 126.3 (CH), 126.2 (CH), 125.9 (CH), 120.2 (CH), 115.5 (CH), 115.0 (CH), 108.8 (CH), 104.0 
(CH), 65.3 (CH2), 65.2 (CH2), 46.8 (Cq), 46.5 (Cq), 35.0 (CH2), 34.9 (CH2), 26.7 (CH3), 26.2 (CH3). 
IR (ATR): 2954, 2927, 2869, 1710, 1470, 1437, 1251, 1139, 907, 731 cm-1. 
MS (ESI) m/z (relative intensity): 575 (66) [M+H]+, 597 (34) [M+Na]+. 
HR-MS (ESI) C37H39N2O4 [M+H]





phenanthren-3-yl] 2,2'-[1-(pyridin-2-yl)-1H-indole-4,6-diyl]bis(2-methylpropanoate) (397m) 
 
The General Procedure C was followed using 1-(pyridin-2-yl)-1H-indole 395a (48.6 mg, 0.25 
mmol), (8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclo 
penta[a]phenan-thren-3-yl 2-bromo-2-methylpropanoate 396m (524 mg, 1.25 mmol), 
Ru(OAc)2(PPh3)2 (18.6 mg, 10 mol %), NaOAc (41.0 mg, 0.50 mmol) in DCE (2.0 mL). Purification 
by column chromatography on silica gel (n-hexane/EtOAc: 5/1) yielded 397m (172.0 mg, 79%) as 
colorless oil. 
1H NMR (400 MHz, CDCl3) δ 8.58 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 8.33 – 8.25 (m, 1H), 7.82 (ddd, J 
= 8.2, 7.4, 2.0 Hz, 1H), 7.70 (d, J = 3.6 Hz, 1H), 7.48 (d, J = 8.2 Hz, 1H), 7.34 (d, J = 1.6 Hz, 1H), 
7.19 (ddd, J = 8.2, 4.9, 0.9, 1H), 7.18 – 7.11 (m, 2H), 6.82 (dd, J = 3.6, 0.8 Hz, 1H), 6.72 (dd, J = 8.5, 
2.6 Hz, 1H), 6.68 – 6.60 (m, 3H), 2.83 – 2.74 (m, 4H), 2.49 (d, J = 8.9 Hz, 1H), 2.44 (d, J = 8.6 Hz, 
1H), 2.36 – 2.29 (m, 2H), 2.25 – 2.17 (m, 2H), 2.09 (dd, J = 18.9, 8.9 Hz, 2H), 2.04 – 1.98 (m, 2H), 
1.98 – 1.89 (m, 5H), 1.84 (s, 6H), 1.80 (s, 6H), 1.65 – 1.28 (m, 11H), 0.86 (s, 3H), 0.86 (s, 3H). 
13C NMR (100 MHz, CDCl3) δ 220.6 (Cq), 220.6 (Cq), 176.6 (Cq), 176.0 (Cq), 152.4 (Cq), 149.0 (CH), 
149.0 (CH), 148.9 (Cq), 148.9 (Cq), 139.3 (Cq), 138.5 (CH), 137.7 (Cq), 137.7 (Cq), 137.0 (Cq), 137.0 
(Cq), 136.5 (Cq), 135.6 (Cq), 126.8 (Cq), 126.1 (CH), 126.1 (CH), 121.4 (CH), 121.3 (CH), 120.3 (CH), 
118.7 (CH), 118.5 (CH), 115.7 (CH), 115.1 (CH), 109.0 (CH), 104.1 (CH), 50.3 (CH), 50.3 (CH), 47.9 
(Cq), 47.9 (Cq), 47.3 (Cq), 46.8 (Cq), 44.0 (CH), 44.0 (CH), 37.9 (CH), 37.9 (CH), 35.8 (CH2), 35.8 
(CH2), 31.5 (CH2), 31.5 (CH2), 29.3 (CH2), 29.2 (CH2), 26.7 (CH3), 26.7 (CH3), 26.3 (CH2), 26.3 (CH2), 
26.3 (CH3), 26.3 (CH3), 25.7 (CH2), 25.7 (CH2), 21.5 (CH2), 21.5 (CH2), 13.7 (CH3), 13.7 (CH3). 
IR (ATR): 2976, 2931, 1734, 1437, 1207, 1150, 1118, 908, 734, 722 cm-1. 
MS (ESI) m/z (relative intensity): 871 (50) [M+H]+, 888 (90) [M+NH4]
+. 
HR-MS (ESI) C57H63N2O6 [M+H]









The General Procedure C was followed using 1-(pyridin-2-yl)-1H-indole 395a (48.6 mg, 0.25 
mmol), ((3aR,5R,5aS,8aS,8bR)-2,2,7,7-tetramethyltetrahydro-5H-bis([1,3]dioxolo)[4,5-b:4',5'-
d]pyran-5-yl) methyl 2-bromo-2-methylpropanoate 396n (512 mg, 1.25 mmol), Ru(OAc)2(PPh3)2 
(18.6 mg, 10 mol %), NaOAc (41.0 mg, 0.50 mmol) in DCE (2.0 mL). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 5/1) yielded 397n (157.4 mg, 74%) as colorless oil. 
1H NMR (400 MHz, CDCl3) δ 8.54 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 8.08 – 8.07 (m, 1H), 7.80 (ddd, J 
= 8.2, 7.4, 2.0 Hz, 1H), 7.59 (d, J = 3.6 Hz, 1H), 7.43 (d, J = 8.3 Hz, 1H), 7.17 (d, J = 1.3 Hz, 1H), 
7.15 (ddd, J = 8.3, 4.9, 0.9 Hz, 1H), 6.62 (dd, J = 3.5, 0.9 Hz, 1H), 5.44 (t, J = 4.9 Hz, 2H), 4.49 (dd, 
J = 7.9, 2.4 Hz, 1H), 4.43 (dd, J = 7.9, 2.4 Hz, 1H), 4.26 – 4.20 (m, 4H), 4.19 – 4.13 (m, 2H), 4.01 
(dd, J = 7.9, 1.8 Hz, 1H), 3.94 (ddd, J = 7.2, 5.1, 1.8 Hz, 1H), 3.89 (ddd, J = 7.2, 5.1, 1.8 Hz, 1H), 
3.86 (dd, J = 7.9, 1.8 Hz, 1H), 1.70 (s, 3H), 1.67 (s, 3H), 1.67 (s, 3H), 1.64 (s, 3H), 1.42 (s, 3H), 1.37 
(s, 3H), 1.36 (s, 3H), 1.35 (s, 3H), 1.27 (s, 3H), 1.25 (s, 3H), 1.19 (s, 3H), 1.19 (s, 3H). 
13C NMR (100 MHz, CDCl3) δ 177.4 (Cq), 176.8 (Cq), 152.3 (Cq), 149.1 (CH), 139.3 (Cq), 138.4 (CH), 
136.7 (Cq), 135.3 (Cq), 126.8 (Cq), 126.0 (CH), 120.2 (CH), 115.5 (CH), 115.0 (CH), 109.4 (Cq), 109.3 
(Cq), 108.9 (CH), 108.6 (Cq), 108.6 (Cq), 104.0 (CH), 96.2 (CH), 96.1 (CH), 70.8 (CH), 70.7 (CH), 
70.5 (CH), 70.5 (CH), 65.8 (CH), 65.7 (CH), 63.4 (CH2), 63.3 (CH2), 46.8 (Cq), 46.6 (Cq), 27.1 (CH3), 
26.6 (CH3), 26.4 (CH3), 26.1 (CH3), 26.0 (CH3), 25.8 (CH3), 25.0 (CH3), 24.2 (CH3). 




MS (ESI) m/z (relative intensity): 851 (30) [M+H]+, 868 (70) [M+NH4]
+. 
HR-MS (ESI) C45H59N2O14 [M+H]






5.4.2 Mechanistic Investigation 
1) Procedure for H/D exchange experiment 
A suspension of 1-(pyridin-2-yl)-1H-indole 395a (0.25 mmol, 1.0 equiv), ethyl α-bromoisobutyrate 
396a (1.25 mmol, 5.0 equiv), Ru(OAc)2(PPh3)2 (10 mol %), NaOAc (2 equiv), and D2O (10 equiv) in 
DCE (2.0 mL) was stirred at 70 °C for 16 h under N2 (Scheme 5.4.1). After cooling to room temperature, 
the mixture was concentrated in vacuo. Purification by column chromatography on silica gel afforded 
the desired product [D]n-397a.  
 
 
Scheme 5.4.1 H/D exchange study for ruthenium-catalyzed C4/C6–H alkylations. 
 
2) Experiment with C7-blocked substrate 
A suspension of 7-methyl-1-(pyridin-2-yl)-1H-indole 395b (0.25 mmol, 1.0 equiv), ethyl α-
bromoisobutyrate 396a (1.25 mmol, 5.0 equiv), Ru(OAc)2(PPh3)2 (10 mol %), and NaOAc (0.50 mmol, 




temperature, the mixture is concentrated in vacuo. Purification by column chromatography on silica 
gel afforded the desired product 397o.  
 
 
Scheme 5.4.2 ruthenium-catalyzed C4/C6–H alkylations with 395b. 
 
Diethyl 2,2'-[7-methyl-1-(pyridin-2-yl)-1H-indole-4,6-diyl]bis(2-methylpropanoate) (397o) 
 
The General Procedure C was followed using 7-methyl-1-(pyridin-2-yl)-1H-indole 395b (52.1 mg, 
0.25 mmol), Ethyl α-bromoisobutyrate 396a (243 mg, 1.25 mmol), Ru(OAc)2(PPh3)2 (18.6 mg, 10 mol 
%), NaOAc (41.0 mg, 0.50 mmol) in DCE (2.0 mL). Purification by column chromatography on silica 
gel (n-hexane/EtOAc: 5/1) yielded 397o (84.0 mg, 71%) as colorless oil. 
1H NMR (400 MHz, CDCl3) δ 8.52 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 7.75 (ddd, J = 7.9, 7.6, 2.0 Hz, 
1H), 7.24 (ddd, J = 7.9, 4.9, 0.9 Hz, 1H), 7.23 (dd, J = 4.9, 4.9 Hz, 1H) , 7.20 (s, 1H), 7.19 (ddd, J = 
7.9, 0.9, 0.9 Hz, 1H), 6.59 (d, J = 3.5 Hz, 1H), 4.11 (q, J = 7.1 Hz, 2H), 4.11 (q, J = 7.1 Hz, 2H), 1.83 
(s, 3H), 1.69 (s, 6H), 1.61 (s, 6H), 1.18 (t, J = 7.1 Hz, 3H), 1.14 (t, J = 7.1 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 178.8 (Cq), 178.0 (Cq), 154.1 (Cq), 148.7 (CH), 137.8 (Cq), 137.7 (CH), 
137.1 (Cq), 134.1 (Cq), 130.4 (CH), 127.2 (Cq), 121.9 (CH), 120.5 (CH), 119.1 (Cq), 115.2 (CH), 103.2 
(CH), 60.7 (CH2), 60.7 (CH2), 46.9 (Cq), 46.5 (Cq), 27.9 (CH3), 26.4 (CH3), 17.4 (CH3), 14.1 (CH3). 
IR (ATR):  2975, 2945, 1732, 1720, 1468, 1438, 1250, 1150, 731, 720cm-1. 
MS (ESI) m/z (relative intensity): 385 (34) [M+H]+, 407 (66) [M+Na]+. 
HR-MS (ESI) C26H33N2O4 [M+H]




5.5 Osmium-Catalyzed Electrooxidative C–H Annulations 
5.5.1 Characterization Data 
Butyl 2-(4-methyl-3-oxo-1,3-dihydroisobenzofuran-1-yl)acetate (400a) 
 
The General Procedure D was followed using 2-methylbenzoic acid 398a (27.2 mg, 0.20 mmol), n-
butyl acrylate 399a (76.9 mg, 0.60 mmol), [OsCl2(p-cymene)]2 (7.9 mg, 5.0 mol %), KI (66.4 mg, 2.0 
equiv), KOAc (39.3 mg, 2.0 equiv) in HFIP (2.0 mL) and H2O (2.0 mL). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 8/1) yielded 400a (39.3 mg, 75%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.49 (t, J = 7.6 Hz, 1H), 7.24 (ddd, J = 7.6, 3.8, 0.8 Hz, 2H), 5.77 (t, J 
= 6.5 Hz, 1H), 4.11 (t, J = 6.5 Hz, 2H), 2.83 (d, J = 6.5 Hz, 2H), 2.64 (s, 3H), 1.61 – 1.52 (m, 2H), 
1.32 (dq, J = 14.6, 7.4 Hz, 2H), 0.88 (t, J = 7.4 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 170.0 (Cq), 169.3 (Cq), 149.2 (Cq), 139.8 (Cq), 133.9 (CH), 131.0 (CH), 
123.3 (Cq), 119.2 (CH), 76.0 (CH), 65.0 (CH2), 39.7 (CH2), 30.4 (CH2), 19.0 (CH2), 17.2 (CH3), 13.6 
(CH3). 
IR (ATR): 2960, 2927, 1745, 1711, 1519, 1371, 1321, 1065, 956, 608 cm-1. 
MS (ESI) m/z (relative intensity): 263 (40) [M+H]+, 285 (60) [M+Na]+. 
HR-MS (ESI) C15H19O4 [M+H]
+: 263.1279, found: 263.1281. 
The spectral data were in accordance with those reported in the literature.[236h] 
 
Butyl 2-(3-oxo-1,3-dihydroisobenzofuran-1-yl)acetate (400b) 
 
The General Procedure D was followed using benzoic acid 398b (24.4 mg, 0.20 mmol), n-butyl 
acrylate 399a (76.9 mg, 0.60 mmol), [OsCl2(p-cymene)]2 (7.9 mg, 5.0 mol %), KI (66.4 mg, 2.0 equiv), 




chromatography on silica gel (n-hexane/EtOAc: 8/1) yielded 400b (35.3 mg, 71%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.90 (d, J = 7.7 Hz, 1H), 7.66 (dd, J = 7.5, 1.1 Hz, 1H), 7.54 (t, J = 7.5 
Hz, 1H), 7.48 (ddd, J = 7.7, 1.1, 0.8 Hz, 1H), 5.87 (t, J = 6.6 Hz, 1H), 4.14 (t, J = 6.6 Hz, 2H), 2.98 – 
2.80 (m, 2H), 1.69 – 1.54 (m, 2H), 1.35 (dq, J = 14.7, 7.4 Hz, 2H), 0.91 (t, J = 7.4 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 169.8 (Cq), 169.3 (Cq), 148.8 (Cq), 134.2 (CH), 129.5 (CH), 126.0 (Cq), 
125.8 (CH), 122.1 (CH), 77.0 (CH), 65.2 (CH2), 39.6 (CH2), 30.5 (CH2), 19.0 (CH2), 13.6 (CH3). 
IR (ATR):  2959, 2933, 1759, 1599, 1466, 1288, 1172, 1059, 748, 571 cm-1. 
MS (ESI) m/z (relative intensity): 249 (40) [M+H]+, 271 (60) [M+Na]+. 
HR-MS (ESI) C14H17O4 [M+H]
+: 249.1124, found: 249.1121. 
The spectral data were in accordance with those reported in the literature.[236h] 
 
Butyl 2-(3-oxo-4-phenyl-1,3-dihydroisobenzofuran-1-yl)acetate (400c) 
 
The General Procedure D was followed using 2-phenyl benzoic acid 398c (39.6 mg, 0.20 mmol), n-
butyl acrylate 399a (76.9 mg, 0.60 mmol), [OsCl2(p-cymene)]2 (7.9 mg, 5.0 mol %), KI (66.4 mg, 2.0 
equiv), KOAc (39.3 mg, 2.0 equiv) in HFIP (2.0 mL) and H2O (2.0 mL). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 8/1) yielded 400c (42.2 mg, 65%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.72 (t, J = 7.6 Hz, 1H), 7.59 – 7.43 (m, 7H), 5.89 (t, J = 6.5 Hz, 1H), 
4.20 (t, J = 6.5 Hz, 2H), 2.96 (dd, J = 6.5, 1.5 Hz, 2H), 1.71 – 1.55 (m, 2H), 1.47 – 1.32 (m, 2H), 0.96 
(t, J = 7.3 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 169.4 (Cq), 168.6 (Cq), 150.1 (Cq), 143.0 (Cq), 136.2 (Cq), 134.0 (CH), 
131.3 (CH), 129.5 (CH), 128.4 (CH), 128.0 (CH), 121.9 (Cq), 120.7 (CH), 75.6 (CH), 65.2 (CH2), 39.8 
(CH2), 30.5 (CH2), 19.1 (CH2), 13.7 (CH3). 
IR (ATR): 2959, 2931, 1760, 1575, 1308, 1236, 1199, 1015, 944, 697 cm-1. 
MS (ESI) m/z (relative intensity): 325 (66) [M+H]+, 347 (34) [M+Na]+. 
HR-MS (ESI) C20H21O4 [M+H]




The spectral data were in accordance with those reported in the literature.[236g] 
 
Butyl 2-(4-bromo-3-oxo-1,3-dihydroisobenzofuran-1-yl)acetate (400d) 
 
The General Procedure D was followed using 2-bromo benzoic acid 398d (40.2 mg, 0.20 mmol), n-
butyl acrylate 399a (76.9 mg, 0.60 mmol), [OsCl2(p-cymene)]2 (7.9 mg, 5.0 mol %), KI (66.4 mg, 2.0 
equiv), KOAc (39.3 mg, 2.0 equiv) in HFIP (2.0 mL) and H2O (2.0 mL). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 8/1) yielded 400d (32.1 mg, 49%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.69 (d, J = 7.7 Hz, 1H), 7.49 (t, J = 7.7 Hz, 1H), 7.43 (d, J = 7.6 Hz, 
1H), 5.79 (t, J = 6.5 Hz, 1H), 4.13 (t, J = 6.7 Hz, 2H), 2.99 – 2.81 (m, 2H), 1.64 – 1.52 (m, 2H), 1.34 
(dq, J = 14.6, 7.4 Hz, 2H), 0.91 (t, J = 7.4 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 169.1 (Cq), 167.1 (Cq), 151.2 (Cq), 135.1 (CH), 134.3 (CH), 124.4 (Cq), 
121.2 (Cq), 121.1 (CH), 75.3 (CH), 65.3 (CH2), 39.4 (CH2), 30.5 (CH2), 19.0 (CH2), 13.6 (CH3). 
IR (ATR): 2959, 2932, 1763, 1722, 1582, 1343, 1207, 1173, 1011, 679 cm-1. 
MS (ESI) m/z (relative intensity): 327 (66) (79Br) [M+H]+, 349 (34) (79Br) [M+Na]+. 
HR-MS (ESI) C14H16
79BrO4 [M+H]
+: 327.0225, found: 327.0226. 
The spectral data were in accordance with those reported in the literature.[266] 
 
Butyl 2-(5-methyl-3-oxo-1,3-dihydroisobenzofuran-1-yl)acetate (400e) 
 
The General Procedure D was followed using 3-methyl benzoic acid 398e (27.2 mg, 0.20 mmol), n-
butyl acrylate 399a (76.9 mg, 0.60 mmol), [OsCl2(p-cymene)]2 (7.9 mg, 5.0 mol %), KI (66.4 mg, 2.0 
equiv), KOAc (39.3 mg, 2.0 equiv) in HFIP (2.0 mL) and H2O (2.0 mL). Purification by column 




1H NMR (400 MHz, CDCl3) δ 7.68 (s, 1H), 7.46 (ddd, J = 7.8, 1.6, 0.8 Hz, 1H), 7.35 (d, J = 7.8 Hz, 
1H), 5.82 (t, J = 6.6 Hz, 1H), 4.14 (t, J = 6.7 Hz, 2H), 2.94 – 2.76 (m, 2H), 2.44 (s, 3H), 1.64 – 1.55 
(m, 2H), 1.40 – 1.29 (m, 2H), 0.91 (t, J = 7.4 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 170.0 (Cq), 169.4 (Cq), 146.2 (Cq), 139.9 (Cq), 135.4 (CH), 126.1 (Cq), 
125.8 (CH), 121.7 (CH), 76.9 (CH), 65.1 (CH2), 39.7 (CH2), 30.5 (CH2), 21.2 (CH3), 19.1 (CH2), 13.7 
(CH3). 
IR (ATR): 2960, 2929, 1771, 1733, 1495, 1290, 1154, 1009, 750, 557 cm-1. 
MS (ESI) m/z (relative intensity): 263 (45) [M+H]+, 285 (55) [M+Na]+. 
HR-MS (ESI) C15H19O4 [M+H]
+: 263.1281, found: 263.1278. 
The spectral data were in accordance with those reported in the literature.[236h] 
 
Butyl 2-(5-chloro-3-oxo-1,3-dihydroisobenzofuran-1-yl)acetate (400f) 
 
The General Procedure D was followed using 3-chloro benzoic acid 398f (31.4 mg, 0.20 mmol), n-
butyl acrylate 399a (76.9 mg, 0.60 mmol), [OsCl2(p-cymene)]2 (7.9 mg, 5.0 mol %), KI (66.4 mg, 2.0 
equiv), KOAc (39.3 mg, 2.0 equiv) in HFIP (2.0 mL) and H2O (2.0 mL). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 8/1) yielded 400f (24.3 mg, 43%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ 8.02 (s, 1H), 7.77 (d, J = 8.1 Hz, 1H), 7.39 (d, J = 8.1 Hz, 1H), 5.81 (t, 
J = 6.5 Hz, 1H), 4.14 (t, J = 6.7 Hz, 2H), 3.00 – 2.78 (m, 2H), 1.59 (dt, J = 14.6, 6.7 Hz, 2H), 1.34 (dq, 
J = 14.6, 7.4 Hz, 2H), 0.91 (t, J = 7.4 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 169.1 (Cq), 168.2 (Cq), 147.4 (Cq), 137.3 (CH), 128.8 (CH), 128.1 (Cq), 
123.8 (CH), 123.6 (Cq), 76.9 (CH), 65.3 (CH2), 39.2 (CH2), 30.5 (CH2), 19.0 (CH2), 13.6 (CH3). 
IR (ATR): 2959, 2932, 1654, 1710, 1418, 1287, 1174, 1071, 1006, 771 cm-1. 
MS (ESI) m/z (relative intensity): 283 (45) [M+H]+, 305 (55) [M+Na]+. 
HR-MS (ESI) C14H16
35ClO4 [M+H]





Butyl 2-(5-bromo-3-oxo-1,3-dihydroisobenzofuran-1-yl)acetate (400g) 
 
The General Procedure D was followed using 3-bromo benzoic acid 398g (40.2 mg, 0.20 mmol), n-
butyl acrylate 399a (76.9 mg, 0.60 mmol), [OsCl2(p-cymene)]2 (7.9 mg, 5.0 mol %), KI (66.4 mg, 2.0 
equiv), KOAc (39.3 mg, 2.0 equiv) in HFIP (2.0 mL) and H2O (2.0 mL). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 8/1) yielded 400g (34.0 mg, 52%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.86 (s, 1H), 7.62 (d, J = 8.2 Hz, 1H), 7.45 (d, J = 8.2 Hz, 1H), 5.84 (t, 
J = 6.6 Hz, 1H), 4.14 (t, J = 6.7 Hz, 2H), 3.00 – 2.78 (m, 2H), 1.60 (dt, J = 14.6, 6.7 Hz, 2H), 1.34 (dq, 
J = 14.6, 7.4 Hz, 2H), 0.91 (s, 3H). 
13C NMR (100 MHz, CDCl3) δ 169.1 (Cq), 168.4 (Cq), 146.9 (Cq), 135.9 (Cq), 134.5 (CH), 127.9 (Cq), 
125.8 (CH), 123.5 (CH), 76.8 (CH), 65.3 (CH2), 39.3 (CH2), 30.5 (CH2), 19.0 (CH2), 13.6 (CH3). 
IR (ATR): 2960, 2934, 1776, 1763, 1425, 1288, 1204, 1175, 1006, 832 cm-1. 
MS (ESI) m/z (relative intensity): 327 (50) (79Br) [M+H]+, 349 (50) (79Br) [M+Na]+. 
HR-MS (ESI) C14H16
79BrO4 [M+H]
+: 327.0229, found: 327.0226. 
 
Butyl 2-(3-oxo-5-(trifluoromethyl)-1,3-dihydroisobenzofuran-1-yl)acetate (400h) 
 
The General Procedure D was followed using 3-trifluoromethyl benzoic acid 398h (38.0 mg, 0.20 
mmol), n-butyl acrylate 399a (76.9 mg, 0.60 mmol), [OsCl2(p-cymene)]2 (7.9 mg, 5.0 mol %), KI 
(66.4 mg, 2.0 equiv), KOAc (39.3 mg, 2.0 equiv) in HFIP (2.0 mL) and H2O (2.0 mL). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 8/1) yielded 400h (33.5 mg, 53%) as a white 
solid. 
M. p. 94 °C 




Hz, 1H), 4.14 (t, J = 6.7 Hz, 2H), 3.05 – 2.82 (m, 2H), 1.63 – 1.55 (m, 2H), 1.34 (dq, J = 14.7, 7.4 Hz, 
2H), 0.91 (t, J = 7.4 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 168.9 (Cq), 168.3 (Cq), 151.9 (Cq), 132.6 (q, JC–F = 33.5 Hz, Cq), 131.1 
(q, JC–F = 3.5 Hz, CH), 127.0 (Cq), 123.2 (CH), 123.2 (d, JC–F = 272.8 Hz, Cq), 123.1 (q, JC–F = 4.1 Hz, 
CH), 77.0 (CH), 65.4 (CH2), 39.0 (CH2), 30.5 (CH2), 19.0 (CH2), 13.6 (CH3). 
19F NMR (282 MHz, CDCl3) δ -62.6. 
IR (ATR): 2962, 2935, 1779, 1734, 1398, 1329, 1168, 1126, 1007, 615 cm-1. 
MS (ESI) m/z (relative intensity): 317 (30) [M+H]+, 339 (70) [M+Na]+. 
HR-MS (ESI) C15H16F3O4 [M+H]
+: 317.0996, found: 317.0995. 
The spectral data were in accordance with those reported in the literature.[236g] 
 
Butyl 2-(5-(dimethylamino)-3-oxo-1,3-dihydroisobenzofuran-1-yl)acetate (400i) 
 
The General Procedure D was followed using 3-(dimethylamino)benzoic acid 398i (33.0 mg, 0.20 
mmol), n-butyl acrylate 399a (76.9 mg, 0.60 mmol), [OsCl2(p-cymene)]2 (7.9 mg, 5.0 mol %), KI 
(66.4 mg, 2.0 equiv), KOAc (39.3 mg, 2.0 equiv) in HFIP (2.0 mL) and H2O (2.0 mL). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 8/1) yielded 400i (39.6 mg, 68%) as a 
colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.27 (d, J = 8.5 Hz, 1H), 7.08 (d, J = 2.4 Hz, 1H), 6.98 (dd, J = 8.5, 2.4 
Hz, 1H), 5.77 (t, J = 6.6 Hz, 1H), 4.14 (t, J = 6.7 Hz, 2H), 3.00 (s, 6H), 2.91 – 2.72 (m, 2H), 1.65 – 
1.55 (m, 2H), 1.35 (dq, J = 14.7, 7.4 Hz, 2H), 0.91 (t, J = 7.4 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 170.9 (Cq), 169.6 (Cq), 151.5 (Cq), 136.2 (Cq), 126.9 (Cq), 122.3 (CH), 
118.7 (CH), 106.9 (CH), 76.9 (CH), 65.0 (CH2), 40.6 (CH3), 40.1 (CH2), 30.5 (CH2), 19.1 (CH2), 13.7 
(CH3). 
IR (ATR): 2959, 2930, 1767, 1758, 1625, 1510, 1345, 1166, 776, 567 cm-1. 




HR-MS (ESI) C16H22NO4 [M+H]
+: 292.1545, found: 292.1543. 
 
Butyl 2-(6-methyl-3-oxo-1,3-dihydroisobenzofuran-1-yl)acetate (400j) 
 
The General Procedure D was followed using 4-methyl benzoic acid 398j (27.2 mg, 0.20 mmol), n-
butyl acrylate 399a (76.9 mg, 0.60 mmol), [OsCl2(p-cymene)]2 (7.9 mg, 5.0 mol %), KI (66.4 mg, 2.0 
equiv), KOAc (39.3 mg, 2.0 equiv) in HFIP (2.0 mL) and H2O (2.0 mL). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 8/1) yielded 400j (43.0 mg, 82%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.76 (d, J = 7.8 Hz, 1H), 7.33 (d, J = 7.8 Hz, 1H), 7.28 – 7.22 (m, 1H), 
5.80 (t, J = 6.6 Hz, 1H), 4.14 (t, J = 6.7 Hz, 2H), 2.93 – 2.77 (m, 2H), 2.46 (s, 3H), 1.64 – 1.56 (m, 
2H), 1.35 (dq, J = 14.7, 7.4 Hz, 2H), 0.91 (t, J = 7.4 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 169.9 (Cq), 169.4 (Cq), 149.4 (Cq), 145.6 (Cq), 130.7 (CH), 125.6 (CH), 
123.4 (Cq), 122.4 (CH), 76.7 (CH), 65.2 (CH2), 39.6 (CH2), 30.5 (CH2), 22.1 (CH3), 19.1 (CH2), 13.7 
(CH3). 
IR (ATR): 2960, 2932, 1768, 1758, 1617, 1314, 1279, 1166, 1012, 687 cm-1. 
MS (ESI) m/z (relative intensity): 263 (60) [M+H]+, 285 (40) [M+Na]+. 
HR-MS (ESI) C15H19O4 [M+H]
+: 263.1278, found: 263.1278. 
The spectral data were in accordance with those reported in the literature.[236h] 
 
Butyl 2-(6-(tert-butyl)-3-oxo-1,3-dihydroisobenzofuran-1-yl)acetate (400k) 
 
The General Procedure D was followed using 4-tert-butyl benzoic acid 398k (35.6 mg, 0.20 mmol), 
n-butyl acrylate 399a (76.9 mg, 0.60 mmol), [OsCl2(p-cymene)]2 (7.9 mg, 5.0 mol %), KI (66.4 mg, 




chromatography on silica gel (n-hexane/EtOAc: 8/1) yielded 400k (40.8 mg, 67%) as a white solid. 
M. p. 96 °C 
1H NMR (400 MHz, CDCl3) δ 7.81 (d, J = 8.2 Hz, 1H), 7.57 (dd, J = 8.2, 1.6 Hz, 1H), 7.47 – 7.42 (m, 
1H), 5.84 (t, J = 6.7 Hz, 1H), 4.15 (td, J = 6.7, 2.7 Hz, 2H), 2.96 – 2.80 (m, 2H), 1.61 (dt, J = 14.6, 6.7 
Hz, 2H), 1.38 – 1.32 (m, 2H), 1.34 (s, 9H), 0.91 (t, J = 7.4 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 169.9 (Cq), 169.5 (Cq), 158.7 (Cq), 149.2 (Cq), 127.2 (CH), 125.4 (CH), 
123.3 (Cq), 118.5 (CH), 77.0 (CH), 65.1 (CH2), 39.8 (CH2), 35.6 (Cq), 31.2 (CH3), 30.6 (CH2), 19.1 
(CH2), 13.7 (CH3). 
IR (ATR): 2967, 2935, 1771, 1750, 1697, 1315, 1280, 1005, 874, 666 cm-1. 
MS (ESI) m/z (relative intensity): 305 (60) [M+H]+, 327 (40) [M+Na]+. 
HR-MS (ESI) C18H25O4 [M+H]
+: 305.1749, found: 305.1747. 
The spectral data were in accordance with those reported in the literature.[236g] 
 
Butyl 2-(6-methoxy-3-oxo-1,3-dihydroisobenzofuran-1-yl)acetate (400l) 
 
The General Procedure D was followed using 4-methoxybenzoic acid 398l (30.4 mg, 0.20 mmol), n-
butyl acrylate 399a (76.9 mg, 0.60 mmol), [OsCl2(p-cymene)]2 (7.9 mg, 5.0 mol %), KI (66.4 mg, 2.0 
equiv), KOAc (39.3 mg, 2.0 equiv) in HFIP (2.0 mL) and H2O (2.0 mL). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 8/1) yielded 400l (47.3 mg, 85%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.79 (d, J = 8.6 Hz, 1H), 7.03 (dd, J = 8.6, 2.2 Hz, 1H), 6.91 (d, J = 2.2 
Hz, 1H), 5.78 (t, J = 6.6 Hz, 1H), 4.15 (t, J = 6.7 Hz, 2H), 3.87 (s, 3H), 2.95 – 2.77 (m, 2H), 1.64 – 
1.56 (m, 2H), 1.35 (dq, J = 14.6, 7.4 Hz, 2H), 0.91 (t, J = 7.4 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 169.6 (Cq), 169.4 (Cq), 164.8 (Cq), 151.6 (Cq), 127.3 (CH), 118.2 (Cq), 
116.7 (CH), 106.2 (CH), 76.2 (CH), 65.2 (CH2), 55.8 (CH3), 39.6 (CH2), 30.5 (CH2), 19.1 (CH2), 13.7 
(CH3). 




MS (ESI) m/z (relative intensity): 279 (60) [M+H]+, 301 (40) [M+Na]+. 
HR-MS (ESI) C15H19O5 [M+H]
+: 279.1229, found: 279.1227. 
The spectral data were in accordance with those reported in the literature.[236g] 
 
Butyl 2-(6-fluoro-3-oxo-1,3-dihydroisobenzofuran-1-yl)acetate (400m) 
 
The General Procedure D was followed using 4-fluorobenzoic acid 398m (28.0 mg, 0.20 mmol), n-
butyl acrylate 399a (76.9 mg, 0.60 mmol), [OsCl2(p-cymene)]2 (7.9 mg, 5.0 mol %), KI (66.4 mg, 2.0 
equiv), KOAc (39.3 mg, 2.0 equiv) in HFIP (2.0 mL) and H2O (2.0 mL). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 8/1) yielded 400m (24.5 mg, 46%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.88 (dd, J = 8.4, 4.8 Hz, 1H), 7.25 – 7.17 (m, 2H), 5.81 (t, J= 6.6 Hz, 
1H), 4.15 (t, J = 6.7 Hz, 2H), 3.02 – 2.78 (m, 2H), 1.65 – 1.57 (m, 2H), 1.35 (dq, J = 14.7, 7.4 Hz, 2H), 
0.91 (t, J = 7.4 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 169.1 (Cq), 168.2 (d, J = 75.8 Hz, Cq), 165.3 (Cq), 151.6 (d, JC–F = 10.3 
Hz, Cq), 128.2 (d, JC–F = 10.4 Hz, CH), 122.0 (d, JC–F = 2.0 Hz, Cq), 117.8 (d, JC–F = 24.0 Hz, CH), 
109.8 (d, JC–F = 24.9 Hz, CH), 76.2 (d, JC–F = 2.9 Hz, CH), 65.3 (CH2), 39.2 (CH2), 30.5 (CH2), 19.0 
(CH2), 13.6 (CH3). 
19F NMR (282 MHz, CDCl3) δ -102.13 (td, J = 8.4, 4.9 Hz). 
IR (ATR): 2961, 1934, 1761, 1723, 1604, 1243, 1008, 882, 742, 682 cm-1. 
MS (ESI) m/z (relative intensity): 267 (30) [M+H]+, 289 (70) [M+Na]+.  
HR-MS (ESI) C14H16FO4 [M+H]
+: 267.1030, found: 267.1027. 








Butyl 2-(6-chloro-3-oxo-1,3-dihydroisobenzofuran-1-yl)acetate (400n) 
 
The General Procedure D was followed using 4-chlorobenzoic acid 398n (31.3 mg, 0.20 mmol), n-
butyl acrylate 399a (76.9 mg, 0.60 mmol), [OsCl2(p-cymene)]2 (7.9 mg, 5.0 mol %), KI (66.4 mg, 2.0 
equiv), KOAc (39.3 mg, 2.0 equiv) in HFIP (2.0 mL) and H2O (2.0 mL). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 8/1) yielded 400n (28.3 mg, 50%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.81 (d, J = 8.6 Hz, 1H), 7.53 – 7.49 (m, 2H), 5.81 (t, J = 6.6 Hz, 1H), 
4.14 (t, J = 6.7 Hz, 2H), 3.01 – 2.78 (m, 2H), 1.64 – 1.56 (m, 2H), 1.35 (dq, J = 14.7, 7.4 Hz, 2H), 0.91 
(t, J = 7.4 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 169.1 (Cq), 168.7 (Cq), 150.4 (Cq), 141.0 (Cq), 130.3 (CH), 127.0 (CH), 
124.5 (Cq), 122.8 (CH), 76.4 (CH), 65.3 (CH2), 39.2 (CH2), 30.5 (CH2), 19.0 (CH2), 13.6 (CH3). 
IR (ATR): 2960, 2932, 1768, 1722, 1617, 1314, 1166, 1012, 904, 687 cm-1. 
MS (ESI) m/z (relative intensity): 283 (55) [M+H]+, 305 (45) [M+Na]+. 
HR-MS (ESI) C14H16ClO4 [M+H]
+: 283.0733, found: 283.0732. 
The spectral data were in accordance with those reported in the literature.[236g] 
 
Butyl 2-(6-bromo-3-oxo-1,3-dihydroisobenzofuran-1-yl)acetate (400o) 
 
The General Procedure D was followed using 4-bromobenzoic acid 398o (40.2 mg, 0.20 mmol), n-
butyl acrylate 399a (76.9 mg, 0.60 mmol), [OsCl2(p-cymene)]2 (7.9 mg, 5.0 mol %), KI (66.4 mg, 2.0 
equiv), KOAc (39.3 mg, 2.0 equiv) in HFIP (2.0 mL) and H2O (2.0 mL). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 8/1) yielded 440o (34.7 mg, 53%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.74 (d, J = 8.7 Hz, 1H), 7.69 – 7.66 (m, 2H), 5.82 (t, J = 6.6 Hz, 1H), 




(t, J = 7.4 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 169.1 (Cq), 168.8 (Cq), 150.5 (Cq), 133.2 (CH), 129.5 (Cq), 127.1 (CH), 
125.8 (CH), 125.0 (Cq), 76.3 (CH), 65.3 (CH2), 39.2 (CH2), 30.5 (CH2), 19.1 (CH2), 13.6 (CH3). 
IR (ATR): 2959, 2933, 1761, 1722, 1588, 1395, 1263, 1210, 1062, 781 cm-1. 
MS (ESI) m/z (relative intensity): 327 (50) (79Br) [M+H]+, 349 (50) [M+Na]+. 
HR-MS (ESI) C14H16
79BrO4 [M+H]
+: 327.0231, found: 327.0226. 
The spectral data were in accordance with those reported in the literature.[236g] 
 
Butyl 2-(6-iodo-3-oxo-1,3-dihydroisobenzofuran-1-yl)acetate (400p) 
 
The General Procedure D was followed using 4-iodobenzoic acid 398p (49.6 mg, 0.20 mmol), n-
butyl acrylate 399a (76.9 mg, 0.60 mmol), [OsCl2(p-cymene)]2 (7.9 mg, 5.0 mol %), KI (66.4 mg, 2.0 
equiv), KOAc (39.3 mg, 2.0 equiv) in HFIP (2.0 mL) and H2O (2.0 mL). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 8/1) yielded 400p (45.6 mg, 61%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.90 – 7.87 (m, 2H), 7.62 – 7.59 (m, 1H), 5.80 (t, J = 6.6 Hz, 1H), 4.15 
(td, J = 6.7, 1.6 Hz, 2H), 2.99 – 2.78 (m, 2H), 1.64 – 1.57 (m, 2H), 1.35 (dq, J = 14.8, 7.4 Hz, 2H), 
0.92 (t, J = 7.4 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 169.1 (Cq), 169.1 (Cq), 150.4 (Cq), 139.0 (CH), 131.7 (CH), 127.0 
(CH), 125.5 (Cq), 102.1 (Cq), 76.2 (CH), 65.3 (CH2), 39.2 (CH2), 30.5 (CH2), 19.1 (CH2), 13.7 (CH3). 
IR (ATR): 2958, 2931, 1765, 1728, 1584, 1395, 1264, 1178, 1007, 678 cm-1. 
MS (ESI) m/z (relative intensity): 375 (60) [M+H]+, 397 (40) [M+Na]+. 
HR-MS (ESI) C14H16IO4 [M+H]
+: 375.0088, found: 375.0089. C14H15IO4Na [M+Na]
+: 396.9909, 
found: 396.9907. 






Butyl 2-(6-(dimethylamino)-3-oxo-1,3-dihydroisobenzofuran-1-yl)acetate (400q) 
 
The General Procedure D was followed using 4-(dimethylamino)benzoic acid 398q (33.0 mg, 0.20 
mmol), n-butyl acrylate 399a (76.9 mg, 0.60 mmol), [OsCl2(p-cymene)]2 (7.9 mg, 5.0 mol %), KI 
(66.4 mg, 2.0 equiv), KOAc (39.3 mg, 2.0 equiv) in HFIP (2.0 mL) and H2O (2.0 mL). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 8/1) yielded 400q (48.9 mg, 84%) as a 
colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.65 (d, J = 8.7 Hz, 1H), 6.72 (dd, J = 8.7, 2.2 Hz, 1H), 6.51 (d, J = 2.2 
Hz, 1H), 5.70 (t, J = 6.6 Hz, 1H), 4.12 (t, J = 6.7 Hz, 2H), 3.05 (s, 6H), 2.82 (dd, J = 6.6, 4.2 Hz, 2H), 
1.63 – 1.54 (m, 2H), 1.34 (dq, J = 14.7, 7.4 Hz, 2H), 0.89 (t, J = 7.4 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 170.4 (Cq), 169.7 (Cq), 154.4 (Cq), 151.7 (Cq), 126.7 (CH), 113.0 (CH), 
112.3 (Cq), 102.4 (CH), 76.2 (CH), 65.0 (CH2), 40.3 (CH3), 40.0 (CH2), 30.5 (CH2), 19.0 (CH2), 13.6 
(CH3). 
IR (ATR): 2958, 2931, 1723, 1605, 1519, 1351, 1116, 1005, 791, 692 cm-1. 
MS (ESI) m/z (relative intensity): 292 (60) [M+H]+, 314 (40) [M+Na]+. 
HR-MS (ESI) C16H22NO4 [M+H]
+: 292.1544, found: 292.1543. 
The spectral data were in accordance with those reported in the literature.[266] 
 
Butyl 2-(1-oxo-1,3-dihydronaphtho[1,2-c]furan-3-yl)acetate (400s) 
 
The General Procedure D was followed using naphthoic acid 398s (34.4 mg, 0.20 mmol), n-butyl 
acrylate 399a (76.9 mg, 0.60 mmol), [OsCl2(p-cymene)]2 (7.9 mg, 5.0 mol %), KI (66.4 mg, 2.0 equiv), 
KOAc (39.3 mg, 2.0 equiv) in HFIP (2.0 mL) and H2O (2.0 mL). Purification by column 




1H NMR (400 MHz, CDCl3) δ 8.99 (d, J = 8.3 Hz, 1H), 8.13 (d, J = 8.3 Hz, 1H), 7.95 (d, J = 8.3 Hz, 
1H), 7.72 (ddd, J = 8.3, 7.0, 1.3 Hz, 1H), 7.63 (ddd, J = 8.3, 7.0, 1.3 Hz, 1H), 7.51 (d, J = 8.3 Hz, 1H), 
5.94 (t, J = 6.6 Hz, 1H), 4.16 (t, J = 6.7 Hz, 2H), 2.94 (d, J = 6.6 Hz, 2H), 1.64 – 1.56 (m, 2H), 1.34 
(dq, J = 14.9, 7.4 Hz, 2H), 0.89 (t, J = 7.4 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 170.1 (Cq), 169.4 (Cq), 150.4 (Cq), 135.7 (CH), 133.5 (Cq), 129.2 (CH), 
129.1 (Cq), 128.4 (CH), 127.5 (CH), 123.6 (CH), 120.3 (Cq), 118.4 (CH), 76.4 (CH), 65.2 (CH2), 39.4 
(CH2), 30.5 (CH2), 19.1 (CH2), 13.6 (CH3). 
IR (ATR): 2961, 2933, 1760, 1734, 1610, 1699, 1340, 1291, 1154, 1009, 844, 596 cm-1. 
MS (ESI) m/z (relative intensity): 299 (70) [M+H]+, 321 (30) [M+Na]+. 
HR-MS (ESI) C18H19O4 [M+H]
+: 299.1278, found: 299.1278. 
The spectral data were in accordance with those reported in the literature.[268] 
 
tert-Butyl 2-(4-methyl-3-oxo-1,3-dihydroisobenzofuran-1-yl)acetate (400t) 
 
The General Procedure D was followed using 2-methylbenzoic acid 398t (27.2 mg, 0.20 mmol), t-
butyl acrylate 399b (76.9 mg, 0.60 mmol), [OsCl2(p-cymene)]2 (7.9 mg, 5.0 mol %), KI (66.4 mg, 2.0 
equiv), KOAc (39.3 mg, 2.0 equiv) in HFIP (2.0 mL) and H2O (2.0 mL). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 8/1) yielded 400t (19.9 mg, 38%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.50 (t, J = 7.6 Hz, 1H), 7.30 – 7.22 (m, 2H), 5.74 (t, J = 6.4 Hz, 1H), 
2.79 (dd, J = 6.4, 2.7 Hz, 2H), 2.67 (s, 3H), 1.42 (s, 9H). 
13C NMR (100 MHz, CDCl3) δ 170.2 (Cq), 168.5 (Cq), 149.5 (Cq), 139.8 (Cq), 133.8 (CH), 131.0 (CH), 
123.6 (Cq), 119.2 (CH), 81.9 (Cq), 40.8 (CH), 29.7 (CH2), 28.0 (CH3), 17.3 (CH3). 
IR (ATR): 2959, 2931, 1760, 1722, 1486, 1304, 1210, 1157, 1005, 627 cm-1. 
MS (ESI) m/z (relative intensity): 263 (45) [M+H]+, 285 (55) [M+Na]+. 
HR-MS (ESI) C15H19O4 [M+H]
+: 263.1278, found: 263.1278. 




Hexyl 2-(4-methyl-3-oxo-1,3-dihydroisobenzofuran-1-yl)acetate (400u) 
 
The General Procedure D was followed using 2-methylbenzoic acid 398u (27.2 mg, 0.20 mmol), n-
hexyl acrylate 399c (93.7 mg, 0.60 mmol), [OsCl2(p-cymene)]2 (7.9 mg, 5.0 mol %), KI (66.4 mg, 2.0 
equiv), KOAc (39.3 mg, 2.0 equiv) in HFIP (2.0 mL) and H2O (2.0 mL). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 8/1) yielded 400u (46.5 mg, 80%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.50 (t, J = 7.6 Hz, 1H), 7.30 – 7.21 (m, 2H), 5.79 (t, J = 6.6 Hz, 1H), 
4.12 (t, J = 6.8 Hz, 2H), 2.85 (d, J = 6.6 Hz, 2H), 2.66 (s, 3H), 1.66 – 1.54 (m, 2H), 1.37 – 1.22 (m, 
6H), 0.86 (t, J = 6.9 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 170.0 (Cq), 169.4 (Cq), 149.3 (Cq), 139.9 (Cq), 133.9 (CH), 131.1 (CH), 
123.4 (Cq), 119.2 (CH), 76.0 (CH), 65.4 (CH2), 39.8 (CH2), 31.4 (CH2), 28.4 (CH2), 25.5 (CH2), 22.5 
(CH2), 17.3 (CH3), 14.0 (CH3). 
IR (ATR): 2960, 2935, 1763, 1739, 1601, 1448, 1328, 1175, 1057, 691cm-1. 
MS (ESI) m/z (relative intensity): 291 (70) [M+H]+, 313 (30) [M+Na]+. 
HR-MS (ESI) C17H23O4 [M+H]
+: 291.1594, found: 291.1591. 
 
Pentan-3-yl 2-(4-methyl-3-oxo-1,3-dihydroisobenzofuran-1-yl)acetate (400w) 
 
The General Procedure D was followed using 2-methylbenzoic acid 398w (27.2 mg, 0.20 mmol), 
pentan-3-yl acrylate 399d (85.3 mg, 0.60 mmol), [OsCl2(p-cymene)]2 (7.9 mg, 5.0 mol %), KI (66.4 
mg, 2.0 equiv), KOAc (39.3 mg, 2.0 equiv) in HFIP (2.0 mL) and H2O (2.0 mL). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 8/1) yielded 400w (35.9 mg, 65%) as a 
colorless oil. 




4.06 (dd, J = 5.8, 2.4 Hz, 2H), 2.86 (d, J = 6.6 Hz, 2H), 2.67 (s, 3H), 1.50 (dt, J = 12.6, 6.4 Hz, 1H), 
1.38 – 1.25 (m, 4H), 0.86 (t, J = 7.4 Hz, 6H). 
13C NMR (100 MHz, CDCl3) δ 170.0 (Cq), 169.5 (Cq), 149.3 (Cq), 139.9 (Cq), 133.9 (CH), 131.1 (CH), 
123.4 (Cq), 119.2 (CH), 76.0 (CH), 67.3 (CH2), 40.2 (CH), 39.8 (CH2), 23.2 (CH2), 23.2 (CH2), 17.3 
(CH3), 11.0 (CH3), 10.9 (CH3). 
IR (ATR): 2960, 2933, 1758, 1730, 1495, 1453, 1310, 1277, 1005, 690 cm-1. 
MS (ESI) m/z (relative intensity): 291 (60) [M+H]+, 313 (40) [M+Na]+. 
HR-MS (ESI) C17H23O4 [M+H]
+: 291.1595, found: 291.1591. 
 
3-Methylbut-3-en-1-yl 2-(4-methyl-3-oxo-1,3-dihydroisobenzofuran-1-yl)acetate (400x) 
 
The General Procedure D was followed using 2-methylbenzoic acid 398x (27.2 mg, 0.20 mmol), 3-
methylbut-3-en-1-yl acrylate 399e (84.1 mg, 0.60 mmol), [OsCl2(p-cymene)]2 (7.9 mg, 5.0 mol %), 
KI (66.4 mg, 2.0 equiv), KOAc (39.3 mg, 2.0 equiv) in HFIP (2.0 mL) and H2O (2.0 mL). Purification 
by column chromatography on silica gel (n-hexane/EtOAc: 8/1) yielded 400x (42.8 mg, 78%) as a 
colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.51 (d, J = 7.6 Hz, 1H), 7.30 – 7.23 (m, 2H), 5.79 (t, J = 6.6 Hz, 1H), 
4.82 – 4.76 (m, 1H), 4.75 – 4.68 (m, 1H), 4.26 (t, J = 6.9 Hz, 2H), 2.85 (d, J = 6.6 Hz, 2H), 2.67 (s, 
3H), 2.34 (t, J = 6.9 Hz, 2H), 1.74 (s, 3H). 
13C NMR (100 MHz, CDCl3) δ 170.0 (Cq), 169.3 (Cq), 149.2 (Cq), 141.3 (Cq), 140.0 (Cq), 133.9 (CH), 
131.1(CH), 123.4 (Cq), 119.2 (CH), 112.5 (CH2), 76.0 (CH), 63.3 (CH2), 39.8 (CH2), 36.6 (CH2), 22.4 
(CH3), 17.3 (CH3). 
IR (ATR): 2959, 2933, 1760, 1735, 1599, 1467, 1345, 1170, 1005, 784, 698 cm-1. 
MS (ESI) m/z (relative intensity): 275 (55) [M+H]+, 297 (45) [M+Na]+. 
HR-MS (ESI) C16H19O4 [M+H]




Phenethyl 2-(4-methyl-3-oxo-1,3-dihydroisobenzofuran-1-yl)acetate (400y) 
 
The General Procedure D was followed using 2-methylbenzoic acid 398y (27.2 mg, 0.20 mmol), 
phenethyl acrylate 399f (85.9 mg, 0.60 mmol), [OsCl2(p-cymene)]2 (7.9 mg, 5.0 mol %), KI (66.4 mg, 
2.0 equiv), KOAc (39.3 mg, 2.0 equiv) in HFIP (2.0 mL) and H2O (2.0 mL). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 8/1) yielded 400y (44.1 mg, 71%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.48 (d, J = 7.6 Hz, 1H), 7.31 – 7.24 (m, 3H), 7.24 – 7.15 (m, 4H), 5.76 
(t, J = 7.0 Hz, 1H), 4.39 – 4.34 (m, 2H), 2.94 (d, J = 7.0 Hz, 2H), 2.83 (dd, J = 6.6, 4.6 Hz, 2H), 2.67 
(s, 3H). 
13C NMR (100 MHz, CDCl3) δ 170.0 (Cq), 169.2 (Cq), 149.2 (Cq), 140.0 (Cq), 137.4 (Cq), 133.9 (CH), 
131.1 (CH), 128.8 (CH), 128.5 (CH), 126.6 (CH), 123.3 (Cq), 119.2 (CH), 75.9 (CH), 65.6 (CH2), 39.8 
(CH2), 34.9 (CH2), 17.3 (CH3). 
IR (ATR): 2959, 2931, 1765, 1730, 1605, 1344, 1277, 1137, 1010, 905, 686 cm-1. 
MS (ESI) m/z (relative intensity): 311 (30) [M+H]+, 333 (70) [M+Na]+. 
HR-MS (ESI) C19H19O4 [M+H]




The General Procedure E was followed using naphthoic acid 398s (34.4 mg, 0.20 mmol), 1,2-di-p-
tolylethyne 401a (123.8 mg, 0.60 mmol), [OsCl2(p-cymene)]2 (7.9 mg, 5.0 mol %), KI (66.4 mg, 2.0 
equiv), KOAc (39.3 mg, 2.0 equiv) in HFIP (2.0 mL) and H2O (2.0 mL). Purification by column 




M. p. 197 °C 
1H NMR (400 MHz, CDCl3) δ 9.84 (d, J = 8.7 Hz, 1H), 7.95 (d, J = 8.7 Hz, 1H), 7.84 (d, J = 8.0 Hz, 
1H), 7.76 (ddd, J = 8.7, 6.9, 1.4 Hz, 1H), 7.59 (ddd, J = 8.0, 6.9, 1.1 Hz, 1H), 7.29 (d, J = 8.0 Hz, 2H), 
7.25 (d, J = 6.9 Hz, 3H), 7.16 (d, J = 8.0 Hz, 2H), 7.01 (d, J = 8.0 Hz, 2H), 2.43 (s, 3H), 2.28 (s, 3H). 
13C NMR (100 MHz, CDCl3) δ 161.5 (Cq), 152.5 (Cq), 141.4 (Cq), 139.1 (Cq), 137.8 (Cq), 135.6 (CH), 
132.5 (Cq), 131.8 (Cq), 131.5 (Cq), 131.2 (CH), 130.0 (Cq), 129.9 (CH), 129.3 (CH), 129.0 (CH), 128.6 
(CH), 128.4 (CH), 130.0 (CH), 126.8 (CH), 122.7 (CH), 116.8 (Cq), 113.7 (Cq), 21.3 (CH3), 21.3 (CH3). 
IR (ATR): 3057, 1712, 1591, 1508, 1216, 1105, 921, 753, 636, 503 cm-1. 
MS (ESI) m/z (relative intensity): 377 (100) [M+H]+. 
HR-MS (ESI) C27H21O2 [M+H]




The General Procedure E was followed using 2-methyl benzoic acid 398s (34.4 mg, 0.20 mmol), 1,2-
diphenylethyne 401b (106.9 mg, 0.60 mmol), [OsCl2(p-cymene)]2 (7.9 mg, 5.0 mol %), KI (66.4 mg, 
2.0 equiv), KOAc (39.3 mg, 2.0 equiv) in HFIP (2.0 mL) and H2O (2.0 mL). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 20/1) yielded 402b (61.3 mg, 88%) as a white solid. 
M. p. 192 °C 
1H NMR (400 MHz, CDCl3) δ 9.85 (d, J = 8.7 Hz, 1H), 7.99 (d, J = 8.7 Hz, 1H), 7.87 (d, J = 7.9 Hz, 
1H), 7.78 (ddd, J = 8.6, 6.9, 1.4 Hz, 1H), 7.62 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H), 7.47 – 7.41 (m, 3H), 
7.40 – 7.34 (m, 2H), 7.31 – 7.27 (m, 2H), 7.26 – 7.17 (m, 4H). 
13C NMR (100 MHz, CDCl3) δ 161.4 (Cq), 152.5 (Cq), 141.0 (Cq), 135.8 (CH), 134.8 (Cq), 132.8 (Cq), 
132.6 (Cq), 131.5 (Cq), 131.5 (CH), 129.5 (CH), 129.2 (CH), 129.1 (CH), 129.1 (CH), 128.4 (CH), 
128.2 (CH), 127.9 (CH), 127.1 (CH), 127.0 (CH), 122.7 (CH), 117.4 (Cq), 114.0 (Cq). 




MS (ESI) m/z (relative intensity): 349 (100) [M+H]+. 
HR-MS (ESI) C25H17O2 [M+H]




The General Procedure E was followed using 2-methyl benzoic acid 398s (34.4 mg, 0.20 mmol), 1,2-
bis(4-methoxyphenyl)ethyne 401c (142.9 mg, 0.60 mmol), [OsCl2(p-cymene)]2 (7.9 mg, 5.0 mol %), 
KI (66.4 mg, 2.0 equiv), KOAc (39.3 mg, 2.0 equiv) in HFIP (2.0 mL) and H2O (2.0 mL). Purification 
by column chromatography on silica gel (n-hexane/EtOAc: 20/1) yielded 402c (67.0 mg, 82%) as an 
orange solid. 
M. p. 217 °C 
1H NMR (400 MHz, CDCl3) δ 9.82 (d, J = 8.6 Hz, 1H), 7.96 (d, J = 8.6 Hz, 1H), 7.84 (d, J = 8.0 Hz, 
1H), 7.75 (ddd, J = 8.6, 6.9, 1.4 Hz, 1H), 7.59 (ddd, J = 8.0, 6.9, 1.1 Hz, 1H), 7.33 (d, J = 8.6 Hz, 2H), 
7.24 (d, J = 8.6 Hz, 1H), 7.18 (d, J = 8.6 Hz, 2H), 6.99 (d, J = 8.6 Hz, 2H), 6.73 (d, J = 8.6 Hz, 2H), 
3.86 (s, 3H), 3.75 (s, 3H). 
13C NMR (100 MHz, CDCl3) δ 161.5 (Cq), 160.0 (Cq), 159.3 (Cq), 152.5 (Cq), 141.7 (Cq), 135.7 (CH), 
132.5 (CH), 132.4 (Cq), 131.6 (Cq), 130.6 (CH), 129.3 (CH), 128.4 (CH), 127.0 (Cq), 126.9 (CH), 
126.8 (CH), 125.3 (Cq), 122.6 (CH), 115.8 (Cq), 114.7 (CH), 113.5 (Cq), 113.3 (CH), 55.3 (CH3), 55.2 
(CH3). 
IR (ATR): 3203, 1703, 1510, 1441, 1247, 1177, 1091, 831, 765, 570 cm-1. 
MS (ESI) m/z (relative intensity): 409 (100) [M+H]+. 
HR-MS (ESI) C27H21O4 [M+H]








The General Procedure E was followed using 2-methyl benzoic acid 398s (34.4 mg, 0.20 mmol), 1,2-
bis(4-fluorophenyl)ethyne 401D (128.5 mg, 0.60 mmol), [OsCl2(p-cymene)]2 (7.9 mg, 5.0 mol %), KI 
(66.4 mg, 2.0 equiv), KOAc (39.3 mg, 2.0 equiv) in HFIP (2.0 mL) and H2O (2.0 mL). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 20/1) yielded 402d (65.3 mg, 85%) as a 
yellow solid. 
M. p. 196 °C 
1H NMR (400 MHz, CDCl3) δ 9.85 (dd, J = 8.7, 1.0 Hz, 1H), 8.05 (d, J = 8.7 Hz, 1H), 7.91 (d, J = 8.0 
Hz, 1H), 7.82 (ddd, J = 8.7, 6.9, 1.4 Hz, 1H), 7.67 (ddd, J = 8.0, 6.9, 1.4 Hz, 1H), 7.38 (dd, J = 9.0, 
5.3 Hz, 2H), 7.30 (dd, J = 9.0, 5.3 Hz, 2H), 7.23 (d, J = 8.7 Hz, 1H), 7.25 – 7.22 (m, 2H), 6.99 – 6.93 
(m, 2H). 
13C NMR (100 MHz, CDCl3) δ 163.6 (d, JC–F = 44.6 Hz, Cq), 161.9 (d, JC–F = 42.2 Hz, Cq), 161.0 (Cq), 
151.8 (Cq), 140.7 (Cq), 136.1 (CH), 133.2 (d, JC–F = 8.0 Hz, CH), 132.6 (Cq), 131.5 (Cq), 131.2 (d, JC–
F = 8.5 Hz, CH), 130.5 (d, JC–F = 3.6 Hz, Cq), 129.6 (CH), 128.8 (d, JC–F = 3.4 Hz, Cq), 128.5 (CH), 
127.2 (CH), 127.0 (CH), 122.3 (CH), 116.5 (d, JC–F = 21.5 Hz, CH), 116.3 (Cq), 115.2 (d, JC–F = 21.8 
Hz, CH), 113.9 (Cq). 
19F NMR (282 MHz, CDCl3) δ -110.52, -112.72. 
IR (ATR): 3501, 1720, 1595, 1510, 1330, 1229, 1106, 833, 730, 530, cm-1. 
MS (ESI) m/z (relative intensity): 385 (100) [M+H]+. 
HR-MS (ESI) C25H15F2O2 [M+H]






Butyl (E)-3-(1-(2-butoxy-2-oxoethyl)-3-oxo-1,3-dihydroisobenzofuran-4-yl)acrylate (426) 
 
The General Procedure D was followed using benzoic acid 398b (24.4 mg, 0.20 mmol), n-butyl 
acrylate 399a (76.9 mg, 0.60 mmol), [OsCl2(p-cymene)]2 (7.9 mg, 5.0 mol %), KI (66.4 mg, 2.0 equiv), 
KOAc (39.3 mg, 2.0 equiv) in HFIP (2.0 mL) and H2O (2.0 mL). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 4/1) yielded 426 (1.5 mg, 2%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ 8.65 (d, J = 16.3 Hz, 1H), 7.73 (d, J = 8.3 Hz, 1H), 7.63 (t, J = 7.6 Hz, 
1H), 7.46 (d, J = 7.6 Hz, 1H), 6.55 (d, J = 16.3 Hz, 1H), 5.80 (t, J = 6.4 Hz, 1H), 4.17 (t, J = 6.7 Hz, 
2H), 4.09 (t, J = 6.7 Hz, 2H), 2.87 (d, J = 6.4 Hz, 2H), 1.69 – 1.61 (m, 2H), 1.59 – 1.50 (m, 2H), 1.39 
(dq, J = 15.2, 7.4 Hz, 2H), 1.29 (dq, J = 14.7, 7.4 Hz, 2H), 0.91 (t, J = 7.4 Hz, 3H), 0.86 (t, J = 7.4 Hz, 
3H). 
13C NMR (100 MHz, CDCl3) δ 169.1 (Cq), 168.8 (Cq), 166.1 (Cq), 149.6 (Cq), 137.2 (CH), 134.9 (Cq), 
134.2 (CH), 126.5 (CH), 123.1 (Cq), 123.0 (CH), 122.9 (CH), 76.0 (CH), 65.1 (CH2), 64.6 (CH2), 39.3 
(CH2), 30.6 (CH2), 30.4 (CH2), 19.1 (CH2), 18.9 (CH2), 13.6 (CH3), 13.5 (CH3). 
IR (ATR): 2960, 2936, 1771, 1730, 1487, 1281, 1172, 1109, 1005, 747, 686 cm-1. 
MS (ESI) m/z (relative intensity): 374 (60) [M+H]+, 396 (40) [M+Na]+. 
HR-MS (ESI) C21H27O6 [M+H]
+: 374.1729, found: 374.1731. 







5.5.2 Reaction Comparison with External Oxidant 
A suspension of o-toluic acid 398a (0.20 mmol, 1.0 equiv), n-butyl acrylate 399a (0.60 mmol, 3.0 
equiv), [OsCl2(p-cymene)]2 (5.0 mol %), oxidant (0.40 mmol, 2.0 equiv), and KOAc (0.40 mmol, 2.0 
equiv) in HFIP (2.0 mL) and H2O (2.0 mL) was stirred at 100 °C for 16 h under N2 (Table 5.5.1). 
Chemical oxidants used were AgOAc, Cu(OAc)2, Mn(OAc)3, PhI(OAc)2, and K2S2O8. Additionally, 
the same reaction was performed under air as a terminal oxidant. 
 
Table 5.5.1 Osmium-catalyzed C–H annulations with external oxidants. 
 
 











5.5.3 Selectivity Comparison with Different Catalysis (1) 
1) Procedure for the reaction with [Cp*RhCl2]2 
A suspension of benzoic acid 398b (0.40 mmol, 2.0 equiv), n-butyl acrylate 399a (0.20 mmol, 0.20 
mmol), [Cp*RhCl2]2 (2.5 mol %), and KOAc (0.40 mmol, 2.0 equiv) in tAmOH (3.0 mL) and H2O 
(1.0 mL) was stirred at 100 °C for 8 h at 4.0 mA of constant current under air (Scheme 5.5.1).  
 
 
Scheme 5.5.1 Rhodium-catalyzed electrooxidative C–H annulation. 
 
2) Procedure for the reaction with [Cp*IrCl2]2 
A suspension of benzoic acid 398b (0.20 mmol, 1.0 equiv), n-butyl acrylate 399a (0.40 mmol, 2.0 
equiv), [Cp*IrCl2]2 (2.5 mol %), benzoquinone (10 mol %), KOAc (0.4 mmol, 2.0 equiv) in tAmOH 
(3.0 mL) and H2O (1.0 mL) was stirred at 100 °C for 18 h at 4.0 mA of constant current under air 
(Scheme 5.5.2).   
 
 







3) Procedure for the reaction with [RuCl2(p-cymene)]2 
A suspension of benzoic acid 398b (0.40 mmol, 2.0 equiv), n-butyl acrylate 399a (0.20 mmol, 1.0 
equiv), [RuCl2(p-cymene)]2 (5.0 mol %), and NaOPiv (0.40 mmo, 2.0 equiv) in tAmOH (3.0 mL) and 
H2O (1.0 mL) was stirred at 100 °C for 18 h at 4.0 mA of constant current under air (Scheme 5.5.3). 
 
 
Scheme 5.5.3 Ruthenium-catalyzed electrooxidative C–H annulation. 
 
4) Procedure for the reaction with [OsCl2(p-cymene)]2 
The General Procedure D was followed using benzoic acid 398b (0.20 mmol, 1.0 equiv), n-butyl 
acrylate 399a (0.60 mmol, 3.0 equiv), [OsCl2(p-cymene)]2 (5.0 mol %), KI (0.40 mmol, 2.0 equiv), 
KOAc (0.40 mmol, 2.0 equiv) in HFIP (2.0 mL) and H2O (2.0 mL) at 100 °C for 16 h at 4.0 mA of 
constant current under N2 (Scheme 5.5.4). 
 
 






5.5.4 Selectivity Comparison with Different Catalysis (2) 
1) Procedure for H/D exchange studies: Ruthenium catalysis (1) 
The General Procedure D was followed using 3-(trifluoromethyl)benzoic acid 398h (0.20 mmol, 1.0 
equiv), n-butyl acrylate 399a (0.60 mmol, 3.0 equiv), [RuCl2(p-cymene)]2 (5.0 mol %), KI (0.40 mmol, 
2.0 equiv), KOAc (0.40 mmol, 2.0 equiv) in HFIP (1.0 mL) and D2O (3.0 mL) at 100 °C for 2 h at 4.0 
mA of constant current under N2 (Scheme 5.5.5).  
 
 




2) Procedure for H/D exchange studies: Ruthenium catalysis (2) 
The General Procedure D was followed using 3-(trifluoromethyl)benzoic acid 398h (0.20 mmol, 1.0 
equiv), [RuCl2(p-cymene)]2 (5.0 mol %), KI (0.40 mmol, 2.0 equiv), KOAc (0.40 mmol, 2.0 equiv) in 










3) Procedure for H/D exchange studies: Osmium catalysis (1) 
The General Procedure D was followed using 3-(trifluoromethyl)benzoic acid 398h (0.20 mmol, 1.0 
equiv), n-butyl acrylate 399a (0.60 mmol, 3.0 equiv), [OsCl2(p-cymene)]2 (5.0 mol %), KI (0.40 mmol, 
2.0 equiv), KOAc (0.40 mmol, 2.0 equiv) in HFIP (1.0 mL) and D2O (3.0 mL) at 100 °C for 2 h at 4.0 
mA of constant current under N2. 
 






4) Procedure for H/D exchange studies: Osmium catalysis (2) 
The General Procedure D was followed using 3-(trifluoromethyl)benzoic acid 398h (0.20 mmol, 1.0 
equiv), [OsCl2(p-cymene)]2 (5.0 mol %), KI (0.40 mmol, 2.0 equiv), KOAc (0.40 mmol, 2.0 equiv) in 
HFIP (1.0 mL) and D2O (3.0 mL) at 100 °C for 2 h at 4.0 mA of constant current under N2.  
 
 






5.5.5 Synthesis of Osmium Complex 
1) Procedure for the synthesis of [OsCl2(p-cymene)]2 
A suspension of OsCl3·xH2O (1.0 mmol, 1.0 equiv) and α-terpinene (9.0 mmol, 9.0 equiv) in 
isopropanol (5.0 mL) was stirred at 85 °C for 16 h under N2. Filtration (Por 3) with MeOH (3 × 5 mL) 
gave yellow solid, which was dried in vacuo for 6 h (Scheme 5.5.9).  
 
 
Scheme 5.5.9 Synthesis of [OsCl2(p-cymene)]2. 
 
2) Procedure for the synthesis of OsCl2(DMSO)(p-cymene) 
A suspension of dimethyl sulfoxide (0.5 mL) and [OsCl2(p-cymene)]2 (0.20 mmol) in dichloromethane 
(5.0 mL) was stirred at room temperature for 16 h under N2. The reaction mixture was concentrated in 
vacuo for 24 h, giving reddish yellow solid (Scheme 5.5.10). 
 
 
Scheme 5.5.10 Synthesis of 427. 
 
3) Procedure for the synthesis of 428 
To a solution of dimethyl sulfoxide (0.1 mL) and OsCl2(DMSO)(p-cymene) (0.20 mmol) in PhMe was 
added dropwise AlMe3 (2.0 M solution in PhMe, 0.15 mL) in the glove box (Scheme 5.5.11). After 
stirring at room temperature for 30 min, reaction vessel was taken out from the glove box. While 
stirring at room temperature for additional 20 min, acetone (1.0 mL) and H2O (0.05 mL) were added 
dropwise (Caution: This step generates gas).  Afterwards, diethyl ether (2.0 mL) was added, then 
forming the white solid. A short Na2SO4 packed filter followed by PTFE filter (Simplepure™, 0.22 
μm) gave yellow solution which was vacuum evaporated for 16 h, giving yellow sold. (Caution: Do 










1H NMR (400 MHz, Benzene-d6) δ 5.06 (d, J = 5.5 Hz, 1H), 4.88 (d, J = 5.5 Hz, 1H), 4.84 (d, J = 5.5 
Hz, 1H), 4.67 (d, J = 5.5 Hz, 1H), 3.01 (s, 3H), 2.66 – 2.59 (m, 1H), 2.56 (s, 3H), 1.86 (s, 3H), 1.43 (s, 
3H), 1.05 (d, J = 7.0 Hz, 3H), 1.02 (d, J = 7.0 Hz, 3H). 
13C NMR (100 MHz, Benzene-d6) δ 99.7 (Cq), 92.9 (Cq), 84.5 (CH), 83.5 (CH), 76.2 (CH), 74.9 (CH), 
49.2 (CH3), 40.7 (CH3), 37.3 (CH3), 30.4 (CH), 23.2 (CH3), 21.9 (CH3), 17.7 (CH3), -16.0 (CH3). 
HR-MS (ESI) C13H23ClOOSS [M]: 454.0755, found: 454.0764. 
 
4) Procedure for the synthesis of 430 
A suspension of OsCl(Me)(DMSO)(p-cymene) (0.20 mmol, 1.0 equiv) and ((1-naphthoyl)oxy)silver 
429 (0.22 mmol, 1.1 equiv) in C6D6 was stirred at room temperature for 16 h (Scheme 5.5.12). During 
the course of reaction, the aliquot was taken to monitor the reaction. When OsCl(Me)(DMSO)(p-
cymene) was fully consumed, the solution was filtered with benzene by PTFE filter (Simplepure™, 
0.22 μm) to remove AgCl (Caution: Benzene is highly toxic. Please use it under ventilated condition). 
The filtrate was vacuum evaporated for 16 h, giving yellow solid. (Caution: Do not use rotary 
evaporator to remove solvents, which may decompose the osmium complex.) The crystal structure of 






Scheme 5.5.12 Synthesis of 430. 
 
Osmium complex 430 
 
1H NMR (400 MHz, CD2Cl2) δ 9.45 (d, J = 8.2 Hz, 1H), 7.92 (d, J = 8.2 Hz, 1H), 7.76 (d, J = 8.2 Hz, 
1H), 7.67 (d, J = 8.2 Hz, 1H), 7.53 – 7.44 (m, 1H), 7.39 – 7.30 (m, 1H), 5.67 – 5.57 (m, 3H), 5.51 (d, 
J = 5.7 Hz, 1H), 2.88 – 2.80 (m, 1H), 2.82 (s, 3H), 2.41 (s, 3H), 2.30 (s, 3H), 1.23 (d, J = 6.9 Hz, 3H), 
1.12 (d, J = 6.9 Hz, 3H). 
13C NMR (100 MHz, CD2Cl2) δ 183.7 (Cq), 160.1 (Cq), 138.1 (CH), 133.3 (Cq), 132.3 (Cq), 131.2 
(CH), 129.8 (Cq), 128.1 (CH), 126.7 (CH), 124.2 (CH), 123.1 (CH), 108.3 (Cq), 98.9 (Cq), 81.7 (CH), 
80.8(CH), 80.2(CH), 79.7(CH), 46.3 (CH3), 42.3 (CH3), 30.9 (CH), 22.6 (CH3), 22.5 (CH3), 18.5 (CH3). 
HR-MS (ESI) C23H27O3OsS [M+H]
+: 575.1290, found: 575.1285. 
 
5) Procedure for the synthesis of 431 
A suspension of 430 (0.20 mmol, 1.0 equiv) and 1,2-di-p-tolylethyne 401a (0.22 mmol, 1.1 equiv) in 
CD3OD was stirred at room temperature for 24 h (Scheme 5.5.13). During the course of reaction, the 
aliquot was taken to monitor the reaction. The solution was concentrated under reduced pressure. 
Purification by column chromatography on silica gel afforded the desired products 431 as a yellow 






Scheme 5.5.13 Synthesis of 431. 
 
Osmium complex 431 
 
1H NMR (400 MHz, CDCl3) δ 8.12 (d, J = 7.9 Hz, 1H), 7.52 – 7.40 (m, 2H), 7.36 (d, J = 7.9 Hz, 1H), 
7.29 (d, J = 7.0 Hz, 1H), 7.24 – 7.15 (m, 1H), 7.09 (d, J = 7.0 Hz, 1H), 7.01 (d, J = 6.2 Hz, 1H), 7.02 
– 6.98 (m, 2H), 6.93 (d, J = 8.2 Hz, 2H), 6.84 (d, J = 8.2 Hz, 2H), 5.45 (d, J = 5.4 Hz, 1H), 5.39 (d, J 
= 5.4 Hz, 1H), 3.91 (d, J = 5.4 Hz, 1H), 3.40 (d, J = 5.4 Hz, 1H), 2.37 (s, 3H), 2.20 (s, 3H), 1.67 – 1.59 
(m, 1H), 1.64 (s, 3H), 1.13 (d, J = 6.8 Hz, 3H), 0.95 (d, J = 6.8 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 175.1 (Cq), 140.2 (Cq), 138.8 (Cq), 137.0 (Cq), 133.4 (Cq), 133.1 (Cq), 
132.6 (CH), 131.5 (CH), 129.5 (CH), 129.3 (CH), 129.1 (Cq), 128.7 (CH), 128.7 (CH), 127.6 (CH), 
127.6 (CH), 125.1 (CH), 125.0 (CH), 123.8 (CH), 110.0 (Cq), 103.0 (Cq), 92.2 (Cq), 85.1 (Cq), 79.0 
(CH), 79.0 (CH), 76.3 (Cq), 74.2 (CH), 51.9 (Cq), 30.1 (CH), 24.8 (CH3), 21.6 (CH3), 21.3 (CH3), 20.9 
(CH3), 17.5 (CH3). 
HR-MS (ESI) C37H35O2Os [M+H]








5.5.6 Reactions with Osmium Complex 
1) Procedure for the stoichiometric reaction with 430 
The General Procedure D was followed using 430 (0.1 mmol, 1.0 equiv), n-butyl acrylate 399a (0.3 
mmol, 3.0 equiv), KI (0.4 mmol, 2.0 equiv), KOAc (0.4 mmol, 2.0 equiv) in HFIP (2.0 mL) and H2O 
(2.0 mL) at 100 °C for 16 h at 4.0 mA of constant current under N2 (Scheme 5.5.14).  
 
 
Scheme 5.5.14 Stoichiometric reaction with osmium complex 430. 
 
2) Procedure for the stoichiometric reaction with 431 
The General Procedure E was followed using 431 (0.1 mmol, 1.0 equiv), KI (0.2 mmol, 2.0 equiv), 
KOAc (0.2 mmol, 2.0 equiv) in HFIP (2.0 mL) and H2O (2.0 mL) was stirred at 100 °C for 16 h at 4.0 
mA of constant current under N2 (Scheme 5.5.15).  
 
 






3) Procedure for the stoichiometric reaction with 431 
The General Procedure E was followed using 431 (0.1 mmol, 1.0 equiv), NaSbF6 (0.2 mmol, 2.0 
equiv), KOAc (0.2 mmol, 2.0 equiv) in HFIP (2.0 mL) and H2O (2.0 mL) was stirred at 100 °C for 16 
h at 4.0 mA of constant current under N2 (Scheme 5.5.16).  
 
 
Scheme 5.5.16 Stoichiometric reaction with osmium complex 431 with NaSbF6. 
 
4) Procedure for the catalytic reaction with 430 
The General Procedure D was followed using naphthoic acid 398s (0.1 mmol, 1.0 equiv), n-butyl 
acrylate 399a (0.3 mmol, 3.0 equiv), 430 (10 mol %), KI (0.2 mmol, 2.0 equiv), KOAc (0.2 mmol, 2.0 










5) Procedure for the catalytic reaction with 430 
The General Procedure E was followed using naphthoic acid 430 (0.1 mmol, 1.0 equiv), 1,2-di-p-
tolylethyne 401a (0.3 mmol, 3.0 equiv), 430 (10 mol %), KI (0.2 mmol, 2.0 equiv), KOAc (0.2 mmol, 
2.0 equiv) in HFIP (2.0 mL) and H2O (2.0 mL) at 100 °C for 16 h at 4.0 mA of constant current under 
N2 (Scheme 5.5.18).  
 
 







5.5.7 In-Operando NMR and HR-ESI-MS Studies 
In a nitrogen filled glove box, a screw top NMR tube was loaded with 430 (0.050 mmol), 401a (0.050 
mmol), (1,3,5-trimethoxybenzene (500 mM stock solution in THF-d8, 0.0125 mmol), and THF-d8 
(475.0 μL) (Scheme 5.5.19). An 1H NMR (400 MHz) spectrum of the resulted solution was then 
obtained. Subsequently, alkyne (0.050 mmol) was added and after homogenization, the progress of the 
reaction was monitored by 1H NMR (400 MHz) spectroscopy at 45 °C by collecting spectra every five 
minutes for a total period of 15 hours (18 data points out of the 180 collected spectra are only presented 
below for clarity, Color legend: Red = 430, Blue = 431, Green = 401a). 
 
 





The General Procedure E was followed using naphthoic acid 398s (0.1 mmol), 1,2-di-p-tolylethyne 
401a (3.0 equiv), [OsCl2(p-cymene)]2 (5.0 mol %), KI (66.4 mg, 2.0 equiv), KOAc (39.3 mg, 2.0 
equiv) in HFIP (2.0 mL) and H2O (2.0 mL) under N2 (Scheme 5.5.20). The reaction mixture was then 
left to stir at 100 °C for 1 minutes at which time a sample (t0) was collected and analyzed by HR-ESI-
MS. Subsequently, the reaction was initiated by passing a constant current of 4.0 mA through the 
reaction mixture followed by sampling at time intervals for a total length of 425 min. Each aliquot 
















5.5.8 Competition Experiment 
1) Procedure for competition experiment (1) 
The General Procedure D was followed using 3-methyl benzoic acid 398e (0.1 mmol, 1.0 equiv), 3-
trifluoromethyl benzoic acid 398h (0.1 mmol, 1.0 equiv), n-butyl acrylate 399a (0.3 mmol, 3.0 equiv), 
[OsCl2(p-cymene)]2 (5.0 mol %), KI (0.2 mmol, 2.0 equiv), KOAc (0.2 mmol, 2.0 equiv) in HFIP (2.0 
mL) and H2O (2.0 mL) at 100 °C for 4 h at 4.0 mA of constant current under N2 (Scheme 5.5.21). After 
cooling to ambient temperature, the electrodes were washed with ethyl acetate (3 × 10 mL). The 
reaction mixtures were extracted with brine (20 mL), dried over Na2SO4, and concentrated under 
reduced pressure. The crude mixture was analyzed by 1H NMR with CH2Br2 as the internal standard.  
 
 






2) Procedure for competition experiment (2) 
The General Procedure E was followed using naphthoic acid 398s (0.20 mmol, 1.0 equiv), 1,2-di-p-
tolylethyne 401a (0.20 mmol, 1.0 equiv), 1,2-bis(4-fluorophenyl)ethyne 401d (0.20 mmol, 1.0 equiv), 
[OsCl2(p-cymene)]2 (5.0 mol %), KI (0.40 mmol, 2.0 equiv), KOAc (0.40 mmol, 2.0 equiv) in HFIP 
(2.0 mL) and H2O (2.0 mL) at 100 °C for 4 h at 4.0 mA of constant current under N2 (Scheme 5.5.22). 
After cooling to ambient temperature, the electrodes were washed with ethyl acetate (3 × 10 mL). The 
reaction mixture was extracted with brine (20 mL), dried over Na2SO4, and concentrated under reduced 
pressure. The crude mixture was analyzed by 1H NMR with CH2Br2 as the internal standard. 
 
 





5.5.9 Hammett Correlation 








5.5.10 KIE Study 
1) Procedure for KIE study (Intermolecular competition reaction) 
The General Procedure D was followed using 398a (0.1 mmol, 1.0 equiv), [D]7-398a (0.1 mmol, 1.0 
equiv), n-butyl acrylate 399a (0.3 mmol, 3.0 equiv), [OsCl2(p-cymene)]2 (5.0 mol %), KI (0.2 mmol, 
2.0 equiv), KOAc (39.3 mg, 2.0 equiv) in HFIP (2.0 mL) and H2O (2.0 mL) at 100 °C for 16 h at 4.0 
mA of constant current under N2 (Scheme 5.5.24). 
 
 
Scheme 5.5.24 Intermolecular kinetic isotope exchange. Note: CH3 of aromatic and CH3 of butyl group 
should be compared. Other C–H bonds were isotopically labelled by post-catalysis H/D exchange 














2) Procedure for KIE study (Two parallel reactions) 
The General Procedure D was followed for four independent reactions using substrate 398a (0.20 
mmol) n-butyl acrylate 399a (3.0 equiv), and another four independent reactions using substrate [D]7-
398a (0.20 mmol) and n-butyl acrylate 399a (3.0 equiv) for specified reaction time (30 min, 60 min, 
90 min, and 120 min). The crude mixture was dried in vacuo for 6 h and analyzed by 1H NMR with 
CH2Br2 as the internal standard (Scheme 5.5.26). Blue line is for 400a and red line is for [D]n-400a. 
 
y = 0.3033x - 0.5
R² = 0.9935



























5.5.11 Crystallographic Information 
X-ray diffraction experiments for all of the compounds were carried out at 100(2) K on a Bruker D8 
Venture four-circle-diffractometer from Bruker AXS GmbH equipped with a Photon II detector 
purchased from Bruker AXS GmbH and using microfocus IµS Cu/Mo radiation from Incoatec GmbH 
with HELIOS mirror optics and single-hole collimator from Bruker AXS GmbH. Intensities were 
integrated and absorption corrections based on equivalent reflections were applied using SADABS. 
The structures were all solved using SHELXT[287] and refined against all F2 in SHELXL using Olex 
2. All of the non-hydrogen atoms were refined anisotropically while the carbon bond hydrogen atoms 
were located geometrically and refined using a riding model. Crystal structure and refinement data are 
given in Table 5.5.2, 5.5.3, and 5.5.4. Crystallographic data for the compounds have been deposited 
with the Cambridge Crystallographic Data Centre as supplementary publication CCDC 2085919, 
2085920 and 2085921. 
 




Empirical formula C13H23ClOOsS 
Formula weight 453.02 
Temperature/K 100 
Crystal system monoclinic 
















Crystal size/mm3 0.151 × 0.113 × 0.1 
Radiation AgKα (λ = 0.56086) 
2Θ range for data collection/° 4.244 to 57.874 
Index ranges -19 ≤ h ≤ 19, -25 ≤ k ≤ 26, -15 ≤ l ≤ 15 
Reflections collected 39100 
Independent reflections 7428 [Rint = 0.0237, Rsigma = 0.0182] 
Data/restraints/parameters 7428/71/160 
Goodness-of-fit on F2 1.116 
Final R indexes [I>=2σ (I)] R1 = 0.0138, wR2 = 0.0311 
Final R indexes [all data] R1 = 0.0146, wR2 = 0.0322 










Empirical formula C29H38O4.5OsS 
Formula weight 680.85 
Temperature/K 100 
Crystal system monoclinic 













Crystal size/mm3 0.121 × 0.061 × 0.029 
Radiation MoKα (λ = 0.71073) 




Index ranges -37 ≤ h ≤ 37, -20 ≤ k ≤ 20, -22 ≤ l ≤ 22 
Reflections collected 83356 
Independent reflections 8195 [Rint = 0.0394, Rsigma = 0.0191] 
Data/restraints/parameters 8195/0/258 
Goodness-of-fit on F2 1.046 
Final R indexes [I>=2σ (I)] R1 = 0.0309, wR2 = 0.0793 
Final R indexes [all data] R1 = 0.0356, wR2 = 0.0824 
Largest diff. peak/hole / e Å-3 2.22/-0.60 
 




Empirical formula C37H34O2Os 
Formula weight 700.84 
Temperature/K 100 
Crystal system monoclinic 
















Crystal size/mm3 0.123 × 0.09 × 0.045 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 4.31 to 61.158 
Index ranges -22 ≤ h ≤ 22, -16 ≤ k ≤ 16, -23 ≤ l ≤ 23 
Reflections collected 84089 
Independent reflections 8602 [Rint = 0.0424, Rsigma = 0.0221] 
Data/restraints/parameters 8602/0/366 
Goodness-of-fit on F2 1.041 
Final R indexes [I>=2σ (I)] R1 = 0.0189, wR2 = 0.0375 
Final R indexes [all data] R1 = 0.0248, wR2 = 0.0395 






5.6 Photo-Induced C–H Arylation by Reusable Heterogeneous Copper Catalyst 
5.6.1 Characterization Data 
2-(p-Tolyl)benzo[d]thiazole (405a) 
 
1) The General Procedure F was followed using benzothiazole 403a (34 mg, 0.25 mmol), 4-
iodotoluene 404a (273 mg, 1.25 mmol), 406 (30 mg, 11 mol %) and LiOtBu (60 mg, 0.75 mmol) in 
Et2O (0.5 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 70/1) yielded 
405a (52.4 mg, 93%) as a light yellow solid. 
2) The General Procedure H was followed using benzothiazole 403a (34 mg, 0.25 mmol), 4-
bromotoluene 447a (273 mg, 1.25 mmol), 406 (30 mg, 11 mol %) and Cs2CO3 (244 mg, 0.75 mmol) 
in Et2O (0.5 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 70/1) 
yielded 405a (28.7 mg, 51%) as a light yellow solid. 
M. p.: 86 ºC. 
1H NMR (300 MHz, CDCl3): δ = 7.96 (dd, J = 8.0, 1.3 Hz, 1H), 7.92 – 7.89 (m, 1H), 7.87 (m, 1H), 
7.78 (dd, J = 8.0, 1.3 Hz, 1H), 7.38 (ddd, J = 8.0, 7.2, 1.3 Hz, 1H), 7.26 (ddd, J = 8.0, 7.2, 1.3 Hz, 1H), 
7.22 – 7.19 (m, 1H), 7.19 – 7.16 (m, 1H), 2.32 (s, 3H). 
13C NMR (75 MHz, CDCl3): δ = 168.0 (Cq), 154.0 (Cq), 141.2 (Cq), 134.8 (Cq), 130.8 (Cq), 129.6 (CH), 
127.4 (CH), 126.1 (CH), 124.9 (CH), 122.9 (CH), 121.4 (CH), 21.5 (CH3). 
IR (ATR): 3024, 2918, 1611, 1445 ,1074, 816, 756, 691, 485, 434 cm-1. 
MS (ESI) m/z (relative intensity): 226 (100) [M+H]+, 248 (60) [M+Na]+. 
HR-MS (ESI): m/z calcd for C14H12NS [M+H]
+: 226.0688, found: 226.0688. 
The spectral data were in accordance with those reported in the literature.[94] 
 
2-Phenylbenzo[d]thiazole (405b)  
 




iodobenzene 404b (255 mg, 1.25 mmol), 406 (30 mg, 11 mol %) and LiOtBu (60 mg, 0.75 mmol) in 
Et2O (0.5 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 70/1) yielded 
405b (49.7 mg, 94%) as a light yellow solid. 
2) The General Procedure H was followed using benzothiazole 403a (34 mg, 0.25 mmol), 
bromobenzene 447b (255 mg, 1.25 mmol), 406 (30 mg, 11 mol %) and Cs2CO3 (244 mg, 0.75 mmol) 
in Et2O (0.5 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 70/1) 
yielded 405b (31.2 mg, 59%) as a light yellow solid. 
M. p.: 115 ºC. 
1H NMR (500 MHz, CDCl3): δ = 8.11 – 8.04 (m, 3H), 7.90 – 7.85 (m, 1H), 7.51 – 7.44 (m, 4H), 7.37 
(ddd, J = 8.3, 7.2, 1.2 Hz, 1H). 
13C NMR (125 MHz, CDCl3): δ = 168.0 (Cq), 154.1 (Cq), 135.0 (Cq), 133.5 (Cq), 130.9 (CH), 128.9 
(CH), 127.5 (CH), 126.2 (CH), 125.1 (CH), 123.2 (CH), 121.5 (CH). 
IR (ATR): 3016, 1510, 1478, 1433, 1313, 1252, 1215, 963, 918, 750 cm–1. 
MS (ESI) m/z (relative intensity): 212 (100) [M+H]+. 
HR-MS (ESI): m/z calcd for C13H10NS [M+H]
+: 212.0530, found: 212.0528.  




1) The General Procedure F was followed using benzothiazole 403a (34 mg, 0.25 mmol), 4-
iodoanisole 404c (293 mg, 1.25 mmol), 406 (30 mg, 11 mol %) and LiOtBu (60 mg, 0.75 mmol) in 
Et2O (0.5 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 70/1) yielded 
405c (47.7 mg, 79%) as a light yellow solid. 
2) The General Procedure H was followed using benzothiazole 403a (34 mg, 0.25 mmol), 4-
bromoanisole 447c (293 mg, 1.25 mmol), 406 (30 mg, 11 mol %) and Cs2CO3 (244 mg, 0.75 mmol) 
in Et2O (0.5 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 70/1) 




M. p.: 134 ºC. 
1H NMR (400 MHz, CDCl3): δ = 8.04 – 7.98 (m, 3H), 7.86 (ddd, J = 8.0, 1.3, 0.7 Hz, 1H), 7.45 (ddd, 
J = 8.3, 7.2, 1.3 Hz, 1H), 7.33 (ddd, J = 8.0, 7.2, 1.3 Hz, 1H), 7.01 – 6.94 (m, 2H), 3.86 (s, 3H). 
13C NMR (100 MHz, CDCl3): δ = 167.8 (Cq), 161.9 (Cq), 154.2 (Cq), 134.8 (Cq), 129.1 (CH), 126.4 
(Cq), 126.2 (CH), 124.8 (CH), 122.8 (CH), 121.5 (CH), 114.4 (CH), 55.5 (CH3). 
IR (ATR): 3061, 2994, 2836, 1604, 1483, 1434, 1256, 1225, 1171, 1027 cm–1. 
MS (ESI) m/z (relative intensity): 242 (100) [M+H]+, 264 (30) [M+Na]+. 
HR-MS (ESI): m/z calcd for C14H12NOS [M+H]
+: 242.0635, found: 242.0634. 




The General Procedure F was followed using benzothiazole 403a (34 mg, 0.25 mmol), 1-iodo-4-
(trifluoromethyl)benzene 404d (340 mg, 1.25 mmol), 406 (30 mg, 11 mol %) and LiOtBu (60 mg, 0.75 
mmol) in Et2O (0.5 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 70/1) 
yielded 405f (64.9 mg, 93%) as a light yellow solid. 
M. p.: 161 ºC. 
1H NMR (400 MHz, CDCl3): δ = 8.22 – 8.14 (m, 2H), 8.09 (ddd, J = 8.0, 1.2, 0.7 Hz, 1H), 7.91 (ddd, 
J = 8.0, 1.2, 0.7 Hz, 1H), 7.76 – 7.69 (m, 2H), 7.51 (ddd, J = 8.2, 7.2, 1.2 Hz, 1H), 7.41 (ddd, J = 8.2, 
7.2, 1.2 Hz, 1H). 
13C NMR (100 MHz, CDCl3): δ = 166.0 (Cq), 154.0 (Cq), 136.8 (d, JC-F = 2 Hz, Cq), 135.2 (Cq), 132.4 
(q, JC-F = 33 Hz, Cq), 127.8 (CH), 126.6 (CH), 126.0 (q, JC-F= 4 Hz, CH), 125.8 (CH), 123.8 (d, JC-F = 
272 Hz, Cq) 123.6 (CH), 121.7 (CH). 
19F NMR (282 MHz, CDCl3): δ = -62.86 (s). 
IR (ATR): 3072, 1324, 1214, 1132, 1067, 970, 847, 744, 668, 624 cm–1. 
MS (ESI) m/z (relative intensity): 280 (100) [M+H]+. 
HR-MS (ESI): m/z calcd for C14H9F3NS [M+H]








The General Procedure F was followed using benzothiazole 403a (34 mg, 0.25 mmol), 1-fluoro-4-
iodobenzene 404e (278 mg, 1.25 mmol), 406 (30 mg, 11 mol %) and LiOtBu (60 mg, 0.75 mmol) in 
Et2O (0.5 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 70/1) yielded 
405e (54.5 mg, 95%) as a light yellow solid. 
M. p.: 101 ºC. 
1H NMR (500 MHz, CDCl3): δ = 8.10 – 8.01 (m, 3H), 7.88 (ddd, J = 7.9, 1.2, 0.6 Hz, 1H), 7.48 (ddd, 
J = 8.3, 7.2, 1.2 Hz, 1H), 7.37 (ddd, J = 8.3, 7.2, 1.2 Hz, 1H), 7.20 – 7.11 (m, 2H). 
13C NMR (125 MHz, CDCl3): δ = 166.7 (Cq), 164.4 (d, JC-F= 252 Hz, Cq), 154.1 (Cq), 135.0 (Cq), 
129.9 (d, JC-F = 3 Hz, Cq), 129.49 (d, JC-F = 9 Hz, CH), 126.39 (CH), 125.22 (CH), 123.16 (CH), 121.59 
(CH), 116.13 (d, JC-F = 22 Hz, CH). 
19F NMR (282 MHz, CDCl3) δ –108.94 (tt, J = 8.5, 5.3 Hz). 
IR (ATR): 3063, 1602, 1519, 1481, 1434, 1314, 1250, 1097, 967, 831 cm–1. 
MS (ESI) m/z (relative intensity): 230 (100) [M+H]+. 
HR-MS (ESI): m/z calcd for C13H9FNS [M+H]
+: 230.0436, found: 230.0434. 




The General Procedure F was followed using benzothiazole 403a (34 mg, 0.25 mmol), 1-chloro-4-
iodobenzene 404f (298 mg, 1.25 mmol), 406 (30 mg, 11 mol %) and LiOtBu (60 mg, 0.75 mmol) in 
Et2O (0.5 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 70/1) yielded 




M. p.: 112 ºC. 
1H NMR (500 MHz, CDCl3): δ = 8.05 (dt, J = 8.2, 0.8 Hz, 1H), 8.02 – 7.98 (m, 2H), 7.88 (ddd, J = 
8.2, 0.8, 0.8 Hz, 1H), 7.48 (ddd, J = 8.2, 7.2, 1.2 Hz, 1H), 7.46 – 7.43 (m, 2H), 7.38 (ddd, J = 8.2, 7.2, 
1.2 Hz, 1H). 
13C NMR (125 MHz, CDCl3): δ = 166.6 (Cq), 154.0 (Cq), 137.0 (Cq), 135.0 (Cq), 132.1 (Cq), 129.2 
(CH), 128.7 (CH), 126.5 (CH), 125.4 (CH), 123.3 (CH), 121.6 (CH). 
IR (ATR): 3062, 1590, 1474, 1433, 1399, 1314, 1287, 1225, 1091, 1015, 389 cm–1. 
MS (ESI) m/z (relative intensity): 246 (100) [M+H]+. 
HR-MS (ESI): m/z calcd for C13H9ClNS [M+H]
+: 246.0139, found: 246.0139. 




The General Procedure F was followed using benzothiazole 403a (34 mg, 0.25 mmol), 1-bromo-4-
iodobenzene 404g (354 mg, 1.25 mmol), 406 (30 mg, 11 mol %) and LiOtBu (60 mg, 0.75 mmol) in 
Et2O (0.5 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 70/1) yielded 
405g (66.0 mg, 91%) as a light yellow solid. 
M. p.: 132 ºC. 
1H NMR (500 MHz, CDCl3): δ = 8.05 (dt, J = 8.2, 0.9 Hz, 1H), 7.94 – 7.89 (m, 2H), 7.86 (ddd, J = 
8.2, 0.9, 0.9 Hz, 1H), 7.61 – 7.57 (m, 2H), 7.48 (ddd, J = 8.2, 7.2, 1.2 Hz, 1H), 7.37 (ddd, J = 8.2, 7.2, 
1.2 Hz, 1H). 
13C NMR (125 MHz, CDCl3): δ = 166.6 (Cq), 154.0 (Cq), 135.0 (Cq), 132.4(Cq), 132.1 (CH), 128.8 
(CH), 126.4 (CH), 125.4 (CH), 125.4 (Cq), 123.2 (CH), 121.6 (CH). 
IR (ATR): 3016, 1574, 1433, 1314, 1215, 1102, 1068, 820, 752, 683, 481 cm–1. 
MS (ESI) m/z (relative intensity): 289 (100) (79Br) [M+H]+,
 291 (100) (81Br) [M+H]+. 
HR-MS (ESI): m/z calcd for C13H9
79BrNS [M+H]+: 289.9635, found: 289.9634. 






The General Procedure F was followed using benzothiazole 403a (34 mg, 0.25 mmol), 1-iodo-3-
methylbenzene 404h (273 mg, 1.25 mmol), 406 (30 mg, 11 mol %) and LiOtBu (60 mg, 0.75 mmol) 
in Et2O (0.5 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 70/1) 
yielded 405h (52.9 mg, 94%) as a light yellow solid. 
M. p.: 63 ºC. 
1H NMR (400 MHz, CDCl3): δ = 8.06 (dd, J = 8.2, 1.2 Hz, 1H), 7.96 – 7.90 (m, 1H), 7.89 (dd, J = 8.0, 
1.2 Hz, 1H), 7.90 – 7.81 (m, 1H), 7.48 (ddd, J = 8.3, 7.2, 1.2 Hz, 1H), 7.37 (ddd, J = 7.8, 7.2, 1.2 Hz, 
2H), 7.33 – 7.25 (m, 1H), 2.44 (s, 3H). 
13C NMR (100 MHz, CDCl3): δ = 168.3 (Cq), 154.1 (Cq), 138.8 (Cq), 135.0 (Cq), 133.5 (Cq), 131.8 
(CH), 128.9 (CH), 128.0 (CH), 126.3 (CH), 125.1 (CH), 124.8 (CH), 123.1 (CH), 121.6 (CH), 21.3 
(CH3). 
IR (ATR): 3056, 2919, 1606, 1557, 1471, 1378, 1312, 1238, 1171, 1092, 1014 cm–1. 
MS (ESI) m/z (relative intensity): 226 (100) [M+H]+, 248 (10) [M+Na]+. 
HR-MS (ESI): m/z calcd for C14H12NS [M+H]
+: 226.0683, found: 226.0685. 




The General Procedure F was followed using benzothiazole 403a (34 mg, 0.25 mmol), 1-iodo-3-
methoxybenzene 404i (293 mg, 1.25 mmol), 406 (30 mg, 11 mol %) and LiOtBu (60 mg, 0.75 mmol) 
in Et2O (0.5 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 70/1) 
yielded 405i (45.8 mg, 76%) as a light yellow solid. 
M. p.: 82 ºC. 




1H), 7.66 (dd, J = 2.6, 1.6 Hz, 1H), 7.63 (ddd, J = 7.6, 1.6, 0.9 Hz, 1H), 7.48 (ddd, J = 8.3, 7.2, 1.3 Hz, 
1H), 7.41 – 7.34 (m, 2H), 7.03 (ddd, J = 8.3, 2.6, 0.9 Hz, 1H), 3.90 (s, 3H). 
13C NMR (100 MHz, CDCl3): δ = 167.9 (Cq), 160.0 (Cq), 154.0 (Cq), 135.1 (Cq), 134.9 (Cq), 130.0 
(CH), 126.3 (CH), 125.2 (CH), 123.2 (CH), 121.6 (CH), 120.2 (CH), 117.3 (CH), 112.0 (CH), 55.5 
(CH3). 
IR (ATR): 3066, 2932, 2834, 2160, 2039, 1582, 1484, 1433, 1287, 1008, 758 cm–1. 
MS (ESI) m/z (relative intensity): 242 (100) [M+H]+, 264 (35) [M+Na]+. 
HR-MS (ESI): m/z calcd for C14H12NOS [M+H]
+: 242.0637, found: 242.0634. 




The General Procedure F was followed using benzothiazole 403a (34 mg, 0.25 mmol), 1-iodo-3-
(trifluoromethyl)benzene 404j (340 mg, 1.25 mmol), 406 (30 mg, 11 mol %) and LiOtBu (60 mg, 0.75 
mmol) in Et2O (0.5 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 70/1) 
yielded 405j (53.0 mg, 76%) as a light yellow solid. 
M. p.: 87 ºC. 
1H NMR (400 MHz, CDCl3): δ = 8.38 – 8.34 (m, 1H), 8.23 (ddd, J = 7.2, 1.3, 0.7 Hz, 1H), 8.09 (ddd, 
J = 8.2, 1.3, 0.7 Hz, 1H), 7.91 (ddd, J = 8.0, 1.3, 0.7 Hz, 1H), 7.73 (ddd, J = 7.8, 1.3, 0.7 Hz, 1H), 7.61 
(ddd, J = 7.8, 1.3, 0.7 Hz, 1H), 7.51 (ddd, J = 8.2, 7.2, 1.3 Hz, 1H), 7.41 (ddd, J = 8.0, 7.2, 1.3 Hz, 
1H). 
13C NMR (100 MHz, CDCl3): δ = 166.1 (Cq), 154.0 (Cq), 135.1 (Cq), 134.4 (Cq), 131.6 (q, JC-F = 32 
Hz, Cq), 130.7 (CH), 129.6 (CH), 127.3 (q, JC-F = 4 Hz, CH), 126.6 (CH), 125.7 (CH), 124.2 (q, JC-F = 
4 Hz, CH), 123.8 (d, JC-F = 273 Hz, Cq), 123.5 (CH), 121.7 (CH). 
19F NMR (282 MHz, CDCl3): δ = -62.76 (s). 
IR (ATR): 3066, 2923, 1613, 1584, 1479, 1442, 1257, 1152, 1076, 937, 880 cm–1. 




HR-MS (ESI): m/z calcd for C14H9F3NS [M+H]
+: 280.0403, found: 280.0402. 




The General Procedure F was followed using benzothiazole 403a (34 mg, 0.25 mmol), 1-fluoro-3-
iodobenzene 404k (278 mg, 1.25 mmol), 406 (30 mg, 11 mol %) and LiOtBu (60 mg, 0.75 mmol) in 
Et2O (0.5 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 70/1) yielded 
405k (52.2 mg, 91%) as a light yellow solid. 
M. p.: 72 ºC. 
1H NMR (500 MHz, CDCl3): δ = 8.07 (dd, J = 8.2, 0.8 Hz, 1H), 7.89 (dd, J = 8.0, 0.8 Hz, 1H), 7.86 – 
7.79 (m, 2H), 7.49 (ddd, J = 8.2, 7.2, 1.2 Hz, 1H), 7.44 (ddd, J = 8.2, 8.0, 5.7 Hz, 1H), 7.39 (ddd, J = 
8.2, 7.2, 1.2 Hz, 1H), 7.17 (ddd, J = 8.2, 2.6, 1.2 Hz, 1H). 
13C NMR (125 MHz, CDCl3): δ = 166.4 (d, JC-F= 3 Hz, Cq), 163.0 (d, JC-F = 247 Hz, Cq), 153.9 (Cq), 
135.6 (d, JC-F = 8 Hz, Cq), 135.0 (Cq), 130.6 (d, JC-F = 8 Hz, CH), 126.5 (CH), 125.5 (CH), 123.4 (CH), 
123.3 (d, JC-F = 3 Hz, CH), 121.6 (CH), 117.8 (d, JC-F = 21 Hz), 114.26 (d, JC-F = 24 Hz). 
19F NMR (282 MHz, CDCl3): δ = –112.02 (ddd, J = 9.2, 8.5, 5.7 Hz). 
IR (ATR): 3053, 2162, 1590, 1457, 1423, 1312, 1230, 1160, 783, 700, 653 cm–1. 
MS (ESI) m/z (relative intensity): 230 (100) [M+H]+. 
HR-MS (ESI): m/z calcd for C13H9FNS [M+H]
+: 230.0437, found: 230.0435. 




The General Procedure F was followed using benzothiazole 403a (34 mg, 0.25 mmol), 1-chloro-3-




Et2O (0.5 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 70/1) yielded 
405l (39.9 mg, 65%) as a light yellow solid. 
M. p.: 96 ºC. 
1H NMR (500 MHz, CDCl3): δ = 8.11 – 8.09 (m, 1H), 8.07 (ddd, J = 8.2, 1.2, 0.7 Hz, 1H), 7.93 (ddd, 
J = 8.0, 7.2, 1.2 Hz, 1H), 7.90 (ddd, J = 8.0, 1.2, 0.7 Hz, 1H), 7.50 (ddd, J = 8.2, 7.2, 1.2 Hz, 1H), 7.46 
– 7.37 (m, 3H). 
13C NMR (125 MHz, CDCl3): δ = 166.3 (Cq), 154.0 (Cq), 135.2 (Cq), 135.1 (Cq), 135.1 (Cq), 130.8 
(CH), 130.2 (CH), 127.4 (CH), 126.5 (CH), 125.7 (CH), 125.5 (CH), 123.4 (CH), 121.7 (CH). 
IR (ATR): 3060, 2924, 1693, 1562, 1457, 1312, 1227, 1070, 975, 862, 782 cm–1. 
MS (ESI) m/z (relative intensity): 246 (100) [M+H]+. 
HR-MS (ESI): m/z calcd for C13H9ClNS [M+H]
+: 246.0140, found: 246.0139. 




The General Procedure F was followed using benzothiazole 403a (34 mg, 0.25 mmol), 1-bromo-3-
iodobenzene 404m (354 mg, 1.25 mmol), 406 (30 mg, 11 mol %) and LiOtBu (60 mg, 0.75 mmol) in 
Et2O (0.5 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 70/1) yielded 
405m (42.8 mg, 59%) as a light yellow solid. 
M. p.: 88 ºC. 
1H NMR (500 MHz, CDCl3): δ = 8.27 – 8.25 (m, 1H), 8.06 (ddd, J = 8.0, 0.9 Hz, 1H), 7.97 (ddd, J = 
7.8, 1.7, 0.9 Hz, 1H), 7.90 (ddd, J = 8.0, 1,2, 0.9 Hz, 1H), 7.60 (ddd, J = 8.0, 2.0, 0.9 Hz, 1H), 7.50 
(ddd, J = 8.2, 7.2, 1.2 Hz, 1H), 7.39 (ddd, J = 8.2, 7.2, 1.2 Hz, 1H), 7.34 (dd, J = 7.9 Hz, 1H). 
13C NMR (125 MHz, CDCl3): δ = 166.1 (Cq), 153.9 (Cq), 135.4 (Cq), 135.1 (Cq), 133.8 (CH), 130.5 
(CH), 130.2 (CH), 126.5 (CH), 126.1 (CH), 125.6 (CH), 123.4 (CH), 123.2 (Cq), 121.7 (CH). 
IR (ATR): 3059, 2923, 1601, 1486, 1455, 1224, 1119, 957, 726, 630, 449 cm–1. 




HR-MS (ESI): m/z calcd for C13H9
79BrNS [M+H]+: 289.9634, found: 289.9634. 




The General Procedure F was followed using benzothiazole 403a (34 mg, 0.25 mmol), 1-iodo-2-
methylbenzene 404n (273 mg, 1.25 mmol), 406 (30 mg, 11 mol %) and LiOtBu (60 mg, 0.75 mmol) 
in Et2O (0.5 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 70/1) 
yielded 405n (20.3 mg, 36%) as a yellow oil. 
1H NMR (400 MHz, CDCl3): δ = 8.09 (ddd, J = 8.2, 1.2, 0.6 Hz, 1H), 7.92 (ddd, J = 8.2, 1.2, 0.6 Hz, 
1H), 7.74 (dd, J = 7.4, 1.4 Hz, 1H), 7.49 (ddd, J = 8.2, 7.4, 1.4 Hz, 1H), 7.42 – 7.37 (m, 1H), 7.37 – 
7.27 (m, 3H), 2.64 (s, 3H). 
13C NMR (100 MHz, CDCl3): δ = 168.0 (Cq), 153.7 (Cq), 137.2 (Cq), 135.6 (Cq), 133.1 (Cq), 131.5 
(CH), 130.5 (CH), 130.0 (CH), 126.1 (CH), 126.1 (CH), 125.1 (CH), 123.4 (CH), 121.3 (CH), 21.3 
(CH3). 
IR (ATR): 2924, 2838, 2612, 1977, 1571, 1500, 1115, 1021, 970, 754, 551 cm–1. 
MS (ESI) m/z (relative intensity): 226 (100) [M+H]+, 248 (5) [M+Na]+. 
HR-MS (ESI): m/z calcd for C14H12NO [M+H]
+: 226.0686, found: 226.0685. 




The General Procedure F was followed using benzothiazole 403a (34 mg, 0.25 mmol), 1-iodo-2-
methoxybenzene 404o (293 mg, 1.25 mmol), 406 (30 mg, 11 mol %) and LiOtBu (60 mg, 0.75 mmol) 
in Et2O (0.5 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 70/1) 




M. p.: 108 ºC. 
1H NMR (400 MHz, CDCl3): δ = 8.51 (ddd, J = 7.9, 1.8, 0.6 Hz, 1H), 8.07 (ddd, J = 8.2, 1.1, 0.6 Hz, 
1H), 7.91 (ddd, J = 7.9, 1.1, 0.6 Hz, 1H), 7.50 – 7.41 (m, 2H), 7.38 – 7.32 (m, 1H), 7.12 (ddd, J = 7.9, 
7.3, 1.1 Hz, 1H), 7.06 (dd, J = 8.2, 1.1 Hz, 1H), 4.05 (s, 3H). 
13C NMR (100 MHz, CDCl3): δ = 163.1 (Cq), 157.2 (Cq), 152.2 (Cq), 136.1 (Cq), 131.7 (CH), 129.6 
(CH), 125.9 (CH), 124.6 (CH), 124.1 (CH), 122.8 (CH), 122.3 (Cq), 121.2 (CH), 111.7 (CH), 55.7 
(CH3). 
IR (ATR): 3007, 2971, 1893, 1519, 1181,1122, 1054, 964, 825, 587, 416 cm–1. 
MS (ESI) m/z (relative intensity): 242 (100) [M+H]+, 264 (30) [M+Na]+. 
HR-MS (ESI): m/z calcd for C14H12NOS [M+H]
+: 242.0637, found: 242.0635. 




The General Procedure F was followed using 6-methoxybenzo[d]thiazole 403b (41 mg, 0.25 mmol), 
4-iodotoluene 404a (273 mg, 1.25 mmol), 406 (30 mg, 11 mol %) and LiOtBu (60 mg, 0.75 mmol) in 
Et2O (0.5 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 70/1) yielded 
405p (35.1 mg, 55%) as a light yellow solid. 
M. p.: 115 ºC. 
1H NMR (400 MHz, CDCl3): δ = 7.93 – 7.88 (m, 3H), 7.33 – 7.30 (m, 1H), 7.28 – 7.23 (m, 2H), 7.06 
(dd, J = 8.9, 2.6 Hz, 1H), 3.86 (s, 3H), 2.39 (s, 3H). 
13C NMR (100 MHz, CDCl3): δ = 165.7 (Cq), 157.6 (Cq), 148.7 (Cq), 140.9 (Cq), 136.2 (Cq), 131.1 
(Cq), 129.6 (CH), 127.1 (CH), 123.5 (CH), 115.4 (CH), 104.2 (CH), 55.7 (CH3), 21.4 (CH3). 
IR (ATR): 3020, 1606, 1488, 1411, 1321, 1119, 968, 903, 747, 667, 479 cm–1. 
MS (ESI) m/z (relative intensity): 256 (100) [M+H]+. 
HR-MS (ESI): m/z calcd for C15H14NOS [M+H]
+: 256.0795, found: 256.0793. 






The General Procedure F was followed using 6-fluorobenzo[d]thiazole 403c (38 mg, 0.25 mmol), 4-
iodotoluene 404a (273 mg, 1.25 mmol), 406 (30 mg, 11 mol %) and LiOtBu (60 mg, 0.75 mmol) in 
Et2O (0.5 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 70/1) yielded 
405q (57.8 mg, 95%) as a light yellow solid. 
M. p.: 149 ºC. 
1H NMR (400 MHz, CDCl3): δ = 7.96 (dd, J = 8.9, 4.9 Hz, 2H), 7.96 – 7.87 (m, 3H), 7.53 (ddd, J = 
8.1, 2.7, 0.5 Hz, 1H), 7.31 – 7.23 (m, 2H), 7.19 (dd, J = 8.9, 2.7 Hz, 1H), 2.43 – 2.37 (m, 3H). 
13C NMR (100 MHz, CDCl3): δ = 167.9 (Cq), 160.3 (d, JC-F = 245 Hz, Cq), 150.8 (Cq), 141.45 (Cq), 
135.87 (d, JC-F = 11.2 Hz, Cq), 130.66 (Cq), 129.71 (CH), 127.31 (CH), 123.86 (d, JC-F = 9.3 Hz, CH), 
114.76 (d, JC-F = 24.6 Hz, CH), 107.74 (d, JC-F = 26.7 Hz, CH), 21.47 (CH3). 
19F NMR (282 MHz, CDCl3): δ = –116.20 (td, J = 8.5, 4.8 Hz). 
IR (ATR): 2916, 2161, 1483, 1441, 1307, 1050, 867, 816, 761, 694, 491 cm–1. 
MS (ESI) m/z (relative intensity): 244 (100) [M+H]+. 
HR-MS (ESI): m/z calcd for C14H11FNS [M+H]
+: 244.0593, found: 244.0591. 




The General Procedure F was followed using 6-chlorobenzo[d]thiazole 403d (42 mg, 0.25 mmol), 
4-iodotoluene 404a (273 mg, 1.25 mmol), 406 (30 mg, 11 mol %) and LiOtBu (60 mg, 0.75 mmol) in 
Et2O (0.5 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 70/1) yielded 
405r (55.8 mg, 86%) as a light yellow solid. 
M. p.: 160 ºC. 




2.1 Hz, 1H), 7.30 – 7.25 (m, 2H), 2.41 (s, 3H). 
13C NMR (100 MHz, CDCl3): δ = 168.7 (Cq), 152.7 (Cq), 141.7 (Cq), 136.1 (Cq), 130.8 (Cq), 130.5 
(Cq), 129.8 (CH), 127.4 (CH), 127.0 (CH), 123.7 (CH), 121.1 (CH), 21.5 (CH3). 
IR (ATR): 2916, 1934, 1585, 1483, 1437, 1304, 1181, 1087, 963, 816, 561 cm–1. 
MS (ESI) m/z (relative intensity): 260 (100) [M+H]+. 
HR-MS (ESI): m/z calcd for C14H11ClNS [M+H]
+: 260.0296, found: 260.0295. 




The General Procedure F was followed using 6-bromobenzo[d]thiazole 403e (53 mg, 0.25 mmol), 
4-iodotoluene 404a (273 mg, 1.25 mmol), 406 (30 mg, 11 mol %) and LiOtBu (60 mg, 0.75 mmol) in 
Et2O (0.5 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 70/1) yielded 
405r (50.2 mg, 66%) as a light yellow solid. 
M. p.: 152 ºC. 
1H NMR (400 MHz, CDCl3): δ = 8.00 (dd, J = 2.0, 0.5 Hz, 1H), 7.96 – 7.92 (m, 2H), 7.87 (dd, J = 8.7, 
0.5 Hz, 1H), 7.58 – 7.53 (m, 1H), 7.31 – 7.25 (m, 2H), 2.41 (s, 3H). 
13C NMR (100 MHz, CDCl3): δ = 168.7 (Cq), 153.0 (Cq), 141.8 (Cq), 136.6 (Cq), 130.5 (Cq), 129.8 
(CH), 129.7 (CH), 127.5 (CH), 124.1 (CH), 124.1 (CH), 118.5 (Cq), 21.5 (CH3). 
IR (ATR): 3061, 1621, 1508, 1459, 1313, 1219, 1126, 1020, 694, 877, 802 cm–1. 
MS (ESI) m/z (relative intensity): 303 (100) (79Br) [M+H]+, 305 (100) (81Br) [M+H]+. 
HR-MS (ESI): m/z calcd for C14H11
79BrNS [M+H]+: 303.9792, found: 303.9790. 







The General Procedure F was followed using benzothiazole 403a (mg, 0.25 mmol), 1,2-dichloro-4-
iodobenzene 404p (341 mg, 1.25 mmol), 406 (30 mg, 11 mol %) and LiOtBu (60 mg, 0.75 mmol) in 
Et2O (0.5 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 70/1) yielded 
405t (37.1 mg, 53%) as a light yellow solid. 
M. p.: 108 ºC. 
1H NMR (500 MHz, CDCl3): δ = 8.19 (d, J = 2.1 Hz, 1H), 8.05 (dd, J = 8.3, 0.9 Hz, 1H), 7.91 – 7.85 
(m, 2H), 7.54 (d, J = 8.3 Hz, 1H), 7.50 (ddd, J = 8.3, 7.2, 1.2 Hz, 1H), 7.40 (ddd, J = 8.3, 7.2, 1.2 Hz, 
1H). 
13C NMR (125 MHz, CDCl3): δ = 165.1 (Cq), 153.9 (Cq), 135.1 (Cq), 135.0 (Cq), 133.5 (Cq), 133.4 
(Cq), 131.0 (CH), 129.0 (CH), 126.7 (CH), 126.5 (CH), 125.7 (CH), 123.5 (CH), 121.7 (CH). 
IR (ATR): 2919, 1621, 1555, 1500, 1451, 1215, 1109, 1054, 821, 742, 640 cm–1. 
MS (ESI) m/z (relative intensity): 279 (100) [M+H]+. 
HR-MS (ESI): m/z calcd for C13H8Cl2NS [M+H]
+: 279.9748, found: 279.9749. 




The General Procedure F was followed using thiazole 403f (21 mg, 0.25 mmol), 4-iodotoluene 404a 
(273 mg, 1.25 mmol), 404a (30 mg, 11 mol %) and LiOtBu (60 mg, 0.75 mmol) in Et2O (0.5 mL). 
Purification by column chromatography on silica gel (n-hexane/EtOAc: 70/1) yielded 405u (37.7 mg, 
86%) as a yellow oil. 
1H NMR (500 MHz, CDCl3): δ = 7.87 – 7.83 (m, 2H), 7.82 (d, J = 3.3 Hz, 1H), 7.26 (d, J = 3.3 Hz, 
1H), 7.24 – 7.20 (m, 2H), 2.37 (s, 3H). 
13C NMR (125 MHz, CDCl3): δ = 168.6 (Cq), 143.5 (CH), 140.2 (Cq), 130.9 (Cq), 129.6 (CH), 126.4 
(CH), 118.3 (CH), 21.4 (CH3). 
IR (ATR): 3067, 1613, 1473, 1328, 1162, 1068, 970, 807, 648, 546 cm–1. 




HR-MS (ESI): m/z calcd for C10H10NS [M+H]
+: 176.0529, found: 176.0528. 




The General Procedure F was followed using 5-phenylthiazole 403g (40 mg, 0.25 mmol), 3-
iodotoluene 404h (273 mg, 1.25 mmol), 406 (30 mg, 11 mol %) and LiOtBu (60 mg, 0.75 mmol) in 
Et2O (0.5 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 70/1) yielded 
405w (52.2 mg, 83%) as a light yellow solid. 
M. p.: 101 ºC. 
1H NMR (300 MHz, CDCl3): δ = 8.00 (s, 1H), 7.82 – 7.79 (m, 1H), 7.74 (ddd, J = 7.7, 1.8, 1.2 Hz, 
1H), 7.62 – 7.59 (m, 1H), 7.59 – 7.57 (m, 1H), 7.45 – 7.28 (m, 5H), 7.24 – 7.21 (m, 1H), 2.42 (s, 3H). 
13C NMR (100 MHz, CDCl3): δ = 167.3 (Cq), 139.0 (Cq), 139.0 (CH), 138.7 (Cq), 133.5 (Cq), 131.4 
(Cq), 130.8 (CH), 129.0 (CH), 128.8 (CH), 128.2 (CH), 126.8 (CH), 126.6 (CH), 123.5 (CH), 21.4 
(CH3). 
IR (ATR): 2918, 2855, 1547, 1515, 1453, 1237, 1109, 1001, 956, 813, 792 cm–1. 
MS (ESI) m/z (relative intensity): 252 (100) [M+H]+, 274 (3) [M+Na]+. 
HR-MS (ESI): m/z calcd for C16H14NS [M+H]
+: 252.0843, found: 252.0841. 




The General Procedure F was followed using 4,5-dimethylthiazole 403h (28 mg, 0.25 mmol), 4-
iodotoluene 404a (273 mg, 1.25 mmol), 406 (30 mg, 11 mol %) and LiOtBu (60 mg, 0.75 mmol) in 
Et2O (0.5 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 70/1) yielded 




M. p.: 62 ºC. 
1H NMR (500 MHz, CDCl3): δ = 7.77 – 7.68 (m, 2H), 7.18 (d, J = 8.0 Hz, 2H), 2.36 (s, 6H), 2.35 (s, 
3H). 
13C NMR (125 MHz, CDCl3): δ = 163.5 (Cq), 149.0 (Cq), 139.4 (Cq), 131.3 (Cq), 129.4 (CH), 126.0 
(CH), 125.9 (Cq), 21.3 (CH3), 14.8 (CH3), 11.4 (CH3). 
IR (ATR): 2955, 2923, 2854, 1810, 1480, 1448, 1143, 1082, 847, 785, 689 cm–1. 
MS (ESI) m/z (relative intensity): 204 (100) [M+H]+. 
HR-MS (ESI): m/z calcd for C12H14NS [M+H]
+: 204.0842, found: 204.0841. 





The General Procedure F was followed using 4,5-dimethylthiazole 403h (28 mg, 0.25 mmol), 1-
chloro-4-iodobenzene 404f (298 mg, 1.25 mmol), 406 (30 mg, 11 mol %) and LiOtBu (60 mg, 0.75 
mmol) in Et2O (0.5 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 70/1) 
yielded 405y (48.7 mg, 87%) as a light yellow solid. 
M. p.: 93 ºC. 
1H NMR (400 MHz, CDCl3): δ = 7.78 (ddd, J = 9.1, 2.9, 2.1 Hz, 2H), 7.35 (ddd, J = 9.1, 2.9, 2.1 Hz, 
2H), 2.36 (s, 6H). 
13C NMR (100 MHz, CDCl3): δ = 161.9 (Cq), 149.5 (Cq), 135.2 (Cq), 132.5 (Cq), 129.0 (CH), 127.2 
(CH), 127.0 (Cq), 14.8 (CH3), 11.5 (CH3). 
IR (ATR): 2922, 1724, 1679, 1611, 1494, 1364, 1257, 1076, 918, 731 cm–1. 
MS (ESI) m/z (relative intensity): 224 (100) [M+H]+. 
HR-MS (ESI): m/z calcd for C11H11ClNS [M+H]
+: 224.0296, found: 224.0295. 







The General Procedure F was followed using benzoxazole 444a (30 mg, 0.25 mmol), 4-iodotoluene 
404a (273 mg, 1.25 mmol), 406 (30 mg, 11 mol %) and LiOtBu (60 mg, 0.75 mmol) in Et2O (0.5 mL). 
Purification by column chromatography on silica gel (n-hexane/EtOAc: 70/1) yielded 447a (41.3 mg, 
79%) as a light yellow solid. 
M. p.: 123 ºC. 
1H NMR (500 MHz, CDCl3): δ = 8.13 (d, J = 8.3 Hz, 2H), 7.79 – 7.69 (m, 1H), 7.60 – 7.50 (m, 1H), 
7.32 – 7.29 (m, 3H), 2.41 (s, 3H). 
13C NMR (125 MHz, CDCl3): δ = 163.2 (Cq), 150.6 (Cq), 142.1 (Cq), 142.0 (Cq), 129.6 (CH), 127.5 
(CH), 124.8 (CH), 124.4 (CH), 124.3 (Cq), 119.8 (CH), 110.4 (CH), 21.6 (CH3). 
IR (ATR): 3024, 2919, 1608, 1579, 1556, 1410, 1200, 1055, 926, 756, 380 cm–1. 
MS (ESI) m/z (relative intensity): 210 (100) [M+H]+. 
HR-MS (ESI): m/z calcd for C14H12NO [M+H]
+: 210.0915, found: 210.0913. 




The General Procedure F was followed using 5-methylbenzo[d]oxazole 444b (33 mg, 0.25 mmol), 
4-iodotoluene 404a (273 mg, 1.25 mmol), 406 (30 mg, 11 mol %) and LiOtBu (60 mg, 0.75 mmol) in 
Et2O (0.5 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 70/1) yielded 
447b (40.7 mg, 73%) as a light yellow solid. 
M. p.: 135 ºC. 
1H NMR (400 MHz, CDCl3): δ = 8.14 – 8.07 (m, 2H), 7.54 – 7.50 (m, 1H), 7.41 (d, J = 8.2 Hz, 1H), 
7.33 – 7.26 (m, 2H), 7.11 (ddd, J = 8.2, 1.7, 0.7 Hz, 1H), 2.47 – 2.45 (m, 3H), 2.41 (s, 3H). 




(CH), 127.5 (CH), 125.9 (CH), 124.5 (Cq), 119.7 (CH), 109.8 (CH), 21.6 (CH3), 21.5 (CH3). 
IR (ATR): 2958, 2866, 1616, 1581, 1268, 1018, 823, 807, 729, 650, 500 cm–1. 
MS (ESI) m/z (relative intensity): 224 (100) [M+H]+, 246 (5) [M+Na]+. 
HR-MS (ESI): m/z calcd for C15H14NO [M+H]
+: 224.1068, found: 224.1070. 




The General Procedure F was followed using 5-(tert-butyl)benzo[d]oxazole 444c (44 mg, 0.25 
mmol), 4-iodotoluene 404a (273 mg, 1.25 mmol), 406 (30 mg, 11 mol %) and LiOtBu (60 mg, 0.75 
mmol) in Et2O (0.5 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 70/1) 
yielded 447c (49.1 mg, 74%) as a light yellow solid. 
M. p.: 113 ºC. 
1H NMR (400 MHz, CDCl3): δ = 8.30 – 8.25 (m, 2H), 7.94 (dd, J = 1.9, 0.6 Hz, 1H), 7.62 (dd, J = 8.6, 
0.6 Hz, 1H), 7.54 (dd, J = 8.6, 1.9 Hz, 1H), 7.49 – 7.44 (m, 2H), 2.57 (s, 3H), 1.54 (s, 9H). 
13C NMR (100 MHz, CDCl3): δ = 163.4 (Cq), 148.7 (Cq), 148.0 (Cq), 142.1 (Cq), 141.8 (Cq), 129.6 
(CH), 127.5 (CH), 124.6 (Cq), 122.5 (CH), 116.3 (CH), 109.6 (CH), 34.9 (Cq), 31.8 (CH3), 21.6 (CH3). 
IR (ATR): 2920, 1616, 1556, 1497, 1462, 1215, 1166, 1118, 1049, 919, 831 cm–1. 
MS (ESI) m/z (relative intensity): 266 (100) [M+H]+. 
HR-MS (ESI): m/z calcd for C18H20NO [M+H]
+: 266.1542, found: 266.1540. 




The General Procedure F was followed using 5-chlorobenzo[d]oxazole 444d (38 mg, 0.25 mmol), 




Et2O (0.5 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 70/1) yielded 
447d (31.1 mg, 51%) as a light yellow solid. 
M. p.: 124 ºC. 
1H NMR (400 MHz, CDCl3): δ = 8.27 – 8.22 (m, 2H), 7.79 (dd, J = 8.5, 0.4 Hz, 1H), 7.71 (dd, J = 2.1, 
0.4 Hz, 1H), 7.48 – 7.44 (m, 3H), 2.58 (s, 3H). 
13C NMR (100 MHz, CDCl3): δ = 163.9 (Cq), 150.8 (Cq), 142.4 (Cq), 141.0 (Cq), 130.4 (Cq), 129.7 
(CH), 127.6 (CH), 125.1 (CH), 123.9 (Cq), 120.2 (CH), 111.1 (CH), 21.7 (CH3). 
IR (ATR): 2956, 2851, 1737, 1461, 1377, 1190, 1121, 1082, 716, 649, 597 cm–1. 
MS (ESI) m/z (relative intensity): 244 (100) [M+H]+. 
HR-MS (ESI): m/z calcd for C14H11ClNO [M+H]
+: 244.0524, found: 244.0524. 




The General Procedure F was followed using benzoxazole 444a (30 mg, 0.25 mmol), iodobenzene 
404b (255 mg, 1.25 mmol), 406 (30 mg, 11 mol %) and LiOtBu (60 mg, 0.75 mmol) in Et2O (0.5 mL). 
Purification by column chromatography on silica gel (n-hexane/EtOAc: 70/1) yielded 447e (39.0 mg, 
80%) as a light yellow solid. 
M. p.: 100 ºC. 
1H NMR (400 MHz, CDCl3): δ = 8.28 – 8.22 (m, 2H), 7.76 (ddd, J = 6.0, 3.3, 0.7 Hz, 1H), 7.57 (ddd, 
J = 6.0, 3.3, 0.7 Hz, 1H), 7.54 – 7.49 (m, 3H), 7.34 (dd, J = 6.0, 3.3 Hz, 2H). 
13C NMR (100 MHz, CDCl3): δ = 163.0 (Cq), 150.8 (Cq), 142.1 (Cq), 131.5 (CH), 129.9 (CH), 127.6 
(CH), 127.2 (Cq), 125.1 (CH), 124.6 (CH), 120.0 (CH), 110.6 (CH). 
IR (ATR): 2922, 2020, 1973, 1555, 1474, 1263, 1182, 1057, 865, 791, 719 cm–1. 
MS (ESI) m/z (relative intensity): 196 (100) [M+H]+. 
HR-MS (ESI): m/z calcd for C13H10NO [M+H]
+: 196.0755, found: 196.0756. 






The General Procedure F was followed using 5-methylbenzo[d]oxazole 444b (33 mg, 0.25 mmol), 
3-iodotoluene 404h (273 mg, 1.25 mmol), 406 (30 mg, 11 mol %) and LiOtBu (60 mg, 0.75 mmol) in 
Et2O (0.5 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 70/1) yielded 
447f (43.0 mg, 77%) as a light yellow solid. 
M. p.: 85 ºC. 
1H NMR (300 MHz, CDCl3): δ = 8.11 – 8.02 (m, 1H), 8.07 – 7.96 (m, 1H), 7.41 (ddd, J = 8.3, 0.3 Hz, 
1H), 7.49 – 7.33 (m, 2H), 7.38 – 7.26 (m, 1H), 7.13 (ddd, J = 8.3, 1.7, 0.7 Hz, 1H), 2.47 (s, 3H), 2.44 
(s, 3H). 
13C NMR (75 MHz, CDCl3): δ = 163.2 (Cq), 148.9 (Cq), 142.2 (Cq), 138.6 (Cq), 134.3 (Cq), 132.1 (CH), 
128.7 (CH), 128.0 (CH), 127.1 (Cq), 126.0 (CH), 124.6 (CH), 119.8 (CH), 109.8 (CH), 21.6 (CH3), 
21.4 (CH3). 
IR (ATR): 2919, 1613, 1483, 1423, 1143, 1055, 971, 873, 815, 631, 478 cm–1. 
MS (ESI) m/z (relative intensity): 224 (100) [M+H]+, 246 (5) [M+Na]+. 
HR-MS (ESI): m/z calcd for C15H14NO [M+H]
+: 224.1071, found: 224.1070. 




The General Procedure F was followed using oxazole 444e (17 mg, 0.25 mmol), 4-iodotoluene 404a 
(273 mg, 1.25 mmol), 406 (30 mg, 11 mol %) and LiOtBu (60 mg, 0.75 mmol) in Et2O (0.5 mL). 
Purification by column chromatography on silica gel (n-hexane/EtOAc: 70/1) yielded 447g (24.3 mg, 
61%) as a yellow oil. 
1H NMR (400 MHz, CDCl3): δ = 7.93 – 7.89 (m, 2H), 7.66 (d, J = 0.8 Hz, 1H), 7.27 – 7.25 (m, 1H), 




13C NMR (100 MHz, CDCl3): δ = 162.2 (Cq), 140.6 (Cq), 138.2 (CH), 129.5 (CH), 128.2 (CH), 126.3 
(CH), 124.8 (Cq), 21.5 (CH3). 
IR (ATR): 2924, 2230, 2211, 2171, 2042, 1976, 714, 686, 585, 487 cm–1. 
MS (ESI) m/z (relative intensity): 160 (100) [M+H]+. 
HR-MS (ESI): m/z calcd for C10H10NO [M+H]
+: 160.0759, found: 160.0758. 




The General Procedure F was followed using 5-phenyloxazole 444f (36 mg, 0.25 mmol), 
iodobenzene 404b (255 mg, 1.25 mmol), 406 (30 mg, 11 mol %) and LiOtBu (60 mg, 0.75 mmol) in 
Et2O (0.5 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 70/1) yielded 
447h (42.0 mg, 76%) as a light yellow solid. 
M. p.: 70 ºC. 
1H NMR (300 MHz, CDCl3): δ = 8.13 – 8.07 (m, 2H), 7.74 – 7.72 (m, 1H), 7.71 – 7.69 (m, 1H), 7.49 
– 7.41 (m, 6H), 7.37 – 7.29 (m, 1H). 
13C NMR (75 MHz, CDCl3): δ = 161.0 (Cq), 151.2 (Cq), 130.2 (CH), 128.8 (CH), 128.7 (CH), 128.3 
(CH), 128.0 (Cq), 127.4 (Cq), 126.2 (CH), 124.1 (CH), 123.4 (CH). 
IR (ATR): 2955, 2923, 2853, 1731, 1684, 1749, 1092, 1014, 934, 685 cm–1. 
MS (ESI) m/z (relative intensity): 222 (100) [M+H]+. 
HR-MS (ESI): m/z calcd for C15H12NO [M+H]
+: 222.0913, found: 222.0913. 








4-iodobenzene 404f (298 mg, 1.25 mmol), 406 (30 mg, 11 mol %) and LiOtBu (60 mg, 0.75 mmol) in 
Et2O (0.5 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 70/1) yielded 
447i (50.5 mg, 79%) as a light yellow solid. 
M. p.: 115 ºC. 
1H NMR (400 MHz, CDCl3): δ = 8.05 – 7.99 (m, 2H), 7.72 – 7.67 (m, 2H), 7.47 – 7.40 (m, 5H), 7.37 
– 7.30 (m, 1H). 
13C NMR (100 MHz, CDCl3): δ = 160.2 (Cq), 151.5 (Cq), 136.4 (Cq), 129.1 (CH), 129.0 (CH), 128.6 
(CH), 127.8 (Cq), 127.5 (CH), 126.0 (Cq), 124.2 (CH), 123.5 (CH). 
IR (ATR): 2956, 2923, 2855, 1727, 1682, 1471, 1133, 761, 725, 383 cm–1. 
MS (ESI) m/z (relative intensity): 256 (100) [M+H]+. 
HR-MS (ESI): m/z calcd for C15H11ClNO [M+H]
+: 256.0521, found: 256.0523. 




The General Procedure F was followed using 5-phenyloxazole 444f (36 mg, 0.25 mmol), 3-
iodotoluene 404h (273 mg, 1.25 mmol), 406 (30 mg, 11 mol %) and LiOtBu (60 mg, 0.75 mmol) in 
Et2O (0.5 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 70/1) yielded 
447j (43.5 mg, 74%) as a light yellow solid. 
M. p.: 89 ºC. 
1H NMR (300 MHz, CDCl3): δ = 7.94 – 7.87 (m, 2H), 7.74 – 7.69 (m, 2H), 7.48 – 7.39 (m, 3H), 7.39 
– 7.29 (m, 2H), 7.29 – 7.24 (m, 1H), 2.43 (s, 3H). 
13C NMR (75 MHz, CDCl3): δ = 161.3 (Cq), 151.1 (Cq), 138.6 (Cq), 131.1 (CH), 128.9 (CH), 128.7 
(CH), 128.4 (CH), 128.0 (Cq), 127.3 (Cq), 126.8 (CH), 124.2 (CH), 123.4 (CH), 123.4 (CH), 21.4 
(CH3). 
IR (ATR): 3055, 1886, 1499, 1231, 1099, 851, 823, 686, 609, 512 cm–1. 




HR-MS (ESI): m/z calcd for C16H14NO [M+H]
+: 236.1071, found: 236.1070. 




The General Procedure F was followed using 5-(4-fluorophenyl)oxazole 444g (41 mg, 0.25 mmol), 
iodobenzene 404b (255 mg, 1.25 mmol), 406 (30 mg, 11 mol %) and LiOtBu (60 mg, 0.75 mmol) in 
Et2O (0.5 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 70/1) yielded 
447k (48.4 mg, 81%) as a light yellow solid. 
M. p.: 90 ºC. 
1H NMR (400 MHz, CDCl3): δ = 8.11 – 8.06 (m, 2H), 7.71 – 7.66 (m, 2H), 7.50 – 7.43 (m, 3H), 7.37 
(s, 1H), 7.16 – 7.10 (m, 2H). 
13C NMR (100 MHz, CDCl3): δ = 162.7 (d, JC-F = 249 Hz, Cq), 161.1 (Cq), 150.4 (Cq), 130.4 (CH), 
128.8 (CH), 127.4 (Cq), 126.3 (CH), 126.1 (d, JC-F = 8 Hz, CH), 124.4 (d, JC-F = 3 Hz, Cq), 123.1 (d, 
JC-F = 1 Hz, CH), 116.1 (d, JC-F = 22 Hz, CH). 
19F NMR (282 MHz, CDCl3): δ = –112.21 (ddd, J = 13.8, 8.7, 5.1 Hz). 
IR (ATR): 2917, 1724, 1608, 1497, 1362, 1323, 1260, 1106, 963, 934, 752 cm–1. 
MS (ESI) m/z (relative intensity): 240 (100) [M+H]+. 
HR-MS (ESI): m/z calcd for C15H11FNO [M+H]
+: 240.0818, found: 240.0819. 




The General Procedure F was followed using 5-(benzo[d][1,3]dioxol-5-yl)oxazole 444h (47 mg, 0.25 




mmol) in Et2O (0.5 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 70/1) 
yielded 447l (58.7 mg, 84%) as a light yellow solid. 
M. p.: 125 ºC. 
1H NMR (400 MHz, CDCl3): δ = 7.98 – 7.90 (m, 2H), 7.28 – 7.26 (m, 2H), 7.25 – 7.23 (m, 1H), 7.20 
(dd, J = 8.1, 1.7 Hz, 1H), 7.14 (dd, J = 1.7, 0.4 Hz, 1H), 6.85 (dd, J = 8.1, 0.5 Hz, 1H), 5.99 (s, 2H), 
2.39 (s, 3H). 
13C NMR (100 MHz, CDCl3): δ = 160.9 (Cq), 150.8 (Cq), 148.2 (Cq), 147.8 (Cq), 140.5 (Cq), 129.5 
(CH), 126.1 (CH), 124.7 (Cq), 122.3 (Cq), 122.2 (CH), 118.2 (CH), 108.8 (CH), 104.8 (CH), 101.3 
(CH2), 21.5 (CH3). 
IR (ATR): 2898, 1726, 1683, 1609, 1545, 1363,1287, 1129, 1062, 963, 776 cm–1. 
MS (ESI) m/z (relative intensity): 280 (100) [M+H]+, 302 (10) [M+Na]+. 
HR-MS (ESI): m/z calcd for C17H14NO3 [M+H]




The General Procedure F was followed using 5-(benzo[d][1,3]dioxol-5-yl)oxazole 444h (47 mg, 0.25 
mmol), iodobenzene 404b (255 mg, 1.25 mmol), 406 (30 mg, 11 mol %) and LiOtBu (60 mg, 0.75 
mmol) in Et2O (0.5 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 70/1) 
yielded 447m (57.7 mg, 87%) as a light yellow solid. 
M. p.: 136 ºC. 
1H NMR (400 MHz, CDCl3): δ = 8.10 – 8.03 (m, 2H), 7.49 – 7.38 (m, 3H), 7.28 (s, 1H), 7.21 (dd, J 
= 8.1, 1.7 Hz, 1H), 7.15 (dd, J = 1.7, 0.4 Hz, 1H), 6.86 (dd, J = 8.1, 0.4 Hz, 1H), 5.99 (s, 2H). 
13C NMR (100 MHz, CDCl3): δ = 160.6 (Cq), 151.1 (Cq), 148.2 (Cq), 147.9 (Cq), 130.2 (CH), 128.8 
(CH), 127.4 (Cq), 126.1 (CH), 122.3 (CH), 122.2 (Cq), 118.3 (CH), 108.8 (CH), 104.8 (CH), 101.4 
(CH2). 
IR (ATR): 2865, 1605, 1349, 1276, 1109, 1088, 964, 854, 774, 589, 422 cm–1. 




HR-MS (ESI): m/z calcd for C16H12NO3 [M+H]
+: 266.0817, found: 266.0815. 




1) The General Procedure G was followed using 1-methyl-1H-benzo[d]imidazole 445a (33 mg, 
0.25 mmol), 4-iodotoluene 404a (273 mg, 1.25 mmol), 406 (30 mg, 11 mol %) and K3PO4 (159 mg, 
0.75 mmol) in THF (0.5 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 
4/1) yielded 446a (35.0 mg, 63%) as a light yellow solid. 
2) The General Procedure H was followed using 1-methyl-1H-benzo[d]imidazole 445a (33 mg, 
0.25 mmol), 4-bromotoluene 447a (273 mg, 1.25 mmol), 406 (30 mg, 11 mol %) and Cs2CO3 (244 mg, 
0.75 mmol) in Et2O (0.5 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 
4/1) yielded 446a (41.1 mg, 74%) as a light yellow solid. 
M. p.: 125 ºC. 
1H NMR (400 MHz, CDCl3) δ 7.80 (ddd, J = 5.4, 2.4, 0.7 Hz, 1H), 7.65 (t, J = 1.9 Hz, 1H), 7.63 (t, J 
= 1.9 Hz, 1H), 7.35 (ddd, J = 5.4, 2.4, 0.7H), 7.31 – 7.33 (m, 1H), 7.30 – 7.31 (m, 1H), 7.28 (m, 2H), 
3.83 (s, 3H), 2.42 (s, 3H). 
13C NMR (100 MHz, CDCl3) δ 153.9 (Cq), 142.9 (Cq), 139.8 (Cq), 136.5 (Cq), 129.3 (CH), 129.3 (Cq), 
127.3 (CH), 122.6 (CH), 122.3 (CH), 119.7 (CH), 109.5 (CH), 31.6 (CH3), 21.4 (CH3). 
IR (ATR): 3419, 3402, 2919, 1936, 1613, 1459, 1381, 1276, 1005, 822, 748 cm–1. 
MS (ESI) m/z (relative intensity): 223 (60) [M+H]+, 245 (40) [M+Na]+. 
HR-MS (ESI): m/z calcd for C15H15N2 [M+H]
+: 223.1237, found: 223.1235. 







1) The General Procedure G was followed using 1-methyl-1H-benzo[d]imidazole 445a (33 mg, 
0.25 mmol), iodobenzene 404b (255 mg, 1.25 mmol), 406 (30 mg, 11 mol %) and K3PO4 (159 mg, 
0.75 mmol) in THF (0.5 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 
4/1) yielded 446b (36.4 mg, 70%) as a light yellow solid. 
2) The General Procedure H was followed using 1-methyl-1H-benzo[d]imidazole 445a (33 mg, 
0.25 mmol), bromobenzene 447b (255 mg, 1.25 mmol), 406 (30 mg, 11 mol %) and Cs2CO3 (244 mg, 
0.75 mmol) in Et2O (0.5 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 
4/1) yielded 446b (41.1 mg, 79%) as a light yellow solid. 
M. p.: 96 ºC. 
1H NMR (400 MHz, CDCl3) δ 7.81 (ddd, J = 5.4, 2.4, 0.7 Hz, 1H), 7.76 – 7.72 (m, 2H), 7.54 – 7.47 
(m, 3H), 7.36 (ddd, J = 5.4, 2.4, 0.7 Hz, 1H), 7.32 – 7.27 (m, 2H), 3.83 (s, 3H). 
13C NMR (100 MHz, CDCl3) δ 153.7 (Cq), 142.9 (Cq), 136.5 (Cq), 130.1 (Cq), 129.7 (CH), 129.4 (CH), 
128.6 (CH), 122.7 (CH), 122.4 (CH), 119.8 (CH), 109.6 (CH), 31.6 (CH3). 
IR (ATR): 3059, 2924, 2159, 1469, 1442, 1382, 1328, 1006, 744, 698 cm–1. 
MS (ESI) m/z (relative intensity): 210 (100) [M+H]+. 
HR-MS (ESI): m/z calcd for C14H13N2 [M+H]
+: 210.1074, found: 210.1073. 




1) The General Procedure G was followed using 1-methyl-1H-benzo[d]imidazole 445a (33 mg, 
0.25 mmol), 4-iodoanisole 404c (293 mg, 1.25 mmol), 406 (30 mg, 11 mol %) and K3PO4 (159 mg, 
0.75 mmol) in THF (0.5 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 
4/1) yielded 446c (36.3 mg, 61%) as a light yellow solid. 
2) The General Procedure H was followed using 1-methyl-1H-benzo[d]imidazole 445a (33 mg, 
0.25 mmol), 4-bromoanisole 447c (255 mg, 1.25 mmol), 406 (30 mg, 11 mol %) and Cs2CO3 (244 mg, 




4/1) yielded 446c (47.1 mg, 79%) as a light yellow solid. 
M. p.: 118 ºC. 
1H NMR (400 MHz, CDCl3) δ 7.79 (ddd, J = 4.9, 2.3, 0.7 Hz, 1H), 7.70 (dd, J = 2.9, 2.3 Hz, 1H), 7.68 
(dd, J = 2.9, 2.3 Hz, 1H), 7.35 (ddd, J = 4.9, 2.3, 0.7 Hz, 1H), 7.29 (dd, J = 2.9, 2.3 Hz, 1H) 7.28 (dd, 
J = 2.9, 2.3 Hz, 1H), 7.03 (dd, J = 2.9, 2.3 Hz, 1H), 7.02 (dd, J = 2.9, 2.3 Hz, 1H).3.86 (s, 3H), 3.83 (s, 
3H). 
13C NMR (100 MHz, CDCl3) δ 160.7 (Cq), 142.9 (Cq), 136.5 (Cq), 130.8 (Cq), 122.5 (CH), 122.5 (Cq), 
122.5 (CH), 122.3 (CH), 119.6 (CH), 114.1 (CH), 109.5 (CH), 55.4 (CH3), 31.7 (CH3). 
IR (ATR): 2938, 2837, 1706, 1611, 1461, 1250, 1177, 1025, 838, 745 cm–1. 
MS (ESI) m/z (relative intensity): 239 (80) [M+H]+, 261 (20) [M+Na]+ 
HR-MS (ESI): m/z calcd for C15H15N2O [M+H]
+: 239.1182, found: 239.1180. 




1) The General Procedure G was followed using 1-methyl-1H-benzo[d]imidazole 445a (33 mg, 
0.25 mmol), 1-fluoro-4-iodobenzene 404e (278 mg, 1.25 mmol), 406 (30 mg, 11 mol %) and K3PO4 
(159 mg, 0.75 mmol) in THF (0.5 mL). Purification by column chromatography on silica gel (n-
hexane/EtOAc: 4/1) yielded 446d (36.7 mg, 65%) as a light yellow solid. 
2) The General Procedure H was followed using 1-methyl-1H-benzo[d]imidazole 445a (33 mg, 
0.25 mmol), 1-bromo-4-fluorobenzene 447d (278 mg, 1.25 mmol), 406 (30 mg, 11 mol %) and Cs2CO3 
(244 mg, 0.75 mmol) in Et2O (0.5 mL). Purification by column chromatography on silica gel (n-
hexane/EtOAc: 4/1) yielded 446d (39.6 mg, 70%) as a light yellow solid 
M. p.: 98 ºC. 
1H NMR (400 MHz, CDCl3) δ 7.80 (ddd, J = 4.5, 2.0, 0.7 Hz, 1H), 7.75 (ddd, J = 5.1, 3.0, 2.3 Hz, 
1H), 7.73 (ddd, J = 5.1, 3.0, 2.3 Hz, 1H), 7.37 (ddd, J = 4.5, 2.0, 0.7, 1H), 7.33 – 7.28 (m, 2H), 7.25 – 




13C NMR (100 MHz, CDCl3) δ 163.6 (d, JC-F = 250.5 Hz, Cq), 152.8 (Cq), 142.8 (Cq), 136.5 (Cq), 
131.4 (d, JC-F = 8.4 Hz, CH), 126.3 (d, JC-F = 3.4 Hz, Cq), 122.9 (CH), 122.5 (CH), 119.8 (CH), 115.9 
(d, JC-F = 22.0 Hz, CH)), 109.9 (CH), 109.6 (CH), 31.6 (CH3). 
19F NMR (282 MHz, CDCl3) δ –110.60 (ddd, J = 13.6, 8.5, 5.2 Hz). 
IR (ATR): 3059, 2951, 2158, 1645, 1606, 1461, 1225, 1097, 843, 744 cm–1. 
MS (ESI) m/z (relative intensity): 227 (70) [M+H]+, 249 (30) [M+Na]+. 
HR-MS (ESI): m/z calcd for C14H12FN2 [M+H]
+: 227.0985, found: 227.0983. 




The General Procedure G was followed using 1-methyl-1H-benzo[d]imidazole 445a (33 mg, 0.25 
mmol), 1-(4-iodophenyl)ethan-1-one 404q (308 mg, 1.25 mmol), 406 (30 mg, 11 mol %) and K3PO4 
(159 mg, 0.75 mmol) in THF (0.5 mL). Purification by column chromatography on silica gel (n-
hexane/EtOAc: 4/1) yielded 446e (29.4 mg, 47%) as a light yellow solid. 
M. p.: 153 ºC. 
1H NMR (400 MHz, CDCl3) δ 8.10 (dd, J = 2.3, 1.8 Hz, 1H), 8.8 (dd, J = 2.3, 1.8 Hz, 1H), 7.89 (dd, 
J = 2.3, 1.8 Hz, 1H), 7.87 (dd, J = 2.3, 1.8 Hz, 1H), 7.83 – 7.81 (m, 1H), 7.41 – 7.39 (m, 1H), 7.33 
(ddd, J = 6.7, 4.1, 1.8 Hz, 2H), 3.88 (s, 3H), 2.66 (s, 3H). 
13C NMR (100 MHz, CDCl3) δ 197.5 (Cq), 152.4 (Cq), 143.0 (Cq), 137.6 (Cq), 136.7 (Cq), 134.6 (Cq), 
129.6 (CH), 128.6 (CH), 123.3 (CH), 122.8 (CH), 120.1 (CH), 109.7 (CH), 31.8 (CH3), 26.8 (CH3). 
IR (ATR): 2932, 1682, 1608, 1463, 1355, 1262, 1011, 834, 744, 604 cm–1. 
MS (ESI) m/z (relative intensity): 251 (80) [M+H]+, 273 (20) [M+H]+. 
HR-MS (ESI): m/z calcd for C16H15N2O [M+H]







Methyl 4-(1-methyl-1H-benzo[d]imidazol-2-yl)benzoate (446f) 
 
The General Procedure G was followed using 1-methyl-1H-benzo[d]imidazole 445a (33 mg, 0.25 
mmol), methyl 4-iodobenzoate 404r (328 mg, 1.25 mmol), 406 (30 mg, 11 mol %) and K3PO4 (159 
mg, 0.75 mmol) in THF (0.5 mL). Purification by column chromatography on silica gel (n-
hexane/EtOAc: 4/1) yielded 446f (41.9 mg, 63%) as a light yellow solid. 
M. p.: 120 ºC. 
1H NMR (400 MHz, CDCl3) δ 8.20 (dd, J = 2.3, 1.7 Hz, 1H), 8.18 (dd, J = 2.3, 1.7 Hz, 1H), 7.87(dd, 
J = 2.3, 1.7 Hz, 1H), 7.85 (dd, J = 2.3, 1.7 Hz, 1H), 7.82 (ddd, J = 4.1, 2.3, 0.8 Hz, 1H), 7.40 (ddd, J 
= 4.1, 2.3, 0.8 Hz, 1H), 7.32 (ddd, J = 6.6, 4.1, 1.7 Hz, 2H), 3.95 (s, 3H), 3.88 (s, 3H). 
13C NMR (100 MHz, CDCl3) δ 166.5 (Cq), 152.5 (Cq), 143.0 (Cq), 136.7 (Cq), 134.5 (Cq), 131.1 (Cq), 
129.9 (CH), 129.4 (CH), 123.2 (CH), 122.7 (CH), 120.1 (CH), 109.7 (CH), 52.4 (CH3), 31.8 (CH3). 
IR (ATR): 2950, 1719, 1612, 1530, 1460, 1274, 1016, 964, 743 cm–1. 
MS (ESI) m/z (relative intensity): 267 (90) [M+H]+, 289 (10) [M+H]+. 
HR-MS (ESI): m/z calcd for C16H15N2O2 [M+H]




The General Procedure G was followed using 1-methyl-1H-benzo[d]imidazole 445a (33 mg, 0.25 
mmol), 1-iodo-3-methylbenzene 404h (273 mg, 1.25 mmol), 406 (30 mg, 11 mol %) and K3PO4 (159 
mg, 0.75 mmol) in THF (0.5 mL). Purification by column chromatography on silica gel (n-
hexane/EtOAc: 4/1) yielded 446g (34.5 mg, 62%) as a light yellow solid. 
M. p.: 119 ºC. 
1H NMR (400 MHz, CDCl3) δ 7.80 (ddd, J = 5.2, 2.3, 0.9 Hz, 1H), 7.61 – 7.60 (m, 1H), 7.50 – 7.49 
(m, 1H), 7.41 (t, J = 7.8 Hz, 1H), 7.39 – 7.37 (ddd, J = 5.2, 2.3, 0.9 Hz, 1H), 7.32 – 7.27 (m, 3H), 3.84 




13C NMR (100 MHz, CDCl3) δ 153.9 (Cq), 142.9 (Cq), 138.6 (Cq), 136.5 (Cq), 130.4 (CH), 130.2 (CH), 
130.1 (Cq), 128.4 (CH), 126.3 (CH), 122.6 (CH), 122.3 (CH), 119.8 (CH), 109.5 (CH), 31.6 (CH3), 
21.4 (CH3). 
IR (ATR): 3050, 2920, 1609, 1589, 1456, 1325, 1256, 793, 742, 659 cm–1. 
MS (ESI) m/z (relative intensity): 223 (100) [M+H]+. 
HR-MS (ESI): m/z calcd for C15H14N2 [M+H]
+: 223.1236, found: 223.1230. 




The General Procedure G was followed using 1-methyl-1H-benzo[d]imidazole 445a (33 mg, 0.25 
mmol), 1-iodo-3-(trifluoromethyl)benzene 404j (340 mg, 1.25 mmol), 406 (30 mg, 11 mol %) and 
K3PO4 (159 mg, 0.75 mmol) in THF (0.5 mL). Purification by column chromatography on silica gel 
(n-hexane/EtOAc: 4/1) yielded 446h (40.7 mg, 59%) as a light yellow solid. 
M. p.: 141 ºC. 
1H NMR (400 MHz, CDCl3) δ 8.06 – 8.04 (m, 1H), 7.97 – 7.93 (m, 1H), 7.82 (ddd, J = 3.6, 1.6, 0.8 
Hz, 1H), 7.77 – 7.73 (m, 1H), 7.68 – 7.62 (m, 1H), 7.40 (ddd, J = 3.6, 1.6, 0.8 Hz, 1H), 7.34 (ddd, J = 
6.4, 3.6, 1.6 Hz, 2H), 3.87 (s, 3H). 
13C NMR (100  MHz, CDCl3) δ 152.0 (Cq), 142.9 (Cq), 136.6 (Cq), 132.5 (CH), 131.3 (d, JC-F = 32.8 
Hz, Cq), 131.1 (Cq), 129.2 (CH), 126.6 (q, JC-F = 3.8 Hz, CH), 125.1 (Cq), 123.7 (d, JC-F = 273.6 Hz, 
CH), 123.3 (CH), 122.8 (CH), 120.1 (CH), 109.7 (CH), 31.7 (CH3). 
19F NMR (282 MHz, CDCl3) δ -62.73 (s). 
IR (ATR): 3108, 3058, 2926, 1460, 1324, 1249, 1122, 1060, 743, 650 cm–1. 
MS (ESI) m/z (relative intensity): 277 (100) [M+H]+. 
HR-MS (ESI): m/z calcd for C15H11F3N2 [M+H]








The General Procedure G was followed using 1-methyl-1H-benzo[d]imidazole 445a (33 mg, 0.25 
mmol), 1-iodo-2-methoxybenzene 404o (293 mg, 1.25 mmol), 406 (30 mg, 11 mol %) and K3PO4 (159 
mg, 0.75 mmol) in THF (0.5 mL). Purification by column chromatography on silica gel (n-
hexane/EtOAc: 4/1) yielded 446i (16.6 mg, 33%) as a light yellow oil. 
M. p.: 97 ºC. 
1H NMR (400 MHz, CDCl3) δ 7.80 (ddd, J = 3.5, 1.7, 0.7 Hz, 1H), 7.56 (dd, J = 7.5, 1.7 Hz, 1H), 7.47 
(ddd, J = 8.3, 7.5, 1.7 Hz, 1H), 7.37 (ddd, J = 3.5, 1.7, 0.7 Hz, 1H), 7.28 (ddd, J = 7.5, 3.5, 1.7 Hz, 
2H), 7.08 (td, J = 7.5, 0.7 Hz, 1H), 7.00 (dd, J = 8.3, 0.7 Hz, 1H), 3.79 (s, 3H), 3.63 (s, 3H). 
13C NMR (100 MHz, CDCl3) δ 157.4 (Cq), 152.0 (Cq), 143.0 (Cq), 136.0 (Cq), 132.2 (CH), 131.5 (CH), 
122.3 (CH), 121.9 (CH), 120.9 (CH), 119.7 (CH), 119.5 (Cq), 110.9 (CH), 109.3 (CH), 55.5 (CH3), 
30.8 (CH3). 
IR (ATR): 3059, 2941, 2837, 1458, 1437, 1251, 1117, 1201, 743, 640 cm–1. 
MS (ESI) m/z (relative intensity): 239 (100) [M+H]+. 
HR-MS (ESI): m/z calcd for C15H15N2O [M+H]
+: 239.1184, found: 239.1182. 






The General Procedure G was followed using 1-methyl-1H-benzo[d]imidazole 445a (33 mg, 0.25 
mmol), (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(R)-6-methyl heptan-2-yl]-2,3,4,7,8,9,10, 




mg, 1.25 mmol), 406 (30 mg, 11 mol %) and K3PO4 (159 mg, 0.75 mmol) in THF (0.5 mL). Purification 
by column chromatography on silica gel (n-hexane/EtOAc: 4/1) yielded 446j (63.6 mg, 41%) as a 
white solid. 
M. p.: 192 ºC. 
1H NMR (400 MHz, CDCl3) δ 8.20 (dd, J = 2.1, 1.5 Hz, 1H), 8.17 (dd, J = 2.1, 1.5 Hz, 1H), 7.86 (dd, 
J = 2.1, 1.5 Hz, 1H), 7.84 (dd, J = 2.1, 1.5 Hz, 1H), 7.83 – 7.81 (m, 1H), 7.40 (ddd, J = 6.3, 2.1, 0.8 
Hz, 1H), 7.30 (ddd, J = 6.3, 3.8, 1.5 Hz, 2H), 5.42 (d, J = 4.5 Hz, 1H), 4.90 (m, 1H), 3.88 (s, 3H), 2.49 
(d, J = 7.7 Hz, 2H), 2.07 – 1.92 (m, 4H), 1.88 – 1.62 (m, 3H), 1.62 – 1.42 (m, 5H), 1.34 – 1.30 (m, 
3H), 1.27 – 1.16 (m, 4H), 1.12 – 1.08 (m, 3H), 1.07 – 0.95 (m, 7H), 0.91 (d, J = 6.5 Hz, 3H), 0.86 (d, 
J = 1.8 Hz, 3H), 0.84 (d, J = 1.8 Hz, 3H), 0.68 (s, 3H). 
13C NMR (100 MHz, CDCl3) δ 165.4 (Cq), 152.6 (Cq), 143.0 (Cq), 139.5 (Cq), 136.7 (Cq), 134.3 (Cq), 
131.8 (Cq), 129.8 (CH), 129.3 (CH), 123.2 (CH), 122.9 (CH), 122.7 (CH), 120.1 (CH), 109.7 (CH),  
75.0 (CH), 56.7 (CH), 56.1 (CH), 50.0 (CH), 42.3 (Cq), 39.7 (CH2), 39.5 (CH2), 38.2 (CH2), 37.0 (CH3), 
36.7 (CH2), 36.2 (CH2), 35.8 (CH), 31.9 (CH2), 31.9 (CH), 31.8 (CH3), 28.2 (Cq), 28.0 (CH), 27.9 
(CH2), 24.3 (CH2), 23.8 (CH2), 22.8 (CH2), 22.6 (CH3), 21.1 (CH2), 19.4 (CH3), 18.7 (CH3), 11.9 (CH3). 
IR (ATR): 2936, 2867, 2248, 1674, 1714, 1465, 1273, 1119, 1016, 736 cm–1. 
MS (ESI) m/z (relative intensity): 621 (100) [M+H]+. 
HR-MS (ESI): m/z calcd for C42H57N2O2 [M+H]





The General Procedure H was followed using 1-methyl-1H-benzo[d]imidazole 445a (33 mg, 0.25 
mmol), 1-bromo-4-[[(1S,2S,5R)-2-isopropyl-5-methylcyclohexyl]oxy]benzene 447e (448 mg, 1.25 




column chromatography on silica gel (n-hexane/EtOAc: 4/1) yielded 446k (48.9 mg, 87%) as a light 
yellow solid. 
M. p.: 137 ºC. 
1H NMR (400 MHz, CDCl3) δ 7.78 (ddd, J = 5.3, 2.3, 0.7 Hz, 1H), 7.68 (dd, J = 2.9, 2.3 Hz, 1H), 7.66 
(dd, J = 2.9, 2.3 Hz, 1H), 7.36 (ddd, J = 5.3, 2.3, 0.7 Hz, 1H), 7.28 (ddd, J = 4.3, 2.3, 0.7 Hz, 2H), 7.02 
(dd, J = 2.9, 2.3 Hz, 1H), 7.00 (dd, J = 2.9, 2.3 Hz, 1H), 4.71 (q, J = 2.6 Hz, 1H), 3.85 (s, 3H), 2.12 
(dd, J = 14.0, 3.3 Hz, 1H), 1.83 – 1.61 (m, 4H), 1.61 – 1.51 (m, 1H), 0.97 (d, J = 6.7, 3H), 0.93 (d, J = 
6.7 Hz, 3H), 0.86 (d, J = 6.7 Hz, 3H), 0.82 (d, J = 6.6 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 159.6 (Cq), 154.0 (Cq), 143.0 (Cq), 136.6 (Cq), 130.8 (CH), 122.4 (CH), 
122.2 (CH), 121.9 (Cq), 119.5 (CH), 115.7 (CH), 109.4 (CH), 73.5 (CH), 47.7 (CH), 37.6 (CH2), 34.9 
(CH2), 31.7 (CH3), 29.3 (CH), 26.2 (CH), 24.8 (CH2), 22.3 (CH), 21.0 (CH), 20.8 (CH). 
IR (ATR): 2922, 2867, 1609, 1460, 1436, 1246, 1172, 962, 836, 741 cm–1. 
MS (ESI) m/z (relative intensity): 363 (100) [M+H]+. 
HR-MS (ESI): m/z calcd for C24H31N2O [M+H]






5.6.2 Synthesis of Hybrid Copper Catalyst 
1) Linker modification:  
To a solution of DIPA (15 mmol, 1.1 equiv) in 40 mL of dried THF (50 mL) was added n-BuLi (2.1 
M, 6.3 mL, 13.2 mmol, 1.0 equiv) dropwise at 0 °C under N2, in-situ generating LDA. After the reaction 
mixture was stirred for 1 h, a solution of 4,4-dimethyl-2,2′-bipyridine (439) (13.2 mmol, 1.0 equiv) in 
dried THF (100 mL) was slowly added under N2, then color was changed to dark brown. After stirring 
the reaction mixture for 1 h, a solution of (3-chloropropyl)trimethoxylsilane (440) (13.2 mmol, 1.0 
equiv) in 10 mL of THF was slowly added at 0 °C under N2. The solution was further stirred for an 
additional 2 h. The reaction mixture was warmed to room temperature and stirred for 24 h. After the 
reaction was quenched with two drops of acetone, the remaining solvent was removed and then dried 
in vacuo at room temperature for 24 h, affording 441. The synthesized 441 are used for the next step 
without further purification (Scheme 5.6.1).  
 
 
Scheme 5.6.1 Synthesis of 441. 
 
2) Grafting 
A suspension of SBA-15 (5.0 g) and the synthesized 441 were refluxed in dried toluene under N2 for 
24 h. The powder was filtered off, washed with toluene, n-hexane, and DCM (each 50 mL), and dried 






Scheme 5.6.2 Synthesis of 442. 
 
3) End-capping 
Hexamethyldisilazane (20 mL) and the isolated 442 in dried toluene (50 mL) was stirred at room 
temperature for 24 h. The powder was filtered off, washed with toluene, n-hexane, and DCM (each 50 
mL), and dried in vacuo at 100 °C for 24 h, providing 443 (Scheme 5.6.3). 
 
 
Scheme 5.6.3 Synthesis of 443. 
 
4) Metallation 
A suspension of CuI (6.0 mmol) and the isolated 443 were stirred in DCM at room temperature for 24 
h. The powder filtered off, washed with DCM, MeCN, and MeOH (each 50 mL), and dried in vacuo 






Scheme 5.6.4 Synthesis of 406. 
 
 
5.6.3 Determination of Catalyst Loading 
ICP-OES analysis was performed by Dr. Volker Karius for the determination of hybrid copper catalyst 
406 loading (Equation 5.6.1) 
 
Amount of Catalyst × ICP-OES result ÷ Molcular weight of copper ÷
amount of substrates × 100 mol %  
= 30 mg ×  
58300 mg
1,000,000 mg
 ×  
1
63.546 mg/mmol
 ×  
1
0.25 mmol
 × 100 mol % = 𝟏𝟏 𝐦𝐨𝐥 %  








5.6.4 Competition Experiment 
A suspension of 1-methyl-1H-benzo[d]imidazole 445a (0.25 mmol, 1.0 equiv), 4-iodoanisole 404c 
(1.25 mmol, 5.0 equiv), 1-fluoro-4-iodobenzene 404e (278 mg, 5.0 equiv), 406 (11 mol %) and K3PO4 
(0.75 mmol, 3.0 equiv) in THF (1.0 mL) was stirred under photo-induced and nitrogen conditions. 
After 24 h the solvent was removed under reduced pressure. Purification by column chromatography 
on silica gel (n-Hexane/EtOAc = 6/1 to 1/1) afforded the desired products 446c and 446d respectively. 
 
 
Scheme 5.6.5 Competition experiment with 445 and 404. 
 
 
5.6.5 Radical Experiment 
A suspension of benzothiazole 403a (0.25 mmol, 1.0 equiv), 4-iodoanisole 404c (1.25 mmol, 5.0 
equiv), 406 (11 mol %), LiOtBu (0.75 mmol, 3.0 equiv) and TEMPO (0.25 mmol, 1.0 equiv) in Et2O 
(0.5 mL) was stirred under photo-induced and nitrogen conditions. Purification by column 
chromatography on silica gel (n-Hexane/EtOAc: 70/1) yielded 405c. 
 
 






5.6.7 On-Off Light Test 
The General Procedure F was followed using benzothiazole 403a (0.25 mmol, 1.0 equiv), 4-
iodotoluene 404a (1.25 mmol, 5.0 equiv), 406 (11 mol %) and LiOtBu (0.75 mmol, 3.0 equiv) in Et2O 
(0.5 mL) for six independent reactions. Every two hours, the light was repeatedly turned off and the 
reaction was performed without irradiation for the next two hours. This process was repeated for 12 
hours and at every time when light conditions were changed, a tube was removed from the photo 
reaction chamber and subjected to determine the yield (Table 5.3.6). 
 




Light On Off On Off On Off 
Accumulated time (h) 2 4 6 8 10 12 







5.6.8 Heterogeneity Test 
1) Reuse test 
A suspension of 5-(benzo[d][1,3]dioxol-5-yl)oxazole 444h (0.25 mmol, 1.0 equiv), iodobenzene 404b 
(1.25 mmol, 5.0 equiv), 406 (22 mol %) and LiOtBu (0.75 mmol, 3.0 equiv) in Et2O (1.0 mL) was 
stirred under photo-induced and nitrogen conditions (Scheme 5.6.7). After 24 h the reaction tube was 
transferred to a glovebox. 406 was carefully filtered through branched filter (Por. 3) with Et2O and 
DCM (each 10 mL). Filtered 406 was dried in vacuo and used for next run. Filtrate was used for either 
















































Isolated yield (%) Copper leaching (ppm)
 






2) Scaled reuse test 
A suspension of benzothiazole 403a (10 mmol, 1.0 equiv), 4-iodotoluene 404a (50 mmol, 5.0 equiv), 
406 (11 mol %) and LiOtBu (30 mmol, 3.0 equiv) in Et2O (10 mL) was stirred under photo-induced 
and nitrogen conditions (Scheme 5.6.8). After 24 h the reaction tube was transferred to a glovebox. 
406 was carefully filtered through branched filter (Por. 3) with Et2O and DCM (each 20 mL). Filtered 
406 was dried in vacuo and used for the second run. The solvent of filtrate was removed under reduced 
pressure. Purification by column chromatography on silica gel afforded 405a. 
 
 
Scheme 5.6.8 Gram-scale reuse test. 
 
3) Filtration test 
A suspension of benzothiazole 403a (0.25 mmol, 1.0 equiv), 4-iodotoluene 404a (1.25 mmol, 5.0 
equiv), 406 (11 mol %) and LiOtBu (0.75 mmol, 3.0 equiv) in Et2O (0.5 mL) was stirred under photo-
induced and nitrogen conditions (Scheme 5.6.9). After 6 hours, reaction tube was transferred to the 
Glove box. 406 was carefully filtered over Celite® with a branched filter (Por. 3). Filtrate was directly 
collected to another pre-dried 10 mL quartz tube and then sealed with septum. The sealed tube was 
transferred to the Luzchem LZC-ICH2 photoreactor and the reaction continued for 18 h. Afterwards, 
the solvent was removed under reduced pressure. Purification by column chromatography on silica gel 
afforded the desired product 405a. 
 
 




5.7 Distal C–H Activation by Reusable Heterogeneous Ruthenium Catalysis 
5.7.1 Characterization Data 
Ethyl 2-(3-(pyridin-2-yl)phenyl)propanoate (409a) 
 
The General Procedure I was followed using 2-phenylpyridine 407a (38.8 mg, 0.25 mmol), ethyl 2-
bromopropanoate 408a (136 mg, 0.75 mmol), 410 (30.0 mg, 10 mol %) and KOAc (49.1 mg, 
0.50 mmol) in 2-MeTHF (2.0 mL). Purification by column chromatography on silica gel (n-
hexane/EtOAc: 10/1) yielded 409a (44.7 mg, 70%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ 8.62 (dd, J = 4.8, 1.4 Hz, 1H), 7.92 (dd, J = 1.8, 0.6 Hz, 1H), 7.82 (dd, 
J = 7.5, 1.8 Hz, 1H), 7.65 (d, J = 1.4 Hz, 1H), 7.64 (dd, J = 2.3, 1.4 Hz, 1H), 7.37 (dd, J = 7.5, 0.6 Hz, 
1H), 7.32 (dd, J = 7.5, 1.8 Hz, 1H), 7.15 – 7.11 (m, 1H), 4.14 – 3.99 (m, 2H), 3.76 (q, J = 7.1 Hz, 1H), 
1.50 (d, J = 7.1 Hz, 3H), 1.14 (t, J = 7.1 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 174.2 (Cq), 157.0 (Cq), 149.4 (CH), 141.0 (Cq), 139.5 (Cq), 136.5 (CH), 
128.8 (CH), 127.7 (CH), 126.1 (CH), 125.4 (CH), 121.9 (CH), 120.4 (CH), 60.5 (CH2), 45.4 (CH), 
18.5 (CH3), 13.9 (CH3). 
IR (ATR): 2936, 2711, 1783, 1461, 1437, 1200, 1161, 773 cm–1. 
MS (ESI) m/z (relative intensity): 278 (20) [M+Na]+, 256 (80) [M+H]+. 
HR-MS (ESI) m/z calcd. for C16H18NO2 [M+H]
+: 256.1334, found: 256.1335.  






Ethyl 2-(3-(pyrimidin-2-yl)phenyl)propanoate (409b) 
 
The General Procedure I was followed using 2-phenylpyrimidine 407b (39.0 mg, 0.25 mmol), ethyl 
2-bromopropanoate 408a (136 mg, 0.75 mmol), 410 (30.0 mg, 10 mol %) and KOAc (49.1 mg, 
0.50 mmol) in 2-MeTHF (2.0 mL). Purification by column chromatography on silica gel (n-
hexane/EtOAc: 10/1) yielded 409b (40.4 mg, 63%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ 8.78 (d, J = 5.0 Hz, 2H), 8.38 – 8.36 (m, 1H), 8.31 (ddd, J = 5.0, 4.2, 
1.7 Hz, 1H), 7.45 – 7.42 (m, 2H), 7.16 (t, J = 4.8 Hz, 1H), 4.18 – 4.04 (m, 2H), 3.81 (q, J = 7.2 Hz, 
1H), 1.54 (d, J = 7.1 Hz, 3H), 1.18 (t, J = 7.1 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 174.4 (Cq), 164.5 (Cq), 157.2 (CH), 141.1 (Cq), 137.8 (Cq), 129.8 (CH), 
128.9 (CH), 127.5 (CH), 126.9 (CH), 119.1 (CH), 60.7 (CH2), 45.6 (CH), 18.64 (CH3), 14.1 (CH3). 
IR (ATR): 2978, 2720, 2012, 1585, 1302, 1143, 1007, 769 cm–1. 
MS (ESI) m/z (relative intensity): 279 (60) [M+Na]+, 257 (40) [M+H]+. 
HR-MS (ESI) m/z calcd. for C15H17N2O2 [M+H]
+: 257.1286, found: 257.1285.  
 
Ethyl 2-(3-(4,5-dihydrooxazol-2-yl)phenyl)propanoate (409c) 
 
The General Procedure I was followed using 2-phenyl-4,5-dihydrooxazole 407c (38.8 mg, 0.25 
mmol), ethyl 2-bromopropanoate 408a (136 mg, 0.75 mmol), 410 (30.0 mg, 10 mol %) and KOAc 
(49.1 mg, 0.50 mmol) in 2-MeTHF (2.0 mL). Purification by column chromatography on silica gel (n-




1H NMR (400 MHz, CDCl3) δ 7.89 (t, J = 1.6 Hz, 1H), 7.83 (dt, J = 7.7, 1.6 Hz, 1H), 7.43 (dt, J = 7.7, 
1.6 Hz, 1H), 7.36 (t, J = 7.7 Hz, 1H), 4.43 (t, J = 9.5 Hz, 2H), 4.23 – 3.99 (m, 4H), 3.74 (q, J = 7.2 Hz, 
1H), 1.51 (d, J = 7.2 Hz, 3H), 1.19 (t, J = 7.1 Hz, 3H).  
13C NMR (100 MHz, CDCl3) δ 174.3 (Cq), 164.7 (Cq), 141.1 (Cq), 130.5 (CH), 128.8 (CH), 128.2 (Cq), 
127.6 (CH), 127.1 (CH), 67.8 (CH2), 61.0 (CH2), 55.1 (CH2), 45.6 (CH), 18.6 (CH3), 14.3 (CH3).  
IR (ATR): 2980, 1732, 1650, 1362, 1194, 1067, 950, 711, 422 cm–1.  
MS (EI) m/z (relative intensity): 247 (21) [M]+, 174 (100), 131 (33), 103 (26).  
HR-MS (EI+) m/z calcd. for C14H17NO3 [M]
+: 247.1208, found: 247.1210. 
 
Ethyl 2-(3-(4-phenyl-4,5-dihydrooxazol-2-yl)phenyl)propanoate (409d) 
 
The General Procedure I was followed using 2,5-diphenyl-4,5-dihydrooxazole 407d (55.8 mg, 0.25 
mmol), ethyl 2-bromopropanoate 408a (125.2 mg, 0.75 mmol), 410 (30.0 mg, 10 mol %) and KOAc 
(49.1 mg, 0.50 mmol) in 2-MeTHF (2.0 mL). Purification by column chromatography on silica gel (n-
hexane/EtOAc: 10/1) yielded 409d (55.7 mg, 69%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.96 (s, 1H), 7.91 (dd, J = 7.6, 1.5 Hz, 1H), 7.47 (d, J = 7.9 Hz, 1H), 
7.44 – 7.31 (m, 6H), 5.66 (dd, J = 10.2, 8.0 Hz, 1H), 4.48 (dd, J = 14.9, 10.2 Hz, 1H), 4.20 – 4.05 (m, 
2H), 4.00 (dd, J = 14.9, 8.0 Hz, 1H), 3.76 (q, J = 7.2 Hz, 1H), 1.52 (d, J = 7.2 Hz, 3H), 1.20 (t, J = 7.2, 
3H).  
13C NMR (100 MHz, CDCl3) δ 174.3 (Cq), 164.0 (Cq), 141.1 (Cq), 130.7 (CH), 129.0 (CH), 129.0 
(CH), 128.9 (CH), 128.5 (CH), 128.1 (Cq), 127.8 (Cq), 127.2 (CH), 125.9 (CH), 81.3 (CH2), 63.3 (CH), 
61.0 (CH2), 45.6 (CH), 18.7 (CH3), 14.3 (CH3).  
IR (ATR): 2979, 1731, 1651, 1337, 1193, 1064, 699 cm–1.  
MS (EI) m/z (relative intensity): 323 (4) [M]+, 250 (10), 217 (100), 189 (12).  
HR-MS (EI+) m/z calcd. for C20H21NO3 [M]




Ethyl 2-(3-(1H-pyrazol-1-yl)phenyl)propanoate (409e) 
 
The General Procedure I was followed using 1-phenyl-1H-pyrazole 407e (36.0 mg, 0.25 mmol), 
ethyl 2-bromopropanoate 408a (136 mg, 0.75 mmol), 410 (30.0 mg, 10 mol %) and KOAc (49.1 mg, 
0.50 mmol) in 2-MeTHF (2.0 mL). Purification by column chromatography on silica gel (n-
hexane/EtOAc: 10/1) yielded 409e (34.2 mg, 56%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.91 (dd, J = 2.5, 0.6 Hz, 1H), 7.70 (dd, J = 1.7, 0.6 Hz, 1H), 7.66 – 
7.64 (m, 1H), 7.55 (ddd, J = 8.0, 2.2, 1.1 Hz, 1H), 7.38 (t, J = 8.0 Hz, 1H), 7.22 (dddd, J = 7.7, 1.7, 
1.1, 0.6 Hz, 1H), 6.44 (dd, J = 2.5, 1.7 Hz, 1H), 4.17 – 4.06 (m, 2H), 3.75 (q, J = 7.1 Hz, 1H), 1.52 (d, 
J = 7.1 Hz, 3H), 1.19 (t, J = 7.1 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 174.1 (Cq), 142.2 (Cq), 141.1 (CH), 140.4 (Cq), 129.6 (CH), 126.8 
(CH), 125.5 (CH), 118.6 (CH), 117.9 (CH), 107.6 (CH), 60.9 (CH2), 45.5 (CH), 18.54 (CH3), 14.1 
(CH3). 
IR (ATR): 2853, 2749, 1987, 1582, 1461, 1203, 1170, 771 cm–1. 
MS (ESI) m/z (relative intensity): 245 (70) [M+H]+, 267 (30) [M+Na]+. 
HR-MS (ESI) m/z calcd. for C14H17N2O2 [M+H]
+: 245.1287, found: 245.1285.  
The spectral data were in accordance with those reported in the literature.[284] 
 
Ethyl 2-(3-(9-isopropyl-9H-purin-6-yl)phenyl)propanoate (409f) 
 
The General Procedure I was followed using 9-isopropyl-6-phenyl-9H-purine 407f (59.6 mg, 0.25 




(49.1 mg, 0.50 mmol) in 2-MeTHF (2.0 mL). Purification by column chromatography on silica gel (n-
hexane/EtOAc: 3/1) yielded 409f (77.8 mg, 92%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ 9.00 (s, 1H), 8.72 (dd, J = 7.4, 1.7 Hz, 1H), 8.68 (dd, J = 1.7, 0.8 Hz, 
1H), 8.17 (s, 1H), 7.55 – 7.45 (m, 2H), 4.97 (sept, J = 6.8 Hz, 1H), 4.12 (q, J = 7.2 Hz, 2H), 3.86 (q, J 
= 7.2 Hz, 1H), 1.66 (d, J = 6.8 Hz, 6H), 1.57 (d, J = 7.2 Hz, 3H), 1.19 (t, J = 7.2 Hz, 3H).  
13C NMR (100 MHz, CDCl3) δ 174.6 (Cq), 154.6 (Cq), 152.2 (Cq), 152.1 (CH), 142.1 (CH), 141.3 (Cq), 
136.2 (Cq), 131.6 (Cq), 129.9 (CH), 129.0 (CH), 129.0 (CH), 129.0 (CH), 60.9 (CH2), 47.4 (CH), 45.8 
(CH), 22.7 (CH3), 18.8 (CH3), 14.2 (CH3).  
IR (ATR): 2979, 1727, 1568, 1446, 1325, 1219, 1176, 1064, 797, 647 cm–1.  
MS (EI) m/z (relative intensity): 338 (60) [M]+, 265 (81), 223 (100), 208 (52).  
HR-MS (EI+) m/z calcd. for C19H22N4O2 [M]
+: 338.1743, found: 338.1735. 
 
Ethyl 2-(2-methyl-5-(pyridin-2-yl)phenyl)propanoate (409g) 
 
The General Procedure I was followed using 2-(p-tolyl)pyridine 407g (42.3 mg, 0.25 mmol), ethyl 
2-bromopropanoate 408a (136 mg, 0.75 mmol), 410 (30.0 mg, 10 mol %) and KOAc (49.1 mg, 0.50 
mmol) in 2-MeTHF (2.0 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 
10/1) yielded 409g (48.5 mg, 72%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ 8.65 (ddd, J = 4.8, 1.8, 1.1 Hz, 1H), 7.87 (d, J = 2.0 Hz, 1H), 7.78 (dd, 
J = 7.9, 2.0 Hz, 1H), 7.74 – 7.63 (m, 2H), 7.25 (d, J = 7.9 Hz, 1H), 7.17 (ddd, J = 6.7, 4.8, 1.8 Hz, 1H), 
4.17 – 4.06 (m, 2H), 3.98 (q, J = 7.1 Hz, 1H), 2.39 (s, 3H), 1.53 (d, J = 7.1 Hz, 3H), 1.18 (t, J = 7.1 
Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 174.7 (Cq), 157.3 (Cq), 149.6 (CH), 139.5 (Cq), 137.6 (Cq), 136.7 (Cq), 
136.6 (CH), 130.9 (CH), 125.3 (CH), 125.2 (CH), 121.8 (CH), 120.3 (CH), 60.7 (CH2), 41.6 (CH), 




IR (ATR): 2971, 2732, 1739, 1460, 1436, 1232, 1159, 771 cm–1. 
MS (ESI) m/z (relative intensity): 292 (20) [M+Na]+, 270 (80) [M+H]+. 
HR-MS (ESI) m/z calcd. for C17H20NO2 [M+H]
+: 270.1492, found: 270.1490.  
 
Ethyl 2-(2-methoxy-5-(pyridin-2-yl)phenyl)propanoate (409h) 
 
The General Procedure I was followed using 2-(4-methoxyphenyl)pyridine 407h (46.3 mg, 0.25 
mmol), ethyl 2-bromopropanoate 408a (136 mg, 0.75 mmol), 410 (30.0 mg, 10 mol %) and KOAc 
(49.1 mg, 0.50 mmol) in 2-MeTHF (2.0 mL). Purification by column chromatography on silica gel (n-
hexane/EtOAc: 10/1) yielded 409h (62.8 mg, 88%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ 8.62 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 7.87 (dd, J = 8.4, 2.3 Hz, 1H), 7.86 
– 7.85 (m, 1H), 7.71 – 7.62 (m, 2H), 7.14 (ddd, J = 7.0, 4.8, 1.8 Hz, 1H), 6.94 (d, J = 8.4 Hz, 1H), 4.12 
(q, J = 7.2 Hz, 2H), 4.02 (q, J = 7.2 Hz, 1H), 3.85 (s, 3H), 1.50 (d, J = 7.2 Hz, 3H), 1.18 (t, J = 7.1 Hz, 
3H). 
13C NMR (100 MHz, CDCl3) δ 174.9 (Cq), 157.6 (Cq), 157.1 (Cq), 149.5 (CH), 136.5 (CH), 132.0 (Cq), 
129.9 (Cq), 126.9 (CH), 126.7 (CH), 121.4 (CH), 119.9 (CH), 110.7 (CH), 60.5 (CH2), 55.5 (CH3), 
39.9 (CH), 17.2 (CH3), 14.2 (CH3). 
IR (ATR): 2960, 2697, 1731, 1463, 1434, 1205, 1162, 770 cm–1. 
MS (ESI) m/z (relative intensity): 308 (20) [M+Na]+, 286 (80) [M+H]+. 
HR-MS (ESI) m/z calcd. for C17H20NO3 [M+H]
+: 286.1441, found: 286.1439.  








Ethyl 2-(2-chloro-5-(pyridin-2-yl)phenyl)propanoate (409i) 
 
The General Procedure I was followed using 2-(4-chlorophenyl)pyridine 407i (47.4 mg, 0.25 mmol), 
ethyl 2-bromopropanoate 408a (136 mg, 0.75 mmol), 410 (30.0 mg, 10 mol %) and KOAc (49.1 mg, 
0.50 mmol) in 2-MeTHF (2.0 mL). Purification by column chromatography on silica gel (n-
hexane/EtOAc: 10/1) yielded 409i (39.1 mg, 54%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ 8.66 (ddd, J = 4.8, 1.8, 1.2 Hz, 1H), 7.95 (d, J = 2.2 Hz, 1H), 7.82 (dd, 
J = 8.4, 2.2 Hz, 1H), 7.72 (ddd, J = 8.4, 7.3, 2.2 Hz, 1H), 7.67 (ddd, J = 7.3, 1.8, 1.2 Hz, 1H), 7.45 (d, 
J = 8.4 Hz, 1H), 7.21 (ddd, J = 7.3, 4.8, 1.2 Hz, 1H), 4.22 (q, J = 7.2 Hz, 1H), 4.18 – 4.12 (m, 2H), 
1.55 (d, J = 7.2 Hz, 3H), 1.20 (t, J = 7.1 Hz, 3H).  
13C NMR (100 MHz, CDCl3) δ 173.9 (Cq), 156.1 (Cq), 149.7 (CH), 138.8 (Cq), 138.4 (Cq), 136.8 (CH), 
134.5 (Cq), 129.9 (CH), 127.0 (CH), 126.6 (CH), 122.3 (CH), 120.4 (CH), 60.9 (CH2), 42.5 (CH), 17.5 
(CH3), 14.1 (CH3). 
IR (ATR): 2960, 2697, 1731, 1463, 1434, 1205, 1162, 770 cm–1. 
MS (ESI) m/z (relative intensity): 312 (20) [M+Na]+, 290 (80) [M+H]+. 
HR-MS (ESI) m/z calcd. for C16H17
35ClNO2 [M+H]





Methyl 2-(1-ethoxy-1-oxopropan-2-yl)-4-(pyridin-2-yl)benzoate (409j) 
 
The General Procedure I was followed using methyl 4-(pyridin-2-yl)benzoate 407j (53.3 mg, 0.25 
mmol), ethyl 2-bromopropanoate 408a (136 mg, 0.75 mmol), 410 (30.0 mg, 10 mol %) and KOAc 
(49.1 mg, 0.50 mmol) in 2-MeTHF (2.0 mL). Purification by column chromatography on silica gel (n-
hexane/EtOAc: 10/1) yielded 409j (47.0 mg, 60%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ 8.69 (ddd, J = 4.8, 1.8, 1.1 Hz, 1H), 8.00 (dd, J = 4.8, 3.0 Hz, 2H), 7.92 
(dd, J = 8.2, 1.8 Hz, 1H), 7.78 – 7.71 (m, 2H), 7.25 (ddd, J = 6.0, 4.8, 3.0 Hz, 1H), 4.67 (q, J = 7.1 Hz, 
1H), 4.36 (q, J = 7.1 Hz, 2H), 4.16 – 4.05 (m, 2H), 1.60 (d, J = 7.1 Hz, 3H), 1.39 (t, J = 7.1 Hz, 3H), 
1.16 (t, J = 7.1 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 174.5 (Cq), 167.3 (Cq), 156.1 (Cq), 149.8 (CH), 142.7 (Cq), 142.5 (Cq), 
136.8 (CH), 131.2 (CH), 129.9 (Cq), 127.1 (CH), 125.1 (CH), 122.8 (CH), 120.9 (CH), 61.1 (CH2), 
60.7 (CH2), 42.4 (CH), 18.3 (CH3), 14.2 (CH3), 14.1 (CH3). 
IR (ATR): 2936, 2711, 2594, 1617, 1455, 1202, 1158, 769 cm–1. 
MS (ESI) m/z (relative intensity): 350 (30) [M+Na]+, 328 (70) [M+H]+. 
HR-MS (ESI) m/z calcd. for C19H22NO4 [M+H]
+: 328.1547, found: 328.1546.  
The spectral data were in accordance with those reported in the literature.[284] 
 
Ethyl 2-(3-(pyridin-2-yl)phenyl)propanoate (409k) 
 
The General Procedure I was followed using 2-phenylpyridine 407a (38.8 mg, 0.25 mmol), ethyl 2-




mmol) in 2-MeTHF (2.0 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 
10/1) yielded 409k (44.7 mg, 70%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ 8.69 (dt, J = 5.2, 1.4 Hz, 1H), 8.02 – 7.91 (m, 1H), 7.86 (dt, J = 7.7, 
1.5 Hz, 1H), 7.80 – 7.68 (m, 2H), 7.43 (t, J = 7.7 Hz, 1H), 7.36 (dt, J = 7.7, 1.5 Hz, 1H), 7.23 (ddd, J 
= 6.6, 4.8, 2.0 Hz, 1H), 3.83 (q, J = 7.1 Hz, 1H), 3.66 (s, 3H), 1.56 (d, J = 7.2 Hz, 3H).  
13C NMR (100 MHz, CDCl3) δ 175.1 (Cq), 157.4 (Cq), 149.8 (CH), 141.2 (Cq), 139.9 (Cq), 136.9 (CH), 
129.2 (CH), 128.1 (CH), 126.5 (CH), 125.9 (CH), 122.3 (CH), 120.8 (CH), 52.2 (CH3), 45.6 (CH), 
18.8 (CH3). 
IR (ATR): 2980, 2951, 1733, 1585, 1462, 1435, 1202, 1165, 770 cm–1. 
MS (EI) m/z (relative intensity): 241 (28) [M]+, 182 (100), 167 (55). 
HR-MS (EI+) m/z calcd. for C15H15NO2 [M]
+: 241.1103, found: 241.1102. 
 
Isobutyl 2-(3-(pyridin-2-yl)phenyl)propanoate (409l) 
 
The General Procedure I was followed using 2-phenylpyridine 407a (38.8 mg, 0.25 mmol), isobutyl 
2-bromopropanoate 408c (157 mg, 0.75 mmol), 410 (30.0 mg, 10 mol %) and KOAc (49.1 mg, 0.50 
mmol) in 2-MeTHF (2.0 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 
10/1) yielded 409l (45.3 mg, 64%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ 8.69 (dd, J = 4.9, 1.4 Hz, 1H), 7.94 (dd, J = 1.6, 1.4 Hz, 1H), 7.87 (dt, 
J = 7.6, 1.4 Hz, 1H), 7.81 – 7.67 (m, 2H), 7.43 (dd, J = 7.6, 7.5 Hz, 1H), 7.39 (dd, J = 7.5, 1.6 Hz, 1H), 
7.23 (ddd, J = 6.6, 4.9, 2.0 Hz, 1H), 3.88 – 3.83 (m, 3H), 1.88 (q, J = 6.7 Hz, 1H), 1.57 (d, J = 7.1 Hz, 
3H), 0.84 (d, J = 6.7 Hz, 6H).  
13C NMR (100 MHz, CDCl3) δ 174.6 (Cq), 157.4 (Cq), 149.8 (CH), 141.4 (Cq), 139.8 (Cq), 136.9 (CH), 
129.1 (CH), 128.2 (CH), 126.5 (CH), 125.8 (CH), 122.3 (CH), 120.8 (CH), 71.0 (CH2), 45.9 (CH), 




IR (ATR): 2963, 1731, 1585, 1566, 1462, 1436, 1195, 1164, 769 cm–1. 
MS (EI) m/z (relative intensity): 283 (22) [M]+, 225 (13), 182 (100), 167 (53).  
HR-MS (EI+) m/z calcd. for C18H21NO2 [M]
+: 283.1572, found: 283.1574. 
 
Methyl 6-bromo-2-(3-(pyridin-2-yl)phenyl)hexanoate (409m) 
 
The General Procedure I was followed using 2-phenylpyridine 407a (38.8 mg, 0.25 mmol), methyl 
2,6-dibromohexanoate 408d (216 mg, 0.75 mmol), 410 (30.0 mg, 10 mol %) and KOAc (49.1 mg, 
0.50 mmol) in 2-MeTHF (2.0 mL). Purification by column chromatography on silica gel (n-
hexane/EtOAc: 10/1) yielded 409m (50.3 mg, 58%) as a brown oil. 
1H NMR (400 MHz, CDCl3): δ 8.69 (dt, J = 5.0, 1.2 Hz, 1H), 7.93 (dd, J = 1.8, 1.7 Hz, 1H), 7.88 (dt, 
J = 7.7, 1.7 Hz, 1H), 7.80 – 7.68 (m, 2H), 7.44 (dd, J = 7.8, 7.7 Hz, 1H), 7.37 (dt, J = 7.8, 1.2 Hz, 1H), 
7.24 (ddd, J = 6.6, 5.0, 1.8 Hz, 1H), 3.67 (s, 3H), 3.67 (t, J = 7.6 Hz, 1H), 3.39 (t, J = 6.6 Hz, 2H), 2.30 
–2.20 (m, 1H), 2.10 – 2.00 (m, 1H), 1.90 – 1.80 (m, 2H).  
13C NMR (100 MHz, CDCl3) δ 174.1 (Cq), 157.2 (Cq), 149.8 (CH), 140.1 (Cq), 139.2 (Cq), 136.9 (CH), 
129.3 (CH), 128.4 (CH), 126.8 (CH), 126.2 (CH), 122.4 (CH), 120.8 (CH), 52.3 (CH3), 51.0 (CH), 
33.2 (CH2), 32.1 (CH2), 30.8 (CH2).  
IR (ATR): 2951, 1732, 1584, 1461, 1435, 1203, 1164, 771 cm–1.  
MS (EI) m/z (relative intensity): 347 (14) [M]+, 288 (18), 268 (100), 208 (61), 168 (61).  
HR-MS (EI+) m/z calcd. for C17H18
79BrNO2 [M]
+: 347.0521, found: 347.0520. 








The General Procedure I was followed using 2-phenylpyridine 407a (38.8 mg, 0.25 mmol), 2-bromo-
N,N-diethylpropanamide 408e (156 mg, 0.75 mmol), 410 (30.0 mg, 10 mol %) and KOAc (49.1 mg, 
0.50 mmol) in 2-MeTHF (2.0 mL). Purification by column chromatography on silica gel (n-
hexane/EtOAc: 10/1) yielded 409n (49.4 mg, 70%) as a yellow oil. 
1H NMR (400 MHz, CDCl3) δ 8.69 (d, J = 5.0 Hz, 1H), 7.91 (s, 1H), 7.85 (dt, J = 7.6, 1.2 Hz, 1H), 
7.76 – 7.70 (m, 2H), 7.42 (dd, J = 7.6, 7.5 Hz, 1H), 7.35 (dd, J = 7.6, 1.2 Hz, 1H), 7.236 – 7.22 (m, 
1H), 3.94 (q, = 7.0, 1H), 3.53 (dq, J = 7.6, 7.1 Hz, 1H), 3.36 (dq, J = 7.6, 7.1 Hz, 1H), 3.23 (dq, J = 
7.6, 7.1 Hz, 1H), 3.10 (dq, J = 7.6, 7.1 Hz, 1H), 1.49 (d, J = 6.8, 3.1 Hz, 3H), 1.10 (t, J = 7.1, 3H), 1.01 
(t, J = 7.1, 3H).  
13C NMR (100 MHz, CDCl3) δ 172.8 (Cq), 157.4 (Cq), 149.8 (Cq), 143.1 (CH), 140.0 (Cq), 136.9 (CH), 
129.4 (CH), 127.9 (CH), 126.1 (CH), 125.4 (CH), 122.3 (CH), 120.8 (CH), 43.3 (CH2), 41.8 (CH2), 
40.4 (CH), 21.2 (CH3), 14.4 (CH3), 13.0 (CH3).  
IR (ATR): 2973, 2932, 1636, 1584, 1461, 1433, 1264, 774, 702 cm–1.  
MS (EI) m/z (relative intensity): 282 (18) [M]+, 225 (14), 182 (26), 167 (30), 100 (100).  
HR-MS (EI+) m/z calcd. for C18H22N2O [M]
+: 282.1732, found: 282.1730. 
 
Ethyl 2-methyl-2-(3-(pyridin-2-yl)phenyl)propanoate (409o) 
 
The General Procedure I was followed using 2-phenylpyridine 407a (38.8 mg, 0.25 mmol), 2-bromo-




mmol) in 2-MeTHF (2.0 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 
10/1) yielded 409o (39.0 mg, 58%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ 8.70 (dt, J = 4.8, 1.5 Hz, 1H), 7.99 (dd, J = 1.9, 1.5 Hz, 1H), 7.84 (dt, 
J = 7.4, 1.6 Hz, 1H), 7.78 – 7.67 (m, 2H), 7.43 (dd, J = 7.5, 7.4 Hz, 2H), 7.23 (ddd, J = 7.5, 4.8, 1.5 
Hz, 1H), 4.14 (q, J = 7.1 Hz, 2H), 1.65 (s, 6H), 1.19 (t, J = 7.1 Hz, 3H).  
13C NMR (100 MHz, CDCl3) δ 176.9 (Cq), 157.7 (Cq), 149.8 (CH), 145.5 (Cq), 139.7 (Cq), 136.8 (CH), 
128.9 (CH), 126.6 (CH), 125.4 (CH), 124.4 (CH), 122.2 (CH), 120.9 (CH), 61.0 (CH2), 46.8 (Cq), 26.7 
(CH3), 14.2 (CH3).  
IR (ATR): 2979, 1726, 1585, 1463, 1253, 1146, 1025, 771 cm–1.  
MS (EI) m/z (relative intensity): 269 (20) [M]+, 196 (100), 180 (21), 167 (18).  
HR-MS (EI+) m/z calcd. for C17H19NO2 [M]
+: 269.1416, found: 269.1415. 
The spectral data were in accordance with those reported in the literature.[84] 
 
(1R,2S,5R)-2-Isopropyl-5-methylcyclohexyl 2-[3-(pyridin-2-yl)phenyl]propanoate (409p) 
 
The General Procedure I was followed using 2-phenylpyridine 407a (38.8 mg, 0.25 mmol), 
(1R,2S,5R)-2-isopropyl-5-methylcyclohexyl 2-bromopropanoate 408g (218 mg, 0.75 mmol), 410 
(30.0 mg, 10 mol %) and KOAc (49.1 mg, 0.50 mmol) in 2-MeTHF (2.0 mL). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 10/1) yielded 409p (52.1 mg, 57%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ 8.69 (dt, J = 4.9, 1.4 Hz, 1H), 7.92 (dd, J = 3.9, 1.9 Hz, 1H), 7.87 (dd, 
J = 7.7, 1.5 Hz, 1H), 7.79 – 7.65 (m, 2H), 7.49 – 7.32 (m, 2H), 7.22 (ddd, J = 6.5, 4.8, 2.1 Hz, 1H), 
4.69 – 4.60 (m, 1H), 3.82 – 3.76 (m, 1H), 2.06 – 1.76 (m, 2H), 1.71 – 1.58 (m, 2H), 1.56 (d, J = 2.7 
Hz, 1H), 1.54 (d, J = 2.7 Hz, 1H), 1.51 – 1.39 (m, 1H), 1.38 – 1.23 (m, 2H), 1.02 – 0.93 (m, 2H), 0.95 




13C NMR (100 MHz, CDCl3) δ 174.2 (Cq), 157.5 (Cq), 149.8 (CH), 141.5 (Cq), 139.8 (Cq), 136.8 (CH), 
129.0 (CH), 128.1 (CH), 126.4 (CH), 125.7 (CH), 122.3 (CH), 120.7 (CH), 74.7 (CH), 47.1 (CH), 46.1 
(CH2), 40.8 (CH), 34.4 (CH2), 31.5 (CH2), 26.1 (CH), 23.4 (CH), 22.1 (CH3), 20.8 (CH3), 18.7 (CH3), 
16.2 (CH3). 
IR (ATR): 2953, 2869, 1726, 1585, 1461, 1198, 1170, 768 cm–1.  
MS (EI) m/z (relative intensity): 365 (18) [M]+, 228 (28), 183 (100), 167 (42), 83 (72).  
HR-MS (EI+) m/z calcd. for C24H31NO2 [M]






The General Procedure I was followed using 2-phenylpyridine 407a (38.8 mg, 0.25 mmol), 
(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,1
4,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl 2-bromopropanoate 408h (391 mg, 
0.75 mmol), 410 (30.0 mg, 10 mol %) and KOAc (49.1 mg, 0.50 mmol) in 2-MeTHF (2.0 mL). 
Purification by column chromatography on silica gel (n-hexane/EtOAc: 10/1) yielded 409q (93.9 mg, 
63%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ 8.70 (dd, J = 5.0, 1.5 Hz, 1H), 7.94 (t, J = 1.7 Hz, 1H), 7.87 (dt, J = 
7.6, 1.5 Hz, 1H), 7.74 (dd, J = 6.6, 1.7 Hz, 2H), 7.43 (dd, J = 7.6, 7.6 Hz, 2H), 7.23 (ddd, J = 6.6, 5.0, 
2.1 Hz, 1H), 5.33 (ddd, J = 21.3, 4.3, 1.8 Hz, 1H), 4.75 – 4.51 (m, 1H), 3.78 (q, J = 7.2 Hz, 1H), 2.40 
– 2.27 (m, 1H), 2.25 – 2.17 (m, 1H), 2.05 – 1.75 (m, 5H), 1.61 – 1.25 (m, 14H), 1.22 – 0.95 (m, 13H), 
0.94 – 0.88 (m, 3H), 0.86 (dd, J = 6.6, 1.8 Hz, 6H), 0.66 (s, 3H).  
13C NMR (100 MHz, CDCl3) δ 174.0 (Cq), 157.4 (Cq), 149.7 (CH), 141.6 (Cq), 139.8 (Cq), 139.7 (Cq), 




74.4 (CH), 56.8 (CH), 56.3 (CH), 50.1 (CH), 46.0 (CH), 42.4 (CH2), 39.9 (CH2), 39.7 (CH2), 38.1 (Cq), 
37.1 (CH2), 36.7 (CH2), 36.3 (CH2), 35.9 (CH), 32.0 (CH2), 32.0 (CH), 28.4 (CH2), 28.2 (CH), 27.7 
(Cq), 24.4 (CH2), 24.0 (CH2), 22.8 (CH3), 21.2 (CH2), 19.5 (CH3), 19.0 (CH3), 18.9 (CH3), 12.0 (CH3).  
IR (ATR): 2935, 2867, 1731, 1585, 1462, 1195, 1165, 769 cm–1.  
MS (ESI) m/z (relative intensity): 618 (100) [M+Na]+, 596 (30) [M+H]+.  
HR-MS (ESI) m/z calcd for C41H58NO2 [M+H]





5.7.2 Preparation of Hybrid Ruthenium Catalyst 
A suspension of [RuCl2(p-cymene)]2 (0.30 g, 0.50 mmol) and resin 448 (triphenylphosphine, polymer 
supported 1.4–2.0 mmol/g on polystyrene 200–400 mesh 2% DVB loading, Fluorochem, 0.50 g) in a 
solvent mixture of DCM (15 mL) and PhMe (15 mL) was refluxed at 110 °C for 2 h under N2 (Scheme 
5.7.1). After cooling to ambient temperature, the mixture was filtered with DCM (50 mL). 410 was 
dried in vacuo at room temperature for 24 h (Scheme 5.7.1). 
 
 
Scheme 5.7.1 Preparation of hybrid ruthenium catalyst. 
 
 
5.7.3 Determination of Catalyst Loading 
ICP-OES analysis was performed by Dr. Volker Karius for the determination of hybrid ruthenium 
catalyst 410 loading (Equation 5.7.1)  
 
𝑛Cat =












∙ 100 mol % = 9.96 mol % 







5.7.4 Competition Experiment 
A suspension of 2-(4-fluorophenyl)-4,5-dihydrooxazole 407k (0.25 mmol, 1.0 equiv) and 2-(4-
methoxyphenyl)-4,5-dihydrooxazole 407l (0.25 mmol, 1.0 equiv), ethyl 2-bromopropanoate 408a 
(0.75 mmol, 1.0 equiv), 410 (10 mol %), KOAc (0.50 mmol, 2.0 equiv) in 2-MeTHF (2.0 mL) was 
stirred at 60 °C for 24 h under N2. After cooling to ambient temperature, the mixture was concentrated 
in vacuo. Purification by column chromatography on silica gel afforded the desired products 409r and 
409s respectively (Scheme 5.7.2).  
 
 







5.7.5 H/D Exchange Study 
A suspension of 2-(4-methoxyphenyl)-4,5-dihydrooxazole 407k (0.25 mmol, 1.0 equiv), ethyl 2-
bromopropanoate 408a (0.75 mmol, 3.0 equiv), 410 (10 mol %), KOAc (0.50 mmol, 2.0 equiv), 
CD3OD (0.1 mL, 10 equiv) in 2-MeTHF (2.0 mL) was stirred at 60 °C for 24 h under N2. After cooling 
to ambient temperature, the mixture was concentrated in vacuo. Purification by column 
chromatography on silica gel afforded the desired products [D]n-407k and [D]n-409r respectively 

















5.7.6 KIE Study 
1) Procedure for KIE study (intermolecular competition reaction) 
A suspension of 407d (0.25 mmol, 1.0 equiv) and [D]5-407d (0.25 mmol, 1.0 equiv), ethyl 2-
bromopropanoate 408a (0.75 mmol, 3.0 equiv), 410 (10 mol %), KOAc (0.50 mmol, 2.0 equiv), in 2-
MeTHF (2.0 mL) was stirred at 60 °C for 24 h under N2 to determine the KIE by intermolecular 
competition fashion. Purification by column chromatography on silica gel afforded the desired mixed 
products of 409d and [D]n-409d. The kinetic isotope effect of this reaction was determined to be kH/kD 
= 1.2 as estimated by 1H NMR spectroscopy (Scheme 5.7.5). 
 
 






2) Procedure for KIE study (two parallel reactions) 
Two parallel reactions under the General Procedure I respectively using substrate 407d (0.25 mmol, 
1.0 equiv) or [D]5-407d (0.25 mmol, 1.0 equiv) were performed to determine the KIE by comparison 
of the initial rates. Each conversion was determined after 2 h by 1H NMR measurement using 1,3,5-











5.7.7 Heterogeneity test 
1) Reuse test 
The General Procedure I was followed using 2-phenylpyridine 407a (0.25 mmol, 1.0 equiv), ethyl 
2-bromopropanoate 408a (0.75 mmol, 3.0 equiv), 410 (10 mol %) and KOAc (0.50 mmol, 2.0 equiv) 
in 2-MeTHF (2.0 mL). After 24 h the reaction tube was transferred to a glovebox. Hybrid-Ru was 
carefully filtered through branched filter (Por. 3) and washed with 2-MeTHF (30 mL). Filtered hybrid 























































<Washing method 1> 
After the completion of the reaction, 410 was carefully filtered through branched filter (Por. 3) and 
washed with DCM, 2-MeTHF, and DCM (each 30 mL). Filtered hybrid ruthenium catalyst was dried 
in vacuo for 24 h. The dried catalyst was directly used for the next run.   
 
<Washing method 2> 
After the completion of the reaction, 410 was carefully filtered through branched filter (Por. 3) and 
washed with DCM, 2-MeTHF, demineralized water, EtOH, and DCM (each 30 mL). Filtered hybrid 
ruthenium catalyst was dried in vacuo for 24 h. The dried catalyst was directly used for the next run.   
 
 







2) Gram-scale reuse test 
The General Procedure I was followed using 2-phenylpyridine 407a (10.0 mmol, 1.0 equiv), ethyl 
2-bromopropanoate 408a (30.0 mmol, 3.0 equiv), 410 (10 mol %) and KOAc (20 mmol, 2.0 equiv) in 
2-MeTHF (10.0 mL). After 24 h the reaction tube was transferred to a glovebox. Hybrid-Ru was 
carefully filtered through branched filter (Por. 3) with 2-MeTHF (60 mL). Filtered hybrid ruthenium 
catalyst was dried in vacuo and used for the second run. The solvent of filtrate was removed under 
reduced pressure. Purification by column chromatography on silica gel afforded 409a (first run: 2.04 
g, 80%; second run: 1.94 g, 76%) as a colorless oil (Scheme 5.7.10). 
 
 






3) Hot filtration test 
The General Procedure I was followed using 2-phenylpyridine 407a (0.25 mmol, 1.0 equiv), ethyl 
2-bromopropanoate 408a (0.75 mmol, 3.0 equiv), 410 (10 mol %) and KOAc (0.50 mmol, 2.0 equiv) 
in 2-MeTHF (2.0 mL). After 2 or 4 hours, reaction tube was transferred to the Glove box. Hybrid-Ru 
was carefully filtered over pre-heated (to 60 oC) Celite® with a branched filter (Por. 3). Filtrate was 
directly collected to another pre-dried Schlenk tube and then sealed with septum. The sealed tube was 
transferred to the same reaction batch and the reaction continued for 22 or 20 h. After cooling to 
ambient temperature, the mixture was concentrated in vacuo. Purification by column chromatography 
on silica gel afforded the desired products 409a (Scheme 5.7.11). 
 
 








5.8 C–H Arylations and Alkylations by Reusable Heterogeneous Manganese Catalyst 
5.8.1 Characterization Data 
N-Butyl-3-(4-methoxyphenyl)picolinamide (413a) 
 
The General Procedure J was followed using N-butylpicolinamide 411a (44.6 mg, 0.25 mmol), (4-
methoxyphenyl)magnesium bromide 412a (1.0 mL, 1.0 M in THF, 1.00 mmol), 416 (30 mg, 9.0 mol 
%), TMEDA (58.1 mg, 0.50 mmol), and 2,3-DCB (95.3 mg, 0.75 mmol). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 1/1) yielded 413a (56.9 mg, 80%) as a white solid. 
M. p. 97 ºC. 
1H NMR (400 MHz, CDCl3) δ 8.48 (dd, J = 4.6, 1.6 Hz, 1H), 7.65 (s, 1H), 7.64 (dd, J = 7.8, 1.6 Hz, 
1H), 7.38 (dd, J = 7.8, 4.6 Hz, 1H), 7.25 (d, J = 8.6 Hz, 2H), 6.92 (d, J = 8.6 Hz, 2H), 3.81 (s, 3H), 
3.34 – 3.32 (m, 2H), 1.57 – 1.48 (m, 2H), 1.39 – 1.29 (m, 2H), 0.90 (t, J = 7.3 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 165.3 (Cq), 159.1 (Cq), 148.3 (Cq), 146.5 (CH), 140.0 (CH), 137.7 (Cq), 
131.6 (Cq), 129.6 (CH), 124.9 (CH), 113.4 (CH), 55.1 (CH3), 39.1 (CH2), 31.6 (CH2), 20.1 (CH2), 13.7 
(CH3).  
IR (ATR): 3398, 2928, 1652, 1510, 1245, 805, 523 cm-1. 
MS (ESI) m/z (relative intensity): 285 (80) [M+H]+, 307 (20) [M+Na]+. 
HR-MS (ESI) C17H21N2O2 [M+H]
+: 285.1599, found: 285.1598. 







The General Procedure J was followed using N-butylnicotinamide 411b (44.6 mg, 0.25 mmol), (4-
methoxyphenyl)magnesium bromide 412a (1.0 mL, 1.0 M in THF, 1.00 mmol), 416 (30 mg, 9.0 mol 
%), TMEDA (58.1 mg, 0.50 mmol), and 2,3-DCB (95.3 mg, 0.75 mmol). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 1/1) yielded 413b (24.2 mg, 34%) as a white solid. 
M. p. 105 ºC. 
1H NMR (400 MHz, CDCl3) δ 8.71 (s, 1H), 8.52 (d, J = 5.2 Hz, 1H), 7.33 (d, J = 8.8 Hz, 2H), 7.20 
(d, J = 5.2 Hz, 1H), 6.93 (d, J = 8.8 Hz, 2H), 5.66 (s, 1H), 3.80 (s, 3H), 3.21 – 3.16 (m, 2H), 1.31 – 
1.19 (m, 2H), 1.12 – 0.98 (m, 2H), 0.78 (t, J = 7.3 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 167.3 (Cq), 160.3 (Cq), 150.5 (CH), 149.5 (CH), 146.5 (Cq), 131.2 (Cq), 
129.6 (CH), 129.4 (Cq), 123.9 (CH), 114.3 (CH), 55.3 (CH3), 39.6 (CH2), 31.0 (CH2), 19.8 (CH2), 13.6 
(CH3). 
IR (ATR): 3274, 2929, 1638, 1516, 1251, 831, 532 cm-1. 
MS (ESI) m/z (relative intensity): 285 (90) [M+H]+, 307 (10) [M+Na]+. 
HR-MS (ESI) C17H21N2O2 [M+H]
+: 286.1561, found: 286.1550. 




The General Procedure J was followed using N-butylisonicotinamide 411c (44.6 mg, 0.25 mmol), 
(4-methoxyphenyl)magnesium bromide 412a (1.0 mL, 1.0 M in THF, 1.00 mmol), 416 (30 mg, 9.0 
mol %), TMEDA (58.1 mg, 0.50 mmol), and 2,3-DCB (95.3 mg, 0.75 mmol). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 1/1) yielded 413c (21.3 mg, 30%) as a white solid. 
M. p. 122 ºC. 
1H NMR (400 MHz, CDCl3) δ 8.61 – 8.57 (m, 2H), 7.51 (d, J = 5.0 Hz, 1H), 7.33 (d, J = 8.9 Hz, 2H), 




0.97 (m, 2H), 0.78 (t, J = 7.3 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 167.1 (Cq), 160.0 (Cq), 150.9 (CH), 148.7 (CH), 142.2 (Cq), 133.5 (Cq), 
130.1 (CH), 128.5 (Cq), 122.2 (CH), 114.4 (CH), 55.3 (CH3), 39.5 (CH2), 31.0 (CH2), 19.8 (CH2), 13.6 
(CH3). 
IR (ATR): 3275, 2929, 1642, 1513, 1250, 834, 548 cm-1. 
MS (ESI) m/z (relative intensity): 285 (90) [M+H]+, 307 (10) [M+Na]+. 
HR-MS (ESI) C17H21N2O2 [M+H]
+: 285.1603, found: 285.1598. 




The General Procedure J was followed using N-butylpyrazine-2-carboxamide 411d (44.8 mg, 0.25 
mmol), (4-methoxyphenyl)magnesium bromide 412a (1.0 mL, 1.0 M in THF, 1.00 mmol), 416 (30 mg, 
9.0 mol %), TMEDA (58.1 mg, 0.50 mmol), and 2,3-DCB (95.3 mg, 0.75 mmol). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 1/1) yielded 413d (14.9 mg, 21%) as a white 
solid. 
M. p. 67 ºC. 
1H NMR (400 MHz, CDCl3) δ 8.67 (d, J = 2.3 Hz, 1H), 8.39 (d, J = 2.3 Hz, 1H), 7.58 (d, J = 8.9 Hz, 
2H), 7.33 (s, 1H), 6.95 (d, J = 8.9 Hz, 2H), 3.83 (s, 3H), 3.42 – 3.37 (m, 2H), 1.58 – 1.54 (m, 2H), 
1.41 – 1.32 (m, 2H), 0.92 (t, J = 7.3 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 164.9 (Cq), 160.6 (Cq), 154.0 (Cq), 144.9 (CH), 144.1 (Cq), 139.9 (CH), 
130.5 (CH), 130.1 (Cq), 113.6 (CH), 55.3 (CH3), 39.4 (CH2), 31.5 (CH2), 20.1 (CH2), 13.7 (CH3). 
IR (ATR): 3273, 2929, 1649, 1514, 1251, 812, 557 cm-1. 
MS (ESI) m/z (relative intensity): 286 (55) [M+H]+, 308 (45) [M+Na]+. 
HR-MS (ESI) C16H21N3O2 [M+H]






The General Procedure J was followed using N-butyl-5-phenylpicolinamide 411f (63.6 mg, 0.25 
mmol), (4-methoxyphenyl)magnesium bromide 412a (1.0 mL, 1.0 M in THF, 1.00 mmol), 416 (30 mg, 
9.0 mol %), TMEDA (58.1 mg, 0.50 mmol), and 2,3-DCB (95.3 mg, 0.75 mmol). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 1/1) yielded 413f (46.0 mg, 51%) as a white 
solid. 
M. p. 90 ºC. 
1H NMR (400 MHz, CDCl3) δ 8.72 (d, J = 2.2 Hz, 1H), 7.83 (d, J = 2.2 Hz, 1H), 7.77 – 7.70 (m, 1H), 
7.63 – 7.60 (m, 2H), 7.53 – 7.38 (m, 3H), 7.31 (d, J = 8.7 Hz, 2H), 6.95 (d, J = 8.7 Hz, 2H), 3.83 (s, 
3H), 3.39 – 3.35 (m, 2H), 1.58 – 1.53 (m, 2H), 1.44 – 1.32 (m, 2H), 0.91 (t, J = 7.3 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 165.1 (Cq), 159.2 (Cq), 146.6 (Cq), 144.9 (CH), 138.3 (CH), 137.9 (Cq), 
137.8 (Cq),136.7 (Cq), 131.7 (Cq), 129.7 (CH), 129.2 (CH), 128.7 (CH), 127.2 (CH), 113.5 (CH), 55.2 
(CH3), 39.2 (CH2), 31.7 (CH2), 20.2 (CH2), 13.8 (CH3). 
IR (ATR): 3399, 2926, 1652, 1510, 1244, 806, 645 cm-1. 
MS (ESI) m/z (relative intensity): 361 (80) [M+H]+, 383 (20) [M+Na]+. 
HR-MS (ESI) C23H25N2O2 [M+H]
+: 361.1909, found: 361.1911. 








methoxyphenyl)magnesium bromide 412a (1.0 mL, 1.0 M in THF, 1.00 mmol), 416 (30 mg, 9.0 mol 
%), TMEDA (58.1 mg, 0.50 mmol), and 2,3-DCB (95.3 mg, 0.75 mmol). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 1/1) yielded 413g (66.4 mg, 85%) as a white solid. 
M. p. 156 ºC. 
1H NMR (400 MHz, CDCl3) δ 8.50 (s, 1H), 7.65 (d, J = 7.8, 2H), 7.43 – 7.39 (m, 1H), 7.25 (d, J = 
8.7 Hz, 2H), 6.92 (d, J = 8.7 Hz, 2H), 3.82 (s, 3H), 3.35 – 3.31 (m, 2H), 1.58 – 1.50 (m, 2H), 1.36 – 
1.21 (m, 6H), 0.88 – 0.84 (t, J = 6.9 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 165.2 (Cq), 159.1 (Cq), 148.3 (Cq), 146.4 (CH), 140.1 (CH), 137.8 (Cq), 
131.6 (Cq), 129.6 (CH), 125.0 (CH), 113.4 (CH), 55.2 (CH3), 39.4 (CH2), 31.5 (CH2), 29.5 (CH2), 26.6 
(CH2), 22.5 (CH2), 14.0 (CH3). 
IR (ATR): 3398, 2929, 1649, 1507, 1245, 807, 558 cm-1. 
MS (ESI) m/z (relative intensity): 313 (80) [M+H]+, 335 (20) [M+Na]+. 
HR-MS (ESI) C19H25N2O2 [M+H]




The General Procedure J was followed using N-cyclohexylpicolinamide 411h (51.1 mg, 0.25 mmol), 
(4-methoxyphenyl)magnesium bromide 412a (1.0 mL, 1.0 M in THF, 1.00 mmol), 416 (30 mg, 9.0 
mol %), TMEDA (58.1 mg, 0.50 mmol), and 2,3-DCB (95.3 mg, 0.75 mmol). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 1/1) yielded 413h (55.9 mg, 72%) as a white solid. 
M. p. 99 ºC. 
1H NMR (400 MHz, CDCl3) δ 8.49 (dd, J = 4.6, 1.7 Hz, 1H), 7.63 (dd, J = 7.8, 1.7 Hz, 1H), 7.55 – 
7.49 (m, 1H), 7.38 (dd, J = 7.8, 4.6 Hz, 1H), 7.25 (d, J = 8.8 Hz, 2H), 6.92 (d, J = 8.8 Hz, 2H), 3.82 
(s, 3H), 1.99 – 1.86 (m, 2H), 1.74 – 1.65 (m, 2H), 1.62 – 1.56 (m, 1H), 1.40 – 1.27 (m, 2H), 1.26 – 




13C NMR (100 MHz, CDCl3) δ 164.4 (Cq), 159.1 (Cq), 148.4 (Cq), 146.5 (CH), 140.0 (CH), 137.8 (Cq), 
131.7 (Cq), 129.6 (CH), 124.9 (CH), 113.4 (CH), 55.2 (CH3), 48.0 (CH), 33.0 (CH2), 25.6 (CH2), 24.9 
(CH2). 
IR (ATR): 3397, 2933, 1671, 1508, 1244, 736, 557 cm-1. 
MS (ESI) m/z (relative intensity): 311 (90) [M+H]+, 333 (10) [M+Na]+. 
HR-MS (ESI) C19H23N2O2 [M+H]
+: 311.1758, found: 311.1754. 




The General Procedure J was followed using N-(1,2,3,4-tetrahydronaphthalen-1-yl)picolinamide 
411i (63.1 mg, 0.25 mmol), (4-methoxyphenyl)magnesium bromide 412a (1.0 mL, 1.0 M in THF, 1.00 
mmol), 416 (30 mg, 9.0 mol %), TMEDA (58.1 mg, 0.50 mmol), and 2,3-DCB (95.3 mg, 0.75 mmol). 
Purification by column chromatography on silica gel (n-hexane/EtOAc: 1/1) yielded 413i (69.9 mg, 
78%) as a white solid. 
M. p. 125 ºC. 
1H NMR (400 MHz, CDCl3) δ 8.47 (dd, J = 4.6, 1.7 Hz, 1H), 7.82 (d, J = 8.8 Hz, 1H), 7.66 (dd, J = 
7.8, 1.7 Hz, 1H), 7.39 (dd, J = 7.8, 4.6 Hz, 1H), 7.31 (d, J = 8.8 Hz, 2H), 7.25 – 7.22 (m, 1H), 7.19 – 
7.11 (m, 1H), 7.11 – 7.05 (m, 1H), 6.97 (d, J = 8.8 Hz, 2H), 5.28 – 5.22 (m, 1H), 3.85 (s, 3H), 2.86 – 
2.70 (m, 2H), 2.12 – 1.96 (m, 2H), 1.96 – 1.76 (m, 3H). 
13C NMR (100 MHz, CDCl3) δ 164.7 (Cq), 159.2 (Cq), 148.4 (Cq), 146.7 (CH), 139.9 (CH), 137.7 (Cq), 
137.6 (Cq), 136.8 (Cq), 131.6 (Cq), 129.7 (CH), 129.0 (CH), 128.8 (CH), 127.1 (CH), 126.1 (CH), 
125.0 (CH), 113.5 (CH), 55.2 (CH3), 47.3 (CH), 30.1 (CH2), 29.3 (CH2), 20.0 (CH2). 
IR (ATR): 3398, 3032 1659, 1506, 1245, 698, 485 cm-1. 




HR-MS (ESI) C23H23N2O2 [M+H]
+: 359.1758, found: 359.1754. 




The General Procedure J was followed using N-benzylpicolinamide 411j (53.1 mg, 0.25 mmol), (4-
methoxyphenyl)magnesium bromide 412a (1.0 mL, 1.0 M in THF, 1.00 mmol), 416 (30 mg, 9.0 mol 
%), TMEDA (58.1 mg, 0.50 mmol), and 2,3-DCB (95.3 mg, 0.75 mmol). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 1/1) yielded 413j (60.5 mg, 76%) as a white solid. 
M. p. 140 ºC. 
1H NMR (400 MHz, CDCl3) δ 8.48 (dd, J = 4.7, 1.6 Hz, 1H), 8.00 (s, 1H), 7.66 (dd, J = 7.8, 1.6 Hz, 
1H), 7.40 (dd, J = 7.8, 4.7 Hz, 1H), 7.34 – 7.21 (m, 5H), 7.28 (d, J = 8.7 Hz, 2H), 6.94 (d, J = 8.7 Hz, 
2H), 4.57 – 4.53 (m, 2H), 3.83 (s, 3H). 
13C NMR (100 MHz, CDCl3) δ 165.2 (Cq), 159.1 (Cq), 147.9 (Cq), 146.6 (CH), 140.1 (CH), 138.4 (Cq), 
138.0 (Cq), 131.5 (Cq), 129.7 (CH), 128.6 (CH), 127.8 (CH), 127.3 (CH), 125.1 (CH), 113.4 (CH), 
55.2 (CH3), 43.4 (CH2). 
IR (ATR): 3397, 2950, 1663, 1508, 1244, 728, 464 cm-1. 
MS (ESI) m/z (relative intensity): 319 (90) [M+H]+, 341 (10) [M+Na]+. 
HR-MS (ESI) C20H19N2O2 [M+H]
+: 319.1447, found: 319.1441. 











The General Procedure J was followed using N-(4-methoxybenzyl)picolinamide 411k (77.6 mg, 0.25 
mmol), (4-methoxyphenyl)magnesium bromide 412a (1.0 mL, 1.0 M in THF, 1.00 mmol), 416 (30 mg, 
9.0 mol %), TMEDA (58.1 mg, 0.50 mmol), and 2,3-DCB (95.3 mg, 0.75 mmol). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 1/1) yielded 413k (65.3 mg, 75%) as a white 
solid. 
M. p. 95 ºC. 
1H NMR (400 MHz, CDCl3) δ 8.47 (dd, J = 4.6, 1.7 Hz, 1H), 7.90 (s, 1H), 7.65 (dd, J = 7.8, 1.7 Hz, 
1H), 7.39 (dd, J = 7.8, 4.6 Hz, 1H), 7.27 (d, J = 8.7 Hz, 2H), 7.21 (d, J = 8.7 Hz, 2H), 6.93 (d, J = 8.8 
Hz, 2H), 6.84 (d, J = 8.8 Hz, 2H), 4.47 (d, J = 5.9 Hz, 2H), 3.83 (s, 3H), 3.77 (s, 3H). 
13C NMR (100 MHz, CDCl3) δ 165.1 (Cq), 159.1 (Cq), 158.9 (Cq), 148.0 (Cq), 146.6 (CH), 140.1 (CH), 
137.9 (Cq), 131.5 (Cq), 130.5 (Cq), 129.7 (CH), 129.2 (CH), 125.1 (CH), 114.0 (CH), 113.5 (CH), 55.3 
(CH3), 55.2 (CH3), 42.9 (CH2). 
IR (ATR): 3398, 2931, 1669, 1511, 1278, 806, 430 cm-1. 
MS (ESI) m/z (relative intensity): 349 (90) [M+H]+, 391 (10) [M+Na]+. 
HR-MS (ESI) C21H21N2O3 [M+H]
+: 349.1551, found: 349.1547. 








(4-methoxyphenyl)magnesium bromide 412a (1.0 mL, 1.0 M in THF, 1.00 mmol), 416 (30 mg, 9.0 
mol %), TMEDA (58.1 mg, 0.50 mmol), and 2,3-DCB (95.3 mg, 0.75 mmol). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 1/1) yielded 413l (53.3 mg, 67%) as a white solid. 
M. p. 164 ºC. 
1H NMR (400 MHz, CDCl3) δ 9.87 (s, 1H), 8.56 (dd, J = 4.6, 1.6 Hz, 1H), 7.69 (dd, J = 7.8, 1.6 Hz, 
1H), 7.55 (d, J = 8.7 Hz, 2H), 7.45 (dd, J = 7.8, 4.6 Hz, 1H), 7.28 (d, J = 8.7 Hz, 2H), 7.10 (d, J = 8.7 
Hz, 2H), 6.94 (d, J = 8.7 Hz, 2H), 3.83 (s, 3H), 2.29 (s, 3H). 
13C NMR (100 MHz, CDCl3) δ 162.4 (Cq), 159.1 (Cq), 147.2 (Cq), 146.3 (CH), 140.8 (CH), 138.7 (Cq), 
135.5 (Cq), 133.6 (Cq), 131.7 (Cq), 129.7 (CH), 129.4 (CH), 125.4 (CH), 119.7 (CH), 113.5 (CH), 55.2 
(CH3), 20.9 (CH3). 
IR (ATR): 3297, 2959, 1651, 1511, 839, 806, 579 cm-1. 
MS (ESI) m/z (relative intensity): 319 (70) [M+H]+, 341 (30) [M+Na]+. 
HR-MS (ESI) C20H19N2O2 [M+H]




The General Procedure J was followed using N-(4-methoxyphenyl)picolinamide 411m (57.1 mg, 
0.25 mmol), (4-methoxyphenyl)magnesium bromide 412a (1.0 mL, 1.0 M in THF, 1.00 mmol), 416 
(30 mg, 9.0 mol %), TMEDA (58.1 mg, 0.50 mmol), and 2,3-DCB (95.3 mg, 0.75 mmol). Purification 
by column chromatography on silica gel (n-hexane/EtOAc: 1/1) yielded 413m (49.3 mg, 59%) as a 
white solid. 
M. p. 127 ºC. 
1H NMR (400 MHz, CDCl3) δ 9.80 (s, 1H), 8.55 (dd, J = 4.6, 1.6 Hz, 1H), 7.68 (dd, J = 7.8, 1.6 Hz, 
1H), 7.56 (d, J = 9.0 Hz, 2H), 7.44 (dd, J = 7.8, 4.6 Hz, 1H), 7.27 (d, J = 8.7 Hz, 2H), 6.93 (d, J = 8.7 




13C NMR (100 MHz, CDCl3) δ 162.3 (Cq), 159.2 (Cq), 156.2 (Cq), 147.3 (Cq), 146.3 (CH), 140.8 (CH), 
138.6 (Cq), 131.7 (Cq), 131.3 (Cq), 129.7 (CH), 125.4 (CH), 121.3 (CH), 114.1 (CH), 113.5 (CH), 55.5 
(CH3), 55.2 (CH3). 
IR (ATR): 3300, 2927, 1657, 1481, 1232, 805, 490 cm-1. 
MS (ESI) m/z (relative intensity): 335 (70) [M+H]+, 357 (30) [M+Na]+. 
HR-MS (ESI) C20H19N2O3 [M+H]




The General Procedure J was followed using N-butylpicolinamide 411a (44.6 mg, 0.25 mmol), (4-
methoxyphenyl)magnesium bromide 412b (1.0 mL, 1.0 M in THF, 1.00 mmol), 416 (30 mg, 9.0 mol 
%), TMEDA (58.1 mg, 0.50 mmol), and 2,3-DCB (95.3 mg, 0.75 mmol). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 1/1) yielded 413n (65.2 mg, 84%) as a white solid. 
M. p. 110 ºC. 
1H NMR (400 MHz, CDCl3) δ 8.49 (dd, J = 4.6, 1.6 Hz, 1H), 7.65 (dd, J = 7.8, 1.6 Hz, 1H), 7.63 (s, 
1H), 7.41 (d, J = 8.7 Hz, 2H), 7.39 (dd, J = 7.8, 4.6 Hz, 1H), 7.27 (d, J = 8.7 Hz, 2H), 3.36 – 3.31 (m, 
2H), 1.57 – 1.46 (m, 2H), 1.37 – 3.31 (m, 2H), 1.34 (s, 9H), 0.90 (t, J = 7.3 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 165.2 (Cq), 150.1 (Cq), 148.2 (Cq), 146.6 (CH), 140.1 (CH), 137.9 (Cq), 
136.3 (Cq), 128.1 (CH), 124.9 (CH), 124.8 (CH), 39.1 (CH2), 34.5 (Cq), 31.5 (CH2), 31.3 (CH3), 20.1 
(CH2), 13.7 (CH3). 
IR (ATR): 3285, 3034, 1685, 1517, 1245, 809, 487 cm-1. 
MS (ESI) m/z (relative intensity): 311 (70) [M+H]+, 333 (30) [M+Na]+. 
HR-MS (ESI) C20H27N2O [M+H]
+: 311.2115, found: 311.2118. 







The General Procedure J was followed using N-butylpicolinamide 411a (44.6 mg, 0.25 mmol), (4-
methoxyphenyl)magnesium bromide 412c (1.0 mL, 1.0 M in THF, 1.00 mmol), 416 (30 mg, 9.0 mol 
%), TMEDA (58.1 mg, 0.50 mmol), and 2,3-DCB (95.3 mg, 0.75 mmol). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 1/1) yielded 413o (82.3 mg, 95%) as a light yellow 
oil. 
1H NMR (400 MHz, CDCl3) δ 8.51 (dd, J = 4.7, 1.6 Hz, 1H), 7.75 (s, 1H), 7.65 (dd, J = 7.8, 1.6 Hz, 
1H), 7.39 (dd, J = 7.8, 4.7 Hz, 1H), 7.33 (d, J = 8.6 Hz, 2H), 7.28 (d, J = 8.6 Hz, 2H), 7.13 – 7.06 (m, 
3H), 7.01 (d, J = 8.6 Hz, 2H), 3.38 – 3.34 (m, 2H), 1.58 – 1.51 (m, 2H), 1.41 – 1.30 (m, 2H), 0.91 (t, 
J = 7.2 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 165.1 (Cq), 156.9 (Cq), 156.6 (Cq), 148.0 (Cq), 146.7 (CH), 140.0 (CH), 
137.5 (Cq), 134.0 (Cq), 129.8 (CH), 129.6 (CH), 125.0 (CH), 123.4 (CH), 119.4 (CH), 117.7 (CH), 
39.1 (CH2), 31.5 (CH2), 20.1 (CH2), 13.7 (CH3). 
IR (ATR): 3288, 2931, 1655, 1519, 1290, 811, 488 cm-1. 
MS (ESI) m/z (relative intensity): 347 (80) [M+H]+, 369 (20) [M+Na]+. 
HR-MS (ESI) C22H23N2O2 [M+H]




The General Procedure K was followed using N-butylpicolinamide 411a (44.6 mg, 0.25 mmol), 
methylmagnesium bromide 414a (0.3 mL, 3.0 M in THF, 1.00 mmol), 416 (30 mg, 9.0 mol %), 
TMEDA (58.1 mg, 0.50 mmol), and 2,3-DCB (95.3 mg, 0.75 mmol). Purification by column 




1H NMR (400 MHz, CDCl3) δ 8.32 (dd, J = 4.6, 1.2 Hz, 1H), 8.09 (brs, 1H), 7.53 (dd, J = 7.8, 1.2 
Hz, 1H), 7.24 (dd, J = 7.8, 4.6 Hz, 1H), 3.38 (td, J = 7.1, 6.1 Hz, 2H), 2.70 (s, 3H), 1.66 – 1.51 (m, 
2H), 1.46 – 1.31 (m, 2H), 0.91 (t, J = 7.3 Hz, 3H).  
13C NMR (100 MHz, CDCl3) δ 165.9 (Cq), 147.4 (Cq), 145.3 (CH), 140.7 (CH), 135.2 (Cq), 125.4 
(CH), 38.9 (CH2), 31.7 (CH2), 20.5 (CH3), 20.2 (CH2), 13.7 (CH3).  
IR (ATR): 3384, 2927, 1574, 1465, 807, 711 cm-1.  
MS (ESI) m/z (relative intensity) 193 (80) [M+H]+, 215 (20) [M+Na]+. 
HR-MS (ESI) m/z calcd for C11H17N2O [M+H]
+ 193.1335, found 193.1337.  




The General Procedure K was followed using N-butylpicolinamide 411a (44.6 mg, 0.25 mmol), 
ethylmagnesium bromide 414b (0.5 mL, 2.0 M in THF, 1.00 mmol), 416 (30 mg, 9.0 mol %), TMEDA 
(58.1 mg, 0.50 mmol), and 2,3-DCB (95.3 mg, 0.75 mmol). Purification by column chromatography 
(n-hexane/EtOAc 8:1) yielded 415b (35.1 mg, 68%) as a colorless oil.  
1H NMR (300 MHz, CDCl3) δ 8.33 (dd, J = 4.6, 1.7 Hz, 1H), 8.04 (brs, 1H), 7.57 (dd, J = 7.8, 1.7 
Hz, 1H), 7.27 (dd, J = 7.8, 4.6 Hz, 1H), 3.41 – 3.37 (m, 2H), 3.16 (q, J = 7.5 Hz, 2H), 1.62 – 1.52 (m, 
2H), 1.44 – 1.31 (m, 2H), 1.23 (t, J = 7.5 Hz, 3H), 0.91 (t, J = 7.2 Hz, 3H).  
13C NMR (75 MHz, CDCl3) δ 165.6 (Cq), 147.2 (Cq), 145.1 (CH), 141.1 (Cq), 139.2 (CH), 125.5 (CH), 
39.0 (CH2), 31.8 (CH2), 26.3 (CH2), 20.3 (CH2), 15.6 (CH3), 13.8 (CH3).  
IR (ATR): 3387, 2962, 1673, 1515, 803 cm-1.  
MS (ESI) m/z (relative intensity) 207 (70) [M+H]+, 229 (30) [M+Na]+. 
HR-MS (ESI) m/z calcd for C12H19N2O [M+H]









The General Procedure K was followed using N-butylpicolinamide 411a (44.6 mg, 0.25 mmol), n-
butylmagnesium bromide 414c (0.5 mL, 2.0 M in THF, 1.00 mmol), 416 (30 mg, 9.0 mol %), TMEDA 
(58.1 mg, 0.50 mmol), and 2,3-DCB (95.3 mg, 0.75 mmol). Purification by column chromatography 
(n-hexane/EtOAc 8:1) yielded 415c (52.1 mg, 89%) as a colorless oil.  
1H NMR (300 MHz, CDCl3) δ 8.34 (dd, J = 4.6, 1.7 Hz, 1H), 8.05 (brs 1H), 7.56 (dd, J = 7.8, 1.7 Hz, 
1H), 7.27 (dd, J = 7.8, 4.6 Hz, 1H), 3.40 (td, J = 7.1, 6.0 Hz, 2H), 3.14 (t, J = 7.7 Hz, 2H), 1.64 – 1.54 
(m, 4H), 1.45 – 1.34 (m, 4H), 0.97 – 0.86 (m, 6H). 
13C NMR (100 MHz, CDCl3) δ 165.9 (Cq), 147.6 (Cq), 145.4 (CH), 140.1 (Cq), 140.1 (CH), 125.5 
(CH), 39.1 (CH2), 33.8 (CH2), 33.0 (CH2), 31.9 (CH2), 22.9 (CH2), 20.3 (CH2), 14.1 (CH3), 13.9 (CH3).  
IR (ATR): 2927, 2864, 1667, 1511, 1434, 807, 605 cm-1.  
MS (ESI) m/z (relative intensity) 235 (40) [M+H]+, 257 (60) [M+Na]+.  
HR-MS (ESI) m/z calcd for C14H22N2O [M+H]
+ 235.1805, found 235.1801. 




The General Procedure K was followed using N-butylpicolinamide 411a (44.6 mg, 0.25 mmol), 
octanemagnesium bromide 414d (1.3 mL, 0.8 M in THF, 1.00 mmol), 416 (30 mg, 9.0 mol %), 
TMEDA (58.1 mg, 0.50 mmol), and 2,3-DCB (95.3 mg, 0.75 mmol). Purification by column 
chromatography (n-hexane/EtOAc 8:1) yielded 415d (53.6 mg, 74%) as a colorless oil.  
1H NMR (400 MHz, CDCl3) δ 8.35 (dd, J = 4.6, 1.6 Hz, 1H), 8.06 (brs, 1H), 7.57 (dd, J = 7.8, 1.6 
Hz, 1H), 7.28 (dd, J = 7.8, 4.6 Hz, 1H), 3.41 (td, J = 7.0, 6.0 Hz, 2H), 3.18 – 3.12 (m, 2H), 1.66 – 1.56 




13C NMR (100 MHz, CDCl3) δ 165.8 (Cq), 147.4 (Cq), 145.2 (CH), 140.0 (Cq), 139.9 (CH), 125.4 
(CH), 39.0 (CH2), 33.1 (CH2), 31.8 (CH2), 31.7 (CH2), 31.5 (CH2), 29.7 (CH2), 29.5 (CH2), 29.3 (CH2), 
22.6 (CH2), 20.2 (CH2), 14.1 (CH3), 13.8 (CH3).  
IR (ATR): 3390, 2925, 1673, 1514, 1461, 807, 613 cm-1.  
MS (ESI) m/z (relative intensity) 291 (80) [M+H]+, 313 (20) [M+Na]+. 
HR-MS (ESI) m/z calcd for C18H31N2O [M+H]




The General Procedure K was followed using N-butylpicolinamide 411a (44.6 mg, 0.25 mmol) and 
isopropylmagnesium bromide 414e (0.33 mL, 3.0 M in THF, 1.00 mmol), 416 (30 mg, 9.0 mol %), 
TMEDA (58.1 mg, 0.50 mmol), and 2,3-DCB (95.3 mg, 0.75 mmol). Purification by column 
chromatography (n-hexane/EtOAc 8:1) yielded 415e (35.8 mg, 65%) as a colorless oil.  
1H NMR (400 MHz, CDCl3) δ 8.33 (dd, J = 4.5, 1.5 Hz, 1H), 7.92 (brs, 1H), 7.74 (dd, J = 8.1, 1.5 
Hz, 1H), 7.31 (dd, J = 8.1, 4.5 Hz, 1H), 4.41 (hept, J = 6.9 Hz, 1H), 3.40 (td, J = 7.2, 6.0 Hz, 2H), 
1.62 – 1.55 (m, 2H), 1.44 – 1.35 (m, 2H), 1.23 (d, J = 6.9 Hz, 6H), 0.93 (t, J = 7.2 Hz, 3H).  
13C NMR (100 MHz, CDCl3) δ 166.2 (Cq), 147.2 (Cq), 145.6 (Cq), 145.0 (CH), 135.4 (CH), 125.6 
(CH), 39.1 (CH2), 31.7 (CH2), 27.5 (CH), 23.6 (CH3), 20.2 (CH2), 13.7 (CH3).  
IR (ATR): 3386, 2958, 2866, 1662, 1511, 855, 655 cm-1.  
MS (ESI) m/z (relative intensity): 221 (20) [M+H]+, 243 (80) [M+Na]+. 
HR-MS (ESI) m/z calcd for C13H21N2O [M+H]







The General Procedure K was followed using N-butylpicolinamide 411a (44.6 mg, 0.25 mmol), 2-
hexylmagnesium bromide 414f (1.4 mL, 0.7 M in THF, 1.00 mmol), 416 (30 mg, 9.0 mol %), TMEDA 
(58.1 mg, 0.50 mmol), and 2,3-DCB (95.3 mg, 0.75 mmol). Purification by column chromatography 
(n-hexane/EtOAc 8:1) yielded 415f (36.7 mg, 56%) as a colorless oil.  
1H NMR (300 MHz, CDCl3) δ 8.32 (dd, J = 4.5, 1.5 Hz, 1H), 7.89 (brs, 1H), 7.72 (dd, J = 8.1, 1.5 
Hz, 1H), 7.32 (dd, J = 8.1, 4.5 Hz, 1H), 4.30 (sext, J = 7.2 Hz, 1H), 3.43 – 3.39 (m, 2H), 1.63 – 1.49 
(m, 4H), 1.45 – 1.34 (m, 2H), 1.30 – 1.19 (m, 3H), 1.22 (d, J = 6.8 Hz, 3H), 1.16 – 1.08 (m, 1H), 0.93 
(t, J = 7.2 Hz, 3H), 0.81 (t, J = 7.2 Hz, 3H).  
13C NMR (100 MHz, CDCl3) δ 166.3 (Cq), 147.7 (Cq), 145.0 (CH), 144.9 (Cq), 136.0 (CH), 125.6 
(CH), 39.1 (CH2), 37.7 (CH2), 32.3 (CH), 31.7 (CH2), 29.8 (CH2), 22.8 (CH2), 22.0 (CH3), 20.2 (CH2), 
14.0 (CH3), 13.8 (CH3).  
IR (ATR): 3387, 2955, 1665, 1511, 806, 708, 659 cm-1.  
MS (ESI) m/z (relative intensity): 263 (70) [M+H]+, 285 (30) [M+Na]+. 
HR-MS (ESI) m/z calcd for C17H29N2O [M+H]
+ 263.4050 found 263.4046. 




The General Procedure K was followed using N-butylpicolinamide 411a (44.6 mg, 0.25 mmol), 
cyclopropylmagnesium bromide 414g (0.9 mL, 1.1 M in THF, 1.00 mmol), 416 (30 mg, 9.0 mol %), 
TMEDA (58.1 mg, 0.50 mmol), and 2,3-DCB (95.3 mg, 0.75 mmol). Purification by column 
chromatography (n-hexane/EtOAc 8:1) yielded 415g (38.2 mg, 70%) as a colorless oil.  
1H NMR (400 MHz, CDCl3) δ 8.29 (dd, J = 3.4, 2.8 Hz, 1H), 8.02 (brs, 1H), 7.26 – 7.25 (m, 1H), 
7.25 – 7.24 (m, 1H), 3.45 – 3.40 (m, 2H), 3.40 – 3.33 (m, 1H), 1.65 – 1.57 (m, 2H), 1.46 – 1.37 (m, 
2H), 1.10 – 1.05 (m, 2H), 0.94 (t, J = 7.3 Hz, 3H), 0.69 – 0.65 (m, 2H).  
13C NMR (100 MHz, CDCl3) δ 166.2 (Cq), 148.3 (Cq), 144.3 (CH), 140.9 (Cq), 133.4 (CH), 125.4 




IR (ATR): 3379, 2960, 1670, 1514, 1465, 805, 651 cm-1.  
MS (ESI) m/z (relative intensity) 219 (80) [M+H]+, 241 (20) [M+Na]+.  
HR-MS (ESI) m/z calcd for C13H19N2O [M+H]




The General Procedure K was followed using N-butylpicolinamide 411a (44.6 mg, 0.25 mmol), 
cyclobutylmagnesium bromide 414h (1.3 mL, 0.8 M in THF, 1.00 mmol), 416 (30 mg, 9.0 mol %), 
TMEDA (58.1 mg, 0.50 mmol), and 2,3-DCB (95.3 mg, 0.75 mmol). Purification by column 
chromatography (n-hexane/EtOAc 8:1) yielded 415h (48.8 mg, 84%) as a colorless oil.  
1H NMR (400 MHz, CDCl3) δ 8.32 (dd, J = 4.6, 1.6 Hz, 1H), 7.88 (brs, 1H), 7.80 (dd, J = 8.0, 1.6 
Hz, 1H), 7.34 (dd, J = 8.0, 4.6 Hz, 1H), 4.67 – 4.53 (m, 1H), 3.44 – 3.34 (m, 2H), 2.47 – 2.35 (m, 2H), 
2.12 – 1.96 (m, 3H), 1.83 – 1.73 (m, 1H), 1.64 – 1.52 (m, 2H), 1.47 – 1.32 (m, 2H), 0.93 (t, J = 7.3 
Hz, 3H).  
13C NMR (100 MHz, CDCl3) δ 165.9 (Cq), 147.4 (Cq), 144.8 (CH), 141.7 (Cq), 136.0 (CH), 125.4 
(CH), 39.0 (CH2), 36.6 (CH), 31.7 (CH2), 29.1 (CH2), 20.2 (CH2), 18.2 (CH2), 13.7 (CH3).  
IR (ATR): 3386, 2959, 1513, 1430, 1188, 807, 631 cm-1.  
MS (ESI) m/z (relative intensity) 233 (60) [M+H]+, 255 (40) [M+Na]+.   
HR-MS (ESI) m/z calcd for C14H21N2O [M+H]




The General Procedure K was followed using N-butylpicolinamide 411a (44.6 mg, 0.25 mmol), 




TMEDA (58.1 mg, 0.50 mmol), and 2,3-DCB (95.3 mg, 0.75 mmol). Purification by column 
chromatography (n-hexane/EtOAc 8:1) yielded 415i (49.4 mg, 64%) as a colorless oil.  
1H NMR (300 MHz, CDCl3) δ 8.34 (dd, J = 4.5, 1.5 Hz, 1H), 7.91 (brs, 1H), 7.76 (dd, J = 8.1, 1.5 
Hz, 1H), 7.32 (dd, J = 8.1, 4.5 Hz, 1H), 4.40 (tt, J = 9.6, 7.5 Hz, 1H), 3.42 (td, J = 7.1, 6.0 Hz, 2H), 
2.18 – 2.11 (m, 2H), 1.77 – 1.70 (m, 4H), 1.62 – 1.36 (m, 6H), 0.93 (t, J = 7.2 Hz, 3H).  
13C NMR (75 MHz, CDCl3) δ = 166.3 (Cq), 147.9 (Cq), 144.8 (CH), 143.3 (Cq), 136.0 (CH), 125.5 
(CH), 39.7 (CH), 39.2 (CH2), 34.7 (CH2), 31.8 (CH2), 25.9 (CH2), 20.3 (CH2), 13.9 (CH3).  
IR (ATR): 3385, 2947, 2859, 1660, 1508, 804, 654 cm-1.  
MS (ESI) m/z (relative intensity): 247 (25) [M+H]+, 269 (75) [M+Na]+.  
HR-MS (ESI) m/z calcd for C15H23N2O [M+H]
+ 247.1803 found 247.1805. 




The General Procedure K was followed using N-butylpicolinamide 411a (44.6 mg, 0.25 mmol), 
cyclohexylmagnesium bromide 414j (0.6 mL, 1.8 M in THF, 1.00 mmol), 416 (30 mg, 9.0 mol %), 
TMEDA (58.1 mg, 0.50 mmol), and 2,3-DCB (95.3 mg, 0.75 mmol). Purification by column 
chromatography (n-hexane/EtOAc 8:1) yielded 415j (53.4 mg, 82%) as a colorless oil.  
1H NMR (400 MHz, CDCl3) δ 8.33 (dd, J = 4.5, 1.5 Hz, 1H), 7.99 (brs, 1H), 7.75 (dd, J = 8.1, 1.5 
Hz, 1H), 7.31 (dd, J = 8.1, 4.5 Hz, 1H), 4.05 (tt, J = 12.0, 3.2 Hz, 1H), 3.40 (td, J = 7.2, 6.0 Hz, 2H), 
1.90 – 1.77 (m, 5H), 1.62 – 1.18 (m, 9H), 0.94 (t, J = 7.2 Hz, 3H).  
13C NMR (100 MHz, CDCl3) δ 166.2 (Cq), 147.2 (Cq), 144.9 (CH), 144.6 (Cq), 136.0 (CH), 125.5 
(CH), 39.1 (CH2), 37.8 (CH), 34.1 (CH2), 31.7 (CH2), 26.7 (CH2), 26.2 (CH2), 20.2 (CH2), 13.8 (CH3).  
IR (ATR): 3382, 2922, 2850, 1663, 1504, 694, 498 cm-1.  
MS (ESI) m/z (relative intensity): 261 (60) [M+H]+, 283 (40) [M+Na]+.  
HR-MS (ESI) m/z calcd for C16H25N2O [M+H]








The General Procedure K was followed using N-butylpicolinamide 411a (44.6 mg, 0.25 mmol), 
cycloheptylmagnesium bromide 414k (1.7 mL, 0.6 M in THF, 1.00 mmol), 416 (30 mg, 9.0 mol %), 
TMEDA (58.1 mg, 0.50 mmol), and 2,3-DCB (95.3 mg, 0.75 mmol). Purification by column 
chromatography (n-hexane/EtOAc 8:1) yielded 415k (37.0 mg, 54%) as a colorless oil.  
1H NMR (300 MHz, CDCl3)
 δ 8.33 (dd, J = 4.5, 1.6 Hz, 1H), 7.98 (brs, 1H), 7.74 (dd, J = 8.0, 1.6 Hz, 
1H), 7.32 (dd, J = 8.0, 4.5 Hz, 1H), 4.32 – 4.18 (m, 1H), 3.43 (td, J = 7.2, 5.9 Hz, 2H), 1.98 – 1.90 
(m, 2H), 1.84 – 1.52 (m, 11H), 1.50 – 1.37 (m, 3H), 0.96 (t, J = 7.2 Hz, 3H).  
13C NMR (75 MHz, CDCl3)
 δ 166.1 (Cq), 146.6 (Cq), 146.2 (Cq), 144.7 (CH), 136.3 (CH), 125.6 (CH), 
46.4 (CH), 39.4 (CH2), 39.2 (CH2), 36.7 (CH2), 31.8 (CH2), 31.4 (CH2), 28.2 (CH2), 27.9 (CH2), 27.6 
(CH2), 20.3 (CH2), 13.9 (CH3).  
IR (ATR): 3383, 2923, 2859, 1670, 1514, 801, 624 cm-1.  
MS (ESI) m/z (relative intensity): 275 (85) [M+H]+, 297 (15) [M+Na]+.  
HR-MS (ESI) m/z calcd for C17H27N2O [M+H]




The General Procedure K was followed using N-cyclohexylpicolinamide 411h (51.1 mg, 0.25 mmol), 
cyclohexylmagnesium bromide 414j (0.6 mL, 1.8 M in THF, 1.00 mmol), 416 (30 mg, 9.0 mol %), 




chromatography on silica gel (n-hexane/EtOAc: 1/1) yielded 415l (49.4 mg, 69%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ 8.30 (dd, J = 4.5, 1.6 Hz, 1H), 7.89 (d, J = 8.8 Hz, 1H), 7.72 (dd, J = 
8.0, 1.6 Hz, 1H), 7.29 (dd, J = 8.0, 4.5 Hz, 1H), 4.09 – 3.99 (m, 1H), 3.97 – 3.84 (m, 1H), 2.02 – 1.93 
(m, 2H), 1.91 – 1.83 (m, 2H), 1.81 – 1.68 (m, 5H), 1.66 – 1.57 (m, 1H), 1.53 – 1.46 (m, 2H), 1.42 – 
1.35 (m, 2H), 1.34 – 1.28 (m, 2H), 1.27 – 1.11 (m, 4H). 
13C NMR (100 MHz, CDCl3) δ 165.2 (Cq), 147.2 (Cq), 144.8 (CH), 144.7 (Cq), 136.0 (CH), 125.5 
(CH), 48.0 (CH), 37.9 (CH), 34.1 (CH2), 33.1 (CH2), 26.7 (CH2), 26.2 (CH2), 25.6 (CH2), 25.0 (CH2). 
IR (ATR): 338, 2925, 1665, 1503, 807, 593, 435 cm-1. 
MS (ESI) m/z (relative intensity): 287 (90) [M+H]+, 309 (10) [M+Na]+. 
HR-MS (ESI) C18H27N2O [M+H]




The General Procedure K was followed using N-(1,2,3,4-tetrahydronaphthalen-1-yl)picolinamide 
411i (63.1 mg, 0.25 mmol), cyclohexylmagnesium bromide 414j (0.6 mL, 1.8 M in THF, 1.00 mmol), 
416 (30 mg, 9.0 mol %), TMEDA (58.1 mg, 0.50 mmol), and 2,3-DCB (95.3 mg, 0.75 mmol). 
Purification by column chromatography on silica gel (n-hexane/EtOAc: 1/1) yielded 415m (68.6 mg, 
82%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ 8.32 (d, J = 9.3 Hz, 1H), 8.28 (dd, J = 4.5, 1.6 Hz, 1H), 7.76 (dd, J = 
8.1, 1.6 Hz, 1H), 7.37 – 7.33 (m, 1H), 7.31 (ddd, J = 8.1, 4.5 Hz, 1H), 7.17 – 7.14 (m, 2H), 7.13 – 7.09 
(m, 1H), 5.38 – 5.29 (m, 1H), 4.15 (tt, J = 11.8, 3.1 Hz, 1H), 2.92 – 2.71 (m, 2H), 2.20 – 2.10 (m, 1H), 
2.02 – 1.74 (m, 8H), 1.63 – 1.48 (m, 2H), 1.43 – 1.32 (m, 2H), 1.31 – 1.19 (m, 1H). 
13C NMR (100 MHz, CDCl3) δ 165.5 (Cq), 146.9 (Cq), 145.0 (CH), 144.8 (Cq), 137.6 (Cq), 137.0 (Cq), 
136.0 (CH), 129.1 (CH), 128.8 (CH), 127.1 (CH), 126.1 (CH), 125.6 (CH), 47.3 (CH), 37.9 (CH), 34.2 
(CH2), 30.3 (CH2), 29.3 (CH2), 26.8 (CH2), 26.3 (CH2), 20.2 (CH2). 




MS (ESI) m/z (relative intensity): 335 (90) [M+H]+, 357 (10) [M+Na]+. 
HR-MS (ESI) C22H27N2O [M+H]




The General Procedure K was followed using N-benzylpicolinamide 411j (53.1 mg, 0.25 mmol), 
cyclohexylmagnesium bromide 414j (0.6 mL, 1.8 M in THF, 1.00 mmol), 416 (30 mg, 9.0 mol %), 
TMEDA (58.1 mg, 0.50 mmol), and 2,3-DCB (95.3 mg, 0.75 mmol). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 1/1) yielded 415n (30.2 mg, 41%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ 8.38 – 8.32 (m, 1H), 8.30 (dd, J = 4.5, 1.6 Hz, 1H), 7.89 (dd, J = 8.8, 
1.6 Hz, 1H), 7.38 – 7.30 (m, 5H), 7.28 – 7.24 (m, 1H), 4.62 (d, J = 6.0 Hz, 2H), 4.16 – 4.03 (m, 1H), 
1.95 – 1.86 (m, 2H), 1.87 – 1.72 (m, 2H), 1.60 – 1.44 (m, 2H), 1.43 – 1.29 (m, 2H), 1.29 – 1.16 (m, 
2H). 
13C NMR (100 MHz, CDCl3) δ 166.0 (Cq), 146.8 (Cq), 145.0 (Cq), 144.9 (CH), 138.5 (Cq), 136.1 (CH), 
128.6 (CH), 127.8 (CH), 127.3 (CH), 125.8 (CH), 43.4 (CH2), 37.9 (CH), 34.2 (CH2), 26.8 (CH2), 26.3 
(CH2). 
IR (ATR): 3381, 2924, 1666, 1504, 698, 601, 480 cm-1. 
MS (ESI) m/z (relative intensity): 295 (70) [M+H]+, 317 (30) [M+Na]+. 
HR-MS (ESI) C19H23N2O [M+H]




The General Procedure K was followed using N-(4-methoxybenzyl)picolinamide 411l (77.6 mg, 0.25 




%), TMEDA (58.1 mg, 0.50 mmol), and 2,3-DCB (95.3 mg, 0.75 mmol). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 1/1) yielded 415o (42.2 mg, 52%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ 8.30 (dd, J = 4.5, 1.6 Hz, 1H), 8.28 – 8.23 (m, 1H), 7.76 (dd, J = 8.0, 
1.6 Hz, 1H), 7.31 (dd, J = 8.0, 4.5 Hz, 1H), 7.28 (d, J = 8.6 Hz, 2H), 6.86 (d, J = 8.6 Hz, 2H), 4.54 (d, 
J = 5.9 Hz, 2H), 4.13 – 4.05 (m, 1H), 3.77 (s, 3H), 1.93 – 1.72 (m, 5H), 1.57 – 1.46 (m, 2H), 1.40 – 
1.30 (m, 2H), 1.27 – 1.20 (m, 1H). 
13C NMR (100 MHz, CDCl3) δ 166.0 (Cq), 158.9 (Cq), 146.9 (Cq), 144.9 (CH), 144.8 (Cq), 136.1 (CH), 
130.6 (Cq), 129.1 (CH), 125.7 (CH), 114.0 (CH), 55.3 (CH3), 42.9 (CH2), 37.9 (CH), 34.2 (CH2), 26.8 
(CH2), 26.3 (CH2). 
IR (ATR): 3387, 2925, 1666, 1508, 1247, 580, 416 cm-1. 
MS (ESI) m/z (relative intensity): 325 (70) [M+H]+, 347 (30) [M+Na]+. 
HR-MS (ESI) C20H25N2O2 [M+H]




The General Procedure K was followed using N-(4-methoxyphenyl)picolinamide 411m (56.8 mg, 
0.25 mmol), cyclohexylmagnesium bromide 414j (0.6 mL, 1.8 M in THF, 1.00 mmol), 416 (30 mg, 
9.0 mol %), TMEDA (58.1 mg, 0.50 mmol), and 2,3-DCB (95.3 mg, 0.75 mmol). Purification by 
column chromatography (n-hexane/EtOAc 8:1) yielded 415p (32.6 mg, 42%) as a colorless oil.  
1H NMR (300 MHz, CDCl3) δ 10.05 (brs, 1H), 8.41 (dd, J = 4.5, 1.5 Hz, 1H), 7.82 (dd, J = 8.1, 1.5 
Hz, 1H), 7.64 (d, J = 9.0 Hz, 2H), 7.38 (dd, J = 8.1, 4.5 Hz, 1H), 6.91 (d, J = 9.0 Hz, 2H), 4.24 – 4.15 
(m, 1H), 3.81 (s, 3H), 1.96 – 1.77 (m, 5H), 1.56 – 1.24 (m, 5H).  
13C NMR (75 MHz, CDCl3) δ 163.5 (Cq), 156.1 (Cq), 146.3 (Cq), 145.4 (Cq), 144.6 (CH), 136.3 (CH), 
131.2 (Cq), 125.9 (CH), 121.5 (CH), 114.1 (CH), 55.5 (CH3), 37.9 (CH), 34.2 (CH2), 26.8 (CH2), 26.3 
(CH2).  




MS (ESI) m/z (relative intensity): 311 (65) [M+H]+, 333 (35) [M+Na]+. 
HR-MS (ESI) m/z calcd for C19H23N2O2 [M+H]
+ 311.1756 found 311.1753. 




The General Procedure K was followed using N-(2-fluorobenzyl)picolinamide 411n (57.8 mg, 0.25 
mmol), cyclohexylmagnesium bromide 414j (0.6 mL, 1.8 M in THF, 1.00 mmol), 416 (30 mg, 9.0 mol 
%), TMEDA (58.1 mg, 0.50 mmol), and 2,3-DCB (95.3 mg, 0.75 mmol). Purification by column 
chromatography (n-hexane/EtOAc 8:1) yielded 415q (52.3 mg, 67%) as a colorless oil.  
1H NMR (300 MHz, CDCl3) δ 8.39 (t, J = 6.3 Hz, 1H), 8.32 (dd, J = 4.5, 1.5 Hz, 1H), 7.75 (dd, J = 
8.1, 1.5 Hz, 1H), 7.40 (td, J = 7.6, 1.8 Hz, 1H), 7.31 (dd, J = 8.1, 4.5 Hz, 1H), 7.25 – 7.20 (m, 1H), 
7.08 (td, J = 7.6, 1.2 Hz, 1H), 7.06 – 7.00 (m, 1H), 4.67 (d, J = 6.3 Hz, 2H), 4.07 (tt, J = 11.5, 3.0 Hz, 
1H), 1.90 – 1.73 (m, 5H), 1.56 – 1.45 (m, 2H), 1.39 – 1.21 (m, 3H).  
13C NMR (75 MHz, CDCl3) δ 165.9 (Cq), 161.0 (d, 
1JC-F = 246.0 Hz, Cq), 146.7 (Cq), 145.0 (CH), 
144.9 (Cq), 136.0 (CH), 130.0 (d, 
3JC-F = 4.3 Hz, CH), 129.0 (d, 
3JC-F = 8.1 Hz, CH), 125.8 (CH), 125.5 
(d, 2JC-F = 14.9 Hz, Cq), 124.2 (d, 
4JC-F = 3.6 Hz, CH), 115.3 (d, 
2JC-F = 21.3 Hz, CH), 37.8 (CH), 37.1 
(d, 3JC-F = 4.2 Hz, CH2), 34.1 (CH2), 26.7 (CH2), 26.2 (CH2).  
19F NMR (282 MHz, CDCl3) δ -118.7 – -118.8 (m).  
IR (ATR): 3381, 2922, 1501, 1227, 805, 625 cm-1. 
MS (ESI) m/z (relative intensity): 313 (20) [M+H]+, 335 (100) [M+Na]+.  
HR-MS (ESI) m/z calcd for C19H22FN2O [M+H]
+ 313.1708 found 313.1707. 









The General Procedure K was followed using N-phenethylpicolinamide 411o (56.3 mg, 0.25 mmol), 
cyclohexylmagnesium bromide 414j (0.6 mL, 1.8 M in THF, 1.00 mmol), 416 (30 mg, 9.0 mol %), 
TMEDA (58.1 mg, 0.50 mmol), and 2,3-DCB (95.3 mg, 0.75 mmol). Purification by column 
chromatography (n-hexane/EtOAc 8:1) yielded 415r (66.3 mg, 86%) as a colorless oil. 
1H NMR (300 MHz, CDCl3) δ 8.22 (dd, J = 4.5, 1.5 Hz, 1H), 8.01 (brs, 1H), 7.67 (dd, J = 8.1, 1.5 
Hz, 1H), 7.25 – 7.10 (m, 6H), 3.97 (tt, J = 11.8, 3.0 Hz, 1H), 3.69–3.53 (m, 2H), 2.86 (t, J = 7.2 Hz, 
2H), 1.79 – 1.67 (m, 5H), 1.55–1.08 (m, 5H).  
13C NMR (75 MHz, CDCl3) δ 166.0 (Cq), 146.9 (Cq), 144.7 (CH), 144.4 (Cq), 138.9 (Cq), 135.7 (CH), 
128.6 (CH), 128.3 (CH), 126.1 (CH), 125.4 (CH), 40.6 (CH2), 37.8 (CH), 35.9 (CH2), 34.1 (CH2), 26.7 
(CH2), 26.2 (CH2).  
IR (ATR): 3385, 2923, 1665, 1000, 806, 697, 497 cm-1.  
MS (ESI) m/z (relative intensity): 309 (100) [M+H]+, 331 (40) [M+Na]+.  
HR-MS (ESI) m/z calcd for C20H25N2O [M+H]
+ 309.1965 found 309.1961. 





5.8.2 Synthesis of Hybrid Manganese Catalyst 
1) Linker modification 
To a solution of DIPA (15 mmol, 1.1 mmol) in 40 mL of dried THF (50 mL) was added n-BuLi (2.1 
M, 6.3 mL, 13.2 mmol, 1.0 equiv) dropwise at 0 °C under N2, in-situ generating LDA. After the 
reaction mixture was stirred for 1 h, a solution of 4,4-dimethyl-2,2′-bipyridine (439) (13.2 mmol, 1.0 
equiv) in dried THF (100 mL) was slowly added under N2, then color was changed to dark brown. 
After stirring the reaction mixture for 1 h, a solution of (3-chloropropyl)trimethoxylsilane (440) (13.2 
mmol, 1.0 equiv) in 10 mL of THF was slowly added at 0 °C under N2. The solution was further stirred 
for an additional 2 h. The reaction mixture was warmed to room temperature and stirred for 24 h. After 
the reaction was quenched with two drops of acetone, the remaining solvent was removed and then 
dried in vacuo at room temperature for 24 h, affording 441. The synthesized 441 are used for the next 
step without further purification (Scheme 5.8.1).  
 
 
Scheme 5.8.1 Synthesis of 441. 
 
2) Grafting 
A suspension of SBA-15 (5.0 g) and the synthesized 441 in dried toluene were refluxed under N2 for 
24 h. The powder was filtered off, washed with toluene, n-hexane, and DCM (each 50 mL), and dried 






Scheme 5.8.2 Synthesis of 442. 
 
3) End-capping 
Hexamethyldisilazane (20 mL) and the isolated 442 in dried toluene (50 mL) was stirred at room 
temperature for 24 h. The powder was filtered off, washed with toluene, n-hexane, and DCM (each 50 
mL), and dried in vacuo at 100 °C for 24 h, providing 443 (Scheme 5.8.3). 
 
 
Scheme 5.8.3 Synthesis of 443. 
 
4) Metallation 
A suspension of MnCl2·4H2O (1.2 g, 6.0 mmol) and the isolated 443 (1.9 g) was stirred in EtOH (50 
mL) at 60 °C for 24 h under N2. The powder was filtered off, washed with excess EtOH (3 × 50 mL), 






Scheme 5.8.4 Synthesis of 416. 
 
 
5.8.3 Determination of Catalyst Loading 
ICP-OES analysis was performed by Dr. Volker Karius for the determination of hybrid manganese 
catalyst 416 loading (Equation 5.8.1). 
 
Amount of Catalyst × ICP-OES result ÷ Molcular weight of manganese ÷
amount of substrates × 100 mol %  
= 30 mg ×  
40930 mg
1,000,000 mg
 ×  
1
54.938 mg/mmol
 ×  
1
0.25 mmol
 × 100 mol % = 𝟗 𝐦𝐨𝐥 %  
 








5.8.4 Heterogeneity Test 
1) Reuse test for hybrid-manganese-catalyzed C–H arylations 
The General Procedure J was followed using N-butylpicolinamide 411a (0.25 mmol, 1.0 equiv), (4-
methoxyphenyl)magnesium bromide 412a (1.00 mmol, 4.0 equiv, 1.0 mL, 1.0 M in THF), 416 (9.0 
mol %), TMEDA (0.50 mmol, 2.0 equiv), and 2,3-DCB (0.75 mmol, 3.0 equiv). After 16 h the reaction 
tube was transferred to a glovebox. 416 was carefully filtered through branched filter (Por. 3) with 
Et2O (3 × 10 mL). Filtered 416 was dried in vacuo for 12 h and used for next run (Scheme 5.8.5). 
 
 
Scheme 5.8.5 Reuse test of hybrid manganese-catalyzed C–H arylation. 
 
2) Reuse test for hybrid-manganese-catalyzed C–H alkylations 
The General Procedure K was followed using N-butylpicolinamide 411a (0.25 mmol, 1.0 equiv), 
cyclohexylmagnesium bromide 414j (1.00 mmol, 4.0 equiv, 1.0 mL, 1.0 M in THF), 416 (9.0 mol %), 
TMEDA (0.50 mmol, 2.0 equiv), and 2,3-DCB (0.75 mmol, 3.0 equiv). Reuse procedure is same as 
described above (Scheme 5.8.6).  
 
 




3) Mercury test 
The General Procedure J was followed using N-butylpicolinamide 414a (0.25 mmol, 1.0 equiv), (4-
methoxyphenyl)magnesium bromide 412a (1.00 mmol, 4.0 equiv, 1.0 mL, 1.0 M in THF), 416 (9.0 
mol %), TMEDA (0.50 mmol, 2.0 equiv), and 2,3-DCB (0.75 mmol, 3.0 equiv). After 2 hours, Hg(0) 
(0.12 mL, 400 equiv to catalyst loading) was added to the Schlenk tube and then the reaction continued 
for 14 h. Afterwards, a saturated aqueous NH4Cl (15 mL) was added and the reaction mixture was 
extracted with EtOAc (3 × 15 mL). The combined organic layers were dried over Na2SO4, filtered, and 




Scheme 5.8.7 Mercury test. 
 
4) Hot-filtration test 
The General Procedure J was followed using N-butylpicolinamide 414a (0.25 mmol, 1.0 equiv), (4-
methoxyphenyl)magnesium bromide 412a (1.00 mmol, 4.0 equiv, 1.0 mL, 1.0 M in THF), 416 (9.0 
mol %), TMEDA (0.50 mmol, 2.0 equiv), and 2,3-DCB (0.75 mmol, 3.0 equiv). After 2 hours, Schlenk 
tube was transferred to a glovebox. 416 was carefully filtered over pre-heated Celite® with a branched 
filter (Por. 3). Filtrate was directly collected to another pre-dried Schlenk tube and then sealed with 
septum. The sealed Schlenk tube was directly transferred to pre-heated oil-bath and the reaction 
continued for 14 h. Afterwards, saturated aqueous NH4Cl (15 mL) was added and the reaction mixture 
was extracted with EtOAc (3 × 15 mL). The combined organic layers were dried over Na2SO4, filtered, 
and concentrated in vacuo. Purification by column chromatography on silica gel afforded the desired 
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